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The hyacinthacine C-type alkaloids are polyhydroxylated pyrrolizidine alkaloids that were 
first isolated in 1999 from the fruits and stalks of Hyacinthoides non-scripta and later in 
2007 from the bulbs of Scilla socialis. Today they comprise hyacinthacines C1, C2, C3, C4 
and C5 and have attracted considerable attention within the large community of those 
interested in iminosugars, since they exhibit inherent glycosidase inhibitory activities. 
Their low to moderate IC50 values (13 – 100 µM) against various α-glucosidases makes the 
hyacinthacine C-type alkaloids important scaffolds towards finding medicines that help 
treat type-2 diabetes as well as the increasing obesity epidemic.  
The hyacinthacine C-type alkaloids can contain up to seven possible stereogenic centres. 
This means that there are 128 unique stereoisomers (64 diastereomers and their 
enantiomers) containing a 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7-tetraol core 
that have potentially different glycosidase inhibitory activities. Their constitutional 
complexity has resulted in structural insecurities in four of the five naturally occurring 
hyacinthacines, namely hyacinthacines C1, C3, C4 and C5. Their configurational ambiguity 
coupled with their relatively low glycosidase inhibitory activity presents an enticing 
challenge for many chemists and so has led to an increasing number of publications that 
detail synthetic work towards this class of compounds. 
To shed light on the current inconsistencies in the literature, the work presented in this 
Ph.D. describes the successful total synthesis and consequent correction of the structures 
for hyacinthacines C1 (Chapter 5), and C5 (Chapter 4B). More specifically, it was found 
that the true structure for hyacinthacine C1 is the C8 epimer of the purported structure. 
Moreover, the true structure for hyacinthacine C5 has the opposite configuration at the three 
contiguous stereogenic centres, C5, C6, and C7, to that of the originally proposed structure.  
The successful pathway that resulted in these compounds was designed around the Petasis 
borono-Mannich acid reaction between 3,5-di-O-benzyl-α,β-L-xylofuranose, 3-amino-1-
butene·hydrochloride and (E)-β-styrenylboronic acid. This led to the synthesis of two key 
amino-diol motifs that when strategically subjected to key steps such as ring-closing 
metathesis, cis-dihydroxylation, cyclic sulfate synthesis, regioselective cyclic sulfate ring-
ii 
 
opening and Swern oxidation/stereoselective reduction, resulted in the synthesis of an 
additional nine hyacinthacine C-type analogues.  
The eleven hyacinthacine C-type analogues synthesized as a part of this study were then 
evaluated as glycosidase inhibitors and compared against the structurally analogous 
casuarine (one of the most powerful glucosidase inhibitors) and a useful SAR was 
developed. With respect to casuarine, hyacinthacine C-type analogues (‒)-6-epi-
hyacinthacine C5 156 and (+)-7-epi-hyacinthacine C5 155 displayed comparable inhibition 
against the α-glucosidase of rat intestinal sucrase (IC50 values of 13 μM and 9.9 μM, 
respectively) and are suitable scaffolds towards investigating potential drug candidates for 
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Chapter 1 : History and development of the 
hyacinthacine C-type Alkaloids 
 
1.1. The importance of natural products 
  
A natural product can be defined as a substance that is produced by life. Such compounds 
are initially isolated from a natural source and if useful, they can be later prepared by 
chemical synthesis in a scalable manner. Whether perceived as good or bad, natural 
products are undeniably one of the most influential compound classes for living and are 
undoubtedly fundamental to the lifestyles of all species. 
Among humans, the impact of natural products can be seen through the example of a cup 
of tea or coffee. These brewed solutions enjoyed by most are rich sources of alkaloids. 
More specifically, theophylline and caffeine (Figure 1.1) are the natural products that most 





Figure 2.1: Natural products theophylline and caffeine. 
 
Another example of a natural product and its impact on lifestyle is nicotine: a component 
of tobacco blends (Figure 1.2). Similarly, this natural product is generally accepted to be 
the potent parasympathomimetic stimulant alkaloid responsible for inducing relaxation 









Figure 2.2: Natural product nicotine. 
 
Even with advancements in medical technology to allow the design of potent drugs for 
medical use, natural products are still actively and widely used on large commercial scales. 
An example of this are the recently introduced Coles™ brand of cold and flu, pain relief 
and decongestant tablets, whereby they solely contain natural product extracts from 
Andrographis paniculate (Green chirayta), Echinacea purpurea (Eastern purple 




Figure 2.3: From left to right, Andrographis paniculate (Green chirayta)1, Echinacea 
purpurea (Eastern purple coneflower)2, Salix alba (white willow)3 and Sambucus nigra 
(Black elderberry).4 
 
Regardless of lifestyle or medicinal use, these examples only scratch the surface of the 
importance and wide spread abundance of natural products in modern lifestyles. For the 
remainder of this Chapter however, the broader focus of this research will address modern 





1.2. Drug discovery and development 
 
New drug discovery has been largely influenced through the examination of natural 
product medicines that have been used for centuries. Interest and investigation into 
naturally occurring medicines excelled in the early 1980s, and by 2002, it was found that 
75% of new drugs for infectious disease and 60% of new drugs for cancer, stemmed from 
natural products.5 However, this statistic was short lived. More specifically, between 2001 
and 2005, only 23 new drugs succeeded from natural product to market to be used as: 
immunosuppressive agents, pain relief, anti-bacterial and anti-fungal agents, treating 
infections, cancer, diabetes, dyslipidemia, atopic dermatitis, Alzheimer’s disease and other 
genetic diseases (tyrosinemia and Gaucher’s disease).6 This 20-year low is perceived as 
the reason for a large number of pharmaceutical companies having reduced or cancelled 
funding towards natural product research programs.6 In addition to this, the late 1990s 
brought a significant paradigm shift amongst pharmaceutical companies and their 
approach to sourcing first-in-class drugs. Technologies such as combinatorial chemistry 
and high-throughput screening (HTS) allowed for high speed assays of large synthetic 
compound libraries, but could not effectively be applied to natural product screening on a 
similar magnitude.6-9  
Today, the research and drug discovery model includes modern molecular biological 
methods (understanding disease mechanisms, biomarkers, surrogate endpoints), HTS, 
structure-based drug design, combinatorial and parallel chemistry, and the sequencing of 
the human genome. This latest research and development (R&D) model is largely 
influenced by the result of six decades of inflation-adjusted costs. On average, introducing 
a new drug to the market doubles in cost approximately every 9 years.10 Despite such 
innovations, there are many doubts and raised concerns over the current R&D model 
simply because the number of drug approvals by the US Food and Drug Administration 
(FDA) are not increasing proportionally with the advancements of the aforementioned 
technologies.11-12 Furthermore, with less emphasis on natural product research and more 
interest in developing large compound libraries, it is unsurprising that a notable reduction 
in the discovery of new chemical entities has also been observed.6  
These alarming facts suggest that the current R&D model should be revised.10 This does 
not necessarily need to become more advanced, rather pharmaceutical natural product 
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research programs should be reconsidered. During the 1980s, natural product research 
rarely considered aqueous extracts. If aqueous extracts of natural products were 
investigated for the following reasons, perhaps similar success observed in the ‘golden era’ 
of new drug discovery would be achieved. 
 
1.3. Polyhydroxylated Alkaloids- Distribution in Nature: 
 
Unlike traditional preparations, drug discovery programs largely extracted natural products 
and promising medicinal agents with the aid of organic solvents such as methanol, 
dichloromethane, chloroform and hexane.13 However, folkloric medicines are almost 
exclusively brewed as water soluble extracts of natural products, and so any ascribed 
therapeutic benefit is likely to be attributed to water soluble components, including 
polyhydroxylated carbohydrate analogues. Of these, the polyhydroxylated alkaloids (PAs) 
prove particularly interesting for organic and medicinal chemists.13 More specifically, they 
display high stereoselectivity and activity for biological systems.13 In conjunction with a 
low molecular weight (~250 Da), heterocyclic nature and large stereoconfiguration scope, 
this class of compound make them an ideal synthetic target.  
Polyhydroxylated alkaloids can also be referred to as iminosugars, azasugars or sugar-
shaped alkaloids, largely owing to their structural resemblance to monosaccharides. As 
their name suggests, their chief difference is that they contain a ring nitrogen in place of 
oxygen. After their initial finding in 1966 (norjirimycin), this class of alkaloid was thought 
to be restricted in Nature,13 however, today they can be subdivided into six ring systems: 
pyrrolines, pyrrolidines, piperidines, pyrrolizidines, indolizidines and nortropanes. These 
can either be monocyclic or bicyclic structures (Selected examples of each are found in 







Table 2.1: Selected examples of the six polyhydroxylated alkaloid classes, along with of 
their distribution and biological activity. 
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iminofuranose to 
be discovered and 
isolated from the 
leaves of Derris 
elliptica (legume) 











The first naturally 
occurring 
pyrroline to be 
discovered and 




1988.26  Nectria lucida F-4490
26  
An immunomodulator 
and inhibitor of α-







One of the first 






substituent at the 
C3 postion. 
Alexine was 















One of the first 
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To date, hundreds of novel polyhydroxylated alkaloids have and continue to be isolated by 
a simple means of reinvestigating the aqueous fractions of previously characterised natural 
products.13 Their initially proposed distribution in Nature is misleading because of 
inadequate extraction methods previously employed. This suggests a huge potential to find 
new subclasses of polyhydroxylated alkaloids in plants, micro-organisms and taxa not 
previously considered to be alkaloid producing.13 More importantly, their analogous 
structure to glycosides -like glucose and mannose- mean that the polyhydroxylated 
alkaloids can interact with enzymes known as glycosidases and might therefore have 
important therapeutic potential towards treating diseases such as viral infections, cancer 
and diabetes. 
 
1.4. Polyhydroxylated alkaloids as glycosidase inhibitors  
 
Essential for existence and found in all domains of life, glycosidases are enzymes that 
catalyse the hydrolysis of carbohydrates and complex glycosides to release simpler 
monosaccharides and oligosaccharides. This large and diverse group of enzymes has been 
extensively studied since the early 1830s.38 Today, these enzymes are well characterised 
and facilitate many functions which range from the digestion of large polysaccharides 
through to developing cellular structural integrity.13, 20 
To ensure a range of unique functions, individual glycosidases must display distinct 
affinity for certain carbohydrate molecules and also for specific anomeric configurations 
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of that sugar.13 It is therefore reasonable that through mimicry of pyranosyl or furanosyl 
moieties, polyhydroxylated alkaloids display the potential to be highly potent and specific 
inhibitors of glycosidases. Furthermore, the number, position and configuration of the 
hydroxy groups of each alkaloid can influence the type of glycosidase inhibited.13  
The above rationale certainly paved way for the development of the oral antidiabetic drug, 
miglitol. This evolution of a naturally occurring polyhydroxylated alkaloid to its 
marketable drug should certainly be explored. However, before this case study is 
examined, we must first consider the mechanisms of enzymatic glycoside hydrolysis.  
 
1.5. Glycosidase hydrolysis 
 
Glycosidases are an extremely efficient class of enzymes. In 1998, Wolfenden et al. were 
able to demonstrate this, where they found that glycosidases were able to enhance the rate 
of catalysis 1017 fold faster than the uncatalyzed reaction (noting that efforts to preserve 
paper (cellulose) books and other rare documents is somewhat futile).39 Additionally, this 
figure  correlates to an estimated dissociation constant for the transition state to be no more 
than 10-22 M, which suggests that the substrate must have a very strong binding affinity for 
the enzyme.39-40 Therefore, the ideal mechanism-based glycosidase inhibitor should mimic 
the transition state formed during glycosidase hydrolysis such that it binds strongly and 
also reversibly to the glycosidase active site.41   
Glycosidases can be segregated into two main groups based on whether the stereochemical 
outcome of the anomeric configuration of the hydrolysed monosaccharide is either retained 
or inverted (Figure 1.4).41-44 For instance, if a carbohydrate enters the active site of a 
retaining glycosidase (Figure 1.4A), the anomeric carbon of the terminal glucose unit 
undergoes a ‘double inversion’ and retains the original stereochemistry. More specifically, 
after an initial attack at the anomeric carbon by a carboxylate nucleophile, a neighbouring 
carboxylic acid residue concurrently donates a proton to the leaving group oxygen. The 
proton deficient carboxylate can then expedite a second nucleophilic attack of a water 
molecule at the anomeric carbon which subsequently displaces the monomeric sugar unit, 
but retains the original stereochemistry.45-46 Comparatively, inverting glycosidases react 
through a single step (SN2) mechanism (Figure 1.4B). To facilitate this process, one 
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carboxylate residue acts as an acid and protonates the glycosidic oxygen. The other 
carboxylic acid residue acts as a base and can deprotonate a water molecule, resulting in a 
nucleophilic attack towards the anomeric carbon.45-46 Common to both glycoside 
hydrolysis pathways is the formation of an oxocarbenium-ion-like transition state which 
proves to be an important characteristic when considering the design of specific 
glycosidase inhibitors. Additionally, through the advancements of an increasing number 
of structural and mechanistic studies, glycoside hydrolases have, and continue to be, 
subcategorized based on their specific mechanism of action. Since the PAs resemble the 
oxocarbenium-ion-like transition state at certain pH levels, scientists are able to exploit 
these scaffolds and design extremely potent and specific inhibitors of glycosidases.41 To 
gain insight into this process, we will investigate the development of the non-insulin 






Figure 2.4: Mechanisms of A) retaining and B) inverting glycosidases. 
 
1.6. Case study: Deoxynorjirimycin to antidiabetic drug miglitol 
 
At a physiological pH, PAs become protonated at their nitrogen atom which leads to the 
formation of a stable complex within the glycosidase active site.41, 47 As seen with the 
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iminosugar 1-deoxynojirimycin (DNJ) in Figure 1.5, its adoption of a comparable 
oxocarbenium-ion-like shape causes the enzyme to have a high affinity for the inhibitor. 
When inside the active site cleft of the enzyme, the iminosugar can form an ion pair with 
the carboxylate moieties resulting in a physical blockage of disaccharides that would 
otherwise be hydrolysed. This partial bond allows for reversibility, where the strength and 
specific inhibition will be largely dependent on the shape, size and stereoconfiguration of 




Figure 2.5: Comparison of DNJ (left) and the oxocarbenium-ion-like transition state of 
glycoside hydrolysis (right).  
 
The importance of PA isolation and research can be clearly seen through the development 
of the pseudomonosaccharide α-glucosidase inhibitor miglitol. Although approved in 1996 
as a NIDDM treatment, miglitol (marketed under the name Glyset™) can be traced back 
to the 1970s through its naturally occurring parent analogue DNJ (Figure 1.6).48-49 Prior to 
its isolation in 1976 from the roots of a Mulberry species (Moraceae), DNJ had already 
been the product of two syntheses reported in 1967 and 1968 by Paulsen et al. and Inouye 
et al. respectively.15, 49-50 Its synthetic attention at this time was largely due to the recent 
isolation of the closely related natural isolate, nojirimycin, an inherent antibiotic.51 It was 
found that relative to norjirimycin, the lack of an anomeric hydroxy group at C1 caused 
DNJ to act as a potent inhibitor of yeast and pancreas glycosidases.52  
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Although this was a noteworthy find, the impressive glycosidase inhibitory activity of DNJ 
could be considered an unsurprising result. In addition to its original isolation, DNJ has 
been well established as a dominant constituent of various Moraceae; a species with a rich 
history in East Asian, folklore-based use and medicine.22, 49, 53-54 In fact, brewed extracts 
of Mulberry leaves are considered a traditional remedy used to treat and prevent “Xiao-
ke” (diabetes), particularly in China.54-55 
Its traditional use, in conjunction with inherent glycosidase inhibitory activity, convinced 
scientists that DNJ would be a promising NIDDM therapeutic. However, this was soon 
dismissed on the basis of in vivo experiments, where DNJ displayed only moderate effects 
on small intestinal D-glucose uptake.56 In light of this result, N-alkyl derivatives of DNJ 
were synthesized on the basis of improved in vivo activity, whereby the N-hydroxyethyl-
DNJ analogue (miglitol) proved most effective for managing postprandial blood glucose 




Figure 2.6: Development of the naturally derived58 DNJ and its analogous marketed 
NIDDM derivative, miglitol.59 
 
Although effective for managing type-2 diabetes, miglitols mechanism and localization 
(small intestine) of glycosidase inhibition led to undesired side effects. As a result of 
preventing the digestion of polysaccharides, flatulence and gastrointestinal discomfort 
were notable in patients and are today the largest deterrents for using this medication.60 
However, it has also been observed that abdominal discomfort is dose-related and can be 
better tolerated with continued use.61-62  
The development of miglitol from the naturally occurring DNJ is a convincing example of 
just how important it is for the present R&D model to include the investigation of natural 
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products as a source for drug scaffolds. The polyhydroxylated nature of DNJ and miglitol 
validate the investigation into unexplored water-soluble components of natural products. 
Although all classes of PAs should be of interest, the polyhydroxylated pyrrolizidine 
alkaloids have gained considerable attention in the literature for their noteworthy 
glycosidase inhibitory activities. For this reason, this class of PA will be the broader focus 
for the remainder of this Chapter. 
 
1.7. Polyhydroxylated Pyrrolizidine Alkaloids 
 
Prior to discussing the polyhydroxylated pyrrolizidine alkaloids, it is worth noting 
pyrrolizidine alkaloids, particularly those that contain a hydroxymethyl substituent at C1, 




Figure 2.7: General structure for pyrrolizidine alkaloids. 
 
Their appreciation is largely a result of the increasing number of deaths to livestock that 
have consumed plants rich in pyrrolizidine alkaloids.63 A memorable example occurred in 
Australia in the late 1970s, whereby a large number of chicken poisonings were reported.64 
On closer inspection, researchers found that the ill-thrift, ascites and degenerative lesions 
on the chickens, were the result of a commercial poultry feed containing heliotrine and 
lasiocarpine: pyrrolizidine alkaloids found in the seeds of Heliotropium stenophyllum 
(Figure 1.8).64 It is more alarming however that many cases of liver disease and cancer in 
humans have been the direct result of pyrrolizidine alkaloid consumption.65-68 This wide 
spread occurrence is not surprising since there have been recorded findings of pyrrolizidine 
alkaloids detected in wheat flour, honey and also cow’s milk.69-71 At least from an 
economic point of view, it remains important that improved methods of detection, 









Figure 2.8: Heliotropium stenophyllum72 along with pyrrolizidine alkaloids heliotrine and 
lasiocarpine. 
 
By the 1980s, pyrrolizidine alkaloids were deemed pernicious upon ingestion and were 
consequently flagged as a world-wide health concern.63 Their toxicity is a result of the 1,2-
unsaturated bond, in combination with an ester at the C9 position (Figure 1.7).63 After 
consumption, hepatic mixed function oxidases convert these pyrrolizidine alkaloids to 
their counter pyrrole derivatives. These metabolic products are highly reactive and can scar 
various organs in the body, particularly rich in thiol containing amino acids.73-74   
During this time, only a few examples existed of pyrrolizidine alkaloids that displayed 
anti-tumour activity75 and neuromuscular blocking activity76 and so this class of alkaloid 
was generally thought to be toxic. However, by the late 1980s, this view drastically 
changed after the discovery of the polyhydroxylated pyrrolizidine alkaloids containing a 
hydroxymethyl substituent at the C3 position.28 The compound first discovered of this 
nature was alexine  and was appropriately named after its source, the legume Alexia 
leiopetala (Figure 1.9).28 Its structure was unequivocally confirmed by X-ray 
crystallography28 and just a few months later, its C7a epimer (also crystalline), australine, 
was reported as a constituent of Castanospermum australe seeds (Figure 1.9).77 Following 
these discoveries, a number of closely related epimers were also isolated from C. 
australe.30, 78-80 Interestingly, alexine and australine along with their related epimers 
displayed notable anti-viral properties as well as low IC50 values towards specific 
glycosidases.28, 77 These findings attracted significant attention to the polyhydroxylated 
pyrrolizidine alkaloids, because contrary to their non-hydroxylated analogues, they proved 









Figure 2.9: Castanospermum australe81 seeds and polyhydroxylated pyrrolizidine 
alkaloid containing a hydroxymethyl substituent at C3: Australine. 
 
Prior to the discovery of alexine and australine, it was perceived that the only glycosidase 
inhibitors were restricted to polyhydroxylated indolizidines (swainsonine), 
polyhydroxylated pyrrolidines (DMDP) and polyhydroxylated piperidines (nojirimycin).77 
The polyhydroxylated pyrrolizidine alkaloids unique structure and hydroxy substitution 
patterns gives rise to their reported antiviral properties and other medicinal applications. 
For this reason, it has become apparent that related analogues of alexine and australine, 
synthetic or naturally derived, are of considerable interest for medicinal chemists 
globally.23, 82-84   
It was therefore an exciting discovery when the first pentahydroxylated pyrrolizidine 
alkaloid, casuarine, was isolated from the bark of Casuarina equisetifolia L (Figure 1.10) 
reported by Nash et al. in 1994.85 Nash and colleagues were initially interested in the bark 
of C. equisetifolia L because of its traditional use as a medicine to treat diarrhoea, dysentery 
and colic.85-86 Perhaps a more convincing reason for Nash et al. to examine this natural 
source, was due to previous reports of prescribed C. equisetifolia L bark extract for the 
treatment of breast cancer in Western Samoa.85 Their investigation started with an GC-MS 
analysis of the extract, where a pentahydroxy- nitrogen-containing species, later 
established to be casuarine, was identified to be one of the major compounds present. 
Moreover, it contained the highest oxidation level to be found in any related naturally 
occurring iminosugar. Glycosidase inhibition studies of casuarine found it to be a highly 









Figure 2.10: Leaves of Casuarina equisetifolia L87 and casuarine. 
 
Casuarine has also been identified as a common constituent within the leaves and seeds of 
Eugenia jambolana (Figure 1.11), a plant native to India known particularly for its various 
medicinal uses including the management of diabetes and bacterial infections.88 In the 
related species, Eugenia uniflora, isolates initially labelled as uniflorine A and B were 
assigned structures containing an indolizidine core. However, by members from the Pyne 
research group, it was later found that both uniflorine A and B were incorrectly assigned 
and were in fact casuarine along with its C6 epimer, respectively (Figure 1.11).89-95 The 
only other naturally occurring casuarine epimer reported in the literature is the C3 epimer 
which was isolated from Myrtus communis L. in 2006 by Fleet et al.96 Compared to 











Figure 2.11: Above: Eugenia jambolana97 (left), Eugenia uniflora98 (middle), Myrtus 
communis L99 (right) Below: (left) 6-epi-casuarine and analogue (right) 3-epi-casuarine. 
 
Since their discovery, casuarine, alexine, australine and related structures have been 
largely sought after due to their inherently selective glycosidase inhibition and are 
consequently perceived as ideal leads for drug candidature. Although no marketable drug 
has yet resulted from this class of compound, scientists have deduced that the 
polyhydroxylated pyrrolizidine alkaloids containing a C3 hydroxymethyl are medicinally 
useful (unlike their unsaturated analogues). Moreover, the absolute configuration as well 
as the degree of oxidation is crucial for selectivity and potency against specific glycosidase 
inhibition.  
 
1.8. The Hyacinthacine Alkaloids: Isolation and Biological activity 
 
One recently discovered subclass of polyhydroxylated pyrrolizidine alkaloid that has 
attracted considerable attention for their inherent glycosidase inhibitory activities are the 
hyacinthacine alkaloids. Despite their analogous structure to casuarine, alexine and 
australine, these alkaloids have been named after their original source, namely the 
Hyacinthaceae subfamily within the Asparagaceae.100 Shown in Figure 1.12, the 
hyacinthacine alkaloids can be divided into three classes: Hyacinthacine A, B and C; 
17 
 
whereby the letter assignment denotes whether 0, 1 or 2 hydroxy/hydroxymethyl 
substituents are found on the B-ring of the alkaloid, respectively.  
 
 
Figure 2.12: Hyacinthacines A1, B1, C1, containing 0, 1 and 2 hydroxy or hydroxymethyl 
substituents on the B-ring of the pyrrolizidine (red), respectively.  
 
The discovery of the hyacinthacine alkaloids can be traced back to the late 1960s and is 
considered an unprecedented find, largely because Asparagaceae is unrelated to the 
Leguminosae, Casuarinaceae and Mytaceae plant families.101 In 1967 a report from The 
Veterinary Record written by Thursby-Pelham, detailed the toxicological effects on 
livestock after consuming Hyacinthoides non-scripta  (Figure 1.13).102 More specifically, 
Thursby-Pelham found that ingestion led to abdominal pain and dysentery in horses and 
lethargy and dullness in cows.102  The plants metabolites however remained a mystery until 
1997, where, prompted by this report and perhaps also the availability of this material, 
Fleet et al. identified the presence of five pyrrolidine alkaloids present in the ethanolic 
fraction of the leaves.103 This was the first report of any such alkaloids from the 
Hyacinthaceae species and although the plant was considered detrimental to livestock 
health, Fleet et al. were able to demonstrate that the isolated pyrrolidine alkaloids were 
potential therapeutic leads. Glycosidase inhibition studies of these isolates found that they 






Figure 2.13: Hyacinthoides non-scripta.104 
 
Two years after this novel finding, several of the same authors led by Asano, reported their 
investigation into the fruits and stalks of the H. non-scripta.105 To further explore the 
natural abundance of similar compounds, their research also detailed the analysis of the 
bulbs of a  related species, Scilla campanulata (Figure 1.14).105   
 
 
Figure 2.14: Scilla campanulata.106 
 
In addition to the isolation of six pyrrolidine alkaloids, three novel polyhydroxylated 
pyrrolizidine alkaloids labelled as hyacinthacine alkaloids were reported (See Table 
1.2).105 More specifically, from the 50% ethanoic extracts of the H. scripta stalks, 
hyacinthacine C1 was isolated, and from the 50% ethanoic extract of the S. campanulata 
bulbs, hyacinthacine B2 was isolated.
105 Hyacinthacine B1 was common in both plants and 
thus found as a constituent in both extracts.105 Although not necessarily potent, these three 
alkaloids gained considerable interest for their selective glycosidase inhibition. 
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Hyacinthacine B1 and B2 both displayed weak inhibition of almond β-glucosidase (IC50 
values of 320 µM and 100 µM, respectively) and bovine liver β-galactosidase (IC50 values 
of 110 µM and 160 µM, respectively). Both alkaloids also showed selective inhibition for 
rat intestinal lactase β-galactosidase, however hyacinthacine B2 proved far more active 
(IC50 = 3.6 µM) than hyacinthacine B1 (IC50 = 270 µM). Interestingly, hyacinthacine C1 
proved moderately active against the amyloglucosidase of Aspergillus niger (IC50 = 84 
µM), whereas hyacinthacine B1 and B2 displayed no inhibition for these two glycosidases.  
Given these noteworthy glycosidase inhibitory activities, the therapeutic potential 
warranted further investigation of the hyacinthacine alkaloids. Since there had not yet been 
a proven synthetic route to access these novel structures, natural product investigation was 
the only viable option. To increase the chance of finding similar novel hyacinthacine 
alkaloids, the same authors reported in 2000, their investigation into the bulbs of the related 
Muscari armeniacum whereby they identified four novel hyacinthacine type alkaloids.107 
More specifically, Asano and co-workers successfully isolated (from 60% ethanoic 
extracts) hyacinthacine C1 as well as new Hyacinthacines A1, A2, A3 and B3 (See Table 
1).107 When tested against a panel of glycosidases, hyacinthacines A1, A2, A3 and B3 
displayed weak to moderate activity against rat intestinal lactase β-galactosidase (IC50 
values of 4.4 µM, 73 µM, 160 µM and 18 µM, respectively) and also A. niger 
amyloglucosidase (IC50 values of 25 µM, 8.6 µM, 17 µM and 51 µM, respectively). 
Hyacinthacine A1 proved to be the only alkaloid active against rat epididymis α-L-
fucosidase (IC50 = 46 µM) and rice α-glucosidase (IC50 = 240 µM). Hyacinthacines A1 and 
A2 also displayed activity against almond β-glucosidase with IC50 values of 250 µM and 
150 µM, respectively.107  
 
Figure 2.15: Muscari armeniacum.108 
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Despite what could be considered a small compound library, Asano and co-workers 
remarked on the difficulty to predict the specificity and potency of glycosidase inhibition 
based on absolute configuration and also the degree of substitution on the pyrrolizidine 
ring.107 Concluding statements from this body of work highlighted the need for a variety 
of highly oxygenated or substituted pyrrolizidine alkaloids to better understand the 
structural requirements for glycosidase inhibtition.107 Concurrently, glycosidase inhibitors 
were also receiving considerable attention as therapeutic agents. In addition to potential 
treatment for NIDDM (type II diabetes), glycosidase inhibitors were also established as 
possible treatments for tumour metastasis, viral infections, and various lysosomal storage 
disorders.13, 29, 109-112 For these reasons, investigation into the hyacinthacine type alkaloids 
also received increased attention and resulted in perhaps the most profitable recordings of 
novel hyacinthacine alkaloids isolated from a single species to date by Asano et al. in 
2002.113 Their report detailed the analysis of the bulbs of the related Scilla sibrica (Figure 
1.16) that were originally purchased from a flower shop in 1999. Specifics of this report 
include 9 kg of S. sibirica bulbs being homogenized in 60% aqueous ethanol, and further 
extracted to give seven new hyacinthacine alkaloids appropriately named hyacinthacines 
A4, A5, A6, A7, B4, B5 and B6 (See Table 1.2).
113 Although the majority of these 
hyacinthacine alkaloids proved relatively inactive towards the selected panel of 
glycosidase enzymes, they still added to the understanding of the structure-activity 
relationships of these and related compounds. In summary, the only active hyacinthacine 
alkaloids were A5, B4, and B5, where they showed inhibitory activity towards the 
amylglucosidase of Aspergillus niger with IC50 values of 110 µM, 89 µM and 110 µM, 
respectively. In addition to this, hyacinthacine B4 displayed a moderate inhibition of 







Figure 2.16: Scilla sibrica.114 
 
Two years later, Asano and co-workers reported findings of long side chain pyrrolidines 
and pyrrolizidines in a closely related Asparagaceae, Scilla peruviana (Figure 1.17).115 
Asano et al. isolated three novel hyacinthacine A1-type related alkaloids along with one 
novel australine type related alkaloid.115 These long-chain hyacinthacine derivatives were 
isolated from 5 kg of bulb plant material using 50% aqueous ethanoic extracts and were 
accordingly named α-5-C-(3-hydroxybutyl)hyacinthacine A1, α-5-C-(1,3-
dihydroxybutyl)hyacinthacine A1, α-5-C-(1,3,4-trihydroxybutyl)hyacinthacine A1 and α-
5-C-(3-hydroxybutyl)-7-epi-australine (See Table 1.2).115 When tested against a panel of 
glycosidases, α-5-C-(1,3-dihydroxybutyl)hyacinthacine A1 and α-5-C-(3-hydroxybutyl)-
7-epi-australine displayed relatively good activity against yeast α-glucosidase (IC50 values 
of 3.6 µM and 6.6 µM, respectively), however only the former alkaloid, along with α-5-C-
(1,3,4-trihydroxybutyl)hyacinthacine A1, proved relatively low inhibition against almond 
β-glucosidase and C. saccharolyticum β-glucosidase with IC50 values of 9.5 µM, 25.4 µM 







Figure 2.17: Scilla peruviana.116 
 
The most recent addition to the naturally occurring hyacinthacine alkaloids is the 2007 
reporting of six new isolates from Scilla socialis (Figure 1.18).117 Kato and co-workers 
initially purchased S. socialis plants in 2003 and cultivated this species in a heated 
greenhouse. Once grown, 2.3 kg of the plant bulbs were homogenized in a 50% ethanol 
solution and further investigated whereby α-5-C-(3-hydroxybutyl)hyacinthacine A2, 
hyacinthacine B7, C2, C3, C4 and C5 were isolated and tested against a panel of selected 
glycosidases (See Table 1.2). Of these results, hyacinthacine C2, C3 and C5 displayed 
noteworthy activity against C. saccharolyticum β-glucosidase with IC50 values of 13 µM, 
25 µM and 48 µM, respectively. Hyacinthacine C4 proved to be the only active compound 
against rice α-glucosidase (IC50 = 110 µM), but shared similar activities with hyacinthacine 
C5 against rat α-glucosidase (IC50 = 45 µM and 77 µM, respectively) and the 
amyloglucosidase of A. niger (IC50 = 57 µM for both C4 and C5). Hyacinthacine C3 
displayed a unique inhibition of bovine liver β-galactosidase with an IC50 value of 52 µM, 
whilst hyacinthacine C2 proved the only alkaloid capable of inhibiting human placenta α-
L-fucosidase with an IC50 value of 17 µM.
117 
 
Figure 2.18: Scilla Socialis.118  
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Table 2.2: Concentration (µM) of the naturally isolated hyacinthacine alkaloids giving 
50% inhibition of various glycosidases (IC50 values). 
 

























1.9. Structural assignment issues with the Hyacinthacine alkaloids 
 
Excluding the three long-chain hyacinthacine A-type analogues, 19 hyacinthacine type 
alkaloids have been isolated and reported between 1999 and 2007. In most cases, 2D NMR 
experiments (gCOSY, HSQC, HMBC) were the sole basis of structure elucidation. 
Moreover, NOE correlations as well as 3JH,H coupling patterns and constants were used to 
determine the relative configuration but were limited such that they were unable to identify 
the absolute configuration of the isolated hyacinthacines. With no X-ray crystallographic 
structures of these complex natural isolates, this has understandably led to inconsistencies 
among the hyacinthacine structures and suggests that their assigned configurations are not 
secure. An immediately obvious example of this can be seen in the proposed structures of 
hyacinthacines C1 and C4. Although reported nearly eight years apart, both alkaloids were 
assigned with identical structures despite their prominent differences in both 1H and 13C 
NMR spectroscopic data and their specific rotations. Despite plausible NOE correlations 
presented for both structures (Figure 1.19), the aforementioned differences between the 
spectroscopic data suggests at least one of these structures to be incorrect.105, 117 
 
 




Therefore, to confirm their structures (as well as the proposed relative and absolute 
configurations) the hyacinthacine alkaloids have been of recent interest for total synthesis. 
Furthermore, total synthesis also allows access to the core structure of these complex 
alkaloids and so presents a great significance to the large community interested in the 
preparation of glycosidase inhibitors and consequent therapeutic iminosugars.  
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To date, 14 of the natural hyacinthacines, A1, A2, A3, A6, A7, B1, B2, B3, B4, B5, B7, C2, C3 
and C5 have been synthesized, along with their related epimers and enantiomers.
119-132 At 
this point, the author notes that an increasing number of reports suggest the confirmation 
of hyacinthacine A5 through methods of total synthesis.
129, 131, 133 To the best of our 
knowledge, hyacinthacine A5 has not yet been synthesized and although epimers of the 
structure have been reported,134 the absolute configuration of the natural isolate is still yet 
to be confirmed. In addition to the aforementioned issues, recent synthetic studies have 
also revealed that the original structures proposed for hyacinthacines B7, C3 and C5 are 
incorrect.126-130 It therefore becomes apparent that structural revision of the original 
isolates is necessary because as demonstrated in Table 1.2, hyacinthacine alkaloid epimers 
determine the degree of specificity as well as the potency for the inhibition of various 
glycosidases. 
 
1.10. Total syntheses of the Hyacinthacine C-type analogues 
 
Each subclass of the hyacinthacine alkaloids displays relatively low glycosidase inhibitory 
activities and so merits their total synthesis. Relative to A-type hyacinthacines, both B and 
C-type analogues have a greater constitutional complexity and as a result, have led to a 
greater number of insecure structural assignments. Synthetic work towards hyacinthacine 
A and B-type analogues has been included in a number of reviews,135-137 with a 
comprehensive analysis completed in 2012 by Pyne et al.138 The hyacinthacine C-type 
analogues on the other hand have attracted considerable interest and there has been a 
number of publications towards their synthetic work that has not yet been summarised. 
When considered from a structural point of view, the hyacinthacine C-type analogues are 
the most diverse subclass of the hyacinthacines. They can contain up to seven possible 
stereogenic centres which means that there are 128 unique possible diastereomers (together 
with their enantiomers) containing a 3-hydroxymethyl-5-methylpyrrolizidine-1,2,6,7-
tetraol core that can be potentially synthesized. Their high degree of oxidation presents a 
remarkably analogous structure to glucose and is therefore an enticing, but challenging 
synthesis for chemists interested in accessing medicinally useful iminosugars. For these 
reasons, the remainder of this Chapter will largely focus on the hyacinthacine C-type 
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alkaloids and will aim to deliver a comprehensive and collective review of all the different 
synthetic approaches towards this subclass of hyacinthacine.  
1.10.1. Yoda et al. 2009 
 
The first synthesis of hyacinthacine C-type analogues was the synthesis of hyacinthacine 
C2 and C3 along with their C5-epimers reported by Yoda et al. in 2009.
128 This synthesis 
was an initial attempt to reveal information regarding structure-activity relationships 
between the hyacinthacine C-type alkaloids and their inhibition against various 
glycosidases. Their synthetic strategy (Scheme 1.1) starts with the preparation of the N-
Boc lactam 1 from commercially available (S)-(–)-2-pyrrolidone-5-carboxylic acid. 
Lactam 1 was subject to a Grignard addition followed by a 1,2-reduction of the resulting 
unsaturated ketone formed by pyrrolidione ring opening to give the corresponding allyl 
alcohol. Subsequent mesylation-cyclization then afforded the N-Boc-2 product. Next, the 
Boc protecting group was replaced with Cbz in a high yielding, three-step procedure to 
give N-Cbz-3. The olefin moiety of N-Cbz-3 was then subject to oxidative cleavage with 
OsO4 and NaIO4 to give aldehyde 4 as a single isomer. A Reformatsky-type allylation of 
4 returned a 79:21 separable mixture of the alcohols 5a and 5b, respectively. To establish 
the methodology, alcohol 5a then underwent TBS protection of the hydroxy group 
followed by a non-selective dihydroxylation of the terminal olefin moiety. The inseparable 
diol mixture was then subject to a selective TBS protection of the primary alcohol, 
affording a high yield (92%) of a 1:1 mixture of separable diastereomers 6a and 6b. In 
separate reactions, mesylation of the secondary alcohols of 6a and 6b followed by Cbz 
deprotection resulted in concerted cyclization to give the pyrrolizidines 7a and 7b. 
Individual global deprotection of both pyrrolizidines afforded hyacinthacine C2 along with 
its epimer, 5-epi-hyacinthacine C2 10 in 72% and 71% yields, respectively. Having 
established the synthetic pathway to hyacinthacine C2, Yoda and co-workers employed a 
similar synthetic methodology to alcohol 5b where they also successfully synthesized 
hyacinthacine C3 along with its epimer, 5-epi-hyacinthacine C3 11. When compared with 
the spectroscopic data of the natural isolates,117 Yoda et al. confirmed only the structure 
for natural hyacinthacine C2 was correct. They found that the characterization data of their 




Scheme 2.1: The first total synthesis of hyacinthacine C2 and proposed structure of C3 and 




1.10.2. Tamayo et al. 2009 
 
At around the same time as Yoda et al., Tamayo and co-workers published their work 
detailing the synthetic approach to making analogues of hyacinthacines C2/C3 from the 
arabinose derived nitrone 12 (Scheme 1.2).139 Their synthesis began with the 1,3-dipolar 
cycloaddition of the chemoenzymatically prepared 3-buten-1,2-diol derivatives 13a or 13b 
to nitrone 12 to afford cycloadducts 14 or 15, respectively. At this stage, methodological 
probing was performed with the pyrroloisoxazolidine 14, which was subsequently 
converted into the mesylate 16. Compound 16 underwent an N-O reduction with 
Zn/AcOH, which after a basic work up, spontaneously cyclized to give the pyrrolizidine 
18. Deacetylation to give 19, followed by a catalytic hydrogenolysis under acidic 
conditions afforded the final product 20. After access to the pyrrolizidine core was 
established, Tamayo and co-workers focused their attention on cycloadduct 15. More 
specifically, deacetylation of 15, followed by a TBDPS protection of the primary alcohol 
afforded 17 in near quantitative yields. Using similar methodology (mesylation, N-O 
reduction, global deprotection), the 5-epimer 24 was obtained. Although they were not 
assessed as potential glycosidase inhibitors, access to these highly oxygenated iminosugars 













Scheme 2.2: The total synthesis of unnatural hyacinthacine C2/C3 analogues 19 and 24 by 
Tamayo et al.139 
 
 
1.10.3. Tamayo et al. 2010 
 
At this stage, hyacinthacines C1, C4 and C3 proved to be insecure in their structural 
assignment. Their glycosidase inhibitory activities proved noteworthy, but difficult to 
predict, especially due to these inconsistencies. For these reasons, Tamayo and co-workers 
were compelled to investigate and report the synthesis of unnatural 7a-epi-hyacinthacine 
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C1 36 and 5,7a-di-epi-hyacinthaicne C1 37 in 2010.
140 From their previous work towards 
the synthesis of hyacinthacine A-type analogues,141 Tamayo et al. recognized that using 
the common precursor, the ,-unsaturated ketone 25, would afford access to both 
hyacinthacine C-type analogues (Scheme 1.3). More specifically, 25 was subject to a 
catalytic dihydroxylation using OsO4 and NMO to afford a single diol diastereomer 26 in 
high yield. The high diastereoselectivity achieved is a result of the steric hindrance created 
by both the Boc protecting group at the amino moiety as well as the benzyl groups at C3 
and C4. Diol 26 was then acetylated in good yield to afford the di-O-acetylated 27, which 
was subsequently reduced with NaBH4 to afford a separable mixture of alcohols 28 and 29 
in a 1:1 ratio (isolated yields of 25% and 22%, respectively). To prepare the pyrrolizidine 
core, alcohols 28 and 29 underwent separate mesylation reactions, followed by an acid-
catalysed N-Boc deprotection to give the secondary amines 32 and 33, respectively. After 
heating at reflux in THF under basic conditions, both amines cyclised to give their 
respective pyrrolidine cores. To both pyrrolizidine mixtures was then added MeONa in 
MeOH to facilitate a one-pot debenzoyl- and deacetylation to afford triols 34 and 35, 
respectively. A final O-benzyl deprotection of 34 and 35 revealed the desired 
hyacinthacine C-type analogues, 7a-epi-hyacinthacine C1 36 and 5,7a-di-epi-
hyacinthaicne C1 37, respectively. Although neither of the synthesized hyacinthacine C-
type analogues were able to resolve the structural discrepancies in the literature, access to 
stereogenic variations of the heavily hydroxylated pyrrolizidine core proves important. 
Their therapeutic potential remains unclear as these compounds were not assessed for their 










Scheme 2.3: The synthesis of unnatural hyacinthacine C1 analogues, 7a-epi-hyacinthacine 




1.10.4. Yu et al. 2011 
 
In the following year, Yu et al. published their findings regarding the synthesis of (–)-
hyacinthacine C5, 6-epi-(–)-hyacinthacine C5 and 7-epi-(–)-hyacinthacine C5 from the L-
arabinose derived cyclic nitrone 38 (Scheme 1.4).129 This not only expanded the number 
of hyacinthacine C-type analogues synthesized, but it was also the first synthesis of the 
enantiomer of natural isolate hyacinthacine C5. Their synthesis began with the addition of 
the lithiated dithiane 39 to the cyclic nitrone 38 which returned the stereoselective 
hydroxylamine intermediate 40. Compound 40 was then subject to Cope-House 
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cyclization conditions which afforded the separable pyrrolizidine N-oxides 41 and 42 in a 
1:1 ratio (55% combined yield). Pyrrolizidine N-oxides 41 and 42 were then separately 
reduced using Zn-HOAc to afford the pyrrolizidines 43 and 44, respectively. Initially 
focusing on the enantiomer of hyacinthacine C5, the dithioketal moiety of pyrrolizidine 43 
was hydrolysed to its corresponding ketone, which was then selectively reduced to the 
corresponding diol 45 in an overall 31% yield. Subsequent debenzylation revealed the final 
product as (–)-hyacinthacine C5. Turning their attention to the related epimers, Yu and 
colleagues initially protected the free hydroxy moiety in 43 using MOMCl, followed by 
hydrolysis of the dithioketal to give the corresponding ketone in 61% yield. A 
stereoselective reduction of the ketone with NaBH4 afforded two separable 
diastereoisomers favouring the desired alcohol 47 in a 5:1 ratio with an overall high yield 
(96%). Global deprotection of the MOM and the O-benzyl groups afforded (–)-7-epi-
hyacinthacine C5 49. Having established the synthetic pathway, Yu and co-workers 
successfully synthesized (–)-6-epi-hyacinthacine C5 52 by subjecting 44 to similar 
methodology. With the three products in hand, Yu et al. reported that none of the 1H and 
13C NMR spectroscopic data matched with those reported for the natural isolate labelled 
(+)-hyacinthacine C5.
117 This led to the conclusion that natural (+)-hyacinthacine C5 was 
in fact, a different isomer. Regardless, all synthetic isomers of this study were assayed as 
potential glycosidase inhibitors and found that (–)-6-epi-hyacinthacine C5 52 is a weak 
inhibitor against the α-glucosidases of rat intestinal maltase (IC50 = 58.5 µM) and rice (IC50 











Scheme 2.4: A total synthesis of the proposed structure of (–)-hyacinthacine C5, (–)-6-epi-






1.10.5. Tamayo et al. 2011 
 
At the same time as Yu et al. and for similar reasons, Tamayo and co-workers also 
published related work detailing a synthetic approach towards (+)-hyacinthacine C5 along 
with its C6, C7-diepimer.130 Their synthesis began with the N-Cbz protected pyrrolidine 
53, a 2,5-dideoxy-2,5-imino-D-mannitol (DMDP) derivative (Scheme 1.5). In this 
synthesis, the primary alcohol of 53 was initially oxidised its corresponding aldehyde 54, 
which was further treated in situ with 1-triphenylphosphoranylidene-2-propanone to afford 
the α,β-unsaturated ketone 55. A non-selective dihydroxylation of 55 with OsO4 and NMO 
returned a 1.4:1 separable mixture of diols 56 and 57, respectively. Individually, both diols 
56 and 57 were subject to reductive amination to form their respective iminium 
intermediates 58 and 59. Prolonged exposure to catalytic hydrogenation conditions over 
Pd/C resulted in a stereospecific hydrogenation occurring anti to the sterically 
encumbering CH2OTBDPS group of both pyrrolizidines. More specifically, both 
pyrrolizidines 60 and 61 were synthesized with the same C5-stereochemistry. Individual 
global deprotections of pyrrolizidines 60 and 61, which included a desilylation and 
hydrogenolysis of the benzyl protecting groups, revealed both (+)-hyacinthacine C5 and 
(+)-6,7-di-epi-hyacinthacine C5 64, respectively. Arriving to a similar conclusion made by 
Yu et al., Tamayo and colleagues also found that neither of their spectroscopic data for 
hyacinthacine C5 and its C6, C7-diepimer 64 matched that of the natural isolate
117 further 
suggesting it to be a different isomer. The final products of this study were not assessed 










Scheme 2.5: The total synthesis of the proposed structure of (+)-hyacinthacine C5 and (+)-







1.10.6. Fischer et al. 2014 
 
By 2014, synthetic work towards the hyacinthacine C-type analogues had revealed several 
structural inconsistencies among their natural isolates. For this reason, and to also expand 
the scope of information pertaining to these compounds, Fischer and co-workers 
investigated the usefulness of asymmetric 1,3-dipolar cycloadditions to prepare optically 
active nitrone templates towards making various polyhydroxylated pyrrolizidine 
analogues.142 One of the iminosugars prepared by Fisher and co-workers can be considered 
an unnatural hyacinthacine C-type alkaloid shown in Scheme 1.6. To obtain this analogue, 
Fischer et al. began their synthesis through the preparation of the mannose-derived nitrone 
65 (Scheme 1.6). The cyclic nitrone 65 underwent a 1,3-dipolar cycloaddition with vinyl 
acetate and afforded a 9:1 separable mixture of isoxazolidines, favouring the formation of 
66 for steric reasons. The acetate moiety of 66 then underwent a SN1-like reaction with 
silylketene acetal 67, which exclusively produced the 2,3a-trans-isoxazolidine 68 in a 69% 
yield. In a two-step procedure, the methyl ester of isoxazolidine 68 was initially reduced 
with LiAlH4, then subsequently protected with tert-butyl(diphenyl)silyl chloride to give 
isoxazolidine 69 in good yield (84% over two steps). The dimethyoxy ketal moiety in 
compound 69 was then hydrolysed to the ketone to give product 70, which was subject to 
N-O bond reduction and then reductive amination by hydrogenation over Pd/C to afford 
the pyrrolizidine 71 as a single isomer. A global deprotection including the removal of the 
silyl and the isopropylidene moieties returned the hexahydroxylated pyrroizidine 73 in 















1.10.7. Vankar et al. 2014 
 
In the same year, Vankar and co-workers reported their synthetic work towards the 
synthesis of homoanolouges of hyacinthacine C5.
143 Their 2014 report details starting from 
the arabinose-based cyclic nitrone 74 which underwent a 1,3-dipolar cycloaddition 
reaction with the D-mannitol-aldehyde derived dipolarphile 75 (Scheme 1.7). The desired 
cycloadduct 76 was obtained in a 9:1 ratio in a combined yield of 88%. Compound 76 was 
then subject to a Zn/HOAc mediated N-O cleavage which produced the cyclic amine 77 
which then underwent selective benzylation at the secondary amine to give 78 in 85% over 
two steps. The ester moiety of 78 was then reduced to its corresponding alcohol to afford 
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diol 79. A non-selective O-benzylation of both hydroxy groups afforded 80, which upon 
removal of the cyclohexylidene acetal, resulted in the formation of the diol 81. The diol 
moiety of compound 81 was then oxidatively cleaved with sodium periodate to give 
aldehyde 82 which was then treated with MeMgI, returning a selective 10:1.2 mixture of 
diastereomers 83a and 83b. The diastereomeric mixture was then oxidised to the respective 
ketone product 84, which after a reductive amination followed by a benzyl ether 
deprotection, afforded the crude hyacinthacine C-type analogue 86. To purify 86, Vankar 
et al. peracetylated the crude mixture, followed by its deprotection. After washing the 























1.10.8. Vankar et al. 2016 
 
In continuation with synthetic efforts towards synthesizing different unnatural analogues 
of bicyclic iminosugars, Vankar et al. reported in 2016, a new strategy for accessing a large 
number of complex hyacinthacine C2/C3 related products.
144 Vankar and co-workers’ 
synthesis of the unnatural hyacinthacine C-type analogues can be summarised in Scheme 
1.8. Their synthetic work began with the oxidation of pyrrolidine 87 to its corresponding 
aldehyde using a CrO3-pyrridine-Ac2O reagent system. The aldehyde formed was then 
45 
 
treated with allylzinc bromide to afford compound 88 which underwent O-benzylation to 
the product 89. The olefin moiety of compound 89 was then subject to a nonselective 
dihydroxylation with OsO4 and NMO which returned an inseparable mixture of diols. A 
selective protection of the primary alcohol in each diol resulted in the corresponding silyl 
ethers 90 and 91, which were readily separable. To establish the methodology, Vankar and 
co-workers quantitatively mesylated the free hydroxy group in compound 90. Without 
purification, the mesylated 90 then underwent a N-Boc deprotection which under basic 
conditions furnished pyrrolizidine 92. A global deprotection, followed by peracetylation 
as a means of purification afforded the pentaacetylate 94. After a comprehensive structural 
analysis, the pentaacetylate 94 was deprotected using aqueous ammonia in methanol which 
gave the final pentahydroxlyated hyacinthacine C2/C3-type analogue 96. Having 
established this synthetic route, Vankar and co-workers then employed a similar reaction 
pathway to diastereomer 91 which successfully converted into compound 97. Vankar et al. 
also readily obtained two more epimers, 107 and 108, from subjecting pyrrolidine 98 to 
the same sequence of reactions. The only notable difference is that the hydroxy group of 
olefin 99 was protected as the acetate 100 instead of the benzyl ether. Of the four 
hyacinthacine C2/3 products synthesized, none matched the putative structure for 
hyacinthacine C3, but they certainly provided a better understanding towards the access to 
these complex iminosugars. Additionally, the biological activities the final products were 
evaluated as potential glycosidase inhibitors against a panel of eight commercially 
available enzymes. The hyacinthacine analogues 96 and 107 displayed selective activity 
against jack bean α-mannosidae (IC50 = 81.2 µM and IC50 = 95 µM, respectively) with 
analogue 107 also displaying moderate activity against coffee bean α-galactosidase (IC50 
= 120 µM). Final remarks from the authors suggested that given these activities, 








Scheme 2.8: A stereodivergent synthesis of hyacinthacine C2/C3 related analogues 96, 107, 





1.10.9. Goti et al. 2017 
 
A recent addition towards the synthesis of the hyacinthacine C-type analogues was 
reported in 2017 by Goti and co-workers through their synthesis of the proposed structure 
of (+)-hyacinthacine C5 and its C5 epimer 120.
131 Their goal was to implement a 
straightforward and convenient synthesis towards these complex iminosugar motifs. To 
access both these structures, their convergent synthesis began with the preparation of both 
the arabinose-derived cyclic nitrone 109 and the racemic 3-methyl-substituted 
benzyloxyallene 110 (Scheme 1.9). The lithiated benzyloxyallene 110 was then added to 
nitrone 109 to form intermediate 111, which upon standing at room temperature for 24 h, 
cyclized to afford a 1:1 separable mixture of 1,2-oxazines 112 and 113. Both oxazines 
were then individually subjected to hydroboration which delivered respective alcohols 114 
and 115. Goti and co-workers were initially focused on establishing the synthetic pathway 
towards the proposed structure of (+)-hyacinthacine C5 and so their attention turned to 
alcohol 114 which was protected to give the penta-benzylated product 116. Next, a 
reductive amination of 116 with samarium diiodide in THF cleaved the N-O bond to give 
the amino-alcohol, which was subsequently converted to pyrrolizidine 118 via mesylation 
of the primary hydroxy group, then spontaneous cyclization. Finally, all benzyl ether 
groups were removed via hydrogenolysis to afford the purported (+)-hyacinthacine C5. 
Using a similar method, 5-epi-hyacinthacine C5 120 was synthesized after alcohol 115 
underwent a reductive amination followed by bis-mesylation of the hydroxy groups which 
concurrently cyclized to give pyrrolizidine 119. After a LiAlH4 reduction of the sulfonyl 
group on 119, the corresponding alcohol was subject to hydrogenolysis to give the globally 









Scheme 2.9: The total synthesis of the proposed structure of (+)-hyacinthacine C5 and 5-







As per the previous reports by Yu et al.129 and Tamayo et al.,130 Goti and co-workers also 
found that the configuration of the putative structure of hyacinthacine C5 was incorrect. 
Neither structure synthesized in this report matched the spectroscopic data of the natural 
isolate. Despite being unable to resolve the true structure of hyacinthacine C5, Goti et al. 
revised the originally reported NOE enhancements for the natural isolate and after finding 
similar NOE correlations in their synthetic products, were able to suggest an alternative 
configuration which could be appropriately labelled as 1-epi-hyacinthacine C4 (Figure 
1.20).  
 
Figure 2.20: The NOE signals reported for the putative hyacinthacine C5 (left) along with 
the revised NOE signals proposed by Goti et al.117, 131  
 
1.11. Project aims:  
 
The history and synthetic development towards the hyacinthacine alkaloids is certainly 
rich and exciting. They have been isolated from the under-explored aqueous fractions of 
various plants and contain an inherent glycosidase activity, making this class of compound 
a suitable lead for the treatment of diabetes, cancer and bacterial infection. Additionally, 
these novel compound motifs are highly complex and in this present day would not be 
conceivably produced by technologies such as combinatorial chemistry. Their 
configurational differences prove vital for their selectivity and potency against inhibiting 
various glycosidases, and so has led to many synthetic approaches towards accessing this 
class of natural product. Structurally, the hyacinthacine C-type analogues can be 
considered the most diverse group of hyacinthacine, as they contain at least six possible 
stereogenic centres and are analogous to glucose. Owing to their complexity, mistakes 
50 
 
have been made when assigning their structures as proved in some cases by total synthesis. 
More recently, this class of compound has been the focus of an increasing number of 
synthetic attempts in hope to elucidate the mistakes and correct the structures currently 
labelled as hyacinthacine C1, C3, C4 and C5. In addition to this, synthetic access to this 
class of compound allows researchers to probe the structure activity relationship for 
glycosidase inhibition, and design related analogues that can be marketed as treatment for 
the illnesses previously mentioned. 
After reviewing the entirety of the synthetic approaches towards the hyacinthacine C-type 
analogues several observations can be made.   
1. All pathways begin with a cyclic pyrrolidine derivative. Of these, just over half 
favour the use of a sugar derived cyclic nitrone. 
2. Although some syntheses are divergent the pathways discussed generally allow no 
more than four hyacinthacine C-type analogues to be synthesized.  
3. All nine publications raise awareness of the hyacinthacine C-type analogues and 
their inherent glycosidase inhibitory activity but only two have been able to assess 
the final products as glycosidase inhibitors.  
4. Natural hyacinthacines C1, C3, C4 and C5 have insecure structures and the true 
structures have not yet been revealed. 
Starting this Ph.D. work in 2015, the aims of this project were to:  
1. Develop a novel synthetic strategy to prepare hyacinthacine C-type analogues in 
an efficient and flexible manner 
2. Elucidate and correct the structure for either hyacinthacine C1, C4 or C5 
3. Generate a moderate number of hyacinthacine C-type configurational analogues 
and use the data generated from glycosidase inhibition studies to determine a 
general structure-activity relationship.  
Overall, these goals were achieved and although they will be discussed in greater detail in 
the remaining Chapters, this work can be briefly summarised in the following paragraph. 
Eleven configurationally different hyacinthacine C-type analogues were successfully 
synthesized using a common but unique pathway. All final products were individually 
assessed as potential glycosidase inhibitors, providing an interesting structure-activity 
relationship. The highlight of this body of work was the elucidation of the correct structure 
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for both natural hyacinthacine C1 and C5, which had been effectively a mystery for the past 
20 and 10 years, respectively. In light of this, all final hyacinthacine C-type analogues 
synthesized in this work are named in accordance to the newly corrected structures for 
hyacinthacine C1 and C5.  
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Chapter 2 : Synthesis of unnatural (+)-7-epi-
hyacinthacine C5 and (‒)-6-epi-hyacinthacine C5. 
 
The crux of this Ph.D. study is the successful synthesis and correction of the structures for 
the natural isolates labelled as hyacinthacine C1
105 and C5
117 and will be discussed later. 
This Chapter describes the strategy employed towards the synthesis of unnatural (+)-7-epi-
hyacinthacine C5 155 and (‒)-6-epi-hyacinthacine C5 156. Accessing both these structures 
proved integral towards establishing the synthetic methodology and foundations that 
would later result in the correction of the aforementioned natural products. Herein, both 
successful and unsuccessful synthetic attempts towards the hyacinthacine C-type 
analogues are presented and will allow the reader to understand the logic that governed the 
methodology which resulted in accessing the remaining nine hyacinthacine C-type 
analogues.  
 
2.1. The Petasis borono-Mannich reaction 
 
The chiral anti-1,2-amino alcohol moiety is a common structural feature of many bioactive 
azasugars including the hyacinthacine alkaloids A2, A3, A5, B3, B4, C3 and C5, as 
highlighted in Figure 2.1.  
 
 




In recent years, the Pyne research group has demonstrated synthetic methods to prepare 
chiral anti-1,2-amino alcohols include: aminolysis of chiral vinyl epoxides, the borono-
Mannich reaction (Petasis reaction) and the borono-Mannich reaction via cyclic N-
acyliminium ions (Figure 2.2 adapted from Pyne et al. review145).  
 
 
Figure 2.2: An adapted figure from the review of Pyne et al. displaying the three reaction 
types studied often used to prepare the 1,2 anti-amino alcohols.145 
 
Of these three synthetic routes, the Pyne research group has explored the efficiency of 
synthesizing bicyclic polyhydroxylated iminosugars containing this motif from a suitably 
prepared borono-Mannich (Petasis) product (Scheme 2.1).89, 92, 126-127, 145-146 The successful 
application of the Petasis borono-Mannich acid reaction in natural product synthesis is 
largely because the resultant anti-1,2-amino alcohol is often obtained in high yields and 
almost exclusively as a single diastereomer and enantiomer.147 Another desirable facet of 
this reaction is the simple experimental procedure that generally involves mixing an aryl 
or vinyl boronic acid, a primary or secondary amine and a chiral α-hydroxy-aldehyde under 
relatively mild conditions.147 Previous Pyne group members, Davis, Machan and 
Ritthiwigrom, demonstrated that the anti-1,2-amino alcohol 121 was the product of the 
multi-component Petasis borono-Mannich acid reaction between (E)-β-styrenylboronic 
acid, allylamine and L-xylose. More importantly, this Petasis product was a viable 
precursor for the synthesis of natural products: (‒)-uniflorine A, (+)-castanospermine, (+)-
casuarine and (+)-australine (Scheme 2.1A).89, 146, 148 Of particular interest to this body of 
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work, both Au126 and Savaspun127 have shown that hyacinthacine B3 and B7 could be 
synthesized from the appropriate anti-1,2-amino alcohol 124; also a product of a Petasis 
borono-Mannich acid reaction between 122, 123 and (E)-β-styrenylboronic acid (Scheme 
2.1B). From these examples, particularly the latter, it was therefore reasonable to propose 
that the hyacinthacine alkaloids shown in Figure 2.1, could be synthesized in a similar 
manner.  
 
Scheme 2.1: Natural products resulting from the Petasis reaction in the Pyne research 
group.89, 92, 126-127, 145-146 
 
 
2.2. Rationale for synthesizing hyacinthacine C5-type analogues 
 
Discussed earlier in Chapter 1, there is a correlation between the degree of oxidation in the 
hyacinthacine alkaloids and the prevalence for misassigned structures. For example, all the 
synthetic attempts towards the A-type hyacinthacine alkaloids have confirmed so far that 
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the natural isolates are correct in their stereoconfigurational assignment.119-123 Synthetic 
attempts towards the hyacinthacine B-type suggest that only one is incorrect: 
hyacinthacine B7.
126 The hyacinthacine C-type (containing the highest relative degree of 
oxidation) have four insecure structures, where only hyacinthacine C2 has been confirmed 
to be the correct stereoconfiguration.105, 117, 128-131 We felt particularly drawn to 
synthesizing the hyacinthacine C-type analogues due to the higher number of relative 
mistakes associated with their structures. Additionally, synthesizing analogues would help 
increase our understanding of the SARs and inherent glycosidase inhibition that these 
iminosugars possess.   
For each of the naturally occurring hyacinthacine C-type alkaloids, it becomes apparent 
that each isolate contains the same absolute configuration at stereocentres C2, C3 and C7a 
(Figure 2.3). The logical outcome of this would be that these stereocentres are the result of 
a similar biosynthetic pathway. If these stereocentres are the correct absolute 
configuration, then the stereoconfiguration of C1 is less ambiguous since the orientation 
can be spectroscopically cross-examined against both C7a and C2. At this point, it seemed 
reasonable that the most likely mistake would occur at the assignment of stereocentres C5, 
C6 or C7 (Figure 2.3). Concurrent to our investigation, synthetic work towards 
hyacinthacine C5 and various analogues was gaining considerable attention. Since their 
first synthetic attempt in 2009,128 there has been an additional eight total syntheses 
detailing access to related pyrrolizidine structures.129-131, 139-140, 142-144 Of these, the putative 
structure for hyacinthacine C5, along with various diastereomers were synthesized in 
2011129-130 and were sought after due to their inherent biological activities against various 
glycosidases. The syntheses of hyacinthacine C5 have shown that the initially proposed 
structure was incorrect since the 1H and 13C NMR spectroscopic data of the synthetic 
structures did not match the natural isolate.117 Until recently, Goti and co-workers re-
interpreted the originally reported NOE enhancements for the natural isolate and proposed 
an alternative configuration based on this interpretation.131 More specifically, their 
interpretations suggested that the true structure for hyacinthacine C5 is actually the 
configuration for 1-epi-hyacinthacine C4 (Chapter 1, Figure 1.20).
131 However, before this 
revision, the only other measure for determining the correct configuration of hyacinthacine 
C5 was to compare the 
1H and 13C NMR spectroscopic data of previously synthesized 
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hyacinthacine C5 analogues with that of the natural isolates. After searching the literature, 
it was evident that no one had yet synthesized the true structure for hyacinthacine C5. 
 
Figure 2.3: General structure for hyacinthacine C-type analogues. 
 
Prior to Goti et al.,131 there were no reported attempts to synthesize hyacinthacine C5 
alkaloids containing both an (R)-C7a nitrogen bridgehead proton and a (R)-C5 methyl. For 
this reason, we initially focused on installing this stereochemical relationship in our final 
hyacinthacine C5 related products. In addition to this, we were particularly interested in 
manipulating the stereocentres at the C6 and C7 whilst simultaneously retaining the 
original stereochemistry proposed in hyacinthacine C5 for stereocentres C7a, C1, C2 and 
C3. As discussed earlier, a close inspection of the putative structure for hyacinthacine C5 
reveals an anti-configuration between the C7a-N and the C1 carbinol and so our synthetic 
strategy was designed around the Petasis borono-Mannich acid reaction to implement this 
key motif.  
Shown in Scheme 2.2, our initial retrosynthetic analysis suggested manipulating the C6 
and C7 hydroxy group stereochemistry at later stages in the synthesis. The final 
hyacinthacine C5-type analogues would be the result obtained from syn-dihydroxylation 
across the alkene in pyrrolizidine 125. The diastereofacial selectivity would be influenced 
by the concave nature of the pyrrolizidine core, as well as possible steric hindrance by the 
(R)-C5 methyl. However, a non-selective dihydroxylation might still afford two syn-diol 
diastereomers which would lead to two possible hyacinthacine C5-type analogues. 
Pyrrolizidine 125, would be obtained by subjecting pyrrolidine 126 to ring closing 
metathesis (RCM) conditions using either Grubbs’ I- or II-generation catalysts. Pyrrolidine 
126 would be synthesised by N-alkylation of the amino-diol 127 using a steric-directed, 
regioselective O-mesylation, then spontaneous cyclisation through the nitrogen. These 
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reactions ultimately rely on synthesizing the stereochemically pure anti-amino-diol 127; 
this is a product derived from the Petasis borono-Mannich acid reaction between 3,5-di-
O-benzyl-α,β-L-xylofuranose, 3-(R)-amino-1-butene·hydrochloride and (E)-β-
styrenylboronic acid. 
 
Scheme 2.2: Retrosynthetic analysis for the synthesis of hyacinthacine C5-type analogues. 
 
 
2.3. Synthesis of 3,5-di-O-benzyl-α,β-L-xylofuranose 
 
Within the Pyne research group, the anti-amino-diol 127 had been previously synthesized 
but not reported in the literature.149 To synthesize this product, 3,5-di-O-benzyl-α,β-L-
xylofuranose was required. This protected sugar can be readily obtained from the 
commercially available L-(‒)-xylose by using a modified three-step procedure employed 
by Terashima and Matsuda150 as well as Baker and Schaue.151 The inherent stereochemistry 
of L-(‒)-xylose was envisioned to produce the stereochemical configuration on the A-ring 
of the final hyacinthacine C-type products. More specifically the hydroxy groups at C3, 
C4 and C6 (Scheme 2.3) should account for the stereochemistry at C1, C2 and C3 in the 
final product, respectively. To prepare this sugar, step one of the synthesis involved 
dissolving L-(‒)-xylose in acetone followed by the addition of two equivalents of 
copper(II) sulphate and a catalytic amount of sulfuric acid. After stirring the reaction for 
24 h, a TLC analysis showed a near quantitative conversion to the corresponding bis-
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acetonide 128. Stirring a solution of 128 in 0.25 M solution of hydrochloric acid for 45 
min returned the mono-acetonide 129 in quantitative yield.  
The second step involved the conversion of acetonide 129 to its respective bis-benzyl ether 
130. This reaction involved dissolving compound 129 in THF, followed by heating at 
reflux for 30 min after the addition NaH, BnBr and a catalytic amount of the transfer 
catalyst, tetrabutylammonium iodide (TBAI). After working up the reaction, the crude 
mixture was purified by column chromatography and product 130 was obtained in overall 
good yield (88%).   
The last step towards the preparation of 3,5-di-O-benzyl-α,β-L-xylofuranose involved an 
acid hydrolysis of the isopropylidene ketal from bis-benzylether 130. This involved stirring 
130 in a solution of acetic acid (30% v/v) followed by the addition of a few drops of 5 M 
HCl. The reaction was heated at 45 oC for 3 h or until the TLC confirmed the full 
consumption of the starting material. After work up, the crude mixture was purified by 
column chromatography to return a waxy solid which by 1H NMR analysis was determined 
to be a 3:1 mixture of anomers of 3,5-di-O-benzyl-α,β-L-xylofuranose.  
Although the products at each step had been well documented, 1H and 13C NMR 
spectroscopic data was still obtained for each product which were consistent with those 
reported in the literature.150  
 




2.4. The synthesis of anti-amino-diol 127 
 
During the final stages of his Ph.D. candidature, Kongdech Savaspun attempted to develop 
a facile route towards the synthesis of hyacinthacine B4 from the anti-amino-diol 127. 
Although unsuccessful, we hypothesized this intermediate to be more suited in our total 
synthesis for accessing hyacinthacine C5-type analogues. The anti-amino-diol 127 proves 
integral to our synthetic plan as it accounts for five of the seven stereocentres required for 
the final hyacinthacine C5-type analogues. Moreover, it incorporates the nitrogen such that 
it adopts the anti-configuration between the C7a-N and the C1 carbinol. Finally, this 
product delivers two suitably placed alkenes for the desired RCM reaction highlighted in 
our retrosynthetic analysis (Scheme 2.2). Fortunately, optimised Petasis reaction 
conditions had been explored.149 Following the procedure described by Savaspun, the 
multicomponent reaction between 3,5-di-O-benzyl-α,β-L-xylofuranose, 3-(R)-amino-1-
butene·hydrochloride and (E)-β-styrenylboronic acid in a solution of ethanol under basic 
conditions, took place over 3 d. Scheme 2.4 shows the proposed mechanism for this 
reaction where the resultant product is dependent on the equilibrium interconversion 
between 3,5-di-O-benzyl-α,β-L-xylofuranose (preferred form) and the respective ring-
opened aldehyde. When the aldehyde is formed, the base (Et3N)-activated 3-(R)-amino-1-
butene can react with the aldehyde to form the iminium ion intermediate A. A key 
component of this intermediate is the availability of an α-hydroxy group.147, 152-153 Provided 
this is available, it is believed that the boron reagent can coordinate to this hydroxy group, 
and subsequently deliver the desired reagent.147, 152-153 In this example, prior to delivery of 
the (E)-β-styrenyl unit, the iminium ion boron-complex B adopts a conformation that 
minimizes the 1,3-allylic strain between the substituents at the α-position and on the N 
atom of the iminium ion. This involves the smallest α-substituent (proton) on the 
stereogenic carbon being eclipsed with the NH of the iminium moiety. As drawn here, the 
(E)-β-styrenyl group is then transferred to the bottom face of the iminium ion to give the 
desired product 127. After 3 d and in comparable yield to Savaspun (~65%), the purified 
product was subject to 1H and 13C NMR spectroscopic studies and was concluded to be the 
anti-amino-diol 127 previously characterised by Savaspun.149 Although extensively 
characterised, key 1H NMR resonances of 127 appeared at δH 6.48 (1H, d, J = 16.0 Hz) 
6.10 (1H, dd, J = 16.0, 8.7 Hz), 5.72 (1H, ddd, J = 17.3, 10.2, 7.2 Hz) and 5.09 (1H, d, J = 
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10.2 Hz) to 4.98 (1H, d, J = 16.8 Hz), and are representative of the olefinic moieties at H7, 
H6, H2′ and H3′cis/trans, respectively (Figure 2.4A).  
 




It was also serendipitously found that the crystalline anti-amino-diol 127 HCl salt could 
form after dissolving 127 in EtOAc and washing the organic layer with 1N HCl. An X-ray 
crystallographic analysis returned the ORTEP plot displayed in Figure 2.4B, and 
unambiguously confirmed the spectroscopically determined absolute configuration of the 














Figure 2.4: A) 1H NMR spectrum (500 MHz, CDCl3) of 127 and B) The ORTEP plot of 
the crystal structure of the C31H38NO4
+ cation of 127 with labelling of selected atoms. 
Anisotropic displacement ellipsoids display 30% probability levels. Hydrogen atoms are 
drawn as circles with small radii, the chloride counter ion is not shown. 
 
2.5. The synthesis of RCM product 132 
 
Following similar methodology to Savaspun, the anti-amino-diol 127 was converted to the 
pyrrolidine 131 using well established mesylation-cyclisation conditions.149 Details of this 
synthesis involved treating the anti-amino-diol 127 with 1.05 equivalents of 
methanesulfonyl chloride in CH2Cl2 at 0 
oC for 1.5 h. A regioselective mesylation was 
anticipated to occur at the C2 hydroxy group since this is less sterically hindered than the 
alternative C4 hydroxy group (Scheme 2.5). Once mesylated, a base-induced cyclisation 
occurred and presumably furnished the pyrrolidine 131 (and consequently formed the A-
ring of the desired product). The 1H and 13C NMR spectroscopic data of 131 were 
consistent with the same product made by Savaspun.149 Unfortunately, due to the overlap 









confidently assigned for this compound. Regardless, Savaspun attempted to synthesize the 
pyrrolizidine core 132 by employing RCM conditions.149 Savaspun’s approach involved 
deactivating the tertiary amine of pyrrolidine 131 with titanium isopropoxide to form a Ti-
N complex.154 This complex was then subject to several different RCM conditions 
involving either Grubbs’ II or Hoveyda Grubbs’ II catalyst (Table 2.1, entries 1-3).149 
Unfortunately, Savaspun abandoned this pathway after each attempt resulted in formation 
of the undesired pyrrole 133. It was concluded that the RCM product 132 was initially 
formed but was prone to aromatization resulting from elimination of H7a from the titanium 
complex. To avoid this problem, we employed an unexplored set of reaction conditions 
which instead of making the Lewis acid complex at N, involved generating the relatively 
mild p-toluene sulfonic acid salt of the tertiary amine 131 (Table 2.1, entry 4).155-156 With 
our weakly deactivated tertiary amine 131 in hand, the compound was heated at reflux in 
CH2Cl2 under an argon atmosphere in the presence of a catalytic amount of Hoveyda 
Grubbs’ II generation ruthenium catalyst over the course of 3 d. To avoid formation of the 
pyrrole 133, careful preparation was required to ensure no water or oxygen entered the 
reaction environment during this time. This stringent set of conditions afforded the desired 
RCM product 132 in 65% yield (Scheme 2.5).  
 







Table 2.1: Results of Savaspuns trialled conditions for RCM of 131 (entries 1-3) and the 
successful conditions (entry 4) employed to generate RCM 132 from this Ph.D. work.  












10 mol% Grubbs’ II 
cat., 0.2 eq. Ti(OiPr)4, 
under N2 
CH2Cl2 45 24 0% 43% 
2 
10 mol% Hoveyda 
Grubbs’ II cat., 1.0 eq. 
Ti(OiPr)4, under Ar 
CH2Cl2 40 20 0% 10% 
3 
10 mol% Grubbs’ II 
cat., 0.3 eq. Ti(OiPr)4, 
under Ar 




20 mol% Hoveyda 
Grubbs’ II cat., 1.0 eq. 
pTsOH, under Ar 




In addition to the mass spectrometric data (a LRESIMS [M+Na]+ ion peak at m/z 388 
[M+Na]+ for 132 and a LRESIMS [M+Na]+ ion peak at m/z 386 for 133), the RCM product 
132 can be largely differentiated from the corresponding pyrrole 133 based on appearance 
of the H1′′ resonance in the 1H NMR spectrum (Figure 2.5). When compared, the 1H NMR 
resonance of the methyl protons, H1′′ in alkene 132, should appear as a doublet and would 
be expected to resonate below δH 2.0. After analysing the spectra from the RCM product 
132 generated by our conditions, the resonance labelled H1′′ appeared as a doublet (J = 5.3 
Hz) at δH 1.26 (Figure 2.5A). In contrast, the 
1H NMR resonance for H1′′ in the pyrrole 
133 appeared as a singlet and resonated at δH 2.11 (Figure 2.5B). This implied the loss of 
a proton H5 and consequently the destruction of this stereocentre. Although we 
successfully obtained the desired RCM product 132, we were unable to obtain reliable 
NOESY data that would confirm the relative stereochemistry of the A-ring of the final 
product. The 1H NMR spectrum displayed in Figure 2.5A shows that the key proton 
resonance peaks for H7a and H3 were overlapping with those of H5 and H1′, respectively, 
and so would have proved redundant for a clear NOESY extrapolation. More importantly, 
we also noted the products tendency to degrade to the previously reported pyrrole 133. 
Upon standing at room temperature for 1 h (in an NMR tube) degradation was noted. 
Figure 2.5A shows a zoomed in region of the 1H NMR spectrum between δH 6.50 – 5.50 
and displays characteristic aromatic peaks of pyrrole 133. Due to the limited amount of 
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product 132, in conjunction with its instability, the purified product was taken through to 
the next step in our planned pathway.   
  
 
Figure 2.5: A) 1H NMR spectrum (500 MHz, CDCl3) of 132 and B) 
1H NMR spectrum 
(500 MHz, CDCl3) of 133.
149 
 
2.6. Attempted cis-dihydroxylation of 132  
 
At this stage, the degradation of alkene 132 to the corresponding pyrrole 133 suggested 
the product to be air sensitive and was suspected to have a low tolerance towards oxidative 
reaction conditions. Since our aim was to install hydroxy groups at C6 and C7 using 
Upjohn cis-dihydroxylation conditions,157 we anticipated difficulty in obtaining the desired 
product. This dichotomy influenced the decision to try only pilot reactions with little 
exploration into optimising reaction conditions. More specifically, alkene 132 was 
dissolved in a 3:1 solution of acetone/water followed by the addition of 2 eq. of N-
A) 














methylmorpholine-N-oxide along with a catalytic amount of potassium osmate dihydrate 
(Scheme 2.6). Unsurprisingly, these conditions only encouraged faster degradation of 132 
to the corresponding pyrrole 133. This was determined by the substantial increase in Rf of 
the new product spot after analysing the reaction mixture by TLC. This Rf was 
characteristic of the pyrrole 133, and not evident of the diol, as this would be considerably 
more polar than the starting alkene 132. Regardless, purification of the reaction was 
achieved and resulted in obtaining the pyrrole 133 which matched the spectroscopic data 
of the pyrrole reported by Savaspun (Figure 2.5B).149   
 
Scheme 2.6: Attempted cis-dihydroxylation of 132. 
 
 
Although two steps (dihydroxylation, then global deprotection) remained towards the final 
product, it was evident that the spontaneous degradation of the RCM product 132 to the 
pyrrole 133 would be difficult and inefficient to work with (even under inert conditions). 
Although compound 132 was successfully synthesized, the strict reaction conditions were 
not easily reproduced and often required lengthy preparation periods. Not many conditions 
were trialled since initial evidence suggested that formation of pyrrole 133 would most 
likely accelerate under oxidative conditions. For this reason, our retrosynthetic pathway 
was revised and focused on forming the B-ring of the hyacinthacine C5-type analogues 
first. 
 
2.7. Revised retrosynthetic strategy towards hyacinthacine C5-type 
analogues 
 
The original retrosynthetic path was reviewed to consider implementing the syn-C6, C7-
diol on the B-ring of the pyrrolizidine before establishing the A-ring. This new 
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retrosynthetic pathway can be summarised in Scheme 2.7. The furnished pyrrolizidine that 
would lead to the hyacinthacine C5-type analogues would be synthesised by N-alkylation 
of the amino-diol 134 implementing a similar procedure used to obtain pyrrolidine 131 
(Scheme 2.5). Prior to this, the hydroxy groups at both C6 and C7 would be installed using 
UpJohn cis-dihydroxylation conditions, and then suitably protected to give 134.157 
Although unsuccessful in our earlier attempt, this was hypothesized to work on the basis 
of similar substrates and reaction conditions employed within the Pyne group.89 The alkene 
in compound 135 would be obtained using Grubbs’ I- or II-generation catalyst and RCM 
conditions. For the RCM reaction to efficiently synthesize, the anti-amino-diol 127 would 
require protection at the secondary amine to give substrate 136. To ensure selectivity and 
efficiency in the proposed reaction scheme, suitable hydroxy or amine protecting groups 
at various stages would also be considered.  
 




2.8. N-Protection of anti-amino-diol 127 
 
It has been well established that unprotected primary and secondary amines interfere with 
Ru-catalysed olefin-metathesis reactions.158 More specifically, their catalyst deactivating 
affect and thus induced impairment of the RCM reaction is caused by coordination and 
thus stabilization of the Ru-catalyst. Towards the end of his Ph.D. candidature, Savaspun 
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briefly explored conditions to convert the anti-amino-diol 127 to its corresponding 
oxazolidinone 137 (Scheme 2.8).149 We envisioned the usefulness of this derivative since 
it simultaneously protected the nitrogen as well as the hydroxy group at C4 of 127. 
Interestingly, the conditions he employed resulted in the formation two products, namely 
the oxazolidine-2-one 137 and the oxazepin-2-one 138 (Scheme 2.8, Table 2.2). This result 
was not necessarily detrimental to the overall synthetic plan since this protecting group 
would be removed at a later stage in the synthesis. However, the main concern with this 
outcome was the number of isomeric products that would result at each stage until 
deprotection. Even if the isomers would separate effectively, characterising both 
compounds at each stage seemed inefficient. Fortunately, a literature search found a report 
by Yahara and colleagues which detailed a one-step conversion between a related 7-
membered oxazepinone to its 5-membered oxazolidinone analogue after simply stirring a 
solution of the oxazepinone in MeOH for 24 h.159 In light of Savaspuns result, we 
considered this might overcome selectivity issues if the procedure established by Yahara 
and co-workers was applied to the mixture of the oxazolidinone and oxazepinone. The 
anti-amino-diol 127 was therefore subject to standard oxazolidinone conditions (CH2Cl2, 
triphosgene, Et3N, 1 h) which returned a mixture of the oxazolidin-2-one 137 and the 
oxazepin-2-one 138 (37% yield, 1:2, respectively, Scheme 2.8, Table 2.2). The mixture of 
was left in HPLC grade MeOH for 20 h, but no conversion of the oxazepin-2-one 138 to 
its 5-membered counterpart 137 was observed. This was confirmed by 1H NMR and TLC 
analysis. However, after piloting the catalytic (0.1 eq.) addition of the non-nucleophilic 
base DBU, followed by 24 h stirring under N2 conditions, 
1H NMR and TLC analysis 
confirmed the complete conversion of 138 to 137 (Scheme 2.9).  
 
 





Table 2.2: Savaspun’s reaction conditions (entry 1-3) and our reaction attempt (entry 4) 
towards synthesizing oxazolidione 137.   
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Further investigations found a strong correlation between increasing the relative molar 
amount of DBU to compound 138, and a faster facile migration of the carbonyl and 
conversion to the desired product 137. Therefore, future attempts to synthesise the 
oxazolidinone involved treatment of a mixture of 137 and 138 with 1.5 eq. DBU in MeOH 
for 4 h so to afforded clean conversion to the desired 5-membered product 137 in an overall 
yield of 37%. In addition to the identical match of the 1H NMR spectrum with Savaspuns 
product, the observed 7.1 Hz vicinal coupling constant J4,5, in the 
1H NMR spectrum of 
137 was consistent with the 4,5-cis relative configuration.160-162   
Despite the clean conversion of oxazepinone 138 to oxazolidinone 137, a collective yield 
similar to Savaspun’s finding was unable to be replicated. After a number of attempts, only 
a maximum yield of 37% could be achieved for the synthesis of oxazolidinone 137 (Table 
2.2, entry 4). In a bid to improve the yield, different nitrogen protecting groups were 
considered. Initial trials explored synthesising the N-Fmoc derivative. To obtain this, the 
anti-amino-diol 127 was dissolved in MeCN, followed by the addition of 2 eq. of Et3N and 
2 eq. of Fmoc chloride and sonicated at 35 oC over 24 h.163 However, as confirmed by TLC 
and 1H NMR analysis, only starting material was recovered. The Boc protecting group was 
then next considered. N-Boc protection of the anti-amino-diol 127 was trialled by 
dissolving 127, Boc anhydride and Et3N in MeCN.
163 The mixture was stirred at room 
temperature for 24 h but only the starting anti-amino-diol 127 was recovered. These results 
suggested the secondary amine 127 to be a poor nucleophile, most likely due to the 
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sterically hindered nature of the N atom. To overcome this issue, increasing the 
susceptibility of the Boc anhydride carbonyl group was considered. A literature search 
identified that using iron chloride as a Lewis acid could promote activation of the carbonyl 
group of Boc anhydride. Shown in Figure 2.6, the oxygen of either carbonyl would 
coordinate to the FeCl3 which would increase the susceptibility towards mild nucleophiles 
such as the secondary amine in the anti-amino-diol 127.164  
 
 
Figure 2.6: Lewis acid promoted Boc protection for mild nucleophiles.164 
 
Therefore, after dissolving both Boc anhydride and FeCl3 in 1:1 MeCN/H2O, the anti-
amino-diol 127 was added to the reaction mixture and stirred at room temperature for 24 
h.164 Unfortunately, these conditions did not work and only returned starting material 127. 
To overcome the steric hinderance of the amino diol, increasing the temperature of the 
reaction was explored. This involved dissolving the anti-amino-diol 127 in 1,2-
dichloroethane, along with the addition of 2 eq. of N,N-diisopropylethyl amine and 2 eq. 
of di-tert-butyl-dicarbonate and the solution was heated at reflux for 2 d. Fortunately, the 
N-Boc diol 139 was obtained in 62% yield with 23% recovered starting material 127 







Scheme 2.9: Synthesis of compound 139. 
 
 
With successful protection of the anti-amino-diol 127 as both the oxazolidine-2-one 137 
and the N-Boc diol 139, both were considered for ring closing metathesis in the next step 
of the synthesis.  
 
2.9. The synthesis of RCM products 140 and 141 
 
Choosing either Grubbs’ I or II catalyst is generally decided based on sensitivity of the 
substrate and the catalyst.165 Both catalysts have been thoroughly documented and so 
understanding their different kinetics can also influence which is used.166-171 Shown in 
Figure 2.7, Grubbs’ I catalyst has been found to readily dissociate from its phosphine 
ligand, PCy3.
168 Upon dissociation, the Ru-species can interact with a number of dienes 
before it is quenched again with the free PCy3 ligand. To stop intermolecular reactions and 
ensure an efficient turnover, RCM reactions involving Grubbs’ I catalyst are often 
performed using dilute conditions.89 In contrast, Grubbs’ II catalyst undergoes a relatively 
inefficient dissociation from its PCy3 ligand (Figure 2.7).
171 However, once dissociated, 
the Ru-species can undergo a four orders-of-magnitude higher rate of reaction relative to 






Figure 2.7: Grubbs’ I and Grubbs’ II cat. mechanism. 
 
Considering that both catalysts were capable of returning the desired RCM products, 
Grubbs’ II generation catalyst was ultimately chosen since Grubbs’ I catalyst is generally 
more reactive, and so is prone to side reactions.165 With a suitable amount of the 
oxazolidinone 137 and the N-Boc alcohol 139 in hand, separate Ru-catalysed RCM 
reactions using 5 mol % Grubbs’ II generation catalyst were employed. The most common 
conditions used in the Pyne research group for similar substrates was to heat the diene with 
a 10% loading Grubbs’ I or II generation catalyst in CH2Cl2 at reflux until the full 
consumption of the starting material.89, 127, 146 For this reason, similar conditions were used, 
trialling first the oxazolidinone 137 (Scheme 2.10). After 4 h, a TLC analysis showed full 
consumption of the starting material as well as only one new spot on TLC with a 
significantly lower Rf. A 
1H NMR analysis of the crude reaction product indicated a clean 
conversion to what was later deduced to be the RCM product 140. Careful monitoring by 
TLC analysis proved important as the alkene group in 140 was prone to migration under 
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extended reaction times and would give an inseparable mixture of olefin-containing 
species as well as lower the yield of the desired product. Using similar conditions, the N-
Boc alcohol 139 also afforded the RCM derivative 141 in comparable yields (70%) 
(Scheme 2.11).  
Shown in Figure 2.8, The 1H NMR spectrum of 140 displayed two, nearly overlapping, 
characteristic cis-alkene resonances for H6 and H7 at δH 5.79 (1H, d, J = 6.6 Hz) and 5.81 
(1H, d, J = 6.6 Hz), respectively. In conjunction with this, the olefinic proton resonances 
from the starting diene 137 had disappeared. To eliminate the possibility that the pyrrole 
had formed, the characteristic H1՛՛ methyl group was examined and found to resonate as a 
defined doublet at δH 1.39 (3H, J = 6.8 Hz). In addition to this, the 
13C NMR spectrum of 
140 only displayed two olefinic-like resonances at δC 137.4 (C7) and 123.8 (C6). These 
alkene 1H and 13C NMR assignments were based upon gCOSY and gHSQC experiments. 
The HRESIMS of 140 showed a characteristic [M+Na]+ ion peak at m/z 432.1787, which 
also established that the desired product had been formed.  
 








Figure 2.8: 1H NMR spectrum (500 MHz, CDCl3) of 140. 
Similar resonances were also observed for the N-Boc pyrrolidine 141. Unfortunately, the 
1H NMR analysis became difficult due to the presence of Boc-induced rotamers and 
consequent broadening of peaks (Figure 2.9). To confirm that this was not the 
corresponding pyrrole derivative, the most reliable evidence was obtained from a the 
HRESIMS of 141 which showed a characteristic [M+Na]+ ion peak at m/z 506.2542. 
Although high-temperature 1H NMR studies can be used to improve the definition of the 
rotamer resonances,172-173 it was hopeful that subjecting the product to further chemical 
manipulation might instead improve the resolution of the 1H NMR spectrum. For this 
reason, the RCM N-Boc diol 141 was also continued through to the next step of the 
synthetic pathway.  
 











2.10. Dihydroxylation of 140 and 141 
 
Although the initial attempts towards synthesis of the syn-diol at C6 and C7 in 132 were 
unsuccessful, this did not deter trying the same conditions on the newly formed RCM 
substrates 140 and 141. In fact, we hypothesized that the reaction would work well for both 
140 and 141 using standard Upjohn cis-dihydroxylation conditions.157 This rationale was 
largely influenced from previous co-workers results within the Pyne group. More 
specifically, implementing these conditions on similar substrates containing an N-carbonyl 
seemed to return high-yielding, high diastereoselective syn-diol products.89, 146 Although 
this is a non-selective dihydroxylation, the high diastereoselectivity of akin substrates 
seems to be influenced by the size of the protecting group attached to the secondary 
amine.174 Considering the mechanism shown in Figure 2.10, the first step in this cycle is 
the sterically influenced cycloaddition between the osmium(VIII)  tetroxide and the alkene 
140 to form the osmate ester A. In the presence of water, the osmate ester is hydrolysed to 
the corresponding diol 142. Since both oxygen atoms were added in a concerted manner, 
their relative stereochemistry remains syn. Interestingly, without the addition of NMO, the 
reaction would require a molar equivalent of the expensive, and toxic OsO4. Here, only a 
catalytic amount is required because the relatively safe and inexpensive NMO can readily 
oxidize the Os(VI) back to the reactive Os(VIII). 
 
 
Figure 2.10: Upjohn cis-dihydroxylation mechanism. 
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Therefore, the RCM product 140 was subject to Upjohn Os(VIII)-catalyzed cis-
dihydroxylation reaction conditions157 which resulted in two diastereomeric diols 142 
(major product) and 143 (minor product) in 78% yield (dr = 3:1 from the crude reaction 
mixture) (Scheme 2.12). Only small amounts of pure compounds 142 and 143 could be 
separated by flash column chromatography (FCC) and so were subject to 1H and 13C NMR 
analysis and other spectroscopic studies for characterisation. Although 2D NMR 
spectroscopic data was obtained for both products, evidence towards their absolute 
configuration will be discussed in Section 2.11.  
 




Interestingly, applying similar dihydroxylation conditions to the N-Boc alkene 141 only 
returned a single diastereomer 144 in high yield (95%) (Scheme 2.13). Fortunately, the 1H 
NMR spectrum of compound 144 displayed clear resonance peaks. The C3, C4 
stereochemistry of compound 144 was determined to be 3S and 4R, respectively after a 2D 
ROESY experiment displayed clear correlations between the (5R)-methyl with the protons 
resonances labelled H3 and H4 (Figure 2.11). Although the dihydroxylation was successful 
for 141, the pathway was discontinued on the basis that it would be difficult to selectively 
protect the newly formed diol at C3, C4 in 144 without impacting on the hydroxy groups 
at C1′ and C3′. Comparatively, compounds 142 and 143 proved superior as it was 
envisioned that forming the acetonide at C6, C7 would not impact on C2′. If both the 
hydroxy group in the alkyl chain were available, such as with the tetraol 144, the acetonide 
would form at the C3, C4 hydroxy groups, as well as potentially form the 6-membered-
C1′ and C3′ acetal 145. Although further investigation is required, these results 
demonstrated how the N-protecting groups on 5-membered pyrrolidines can sterically 
influence the selectivity of the Upjohn Os(VIII)-catalyzed cis-dihydroxylation reaction. 
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Figure 2.11: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 144 
(hydroxy and benzyl protons not shown). 
 
At this point in the course of the project, a colleague within the Pyne research group found 
that N-Boc products could be converted to the corresponding oxazolidinones provided 
there is an α-hydroxy group present.175 This motif was recognized in our N-Boc substrate 
139 and so following a similar procedure, a base-induced (1.5 eq. NaH, THF) conversion 
of 139 to the oxazolidinone 137 was employed and proved successful (85%) with no 
observable formation of the oxazepinone 139. A comparison of the 1H and 13C NMR 
spectroscopic data was consistent with our initial oxazolidione 137 product. After 
comparing both pathways to access the oxazolidinone 137 (triphosgene vs Boc anhydride), 
















base mediate conversion to 137 proved the better yielding (55% over two steps, compared 
to 37% after one step).   
 
2.11. The synthesis of acetonides 146 and 147 
 
Although syn-dihydroxylation of the RCM product 140 was not completely selective, the 
inseparable mixture of diastereomers 142 and 143 still proved important as there was the 
potential to synthesize two hyacinthacine C5-type analogues. With the inseparable mixture 
of diols 142 and 143 in hand, it was decided that conversion to their respective C6, C7 
acetonides would differentiate the characteristics of both diastereomers and allow for their 
efficient separation by column chromatography. Having previous experience with the 
formation of the acetonide 6 from L-xylose, the same reaction conditions were applied to 
the mixture of diols 142 and 143 (Scheme 2.14). This resulted in a clean conversion to 
acetonides 146 and 147, respectively and also accentuated the Rf difference between the 
resultant diastereomers allowing for easier separation by column chromatography. The 
major diastereomer 146 obtained was the result from syn-dihydroxylation to the alkene 
face of 142 that was anti to the C5 methyl substituent due to steric directing effects. An 
extensive ROESY NMR analysis of 146 found key correlations between H1՛՛‒H8a, H1՛՛‒
3a, H8a‒H3a, H8‒H3b and H3b‒H4 (Figure 2.12 and Figure 2.14) which were consistent 
with the assigned configurations. In comparison, 1D NOE difference studies on 147 
showed NOE enhancements between H8‒H8a, H8‒H3a, H8a‒H3a, H3a‒H3b and H3b‒
H4 (Figure 2.13 and Figure 2.14). These were consistent with the structure assigned to 
147.   
 










Figure 2.13: Selected 1D-NOE irradiation spectrums (500 MHz, CDCl3) of A) H8a and 










































Figure 2.14: 2D ROESY and 1D NOE difference NMR spectrum key observed 
correlations projected onto DFT minimized molecular models [B3LYP/6-31G(d)] of 
acetonides 146 and 147, respectively (C4 alkyl chain not shown). 
 
2.12. Attempts to hydrolyse and cyclize oxazolidinones 146 and 147 
 
Before hydrolysing the oxazolidinone group in acetonides 146 and 147, individual samples 
were subject to mesylation of the hydroxy group at C3′. It was anticipated that mesylation 
of the only free hydroxy groups in these compounds would require less stringent molar 
equivalents of methane sulfonyl chloride (often difficult to measure an exact equivalent on 
smaller scales). In addition to this, mesylation of the only hydroxy group, followed by base 
hydrolysis of the oxazolidinone, may result in a one pot deprotection and consequent 
cyclization of intermediate 148 (Scheme 2.15). As anticipated, mesylation of both 
acetonides 146 and 147 worked reasonably well and afforded near quantitative amounts of 
the respective mesylates 148 and 150 (Scheme 2.15). Both compounds were then subject 
to standard microwave base-induced hydrolysis conditions,127 which involved dissolving 
the mesylate in ethanol, followed by the addition of a few drops of NaOH solution, then 
microwave heating (200 W, 100 oC) for 1 h. After this time, no observable product was 
obtained, rather, both reactions returned a complex mixture as indicated from the many 
spots observed by TLC analysis as well as the indistinguishable 1H NMR spectra. Although 
a theoretically good idea, the poor results from this approach influenced the decision to 












































followed by mesylation-cyclisation on the respective amino diols 152 and 153. This 
approach resulted in a good yield of both amino diols 152 and 153, respectively (Scheme 
2.16). These were then individually subject to similar mesylation-cyclisation conditions 
initially used to convert the anti-amino-diol 127 to the pyrrolidine 131.  
 













2.13. Synthesis of pyrrolizidines 149 and 151 
 
To furnish the pyrrolizidine core found in the hyacinthacine C5-type analogues, precedent 
work with similar amino alcohols have employed treatment with a stoichiometric amount 
of MsCl under basic conditions (Et3N).
127-128, 130-131, 144 Having already had experience with 
this reaction to obtain pyrrolidine 131 from anti amino diol 127, this method was employed 
for both amino diols 152 and 153 (Scheme 2.17). The mesylation-cyclization of 152 
afforded a 30% yield of pyrrolizidine 149 as well as a 32% yield of the N,O-dimesylated 
adduct 154 (Scheme 2.17). In an attempt to improve the yield of the desired product, Appel 
cyclization reaction conditions176 were used and fortunately returned the same 
pyrrolizidine 149 with an improved yield of 87% (Scheme 2.17A). Interestingly, both 149 
and 154 crystallized after purification by column chromatography (Figure 2.15).  
The large colourless crystals obtained for 149 were subject to single crystal X-ray 
structural analysis which unambiguously confirmed the absolute configuration initially 
proposed for 149 (Figure 2.16). In addition to this, the crystal structure established that 
mesylation occurs preferably at the hydroxy group of C3′ as opposed to C1′, which would 
otherwise could have returned the 4-membered bicyclic N-heterocycle (azetidine). 
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Comparatively, mesylation, then heat-induced cyclization of the O-mesylate of 153 proved 
extremely regioselective, returning product 151 in high yield (87%) (Scheme 2.17B). Since 
no crystal structure was obtained for this product, the pyrrolizidine was subject to extensive 
1D and 2D NMR spectroscopic experiments. More specifically, to confirm the newly 
formed stereochemistry on the A-ring of the pyrrolizidine 151, 1D NOE difference studies 
were run where NOE enhancements were observed between H8b‒H3a, H7‒H8a, H1՛՛‒H6, 
H1՛‒H7, H8a‒H8b and H4‒H3a (Figure 2.16). These were consistent with the structure 
assigned to 151.   
 










Figure 2.15: (left) Crystals of 149 and the ORTEP plot of the crystal structure for a 
C26H33NO5 molecule of 149 with labelling of selected atoms. Anisotropic displacement 
ellipsoids display 30% probability levels. Hydrogen atoms are drawn as circles with small 
radii. (Right) Crystals of 154 and the ORTEP plot of the crystal structure for a 
C28H39NO10S2 molecule of 154 with labelling of selected atoms. Anisotropic displacement 





Figure 2.16: Selected 1D-NOE irradiation spectrums (500 MHz, CDCl3) of A) H8b, B) 
H8a and C) H1՛՛ of 151. 
 
This contrast in the formation of both pyrrolizidine 149 and 151 was intriguing, and the 
differing yields from each reaction pathway can be attributed to steric factors. More 
specifically, mesylation, then cyclisation of the amino diol 152 returned nearly equal 
amounts of the bis-mesylate 154 and the pyrrolizidine 149. Confirmed by the crystal 
structure for the bis-mesylate 154, regioselectivity of the mesylation of the hydroxy group 
























at C1′. To form the pyrrolizidine 149, an intramolecular SN2 displacement (shown earlier 
in Scheme 2.15) then takes place. When the 1H NMR spectrum for 154 was obtained, the 
only certainty was that two mesylates resided in the compound; it was difficult to 
determine the bis-mesylation regioisomer obtained. However, prior to obtaining a crystal 
structure there were a few 1H NMR spectrum characteristics that were supportive of 
mesylation at the nitrogen and the hydroxy group at C3′. Shown in Figure 2.17B, two 
mesylate peaks with different 1H NMR chemical shifts were present. Although it was not 
definitive, it was proposed that the mesylate shift at δH 2.98 was characteristic of N-
mesylation177 and the other at δH 3.06 would more likely resonate with a de-shielding effect 
induced if the mesylate group was attached to a hydroxy group. Comparison of the 1H 
NMR spectra for both the parent amino-diol 152 (Figure 2.17A) and the bis-mesylate 154 
(Figure 2.17B), we noted significant differences in chemical shifts for proton resonances 
labelled H4 (δH 3.08 and 4.38, respectively), H6 (δH 3.05 and 3.95, respectively) and H1′′ 
(δH 1.05 and 1.36, respectively). This de-shielding effect was convincing enough to 
hypothesize that the secondary amine of amino-diol 152 had undergone mesylation. After 
a gCOSY analysis, we also identified that the H3′ resonance had shifted from δH 4.06 in 
152, to δH 5.00 in 154. In a similar manner, the resonance identified as H1′ in both 
structures 152 and 154, had changed chemical shift slightly from δH 3.74 to δH 3.90, 
respectively. This comparison supported the claim that both the nitrogen and the hydroxy 













Figure 2.17: A) 1H NMR spectrum (500 MHz, CDCl3) of 152 and B) 
1H NMR spectrum 
(500 MHz, CDCl3) of 154.  
 
Obtaining both the pyrrolizidine 149 and the bis-mesylate 154 led to the rationalization 
that C3′ O-mesylation and N-mesylation occurs at comparable rates. If O-mesylation at 
C3′ occurs first, then the molecule will undergo a spontaneous intramolecular cyclization 
to give 149. If N-mesylation occurs, then cyclisation is prevented and will eventually result 
in product 154 provided a second mesylation occurs. In contrast, reversing the orientation 
of the acetonide at C6a and C3a, such as for compound 153, O-mesylation at C3′ is 
preferred. However, heat was required to furnish pyrrolizidine 151. Since the only 
difference between both amino diols 152 and 153 was the orientation of the acetonide, it 
is proposed that this moiety sterically hinders the secondary amine in compound 153 
whereas the secondary amine in compound 152 is more susceptible to mesylation. 
Interestingly, employing Appel cyclisation conditions resulted in exclusive formation of 
pyrrolizidine 149 (Scheme 2.18). Since no nitrogen bound triphenylphosphine was 
observed, it is assumed that the in situ formed triphenyphosphine bromide is too sterically 
encumbering to bind to the secondary amine and so instead binds selectively to the hydroxy 















bromide anion, our crystal structure and improved yield of 149 displays the preference for 
intramolecular cyclization via the SN2 N-alkylation pathway (Scheme 2.18).  
 




2.14. Global deprotection of pyrrolizidines 149 and 151 
 
After successfully furnishing the pyrrolizidine core, individual samples of 149 and 151 
were then globally deprotected under hydrogenolysis conditions over PdCl2 to return novel 
hyacinthacine C5-type compounds (+)-7-epi-hyacinthacine C5 155 [[α]𝐷
25+5.4 (c 1.00, 
H2O)] and (‒)-6-epi-hyacinthacine C5 156 [[α]𝐷
25-7.2 (c 1.00, H2O)] (Scheme 2.19) in good 
to high yields (87% and 98%, respectively), following purification and neutralization by 







Scheme 2.19: Global deprotection of pyrrolizidines 149 and 151 to give (+)-7-epi-
hyacinthacine C5 155 and (‒)-6-epi-hyacinthacine C5 156, respectively. 
 
 
All spectroscopic experiments used to determine the final structures have been included in 
the appendix. After confidently identifying and assigning each proton resonance through 
a gCOSY analysis, the relative configurations of each compound was extensively studied. 
For 155, an extensive ROESY NMR analysis found key correlations between H9‒H3, H9‒
H6, H9‒H7, H7‒H6, H7‒H1 and H2‒H8 (Figure 2.18) which were consistent with the 
assigned configurations. Similarly, compound 156 was subject to extensive ROESY NMR 
analysis, where key correlations between H9‒H3, H6‒H5, H6‒H7, and H7a‒H7 were 
observed (Figure 2.19). The 1H and 13C NMR spectroscopic data of both synthetic 155 and 
156 were also compared with the natural isolates labelled hyacinthacine C1, C4 and C5 
(Table 2.3 and Table 2.4). When compared, both synthetic 155 and 156 did not 
spectroscopically match with any of the questionable natural products. Additionally, a 
Scifinder Scholar™ search could not identify these structures in the literature and so it was 
concluded that (+)-7-epi-hyacinthacine C5 155 and (‒)-6-epi-hyacinthacine C5 156 are 






Figure 2.18: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of (+)-
7-epi-hyacinthacine C5 155 (hydroxy protons not shown). 
 
 
Figure 2.19: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of (‒)-

























































H3 H7a H5 
H8 
















Table 2.3: Comparison of the literature 1H NMR spectroscopic data of natural (+)-
hyacinthacine C1
105 ( z, D2O), natural (+)-hyacinthacine C4
117 ( z, D2O) and 
natural (+)-hyacinthacine C5
117 ( z, D2O) with synthetic 155 and synthetic 156 (500 
MHz, D2O). 
 
Table 2.4: Comparison of the literature 13C NMR spectroscopic data of natural (+)-
hyacinthacine C1
105 ( z, D2O), natural (+)-hyacinthacine C4
117 ( z, D2O) and 
natural (+)-hyacinthacine C5
117 ( z, D2O) with synthetic 155 and synthetic 156 (125 
MHz, D2O). 
 
2.15. Chapter 2: Final remarks 
 
The synthetic strategy employed towards the synthesis of hyacinthacine C5-type analogues 
in this Chapter has been described. If the successful pathway alone were presented, the 
reader would question the number of seemingly “unnecessary” steps. Hopefully, the reader 









1 4.15, t (3.9) 4.18, t (4.0) 4.01, t (7.6) 3.90-3.78, m 4.39-4.28, m 
2 4.00, dd (3.9, 9.0) 4.00, dd (4.0, 8.7) 3.80, t (7.6) 3.94, t (7.3) 3.91, t (8.3) 
3 3.44, dt (4.4, 9.0) 3.38, dt (4.6, 8.7) 3.01, m 
3.10, dt (5.0, 
7.2) 
3.38, p (4.8) 
5 3.29, dt (3.9, 7.0) 2.96, dq (6.9, 9.2) 2.81, dq (6.9, 7.6) 3.21-3.13, m 
3.24, dt (5.4, 
7.0) 
6 3.89, dd (3.9, 4.6) 3.90, dd (8.2, 9.2) 3.60, t (7.6) 3.90-3.78, m 4.03, t (4.5) 
7 4.50, dd (4.6, 8.6) 4.15, t (8.2) 3.99, t (7.6) 
4.15, dd (2.7, 
5.0) 
4.39-4.28, m 
7a 3.66, dd (3.9, 8.6) 3.57, dd (3.7, 8.2) 3.24, t (7.6) 3.21-3.13, m 3.31, t (7.6) 
8 3.66, m 3.65, d (4.6) 
3.55, dd (4.1, 12.0) 
3.50, dd (5.3, 12.0) 
3.71-3.59, m 3.67, d (4.8) 
9 1.27, d (7.0) 1.29, d (6.9) 1.13, d (6.9) 1.26, d (7.0) 1.25, d (7.1) 
 13C NMR () 
position (+)-hyacinthacine C1105 (+)-hyacinthacine C4117 (+)-hyacinthacine C5117 155 156 




2 77.7 77.3 81.0 77.9 78.5 
3 64.7 65.1 65.1 62.2 62.2 
5 60.4 62.0 61.4 58.8 57.2 




7 75.7 80.0 77.8 73.6 70.8 
7a 68.3 67.3 69.2 72.6 67.5 
8 65.9 66.4 65.7 62.9 63.1 
9 12.8 16.0 15.7 13.2 10.9 
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will agree that our pathway must first furnish the B-ring of the pyrrolizidine prior to the 
A-ring to avoid formation of the pyrrole 133. Although not explored, the author notes that 
it would be worth subjecting RCM intermediate 132 to hydrogenation conditions, as this 
may provide a short facile route to a number of hyacinthacine A-type alkaloid analogues. 
In conclusion, this was the first known synthesis of the unnatural (+)-7-epi-hyacinthacine 
C5 155 and (‒)-6-epi-hyacinthacine C5 156. Establishing this pathway was important, and 
the reader will see how it was the basis for accessing the remaining nine hyacinthacine C5-
type analogues. Although the hyacinthacine alkaloids synthesised in this Chapter did not 
match with any of the ambiguous structures for hyacinthacine C1, C4 or C5, they were still 
assessed as glycosidase inhibitors and their biological activities will be discussed in 





Chapter 3 : Synthesis of unnatural (‒)-5,6-di-epi-
hyacinthacine C5 
 
The methodology towards accessing hyacinthacine C5-type analogues was established 
through the synthesis of unnatural (+)-7-epi-hyacinthacine C5 155 and (‒)-6-epi-
hyacinthacine C5 156. As per the nature of total synthetic pathways, the reader can assume 
that some of the foundational compounds (3,5-di-O-benzyl-α,β-L-xylofuranose, the anti-
1,2-amino diol 127 the RCM products and the C6, C7-diols) have been synthesized a large 
number of times to accommodate divergent pathways throughout the course of this work. 
Of these, the anti-1,2-amino diol 127 was synthesized many times. One of the reagents 
required for this reaction is 3-amino-1-butene·hydrochloride, which at later stages in the 
project became difficult to acquire. Herein, the reader will see how synthesizing this 
starting amine resulted in the synthesis of the third unnatural hyacinthacine C5-type 
analogue (‒)-5,6-di-epi-hyacinthacine C5. 
 
3.1. The Gabriel synthesis of 3-amino-1-butene·hydrochloride 
 
The 3-(R)-amino-1-butene·hydrochloride used in the Petasis borono-Mannich reaction was 
originally purchased from a company called NetChemTM. Unfortunately, during the later 
years of this work, NetChemTM became unresponsive and so we could not reliably 
purchase this starting material as a pure enantiomer. Comparatively, other chemical 
suppliers often listed small amounts of the amine at high costs. As an up-to-date example, 
the US company, Enamine Building BlocksTM, retails 5 g of the enantiomerically pure 3-
(R)-amino-1-butene·hydrochloride for AUD $4914; this value far exceeded the original 
purchase price of this product when the project first started. Even though we were 
confident that this material would be profitable towards accessing additional hyacinthacine 
C5-type analogues, the exponential price increase in combination with the need to find a 
reliable chemical company, influenced the decision to consider synthesizing this starting 
product from a cheaper derivative. 
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After searching the literature, it became apparent that the desired primary amine could be 
made from implementing a two-step Gabriel synthesis using a suitable alkyl halide.178 The 
difficulty (and partially justified cost) is that the 3-(S)- and 3-(R)-amino-1-
butene·hydrochloride are hard to separate as pure enantiomers. Despite this predicament, 
we ultimately could not justify the current expense of the stereochemically pure amine. 
Therefore, the decision was made to synthesize racemic 3-amino-1-butene·hydrochloride 
and at a later point, consider resolving its enantiomers.  
Interestingly, synthesizing the racemic 3-amino-1-butene·hydrochloride is relatively 
simple and reported as high yielding.179, 180 More specifically, based on the precedent 
literature by Pallavicini et al. and Wang et al., the related alkyl halide chosen to undergo 
this transformation was 3-chloro-1-butene, which could be readily purchased.179, 180 
3-Chloro-1-butene could be obtained from Sigma Aldrich™ in two packing sizes of 5 mL 
and 100 mL at $48.00 and $215.00 AUD, respectively. The latter of these was purchased 
for economic value, especially considering that synthesizing the racemate would diminish 
the yield of our desired 3-(R)-amino-1-butene·hydrochloride by at least half. Therefore, 
starting with 5 g of 3-chloro-1-butene, Gabriel’s synthesis and methodology were 
employed. Shown in Scheme 3.1A, this initially involved dissolving both 3-chloro-1-
butene and potassium phthalimide in a solution of DMF, followed by heating at reflux for 
3 h. The general mechanistic consideration for this reaction occurs via displacement of the 
halogen via an SN2 attack of the phthalide to give a racemic mixture of the N-substituted 
phthalimide 157. When this reaction was performed, colourless needle-like crystals of the 
N-substituted phthalimide 157 were obtained in high yield (80%). The phthalimide of 
racemate 157 was then cleaved using hydrazine hydrate along with heating the mixture at 
60 oC in ethanol for 3 h. After this time, the reaction mixture had formed a gelatinous white 
semi-solid which was then subject to an excess amount of concentrated hydrochloric acid 
to return the desired 3-amino-1-butene·hydrochloride. This product was purified by a 
series of acid-base extractions, and the HCl salt of this amine was formed by the addition 
of 4 N HCl/EtOH followed by concentration in vacuo. The 1H and 13C NMR spectroscopic 
data of the phthalimide intermediate 157 as well as the 3-amino-1-butene·hydrochloride, 
matched with those in the literature.179  
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This method is known as the Ing-Manske procedure181 and can be described by the 
mechanism shown in Scheme 3.1B. Hydrazinolysis occurs when a hydrazine unit attacks 
one of the carbonyls of the phthalimide moiety of 157. This results in a cascade ring 
opening (Scheme 3.1B, intermediates A and B) which then allows for an intramolecular 
nucleophilic attack at the remaining carbonyl from the other half of the attached hydrazine 
unit (Scheme 3.1B, intermediate C). This attack at the second carbonyl liberates the final 
primary amine, as well as the phthalhydrazide by-product.178 
 
Scheme 3.1: A) Garbiel synthesis of 3-amino-1-butene·hydrochloride from 3-chloro-1-






While methods have been published for the resolution of the 3-amino-1-
butene·hydrochloride,179, 180 the decision was made to subject the racemic amine to the 
Petasis reaction which would afford a diastereomeric mixture of the anti-1,2-amino-diols 
127 and 161 (Scheme 3.2). Considering the basis of diastereomeric resolution, it was 
envisioned that the amine would be incorporated into a larger stereochemically defined 
motif which would display different chemical properties that might result in efficient 
separation of both (1′S) and (1′R)-anti-amino-diols 127 and 161, by column 
chromatography. Additionally, the resultant (1′S)-diastereomer 161 was valued since it 
would lead to potential hyacinthacine C5-type derivatives containing the (5S)-methyl and 
would prove important for gaining insight towards the SARs of glycosidase inhibition. If 
the envisioned diastereomers would not separate at any point during the synthetic pathway, 
then other purification methods would be considered.179, 180   
 
3.2. Synthesis of anti-amino diols 127 and 161 
 
In a similar manner to the synthesis described in Chapter 2, but included for clarity, a 
retrosynthetic analysis towards hyacinthacine C5-type analogues containing a (5S)-methyl 
is shown in Scheme 3.2. The reader will find that this retrosynthetic analysis is quite 
specific and has been generated based on the reasonable success we experienced with the 
previously synthesized unnatural (+)-7-epi-hyacinthacine C5 155 and (‒)-6-epi-
hyacinthacine C5 156. The intention of this pathway was to synthesize more of the (1′R)-
methyl anti-1,2-amino-diol 127 for later divergency as well as explore the possibility of 
synthesizing (5S)-methyl hyacinthacine C5-type analogues. In hope that diastereomeric 
resolution via synthesis of the anti-1,2-amino-diols 127 and 161 would allow separation 
of the (1′S)- and (1′R)-methyl products, obtaining pure (5S)-methyl hyacinthacine C-type 
analogues would demonstrate the flexibility and effectiveness of this synthetic pathway. 
Additionally, this result would be an interesting contrast for resultant SAR studies, where 
we could compare the impact of the stereochemistry of C5 in the final hyacinthacine C-
type analogues. The retrosynthetic plan shown in Scheme 3.2 details that the pyrrolizidine 
core would be derived from acetonide 158. Similarly, cis-dihydroxylation would result 
from UpJohn cis-dihydroxylation157 across the alkene of RCM adduct 159. The alkene of 
159 would be obtained using Grubbs’ I- or II-generation catalyst under ring-closing 
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metathesis conditions on the suitably prepared oxazolidinone 160. Oxazolidinone 160 
would be formed by subjecting the anti-1,2-amino-diol 161 to either N-Boc formation then 
treatment with sodium hydride or by triphosgene under basic conditions. The 
diastereomeric mixture of anti-1,2-amino-diols, 127 and 161, would be derived from the 
Petasis borono-Mannich reaction between 3,5-di-O-benzyl-α,β-L-xylofuranose, racemic 3-
amino-1-butene·hydrochloride and (E)-β-styrenylboronic acid. 
 
Scheme 3.2: Retrosynthetic analysis for the synthesis of hyacinthacine C5-type analogues 




Following this procedure, racemic 3-amino-1-butene·hydrochloride was treated with 3,5-
di-O-benzyl-α,β-L-xylofuranose and (E)-β-styrenylboronic acid using the same conditions 
we employed for the synthesis of anti-1,2-amino-diol 127 (Scheme 3.3). This afforded an 
approximate 1:2.5 inseparable mixture of anti-1,2-amino-diol 127 and 161, respectively as 
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determined by the relative resonance intensities in the 1H NMR spectrum (Figure 3.1). 
Since this mixture could not be separated into pure diastereomers, the 1H NMR resonance 
peaks for anti-1,2-amino-diol 161 were deciphered by the process of elimination through 
comparison of the previously characterized anti-1,2-amino-diol 127. This result indicated 
some degree of kinetic preference for the reaction of the iminium ion intermediate arising 
from the (S)-enantiomer 161 of the amine component. Allowing the mixture a longer 
reaction time in future might afford a 1:1 mixture of anti-1,2-amino-diols 127 and 161.  
 




In hindsight, the poor separation of anti-1,2-amino-diols 127 and 161 was not a surprising 
result. It is well established that compounds containing amines or quaternary ammonium 
salts often exhibit sever peak tailing and broad overlapping bands on silica gel; they do not 
follow a regular hydrophobic retention behaviour.182 This phenomenon was experienced 
even with the pure (1′R)-anti-1,2-amino-diol 127 described in Chapter 2, as the product 
contained poor TLC peak symmetry and eluted over an excessive number of otherwise 









Figure 3.1: 1H NMR spectrum (500 MHz, CDCl3) of the inseparable 1:2.5 mixture of 127 
and 161. 
 
3.3. N-protection of the anti-1,2-amino-diols 127 and 161  
 
In Chapter 2, two different protecting groups of the anti-1,2-amino-diol 127 were trialled 
and results were described. More specifically, this entailed the synthesis of N-Boc 139 and 
the oxazolidinone 137. Due to the previously described selectivity issues, it was found that 
oxazolidinone 137 was more amendable for our synthetic approach. Therefore, attempts to 
subject the mixture of (1′R)- and (1′S)-anti-1,2-amino-diols 127 and 161, respectively to 
similar conditions were employed. It was envisioned that synthesizing the oxazolidinone 
of the mixture may lead to better separation of the diastereomers as a result of increasing 
the molecules rigidity which would accentuate the subtle characteristic differences 
between both compounds. Considering anti-1,2-amino-diol 127, we concluded that 
synthesizing the N-Boc product 139, then base induced cyclization to the respective 
oxazolidinone 137 returned an overall better yield than compared to when the starting anti-
1,2-amino-diol 127 was subject to triphosgene under basic conditions. In hope that this 
would be similar for anti-1,2-amino-diol 161, a pilot reaction of the diastereomeric mixture 
of anti-1,2-amino-diols 127 and 161 was subject to N-Boc protection using our established 
conditions. Unfortunately, this seemed to only work moderately well for the minor anti-
1,2-amino-diol 127, whilst only returning predominantly starting material for the major 
anti-1,2-amino-diol 161. Although this reaction was only tried once, these preliminary 
results suggest it could potentially be used as a method of purification, as diastereomer 127 
can be converted to its N-Boc derivative 139. The obvious inefficiency with this method 










Boc the mixture of anti-1,2-amino-diols 127 and 161 would need to be performed and 
purified several times before a majority of the minor anti-1,2-amino-diol 127 is removed 
from the mixture as the N-Boc derivative 139. Our attention then focused on synthesizing 
oxazolidinones 137 and 160 using triphosgene. Therefore, the diastereomeric mixture of 
127 and 161 was subject to triphosgene/Et3N conditions, where unsurprisingly, an 
inseparable mixture of two oxazolidinones 137 and 160 and two oxazepinones 138 and 
162 were obtained in an overall yield of 43% (Scheme 3.4). Unfortunately, the ratio of 
these four products was unable to be determined due to the complexity of the 1H NMR 
spectrum even after column purification (Figure 3.2). The N-Boc pathway for the mixture 
of anti-1,2-amino-diols 127 and 161 was never re-visited. This is acknowledged with the 
explanation that enough product from the triphosgene protection of the mixture of anti-
1,2-amino-diols 127 and 161 was obtained and never needed to be synthesized for the 
remainder of this project. 
 
Scheme 3.4: Formation of the oxazolidinones 137 and 160 along with the oxazepinones 






Figure 3.2: 1H NMR spectrum (500 MHz, CDCl3) of the inseparable mixture of 137, 160, 
138 and 162. 
 
3.4. Oxazepinones 138 and 162 conversion to oxazolidinones 137 and 
160, respectively 
 
The inseparable mixture of the four diastereomers 160, 137, 138 and 162 was then subject 
to our established conditions that would induce a facile migration of the carbonyl group to 
give exclusively the oxazolidinone products 160 and 137 (Scheme 3.5). This fortuitously 
resulted in returning a clean conversion of both oxazepinones 138 and 162 to their 
respective oxazolidinones 137 and 160 (1:2 mixture, Figure 3.3). The reaction mixture still 
proved inseparable by TLC and column chromatography. Oxazolidinone 160 was 
characterized by the process of elimination from comparison of the 1H and 13C NMR 
spectrum of the diastereomeric mixture with the same data used to characterise the pure 










Scheme 3.5: Facile carbonyl migration: conversion of oxazepinones 138 and 162 to 





Figure 3.3: 1H NMR spectrum (500 MHz, CDCl3) of the inseparable mixture of 137 and 
160. 
 
3.5. Synthesis of compounds 140 and 149 
 
Having experienced reasonable success in our previous RCM reaction with the 
oxazolidinone 137, it was thought that treating the resultant mixture of oxazolidinones 137 







159, respectively. In addition to this, it was hypothesized that increasing the rigidity of the 
structures via synthesis of the bicyclic core might accentuate the subtle chemical 
differences between both diastereomers, enough for them to at least separate using standard 
column chromatography methods. Applying these conditions, both RCM products 140 and 
159 were successfully synthesized and fortuitously separated after column 
chromatography in 27% and 53% yields, respectively (Scheme 3.6). The diastereoselective 
resolution was therefore successful when the rigidity of the structure was increased. 
Interestingly, column chromatography proved effective since there was a significant Rf 
difference (Figure 3.4, Rf = 0.20 for 140 and Rf = 0.45 for 159) between each RCM product 
using 1:1 EtOAc/n-hexane as the solvent system. Spectroscopic data for the minor isomer 
matched that of the previously synthesized 140.  
To confirm that the major isomer 159 was the desired RCM product, the HRESIMS and 
1H NMR spectrum were examined. More specifically, the HRESIMS of 159 showed a 
characteristic [M+Na]+ ion peak at m/z 432.1782. After examining the 1H NMR spectrum 
(Figure 3.5), a proton resonance was found to reside at δH 4.86 (1H, dd, J = 8.5, 4.8 Hz) 
and proved characteristic of H7a. In addition to this, the observed 8.5 Hz vicinal coupling 
constant J1,7a between resonances labelled H1 and H7a were consistent with the 4,5-cis 
relative configuration in 159. To eliminate the possibility that the corresponding pyrrole 
had formed, careful inspection of the resonance labelled H1′′ at δH 1.21 (3H, J = 6.8 Hz) 
revealed that it appeared with the multiplicity of a doublet; this would otherwise appear as 
















Figure 3.4: The thin-layer-chromatography plate (solvent: 1:1 EtOAc/n-hexane) showing 




Figure 3.5: 1H NMR spectrum (500 MHz, CDCl3) of 159. 
 
3.6. Synthesis of compound 163 
 
Having successfully formed and separated the RCM product 159 from its (5R)- isomer 
140, we next focused our attention on establishing the syn-diol at C6 and C7. To do this, 
compound 159 was subject to UpJohn cis-dihydroxylation (Scheme 3.7).157 Interestingly, 
applying these reaction conditions to compound 159 resulted in the formation of a single 
diastereomer 163. An extensive ROESY NMR analysis shown in Figure 3.6, indicated that 
the syn-diol at C6, C7 of 163 formed anti to the (5S)-methyl. Key correlations confirming 
this stereoconfiguration were observed between the resonances labelled H1′′‒H6, H7‒H7a, 
and H7a‒H1. The product was also crystalline (Figure 3.7) and so was examined by X-ray 
crystallographic analysis. This unambiguously confirmed the absolute configuration 
deduced by NMR spectroscopy for compound 163.   
 











Figure 3.6: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed correlations 
projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 163. 
 
 
Figure 3.7: Crystals of 163 (left) and the ORTEP plot of the crystal structure for 
C24H29NO7 molecule of 163 (right) with labelling of selected atoms. Anisotropic 
displacement ellipsoids display 30% probability levels. Hydrogen atoms are drawn as 































3.7. Synthesis of acetonide 158 
 
Having obtained the pure syn-diol 163, the next step in the synthetic pathway was to protect 
the C6, C7 diol as the corresponding acetonide. In a similar manner described in Chapter 
2, syn-diol 163 was dissolved in acetone followed by the addition of two equivalents of 
copper(II) sulphate and a catalytic amount of sulfuric acid. After stirring the reaction for 1 
h, a TLC analysis showed a near quantitative conversion to the respective acetonide 158 
(Scheme 3.8). In addition to the HRESIMS of 158 which showed a characteristic [M+Na]+ 
ion peak at m/z 506.2182, both the 1H NMR and the 13C NMR spectrum displayed key 
resonances that correspond to the newly formed acetonide 158. More specifically, through 
the comparison of the 13C NMR spectroscopic data between the parent syn-diol 163 and 
the acetonide 158 (Figure 3.8). In this comparison, acetonide 158 displays three additional 
carbon resonances at δC 112.7, 26.3 and 24.1 which coincide with C2 and both the methyl 
carbons contingent at C2, respectively. Although subject to extensive 1D and 2D NMR 
studies, the compound fortuitously crystalized (Figure 3.9) and so the relative 
configuration was unequivocally confirmed by single-crystal X-ray studies.  
 







Figure 3.8: A) 13C NMR spectrum (125 MHz, CDCl3) of 163 and B) 
13C NMR spectrum 
(125 MHz, CDCl3) of 158 with C2 and C2 contingent methyl resonances for 158 
highlighted in red. 
 
 
Figure 3.9: Crystals of 158 (left) and the ORTEP plot of the crystal structure for 
C27H33NO7 molecule 158 (right) with labelling of selected atoms. Anisotropic 
displacement ellipsoids display 30% probability levels. Hydrogen atoms are drawn as 







3.8. Synthesis of compound 166 
 
With the acetonide 158 in hand, studies towards a one-pot oxazolidinone hydrolysis 
followed by annulation to give 165 were explored. Despite our unsuccessful attempts 
reported in Chapter 2, we recognized that acetonide 158 had exhibited differing properties 
(i.e. formed crystals) compared to the related acetonide 147 (resultant oil).  These notably 
different properties were the result of a single stereocentre difference. Therefore, it was 
optimistically envisioned that the (8S)-methyl acetonide would react differently relative to 
the (8R)-methyl containing acetonide 147. More specifically, if 158 was subject to 
mesylation at C2′, followed by base-induced microwave hydrolysis, then pyrrolizidine 165 
might form. Consequently, acetonide 158 underwent mesylation at C2′ using an excess 
amount of methanesulfonyl chloride and Et3N (Scheme 3.9A). This provided the 
mesylated product 164 in near quantitative yields which after purification, was then subject 
to base-induced microwave hydrolysis. Unfortunately, when subject to these conditions, 
no observable product was formed, rather, a complex mixture of products was obtained. 
Although unsuccessful, the curiosity towards the feasibility of this one-pot deprotection 
and subsequent cyclisation was satisfied; our results suggest that the one-pot oxazolidinone 
hydrolysis then cyclisation is inefficient for this synthetic pathway. Hydrolysis of the 
oxazolidinone before mesylation was concluded to be the optimal approach towards 
synthesizing the desired hyacinthacine C-type analogues. Therefore, subjecting the larger 
bulk of the acetonide 158 to base-mediated microwave hydrolysis of the oxazolidinone 















3.9. Synthesis of pyrrolizidine 165  
 
To furnish the pyrrolizidine core, the amino-diol 166 was reacted with a stoichiometric 
amount of methanesulfonyl chloride (Scheme 3.10) and returned two equally intense 
product spots as determined by TLC analysis.  
 
Scheme 3.10: Synthesis of pyrrolizidine 165. 
 
 
Prior to purification by column chromatography, TLC analysis was undertaken again but 
with two parallel areas marked with samples of the crude reaction mixture. Shown in 
Figure 3.10, a similar process to that of preparative TLC was used in order to determine 
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the products formed in this reaction. More specifically, only one half of the TLC was 
stained and processed. It was assumed that the observed spot stains were mirrored on the 
unprocessed half of the TLC plate and so the silica where it was assumed these spots 
presided, was gently scrapped off and washed with HPLC grade methanol. The methanolic 
extracts of the spots with Rf values of 0.45 and 0.35 were then filtered and subsequently 
analysed by LRESIMS and resulted in the ion peaks at m/z 536 and 440, respectively. 
These were characteristic of the [M+H]+ ion for the single mesylated product 167, as well 
as the [M+H]+ ion for the pyrrolizidine 165, respectively. After purification, the suspected 
pyrrolizidine 165 was the subject of extensive spectroscopic analysis and deduced to be 
the target compound. Shown in Figure 3.11, the ROESY analysis of pyrrolizidine 165 
displays clear correlations between H1′′‒H3a, H3a‒H8b, H8b‒H8a, H8a‒H7 and H7‒H1′, 
suggesting the desired absolute configuration had formed on both A and B-rings of the 




Figure 3.10: The thin-layer-chromatography plate (solvent: 5:95 MeOH/CH2Cl2) showing 
the different spots for products 167 and 165 according to their respective Rf values. The 
reaction mixture was spotted on both halves of the TLC plate, but only one side was 
processed as indicated by the blue shading. The unprocessed half had the silica removed 






Figure 3.11: 2D ROESY NMR (500 MHz, CDCl3) with key observed correlations 
projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 165. 
 
Comparatively, the suspected singularly mesylated compound was determined to be the 
mesylated amino-diol 167. In addition to the LRESIMS, examination of the 1H NMR 
spectrum also indicated the formation of this product. Interestingly, it was initially thought 
that the mesylate chemical shift in the 1H NMR spectrum at δH ~2.95 (3H, s) was reflective 
of N-mesylation and so prevented annulation. However, on closer inspection of the 1H 
NMR spectrum for both the starting amino-diol 166 and the mesylate adduct 167, strong 
evidence suggested that the hydroxy group at C3′ had undergone mesylation. More 
specifically, it was noted that the proton resonances deduced to be H1′′, H6, and H4 
remained relatively unshifted between both spectra at δH ~ 1.00, 3.20 and 3.09, respectively 
(Figure 3.12). In our earlier finding, the same proton chemical shifts for the N-mesylate 
154 were significantly deshielded in the 1H NMR spectrum. It was therefore confidently 
deduced that N-mesylation was not apparent in 167. The only other sites that mesylation 
could occur were at the hydroxy groups at C1′ and C3′. From the 1H NMR spectrum 
comparison between the parent amino-diol 166 and the mesylate adduct, convincing 
evidence was found to support C3′ hydroxy mesylation. More specifically, the resonance 
labelled as H1′ in 167 remained relatively unshifted at δH ~ 4.00 when compared with the 
1H NMR spectrum of the parent amino-diol 166. Comparatively, the 1H NMR chemical 
shifts for the resonances labelled H3′ in both 166 and 167 were significantly different at 




























δH ~ 4.00 (1H, m) and 5.00 (1H, bs), respectively. This was consistent with the C3′ hydroxy 
mesylation deshielding effect and true for structure 167. To further strengthen this 
argument, it was hypothesized that if the proposed structure was in fact mesylate 167, then 
subjecting this compound to heat in the presence of a non-nucleophilic base should induce 
cyclization to afford the previously obtained pyrrolizidine 165. Therefore, compound 167 
was dissolved in DCE, followed by the stoichiometric addition of Et3N and heating the 
solution at reflux overnight. After this time, the starting material spot had completely 
disappeared to quantitatively return a TLC spot characteristic of pyrrolizidine 165. After 
purification by column chromatography, the resultant product was obtained in a high yield 
(76%) and confirmed to be the desired pyrrolizidine 165 by 1H and 13C NMR spectroscopic 




Figure 3.12: A) 1H NMR spectrum (500 MHz, CDCl3) of 166 and B) 
1H NMR spectrum 
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3.10. Synthesis of (‒)-5,6-di-epi-hyacinthacine C5 169 
 
With a suitable amount of the pyrrolizidine 165 in hand, the final step in the synthesis was 
to globally deprotect this compound. The pyrrolizidines 149 and 151 synthesized in 
Chapter 2 were converted to their corresponding hyacinthacine C5-type analogues via 
hydrogenolysis over PdCl2. After cleaving the O-benzyl ethers, the in situ generated HCl 
eventually deprotects the acetonide and reveals the final products after the hydrochloride 
salt is neutralized by basic ion-exchange chromatography. However, deprotection of 
pyrrolizidine 165 occurred over two steps to reveal (‒)-5,6-di-epi-hyacinthacine C5 169 
(Scheme 3.11). This entailed first deprotecting the acetonide moiety of pyrrolizidine 165 
followed by hydrogenolysis of both O-benzyl ethers. Although it was likely that a one-pot 
global deprotection of pyrrolizidine 165 would have resulted using our initial procedure, 
deprotection of the acetonide first provided the intermediate 168 which was extensively 
characterized prior to the final deprotection. Considering the stereogenic complexity of the 
final products, it is of paramount importance that the synthesis of the correct structure and 
absolute configuration at each stage has been achieved; all final structures and any possible 
intermediates should be subject to extensive NMR spectroscopic analysis. More 
specifically, pyrrolizidine 165 was dissolved in an EtOH/H2O (1:9, respectively) solution 
followed by the addition of a few drops of HCl. After stirring at room temperature for 4 h, 
the desired product 168 was obtained in near quantitative yield after neutralizing the HCl 
salt with aqueous NaHCO3. Compound 168 was then subject to various spectroscopic 
experiments. Of these, an extensive ROESY NMR analysis (Figure 3.13) displayed key 
correlations between H1′′‒H6, H1′′‒H1′, H5‒H3, H6‒H7, H7‒H7a, and H1‒H3 and 
therefore confirmed the absolute configuration depicted in pyrrolizidine 168. After 
confirming the synthesis and absolute configuration of pyrrolizidine 168, the O-benzyl 
ethers of this compound were then removed by hydrogenolysis over PdCl2, and the final 
hyacinthacine C5-type alkaloid 169 was neutralized by basic ion-exchange 
chromatography. This returned (‒)-5,6-di-epi-hyacinthacine C5 [[α]𝐷
25-6.9 (c 1.00, H2O)] 
169 which was the subject of extensive NMR spectroscopic experiments and found to 
spectroscopically match (consistent 0.8 – 1.4 ppm difference in the 13C NMR Table 3.1) 
with its enantiomer 49 [lit.129[α]𝐷
20+4.3 (c 0.35, H2O)]  reported synthesized by Yu et al. 
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in 2011129 (Figure 3.14). In a similar manner, this compound was also assessed for its 
glycosidase inhibitory potential which will be discussed in Chapter 6.  
Scheme 3.11: Global deprotection of pyrrolizidine 165 via two steps: acid hydrolysis of 
the acetonide to give 168, then hydrogenolysis of the O-benzyl ethers to give (‒)-5,6-di-




Figure 3.13: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 168. 
 
 
Figure 3.14: Our synthetic (‒)-5,6-di-epi-hyacinthacine C5 169 and its enantiomer 49 






































Table 3.1: Comparison of literature 1H NMR (600 MHz, D2O) and 
13C NMR (75 MHz, 
D2O) data of Yu et al. Lit. (–)-7-epi-hyacinthacine C5 49
129 with the 1H NMR (500 MHz, 
D2O) and 




3.11. Chapter 3: Final remarks 
 
The total synthesis of our third hyacinthacine C5-type analogue has been described. The 
thorough spectroscopic analysis of each synthetic intermediate, as well as the X-ray 
analysis of both crystal structures for 163 and 158 helped us to confidently assign the 
absolute configuration for the resultant (‒)-5,6-di-epi-hyacinthacine C5 169. This products 
enantiomer, 49, was synthesized in 2011 by Yu et al.129 and it was reassuring to find that 
the 1H and 13C NMR spectroscopic data were a close match for both products. This further 
validates our synthetic approach towards accessing the pyrrolizidine core via our 
mesylation-cyclisation method. Although the chief focus of this project was to synthesize 
hyacinthacine C5-type analogues containing the (5R)-methyl, we were pleased to readily 
obtain the hyacinthacine C-type derivatives containing the (5S)-methyl. (‒)-5,6-Di-epi-
hyacinthacine C5 169 was cross examined with the hyacinthacine C5-type natural products 
and did not match any of the spectroscopic data reported for hyacinthacines C1, C4 or C5. 
However, its synthesis provided an important foundation towards accessing the remaining 
hyacinthacine C5-type analogues described in this body of work. Additionally, the inherent 
glycosidase inhibitory activity of this product was assessed and provided valuable 
information towards SAR studies (Chapter 6).   
 1H NMR ( J in Hz) 13C NMR () 
position 
(–)-7-epi-
hyacinthacine C5 49 
(Yu et al.)129 
(‒)-5,6-di-epi-
hyacinthacine C5 169 
(–)-7-epi-
hyacinthacine C5 49 




1 4.42, t (7.2) 4.33, t (7.4) 73.0 73.8 
2 3.97, t (7.8) 3.89, t (8.7) 77.7 78.7 
3 2.92-3.12, m 2.78, dt (4.3, 9.1) 71.0 71.5 
5 2.92-3.12, m 2.84, dq (6.4, 12.7) 63.5 64.0 
6 3.85-3.78, m 3.76-3.68, m 79.0 79.8 
7 4.24, t (3.6) 4.13, t (4.1) 70.0 70.6 
7a 3.52-3.45, m 3.26, dt (2.8, 5.7) 68.2 68.6 
8 
3.74, dd (4.2, 12.6) 
3.85-3.78, m 
3.65, dd (4.7, 11.9) 
3.76-3.68, m 
60.8 62.2 
9 1.31, d (6.0) 1.20, d (6.2) 17.2 18.3 
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Chapter 4 -Part A: Initial attempts to synthesize 
hyacinthacine C5-type analogues with an anti- C6, 
C7 diol 
 
The segment that comprises Chapter 4 is disclosed in two parts. Chapter 4-Part A describes 
the unsuccessful attempts towards accessing an anti-diol configuration at the C6, C7 
stereocentres in the final hyacinthacine C5-type analogues. Although ineffectual, the author 
notes that these attempts were an important foundation that ultimately influenced the 
successful pathway towards accessing these compounds. However, this will be discussed 
in greater detail in Chapter 4-Part B.  
 
4A.1. Rationale for synthesizing hyacinthacine C5-type compounds 
containing a C6, C7 anti-diol configuration 
 
Up until this point in the Ph.D. work, three hyacinthacine C5-type analogues had been 
successfully synthesized. A spectroscopic cross examination of these synthetic analogues 
with the hyacinthacine C-type natural products C1, C4 and C5 revealed that they did not 
match and so the true structures of these natural isolates were still yet to be discovered. 
With seven stereocentres in our final products, it was calculated that 64 possible 
diastereomers (excluding their enantiomers) could be synthesized. Since only a few 
hyacinthacine C-type analogues had been synthesized in the literature so far, a 1H NMR 
spectrum pattern that related the absolute configuration with specific proton or carbon 
chemical shifts could not be generated. With reasonable certainty that most of the 
originally reported stereocentres for the hyacinthacine C-type natural products would be 
correct, we continued our investigation towards synthesizing closely related diastereomers 
of the hyacinthacine C5-type compounds synthesized in Chapters 2 and 3. More 
specifically, our chief focus was to implement an anti-diol configuration at the hydroxy 
stereocentres labelled C6 and C7 in the final products. Details of this are described in our 
retrosynthetic analysis shown in Scheme 4A.1. Having been influenced by the success of 
our previous synthetic pathways described in Chapter 2 and 3, we envisioned that the final 
pyrrolizidine core containing the C6, C7 anti-diol configuration would be obtained by 
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firstly removing the protecting group 1 (PG1) of compound 170 or 171, then oxazolidinone 
hydrolysis followed by cyclization of the resultant amino diol. The key reaction to ensure 
that the anti-diol configuration at C6, C7 will appear in the final product, would be the 
selective ring-opening of the epoxide 172. It was envisioned that the ring-opening the 
epoxides 172-(6S)-methyl and 172-(6R)-methyl could each afford two potential (four in 
total) C6, C7 anti-diol diastereomers 170 and 171. The acetonide protecting group 
described in Chapters 2 and 3 would not work for the resultant C6, C7 anti-diols 170 and 
171 since they contain an opposite stereoconfiguration and so a different protecting group 
synthesis [protecting group 2 (PG2)] would be trialled. The desired epoxide 172 would 
form across the alkene of either RCM products 173 or 174, as the alkene displayed 
susceptibility towards syn-dihydroxylation using UpJohn cis-dihydroxylation 
conditions157 and so a similar reactivity towards epoxidation was envisioned. For this 
reason, we believed the alkene in RCM products 173 or 174 would undergo a 
stereoselective epoxidation that would occur opposite to either the (5R)-methyl (173) or 




















Scheme 4A.1: Retrosynthetic analysis for hyacinthacine C5-type analogues containing a 




4A.2. O-PMB protection of 137 to give 175 
 
At the time this reaction pathway was considered, a substantial amount of the 
oxazolidinone intermediate 137 was on hand and so this compound became the model 
study to explore the feasibility of this reaction pathway. With 137 in hand, we considered 
protecting the compounds only free hydroxy group at C2′′′′ as the O-PMB ether for several 
reasons. The PMB protecting group presented itself as a suitable candidate for this pathway 
as it has been thoroughly explored (synthesized and selectively removed) on similar 
substrates by previous members from the Pyne research group.184 Its primary purpose in 
this pathway was to prevent the hydroxy group at C2′′′′ from intramolecularly attacking 
and cyclising at C6 or C7 during the ring-opening of the epoxide 172. In addition to this, 
synthesizing the O-PMB ether factors a selective deprotection of this hydroxy group prior 
to cyclization to afford the pyrrolizidine core. Using this basis, the hydroxy group at C2′′′′ 
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of oxazolidinone 137 was subject to O-PMB protection by dissolving compound 137 in 
THF, followed by heating to 30 oC for 18 h after the addition of NaH, 4-methoxybenzyl 
chloride and a catalytic amount tetrabutylammonium iodide (TBAI) (Scheme 4A.2A). In 
this example, addition of TBAI is used to displace the chlorine atom in the 4-
methoxybenzyl chloride reagent; this forms 4-methoxybenzyl iodide (PMBI) which is far 
more reactive and can readily react with the present nucleophilic hydroxy group at C2′′′′. 
This salt also acts as a phase transfer catalyst in this reaction by solubilizing the alkoxide 
anion. After a TLC analysis indicated full consumption of the starting material, the crude 
mixture was purified by column chromatography and the O-PMB protected product 175 
was obtained in a good yield of 86%. An LRESIMS experiment of the sample initially 
confirmed the successfulness of this reaction, as it displayed a characteristic LRESIMS 
[M+Na]+ ion peak at m/z 656. The 1H NMR spectrum also displayed a characteristic singlet 
resonance at δH 3.87 (3H) which was identified to be the OCH3 of the newly added PMB 
group. This evidence and the additional aromatic resonances δH 7.38 – 7.06 (17H, m, ArH) 
and δH 6.88 (2H, dd, J = 8.2, 4.7 Hz, ArH) suggested the successful synthesis of product 
175. 
 
Scheme 4A.2: O-PMB protection of the oxazolidinone 137. 
 
 
4A.3. Synthesis of compound 176 
 
Compound 175 was then subject to our established RCM reaction conditions (Scheme 
4A.3). As anticipated, employing this procedure returned the RCM product 176 in a high 
yield of 78%. Formation of the respective pyrrole was initially disregarded on the basis of 
a HRESIMS experiment which found a [M+H]+ ion peak at m/z 530.2540. Additionally, 
the 1H NMR spectrum showed that the multiplicity of the resonance labelled H1′′ at δH 
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1.24 (3H, J = 6.8 Hz), appeared as a doublet and so was concluded to be the intended RCM 
product 176.   
 




Figure 4A.1: 1H NMR spectrum (500 MHz, CDCl3) of 176. 
 
4A.4. Attempts to synthesize epoxide 179 
 
The RCM compound 176 was then considered for epoxidation of the alkene at C6, C7. 
Deciding the appropriate reaction conditions was largely influenced by precedent results 
reported by a previous group member Thunwadee Ritthiwigrom.183 Shown in Scheme 
4A.4, Ritthiwigrom found that epoxidation of the alkene moiety of 177, using 1,1,1-
trifluoroacetone and oxone,185-188 returned exclusively the desired β-epoxide 178 in a high 
yield (81%). The high d.r. was attributed to the steric influence exerted by the C2 α-side 
chain. 










In this example, we noticed that both the starting material 177 and final product 178 from 
Ritthiwigrom’s work were analogous to our RCM intermediate 176 and the desired 
epoxide 179, respectively. We therefore hypothesized that subjecting 176 to the procedure 
described by Ritthiwigrom would result in a highly stereoselective synthesis of epoxide 
179. The envisioned diastereoselectivity can be explained considering the mechanism 
shown in Scheme 4A.5. More specifically, the dioxirane E is formed in situ from an initial 
reaction between 1,1,1-trifluoroacetone A and oxone® B to give intermediate D. After the 
sulfate ion is lost from D, the dioxirane E will then collapse back to give 1,1,1-
trifluoroacetone A after it has attacked the alkene at the less sterically hindered face present 
in the olefin containing species such as the RCM compound 176. For RCM 176, the 
envisioned stereochemistry proposed in 179 would be due to the potential steric hindrance 
that the C1 α-side chain might offer. In addition to this, the orientation of the (5R)-methyl 
group in 176 would also be a determining factor towards this diastereoselectivity as 













Therefore, the RCM product 176 was subject to the epoxidation procedure reported by 
Ritthiwigrom but no product 179 was observed. Instead, only starting material 176 was 
recovered along with initial signs of degradation to a complex mixture. Although several 
attempts to synthesize epoxide 179 are summarised in Table 4A.1, it was clear that only 
starting material 176 would be recovered each time (Scheme 4A.6). Therefore, an attempt 
to synthesize epoxide 179 was performed using the peracid mCPBA (Table 4A.1). Known 
as the Prilezhaev reaction, peracids such as mCPBA contain a high degree of polarisation 
within their peracid moiety.189 This results in a strong electrophilic oxygen atom that can 
add to alkenes.  Shown in Scheme 4A.7, the electrophilic hydroxy group in mCPBA would 
ideally react with 176 by adding the electrophilic oxygen to the C6, C7 alkene to form a 
cyclic “butterfly” transition state A. This procedure and mechanism is believed to be 
concerted and ultimately results in the synthesis of the desired epoxide as well as 3-
chlorobenzoic acid as a by-product. Unfortunately, this proved unsuccessful even when 
freshly recrystalized mCPBA was used and only returned a series of complex mixtures as 
deduced by TLC analysis and 1H NMR experiments of the crude reaction mixtures. After 
several attempts and various reaction conditions (Table 4A.1) we concluded that our 
substrate 176 would not readily undergo the formation of epoxide 179 and so our 




Scheme 4A.6: Attempts to synthesize epoxide 179. 
 
 








Table 4A.1: Epoxidation reaction conditions and attempts towards synthesizing epoxide 
179.   







MeCN 0 oC 1 h 






MeCN 0 oC 2 h 
 Starting material 





MeCN 0 oC 1 h 
Starting material 






MeCN 45 oC 1 h 
Starting material 
176 + complex 
mixture 




DCE 60 oC 1 h Complex mixture 
 
4A.5. Cis-dihydroxylation then cyclic sulfate synthesis of RCM product 
176 
 
Despite our unsuccessful attempts to synthesize the epoxide 179, a review of previous 
Ph.D. students works within our laboratory found that related anti-diol products were not 
always obtained from ring-opening the respective epoxide. Since 2003, Sharpless cyclic 
sulfate chemistry has become an integral procedure within the Pyne research group and 
has undoubtedly led to the synthesis of many natural products that contain anti-diol 
relationships.174, 183, 190-191 Shown in Scheme 4A.8 and considering syn-diol 180 as an 
example, this procedure operates through the conversion of the syn-diol 180 to the 
corresponding cyclic sulfate 181. Cyclic sulfate 181 then undergoes a regioselective SN2 
ring-opening of the cyclic sulfate with an oxygen nucleophile like cesium benzoate 
(Scheme 4A.8). Acid hydrolysis then cleaves the resultant sulfate ester which in this 
example, reveals the C6, C7 anti-protected-diol product 182.  
Having experienced reasonable success with our earlier established syn-dihydroxylation 
procedure described in Chapters 2 and 3, we envisaged that synthesizing the C6, C7 syn-
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diol 180 followed by its conversion to the C6, C7 anti-protected-diol 182 via Sharpless 
cyclic sulfate chemistry190 might prove to be a more reliable approach than epoxidation. 
We were particularly confident this would work, especially since the literature regarding 
the synthesis of cyclic sulfites and cyclic sulfates suggests they readily form from syn-1,2-
diols and are considered to be a more reactive variant of their related epoxides.190  
 
Scheme 4A.8: The mechanism for the formation of cyclic sulfate 181 and its ring-opening 
with cesium benzoate. 
 
 
Therefore, the RCM product 176 was initially subject to UpJohn cis-dihydroxylation157 
reaction conditions and returned two separable products which were spectroscopically 
deduced to be diol diastereomers 180 (62% yield) and 183 (18% yield) (Scheme 4A.9). 
The resultant d.r. was expected since a similar result was obtained and described in Chapter 
2. Since a larger portion of 180 was acquired, it was decided that this diastereomer would 
be used as the pilot study for the conversion to its respective C6, C7 anti-protected-diol 
182. Therefore, the ROESY NMR analysis of the parent diol 180 is shown in Figure 4A.2 
and will be referred to in a later comparison of the resultant products. Key correlations for 
180 were observed between H1′′‒H6 and H1′′‒H7 and so confirm the designated C6, C7 








Figure 4A.2: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 180 
(PMB ether not shown). 
 
Following our synthetic plan, diol 180 was then converted to the respective cyclic sulfate 
181. This was successfully performed by dissolving diol 180 in CH2Cl2, followed by the 
addition of an excess amount of Et3N and sulfuryl chloride (Scheme 4A.10). After stirring 
at 0 oC for 1 h, a TLC analysis indicated that the diol had quantitatively converted to a new 
product. An initial LRESIMS [M+H]+ ion peak at m/z 626 was observed and matched with 
the cyclic sulfate 181. Upon standing at room temperature over-night, the product had 
changed from a light-yellow oil colour to an orange brown and so a second TLC analysis 














to the yield and so for the remainder of this Ph.D. work, it was decided that the crude 
mixture of future cyclic sulfate derivatives should be subject to ring-opening as soon as 
they are synthesized. Despite the loss of the product, the cyclic sulfate 181 was quickly 
purified by column chromatography and subsequently subject to an SN2 ring-opening of 
the cyclic sulfate.  
 
Scheme 4A.10: Synthesis of the cyclic sulfate 181. 
  
 
4A.6. Ring-opening the cyclic sulfate 181 with cesium benzoate 
 
The cyclic sulfate 181 was then subject to ring-opening reaction conditions using an in situ 
formed benzoate anion as the nucleophile (Scheme 4A.11). More specifically, compound 
180 was dissolved in anhydrous DMSO followed by the addition of benzoic acid and 
cesium carbonate and heated at 40 oC for 3 h. After this time, a solution of THF, H2O and 
H2SO4 (8:3:1) was added to the reaction and the mixture was stirred at 40 
oC for 24 h. After 
a TLC analysis indicated full consumption of the starting material, the reaction mixture 
was neutralized with NaHCO3 and extracted using EtOAc. Unfortunately, an initial 
1H 
NMR spectrum of the crude reaction mixture indicated a largely complex mixture of 
products had formed. Regardless, the reaction was purified by column chromatography 
and a small amount of an inseparable mixture of single benzoate regioisomers 182 and 184 
was obtained. Although the TLC analysis indicated a single spot which had a LRESIMS 
[M+H]+ ion peak at m/z 668, there were many convoluted 1H NMR resonances; this was 
characteristic of two products. Unfortunately, the resolution was not clear enough to 
determine the diastereotopic ratio between both regioisomers. Since the mixture remained 
inseparable, we were persuaded to hydrolyse the benzoate in 182 and 184 to give the 
corresponding diol diastereomers 185 and 186, respectively. It was envisioned that both 
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diol products might be easier to separate, and so each resultant diastereomer could then be 
extensively characterised and also compared with the parent diol 180.  
 
Scheme 4A.11: Ring-opening of cyclic sulfate 181 with in situ formed cesium benzoate, 
then sulfate hydrolysis to give benzoate regioisomers 182 and 184. 
 
 
4A.7. Methanolysis of benzoates 182 and 184 
 
The inseparable mixture of benzoate regioisomers 182 and 184 was therefore subject to 
methanolysis using K2CO3 (1.5 eq.) in methanol which returned a near quantitative mixture 
of separable diols 185 and 186, respectively (17% and 7% yield, respectively over two 
steps) (Scheme 4A.12).183 Although the Rf for both products were considerably close, their 
successful separation was achieved and so extensive characterisation for both 
diastereomers was performed. For products 185 and 186, individual HRESIMS 
experiments found [M+H]+ ion peaks at m/z 564.6401 and 564.6498, respectively. More 
importantly, the 1H NMR spectra of both products were comparatively different from one 
another and did not match either of the earlier synthesized diol products 180 and 183. At 
this point, through comparison of the 1H NMR spectra in conjunction with the well-
established mechanisms of this reaction, it was confidently ascertained that both diols 185 
and 186 were diastereomeric C6, C7 anti-diol products. It was rationalized that the 
benzoate nucleophile would regioselectively ring-open the cyclic sulfate 181 at the 
relatively less hindered stereocentre C3a. Therefore, our initial suspicion was that the 
larger yielding of the two diol products was the C6, C7 anti-diol 185. This was confirmed 
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based on an extensive ROESY analysis, whereby strong resonance correlations were 
observed between H1′′‒H6 and H7‒H7a (Figure 4A.3). The configuration of the minor 
diastereomer 186 was deduced in a similar manner with the finding of a key resonance 
correlation between H1′′‒H7 (Figure 4A.4).  
 
















Figure 4A.3: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 185 
(PMB ether not shown). 
 
Figure 4A.4: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 186 
(PMB ether not shown). 
 
 





























To ensure that the C3′ hydroxy group undergoes a selective mesylation, both diols 185 and 
186 were individually subject to C6, C7 hydroxy group protection. Since the acetonide is 
only suited for synthesizing cyclic syn-diols, it was decided that both these hydroxy groups 
would undergo the conversion to their respective O-benzyl ethers which would later be 
removed in the final hydrogenolysis deprotection step. We envisioned that this would then 
allow for selective O-PMB deprotection, followed by subsequent oxazolidinone hydrolysis 
then annulation to give the desired pyrrolizidine core. Using our already established O-
benzyl ether synthetic procedure, (NaH, TBAI, BnBr, THF), both diols 185 and 186 were 
individually subject to this methodology (Scheme 4A.13). When attempted, only 185 was 
successfully protected and purified by column chromatography to give 187. Unfortunately, 
the other diastereomer 186 proved relatively inert to these reaction conditions (mostly 
starting material recovered). Although the desired product 188 may have been synthesized 
in small amounts, its recovery by column chromatography proved inefficient and the 
synthesis of 188 was unable to be confirmed. An attempt to synthesize 188 was only 
performed once and so further investigation is required to determine the seemingly inert 
starting material 186. Therefore, only 187 was available for an extensive ROESY NMR 
analysis. However, the significant closeness and overlap of key proton resonances (H7 
overlapping with H6 and H2′ overlapping with H5) made these stereochemical analyses 
difficult for 187 (Figure 4A.5). Since this was only a protective step, there was no reason 
to doubt the stereochemical assignments deduced in Section 4A.7. For this reason, 
compound 187 was taken through to the next stage of the synthesis which entailed the 













Figure 4A.5: 1H NMR spectrum (500 MHz, CDCl3) of 187 with overlapping key 
resonances highlighted in red. 
 
4A.9. O-PMB deprotection of 187 
 
It was unfortunate that diol 186 seemed inert to the O-benzyl ether conversion of the 
hydroxy groups at both C6 and C7. However, this procedure and set of conditions for the 
O-benzyl ether synthesis of diol 186 was only performed once and so these preliminary 
results may be unreliable. Further attempts could not be explored as this material was 
difficult to generate since it was the minor isomer of a relatively low yielding ring-opening 
of the cyclic sulfate 181. If the C6, C7 hydroxy benzylation of 186 was successful, the 
inefficiency of generating this material proved impractical. In contrast, the benzyl-ethers 










hydrolysis. Following a similar procedure reported by a previous group member, Karl 
Lindsay, compound 187 was treated with DDQ (2 eq.) in a CH2Cl2 and H2O (20:1) 
mixture.184 The reaction was stirred at 30 oC for 4 h and the full consumption of the starting 
material after this time was determined by TLC analysis. Unfortunately, the 1H NMR 
spectrum and the TLC analysis of the crude reaction mixture displayed a complex 
combination of products. Ideally, the desired product 189 would have formed via a single 
electron transfer (SET) resulting in complexs B-D (Scheme 4A.15). Complex D would 
then aromatize to generate complex E which would decompose to give the desired alcohol 
189 and the p-anisaldehyde by-product. However, the substrate 187 seemed to have 
undergone several different chemical transformations that were not extensively explored. 
Due to the small scale that this reaction was performed on (30 mg of compound 187), O-
PMB deprotection was never re-considered and so this pathway was discontinued. In the 
interest of time and reaction economy, this reaction pathway ultimately proved to be an 
unjustified expense. For these reasons, access to the hyacinthacine C-type analogues was 
reconsidered and will be discussed in detail in Chapter 4-Part B.  
 













4A.10. Chapter 4-Part A: Final remarks  
 
The initial attempt to access the hyacinthacine C5-type analogues containing a C6, C7 anti-
diol configuration has been described in this Chapter. Although it might not be apparent at 
first, exploring the feasibility of this pathway consumed a large portion of time and 
material allocated for the Ph.D. work described. The poor yield of the ring-opening of the 
cyclic sulfate 181 with the in situ formed benzoate anion delayed the progress of the 
pathway significantly and so this resulted in a lack of experimental conditions explored. 
The difficulty to synthesize more of the benzoate regioisomers 182 and 184 in conjunction 
with the seemingly difficult O-PMB removal of the diastereomer 187, diminished any 
enthusiasm to repeat this reaction series. These factors in conjunction with the short time 
remaining for this Ph.D. work led to a revision of the described pathway. This decision 
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proved successful and resulted in the synthesis of four C6, C7, anti-diol hyacinthacine C5-







Chapter 4 -Part B : Synthesis of putative (+)-
hyacinthacine C5, (+)-5-epi-hyacinthacine C5, the 
corrected structure of natural hyacinthacine C5 
and (+)-6,7-di-epi-hyacinthacine C5 
 
The unsuccessful attempts towards synthesizing hyacinthacine C5-type analogues 
containing a C6, C7 anti-diol configuration were described in Chapter 4-Part A. The 
pathway was discontinued largely based on its uneconomical yields, the unreactivity of 
key intermediates and the limited remaining timeframe for this work. However, these 
results helped influence the new revised pathway which ultimately led to the synthesis of 
our desired products. More specifically, it was found that the C6, C7 anti-diol 
configuration could be implemented after the pyrrolizidine core had been formed. Herein, 
the synthesis of the putative structure of hyacinthacine C5, the corrected structure of 
hyacinthacine C5, and two analogues that had been previously synthesized in the literature 
are described. These results in addition to the successful pathways described in Chapters 
2 and 3 were summarised as a manuscript and accepted for publication in the ACS Journal 
of Organic Chemistry.132 Full NMR spectroscopic experiment data are available in the 
related Supporting Information for this article. 
 
4B.1. Revised synthetic strategy towards hyacinthacine C5-type 
analogues containing a C6, C7 anti-diol configuration 
 
Chapter 4-Part A concluded that the C6, C7 alkene of RCM compound 176 was not 
susceptible to epoxidation. However, when 176 was subject to UpJohn cis-dihydroxylation 
parameters, the diol(s) 180 and 183 readily formed. Diol 180 was then converted to the 
respective cyclic sulfate 181, which then underwent a SN2 ring-opening of the cyclic 
sulfate moiety with benzoate and returned two benzoate regioisomers 182 and 184. 
Unfortunately, this was a low yielding reaction and so in conjunction with other 
contributing factors, this reaction pathway was discontinued. In contrast, Chapters 2 and 3 
demonstrated that the pyrrolizidine core containing the C6, C7 syn-diol was readily 
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accessible. It was therefore decided that the pyrrolizidine core would need to be 
synthesized first prior to establishing the C6, C7 anti-diol. After reviewing the successful 
synthetic pathway described in Chapters 2 and 3, an opportunity to perform our established 
C6, C7 anti-diol chemistry using pyrrolizidines 165, 149 and 151 was recognized and is 
shown in Scheme 4B.1. More specifically, pyrrolizidines 165, 149 and 151 contain two 
different hydroxy protecting groups within the compound and are specific to either the A 
or B ring of the bicyclic compound. On the A-ring of the pyrrolizidine, the hydroxy groups 
at C6 and C7 were protected as their respective O-benzyl ethers. On the B-ring of the 
pyrrolizidine, the syn-diol moiety at C8b and C3a was protected as the respective 
acetonide. The only remaining hydroxy group that is unprotected is found at C8. We 
therefore envisioned protecting this hydroxy group at C8 to give 190, followed by a 
selective deprotection of the acetonide under acidic conditions. Then, employing our 
procedure to synthesize the cyclic sulfate 191, followed by an SN2 ring-opening of the 
cyclic sulfate moiety with benzoate would likely result in the synthesis of potentially six 
benzoate regioisomers. Methanolysis of the C6 or C7 benzoate group would return four 
diols, 192, 193, 194 and 195 which after hydrogenolysis and purification by ion-exchange 














Scheme 4B.16: Revised Synthetic plan towards the C6, C7 anti-diol containing 
hyacinthacine C5-type analogues. 
 
 
At the time this reaction pathway was considered, pyrrolizidine 165 was on hand and so 
became the model study for this work. This led to the successful synthesis of the proposed 
structure for (+)-hyacinthacine C5 and (+)-5-epi-hyacinthacine C5. However, for clarity, 
the results and procedures employed on each pyrrolizidine analogue 165, 149 and 151 will 
be presented at their appropriate segments. It is also noted that employing this synthetic 
pathway for pyrrolizidines 149 and 151 ultimately lead to the same hyacinthacine C5-type 
products. Both pyrrolizidines were still subject to the same procedures and have been 
included since they resulted in noteworthy diastereotopic ratios of the desired C6, C7 anti-






4B.2. O-Benzyl ether synthesis at C8 of pyrrolizidines 165, 149 and 151 
 
The pyrrolizidines 165, 149 and 151 were considered for the protection of their remaining 
free hydroxy group at C8 due to foreseen selectivity issues during the formation of their 
respective cyclic sulfate. The decision was made to convert the hydroxy group to its O-
benzyl ether since we were familiar with this procedure and had previously obtained 
reasonably reliable results and overall high yields. Therefore, individual samples of 
pyrrolizidine 165, 149 and 151 were subject to O-benzyl protection using NaH, TBAI, 
BnBr, THF, and were successful after returning products 196, 197 and 198, respectively 
in yields of 87%, 89% and 78%, respectively (Scheme 4B.2). After purification, each 
product was extensively characterized but will be discussed in further detail in the next 
Section 4B.3. 
 






4B.3. Acid hydrolysis of the acetonide from pyrrolizidines 196, 197 and 
198 
 
With the protected pyrrolizidines 196, 197 and 198 in hand, each was individually subject 
to acid hydrolysis of the acetonide. This was performed in a similar manner to the 
acetonide hydrolysis of pyrrolizidine 165 described in Chapter 3 which entailed dissolving 
the compound in a solution of EtOH/H2O (9:1, respectively), followed by the addition of 
several drops of 5 M HCl (Scheme 4B.3). The reaction was then stirred at room 
temperature until full consumption of the starting material was confirmed by TLC analysis. 
After neutralizing the HCl salt with aqueous NaHCO3 a generally high yield was obtained 
for each resultant diol, 199, 200 and 201. In addition to this, the full consumption of the 
starting material was easily confirmed by the Rf change since each new product became 
significantly more polar.  
 





All three pyrrolizidine diols were extensively characterized. Although we were confident 
their relative configurations assigned in both Chapters 2 and 3 had not changed, their 
characterisation is included for a later comparison and proof of the respective resultant C6, 
C7 anti-diol products formation. More specifically, syn-diol 199 was subject to an 
extensive ROESY NMR analysis where key correlations between H1''‒H6, H1''‒H7a 
(weak), H6‒H7 and H5‒H3 are shown below (Figure 4B.1).  
 
  
Figure 4B.6: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 199 
(C1 O-benzyl ether not shown). 
 
Syn-diols 200 and 201 were also extensively characterized through NOE experiments to 
confirm their relative configurations. These results can be found in the Supporting 
Information accompanying the resultant ACS Journal of Organic Chemistry publication, 
but the for the purpose of this work, selected NOE enhancements for 200 are included and 




































Figure 4B.7: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 200 of A) H7 and B) 
H6 and their respective key observed correlations projected onto Bottom: a DFT 
minimized molecular model [B3LYP/6-31G(d)] of 200 (C1 O-benzyl ether not shown).  
 
Similarly, 201 was also subject to extensive NOE experiments, but for brevity only the 
enhancements for H6 and H7 are included and display key positive correlations between 











































Figure 4B.8: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 201 of A) H7 and B) 
H6 and their respective key observed correlations projected onto Bottom: a DFT 
minimized molecular model [B3LYP/6-31G(d)] of 201 (C1 O-benzyl ether not shown). 
 
4B.4. Synthesis of cyclic sulfates 202, 203 and 204, then ring-opening 
with in situ formed cesium benzoate  
 
In three separate reactions, the diols 199, 200 and 201 were each dissolved in CH2Cl2, 
followed by the addition of an excess amount of Et3N (2.5 eq.) and sulfuryl chloride (1.5 
eq.) (Scheme 4B.4). These reaction conditions converted 199, 200 and 201 to the 
corresponding cyclic sulfates 202, 203 and 204, respectively. Described in Chapter 4A, 
our previous experience with the fast degrading nature of the cyclic sulfate 181 influenced 
the decision to use the crude reaction mixture in the next step of the synthetic pathway 





































the LRESIMS [M+H]+ ion peak at m/z 552 and TLC analysis to indicate full consumption 
each starting diol and formation of their respective cyclic sulfate products. Each cyclic 
sulfate then underwent subsequent SN2 ring-opening with CsOBz (prepared in situ from 
Cs2CO3 and BzOH) and each individual result is discussed below.  
 
Scheme 4B.19: Synthesis of of cyclic sulfates 202, 203 and 204. 
 
 
4B.4.1. Ring opening cyclic sulfate 202 
 
Ring opening the cyclic sufate 202 with the in situ generated CsOBz returned regioisomers 
205 and 206 in isolatable yields of 61% and 12%, respectively (Scheme 4B.5). The regio- 
and stereochemistry of 205 was determined through observed correlations from both 
gCOSY and ROESY NMR analysis. More specifically, it was observed that the resonance 
for the proton sharing the stereogenic carbon with the newly added benzoate proved the 
most deshielded and characteristically appeared slightly above δH 5.0 ppm. Analysis of the 
gCOSY of 205 found a strong correlation between H1″ (δH 1.24 ppm) and H5 (δH 3.21 
ppm), which was subsequently found to correlate with H6 (δH 3.94 ppm) (Figure 4B.4). 
The H6 correlation with the lone triplet resonance at δH 5.13 ppm (otherwise H7) clearly 
indicated that the benzoate group was at C7 as opposed to C6. With the regiochemistry 
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established, our focus turned to confirming the stereoconfiguration of the benzoate at C7. 
Consulting the ROESY experiment for 205, we noted a relatively weaker correlation 
between H6−H7 than that observed between H6−H7 in the parent diol 199. Additionally, 
the H1″−H6 relationship showed to be far more intense and so collectively suggested 
successful inversion at C7 (Figure 4B.5). Similarly, the gCOSY analysis of compound 206 
identified H5 to strongly correlate with the doublet resonance at δH 5.31 ppm, which was 
logically assigned H6 (Figure 4B.6). Although the ROESY analysis showed a weak 
correlation between H6−H7, it undoubtedly found that the correlation between H5−H6 was 
of stronger intensity (Figure 4B.7). Here, the diastereoselectivity of the synthesized 
regioisomers 205 and 206 is a result of steric hindrance induced by the C4 methyl 
stereochemistry from the cyclic sulfate 202. These results suggest that the large benzoate 
nucleophile attacks the less sterically hindered carbon at C7 resulting in the dominant 
product 205. The reaction is not completely selective since the C6 benzoate regioisomer 
206 was also obtained. 
 
Scheme 4B.20: Ring-opening of cyclic sulfate 202 with in situ formed cesium benzoate, 












Figure 4B.9: gCOSY NMR spectrum (500 MHz, CDCl3) of 205 and a DFT minimized 
molecular model [B3LYP/6-31G(d)] of 205 (O-benzyl ethers not shown). 
 
 
Figure 4B.10: 2D ROESY NMR spectrum (500 MHz, CDCl3) with the H1″−H6 
correlation projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 205 





























































Figure 4B.11: gCOSY NMR spectrum (500 MHz, CDCl3) of 206 and a DFT minimized 
molecular model [B3LYP/6-31G(d)] of 206 (O-benzyl ethers not shown). 
 
  
Figure 4B.12: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 206 



























































4B.4.2. Ring opening of cyclic sulfate 203 
 
Ring-opening of 203 gave an inseparable mixture of two pyrrolizidines, 207 and 208, in a 
49% yield (Scheme 4B.6). We were confident both these regioisomers had formed on the 
basis of LRESIMS [M+H]+ ion peak at m/z 594 of the purified product, as well as the 
appearance of characteristic resonance peaks for two regioisomers displayed in the 1H 
NMR spectra of the purified products. Unfortunately, the ratio between both diastereomers 
was difficult to ascertain by 1H NMR analysis and so the mixture was taken through to the 
next step in hope that the resultant C6, C7 diols would separate. 
 
Scheme 4B.21: Ring-opening of cyclic sulfate 203 with in situ formed cesium benzoate, 
then sulfate hydrolysis to give benzoate regioisomers 207 and 208. 
 
 
4B.4.3. Ring opening of cyclic sulfate 204 
 
Ring opening the cyclic sufate 204 with in situ formed CsOBz returned a 2:1 mixture of 
separable benzoate pyrrolizidines regioisomers 209 and 210, in yields of 39% and 23%, 
respectively (Scheme 4B.7). Due to their ease of separation, compounds 209 and 210 were 
the attention of gCOSY and extensive NOE analysis. It was observed that the proton 
sharing the stereogenic carbon with the newly added benzoate proved the most deshielded 
and characteristically appeared at δH >5.0 ppm. More specifically, the gCOSY analysis of 
209 identified a strong correlation between H1″ (δH 1.32 ppm) and H5 (δH 3.42−3.30 ppm) 
which was subsequently found to correlate with the most deshielded proton at δH 5.04 ppm, 
namely H6 (Figure 4B.8). After the remaining protons were identified in a similar manner, 
NOE experiments of 209 identify key correlations between H6−H1″, H6−H3, H7a−H7, 
and H7a−H5 (Figure 4B.8).  Using a similar method of reasoning, 210 was identified to 
have resulted from SN2 attack of the benzoate anion at the C8b position of the cyclic sulfate 
149 
 
204. Subsequent NOE experiments included in this Chapter display key correlations 
between H1″−H3, H5−H6, H7−H1, H7a−H2, and H1′−H2 (Figure 4B.9). The reigo-
selectivity of the products formed is similar to the results obtained for the ring opening of 
cyclic sulfate 202. More specifically in cyclic sulfate 204, the benzoate nucleophile slightly 
favours attack at C8b. However, because the C4 methyl of the cyclic sulfate 204 is on the 
concave face of the molecule, the regioisomeric ratio is relatively closer to equal amounts 
for each regio-isomer 209 and 210 obtained. 
 
Scheme 4B.22: Ring-opening of cyclic sulfate 204 with in situ formed cesium benzoate, 
















Figure 4B.13: Top: gCOSY NMR spectra (500 MHz, CDCl3) of 209 and Bottom: Selected 
1D-NOE spectra (500 MHz, CDCl3) of 209 of A) H6 and B) H7a and their respective key 
observed correlations projected a DFT minimized molecular model [B3LYP/6-31G(d)] of 






















































Figure 4B.14: Top: gCOSY NMR spectra (500 MHz, CDCl3) of 210 and Bottom: Selected 
1D-NOE spectra (500 MHz, CDCl3) of 210 of A) H6 and B) H7 and their respective key 
observed correlations projected a DFT minimized molecular model [B3LYP/6-31G(d)] of 
210 (C1, C2 and C1′ O-benzyl ether not shown). 
 
4B.5. Methanolysis of the benzoates 205, 206, 209, 210 and the 
inseparable mixture of 207 and 208 
 
The individual benzoate regio-isomers 205, 206, 209, 210 and the inseparable mixture of 





















































by using the same procedure described in Chapter 4A, which involved dissolving each 
compound in methanol, followed by the addition of K2CO3.  
4B.5.1. Methanolysis of benzoates 205 and 206 
 
Methanolysis of the benzoate regio-isomers 205 and 206 returned diols 211 (79% yield) 
and 212 (90% yield), respectively (Scheme 4B.8).  
 
Scheme 4B.23: Methanolysis of 205 and 206 to give diol products 211 and 212, 
respectively. 
 
The HRESIMS of 211 and 212 displayed [M+H]+ ion peaks at m/z 490.2617 and 490.2613, 
respectively. An initial comparison of the 1H NMR spectra of 211 and 212 with that of the 
parent syn-diol 199 clearly indicated that these were not the same product. This, in 
combination with an extensive NMR analysis, suggested that the single-stereocentre at 
either C6 or C7 for compounds 211 and 212, respectively had undergone inversion. 
Interestingly, diol 211 was found to be the enantiomer of the pyrrolizidine 45 reported by 
Yu et al. in 2011 (Figure 4B.10) and so it was reassuring to find an identical match in both 
the 1H and 13C NMR (Δ δH = 0.01−0.03 ppm, Δ δC = 0.1−0.2 ppm) spectroscopic data 
when compared with this reported literature compound (Table 4B.1).129 In addition to this, 
compound 211 fortuitously crystallized and so allowed the unequivocal confirmation of its 





Figure 4B.15: Our synthetic 211 and its enantiomer 45 which was synthesized in 2011 by 
Yu et al.129 
 
 
Figure 4B.16: Crystals of 211 (left) and the ORTEP plot of the crystal structure of the 
C30H35NO5 molecule of 211 with labelling of selected atoms, showing only one set of sites 
for the disorder in the benzyl groups. Anisotropic displacement ellipsoids display 30% 














Table 4B.2: Comparison of literature 1H NMR (600 MHz, CDCl3) and 
13C NMR (75 MHz, 
CDCl3) data of Yu et al. Lit. 45
129 with the 1H NMR (500 MHz, CDCl3) and 
13C NMR 
(125 MHz, CDCl3) of our synthetic 211.  
 
Focusing our attention to the related diol 212, a ROESY analysis displayed a key 
correlation between H5−H6 which corroborated with the fact that the earlier benzoate 
inversion had successfully occurred at C6 (Figure 4B.12).  
 
  
Figure 4B.17: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 212. 
 
 1H NMR ( J in Hz) 13C NMR () 
position 45 (Yu et al.)
129
  211 45 (Yu et al.)
129
 211 
1 4.08, t (3.3) 4.07, t (3.6) 87.4 87.2 
2 4.12, t (3.4) 4.10, t (3.6) 86.0 86.0 
3 3.27-3.22, m 3.23, dt (4.5, 9.8) 69.1 69.2 
5 2.99-2.91, m 2.93, dq (6.4, 12.6) 65.2 65.3 
6 3.67, t (8.0) 3.68, t (8.1) 83.2 83.1 
7 3.98, t (7.5) 3.97, t (7.5) 80.2 80.2 
7a 3.41, dd (3.9, 7.4) 3.48-3.40, m 72.2 72.3 
1´ 3.47, d (6.5) 3.48-3.40, m 71.5 71.3 





























4B.5.2. Methanolysis of benzoates 209 and 210 
 
Individual base-mediate hydrolysis of the benzoate group in pyrrolizidines 209 and 210 
returned their respective diols 213 (90%) and 214 (83%) (Scheme 4B.9). The HRESIMS 
of 213 and 214 found [M+H]+ ion peaks at m/z 490.2608 and 490.2615, respectively.  
 
Scheme 4B.24: Methanolysis of benzoates 209 and 210 to give diol products 213 and 214, 
respectively.  
 
After conducting NMR spectroscopic experiments for both products, it was noted that the 
1H and 13C NMR spectra of these pyrrolizidines were different to that of their parent 
pyrrolizidines 200 and 201, and so clearly indicated successful configurational inversion 
at either C6 or C7, respectively.  
For diol 213, a ROESY NMR analysis indicated the successful inversion at C6, as key 
correlations between H1′′−H6 and H7−H7a were identified (Figure 4B.13). 
Comparatively, a ROESY NMR analysis for diol 214 displayed a distinct correlation 
between H5−H6 indicating a syn-relationship between the protons, suggesting that the C6 
hydroxy group is on same face as the (5R)-methyl group and has not inverted (Figure 
4B.14). This evidence therefore suggested the inversion at C7 since it is the only other site 






Figure 4B.18: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 




Figure 4B.19: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 




















































4B.5.3. Methanolysis of the inseparable mixture of benzoates 207 and 208 
 
The inseparable mixture of benzoates 207 and 208 was also subject to methanolysis which 
resulted in a clean hydrolysis of their benzoate moieties to give the separable pyrrolizidine 
diols 213 and 214 in a 1:4 ratio. The 1H and 13C NMR spectra of both products matched 
the respective diols obtained from hydrolysis of benzoates 209 and 210 described above. 
This led us to believe their respective benzoate pyrrolizidines, 207 and 208, were originally 
synthesized in an approximately 1:4 ratio. Here, the ring-opening of cyclic sulfate 203 
seems to return a contrasting regio-selectivity to our prior results. More specifically, the 
regiochemical outcome of the ring-opening reaction of the cyclic sulfate 203 with CsOBz 
can be best described by considering the two possible reactive conformations 203A and 
203B of cyclic sulfate 203, and the preference for 1,2-diaxial-like ring opening as shown 
in Scheme 4B.10. In this example, attack predominates at C3a of conformer 203A resulting 
in 208 as the major regioisomer. When considering conformation 203B, attack at C8b is 
less likely to occur (to give 207) due to unfavourable steric interactions between the 
nucleophile (−OBz) and the pseudoaxial C4 methyl group and the pseudoaxial proton H8a. 
 
Scheme 4B.25: Proposed reactive conformers of 203 to give the major benzoate 208 along 







4B.6. Hydrogenolysis of pyrrolizidines 211, 212, 213 and 214 
 
Confident that we had successfully synthesized all four diastereomers 211, 212, 213 and 
214, the final step in the synthesis was to hydrolyse the O-benzyl ethers from each of these 
compounds. To do this, each pyrrolizidine was individually subject to hydrogenolysis over 
PdCl2 and stirred until LRESIMS confirmed full consumption of the starting material. All 
final products were then neutralized by basic ion-exchange chromatography and returned 
the hyacinthacine C5-type related alkaloids as described.  
 
4B.6.1. Hydrogenation of pyrrolizidines 211 and 212 
 
Debenzylation of pyrrolizidines 211 and 212 returned the putative structure of 
hyacinthacine C5 [[α]𝐷
25+9.5 (c 1.00, H2O)] along with its (+)-5-epi-hyacinthacine C5 215 
[[α]𝐷
25+10.3 (c 1.00, H2O)], respectively (Scheme 4B.11). Since we were confident in their 
structures and absolute configurations, it was unsurprising to find that the 1H and 13C NMR 
spectroscopic data of our synthetic purported hyacinthacine C5 and 215 matched their 
literature reported structures. More specifically, a close spectroscopic match was noted for 
our synthetic purported hyacinthacine C5 and the previously synthesized proposed 
structure of (+)‒hyacinthacine C5 (Table 4B.2: Δ δH = 0.01−0.04 ppm, Δ δC = 0.6− 0.7 
ppm) [lit.130 [α]𝐷
30+8.0 (c 1.00, H2O)]. Synthetic 215 also proved to be a close 
spectroscopic match with Tamayo and coworkers synthetic hyacinthacine C-type analogue 
64 (lit.130 [α]𝐷
30+1.5 (c 1.00, H2O)] An internal reference was not included in the NMR 
sample of 215 since it would be difficult to remove prior to glycosidase testing. Therefore, 
the 1H NMR spectrum of 215 was referenced to the D2O solvent residual peak at 4.79 ppm 
and the 1H NMR spectrum resonance peaks were consistently close with those of 64 (Table 
4B.3: Δ δH = 0.02−0.03 ppm). The 
13C NMR of 215 was referenced to internal MeOH, but 
the chemical shifts shown in Table 4B.3 were consistently shifted 2.5−2.6 ppm when 
compared with the 13C NMR of 64. Comparatively, the 1H and 13C NMR chemical shifts 
reported for 64 are expressed in reference to the internal standard sodium 3-
(trimethylsilyl)propionate (TPS) in D2O.
130 This satisfactorily explains the slight NMR 




Scheme 4B.26: Hydrogenolysis of 211 and 212 to give the putative structure of 
hyacinthacine C5 and hyacinthacine C5-type analogue 215, respectively. 
 
Table 4B.3: Comparison of the literature 1H NMR (500 MHz, D2O) and 
13C NMR (125 
MHz, D2O) spectroscopic data of Tamayo et al. Lit. (+)-hyacinthacine C5
130 with the 1H 
NMR (500 MHz, D2O) and 
13C NMR (125 MHz, D2O) data of our synthetic purported 
compound for (+)-hyacinthacine C5. 
 1H NMR ( J in Hz) 13C NMR () 
position 
(+)-hyacinthacine C5 
(Tamayo et al.)130 
The purported (+)-
hyacinthacine C5 
from this work 
(+)-hyacinthacine C5 
(Tamayo et al.)130 
The purported (+)-
hyacinthacine C5 
from this work 
1 4.19, t (6.9) 4.15, t (7.0) 79.6 80.2 
2 3.99, t (6.9) 3.96, t (7.0) 78.7 79.3 
3 2.97-2.93, m 2.96-2.87, m 65.3 66.0 
5 2.97-2.93, m 2.96-2.87, m 70.4 71.1 
6 3.72-3.66, m 3.74-3.61, m 82.3 82.9 
7 4.15, t (6.9) 4.11, t (7.1) 79.0 79.6 
7a 3.08, t 3.05, t (6.8) 70.5 71.2 
8 3.72-3.66, m 3.74-3.61, m 62.2 62.9 








Table 4B.4: Comparison of the literature 1H NMR (500 MHz, D2O) and 
13C NMR (125 
MHz, D2O) spectroscopic data of Tamayo et al. Lit. 64
130 with the 1H NMR (500 MHz, 
D2O) and 
13C NMR (125 MHz, D2O) data of our synthetic 215. 
 
4B.6.2. Hydrogenation of pyrrolizidines 213 and 214 
 
Debenzylation of 213 and 214 returned hyacinthacine C5-type compounds (+)-6,7-di-epi-
hyacinthacine C5 216 [[α]𝐷
25+5.2 (c 1.00, H2O)] and 217 [[α]𝐷
25+6.8 (c 1.00, H2O)] 
(Scheme 4B.12). To our fortune and as hypothesized by Reissig and Goti et al.,131 the 1H 
and 13C NMR spectroscopic data of our synthetic 216 were found to be essentially identical 
with those of the isolate labelled hyacinthacine C5 [lit.
117 [α]𝐷 +1.5 (c 0.22, H2O)] in 2007 
(Table 4B.4). An internal standard was not included in the NMR sample of 216 since it 
would be difficult to remove prior to glycosidase testing. Therefore, the 1H NMR chemical 
shifts of 216 were referenced to the D2O solvent residual peak at 4.79 ppm and the 
1H 
NMR spectrum resonance peaks were consistently close with those of the isolate labelled 
hyacinthacine C5 (Table 4B.4: Δ δH = 0.11−0.15 ppm). The 
13C NMR of 216 was 
referenced to internal MeOH, but the chemical shifts shown in Table 4B.4 were 
consistently shifted 2.9−3.0 ppm when compared with the 13C NMR of the isolate labelled 
hyacinthacine C5. Comparatively, the 
1H and 13C NMR chemical shifts reported for the 
natural isolate labelled hyacinthacine C5 are expressed in reference to the internal standard 
sodium 3-(trimethylsilyl)propionate (TPS) in D2O.
117 
 1H NMR ( J in Hz) 13C NMR () 
position 











1 4.31, t (7.5) 4.28, t (7.5) 73.1 75.6 2.5 
2 3.99, t (7.5) 3.96, t (8.4) 78.7 81.2 2.5 
3 2.81, m 2.78, dd (4.6, 9.3) 70.6 73.1 2.5 
5 3.16, m 3.14, q (4.9, 6.1) 62.7 65.2 2.5 
6 4.15, m 4.13, dd (2.4, 4.2) 79.7 82.2 2.5 
7 4.24, m 4.21, dd (2.4, 4.7) 74.3 76.8 2.5 
7a 3.49, m 3.46, dd (4.6, 7.2) 69.1 71.6 2.5 
8 
3.71, dd (4.7) 
3.80, dd (4.0, 11.9) 
3.68, dd (4.6, 12.0) 
3.78, dd (4.0, 12.3) 
61.6 64.2 2.6 
9 1.19, d (6.7) 1.17, d (6.9) 14.0 16.5 2.5 
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Thus, the correct structure of natural hyacinthacine C5 has the opposite configuration at the 
three contiguous stereogenic centres, C5, C6, and C7, to that of the originally proposed 
structure. The authors on the isolation of this natural product had determined the correct 
relative configurations of the individual A and B-rings of hyacinthacine C5 but had 
incorrectly assigned the absolute configuration of the A-ring. Confirmation of these 
assignments were made through detailed NOESY studies which unequivocally showed 
216 to be the correct structure (included in the Appendix for this work). 
 
Scheme 4B.27: Hydrogenolysis of 213 and 214 to give the corrected structure of 












Table 4B.5: Comparison of literature 1H NMR (500 MHz, D2O) and 
13C NMR (125 MHz, 
D2O) spectroscopic data of Kato et al. Lit. (+)-hyacinthacine C5117
 with the 1H NMR (500 
MHz, D2O) and 
13C NMR (125 MHz, D2O) data of our synthetic 216. 
 
However, when comparing the NMR spectroscopic data of our synthetic hyacinthacine C5-
type analogue 217 [[α]𝐷
25+6.8 (c 1.00, H2O)] and its HCl salt 217.HCl [[α]𝐷
25-4.5 (c 1.00, 
H2O)] with those reported for the same compound 120 [lit.
131 [α]𝐷
21+0.75 (c 0.48, H2O)], 
prepared by Reissig and Goti et al. we noted significant spectroscopic differences (Table 
4B.5 and Table 4B.6). In the 1H NMR spectrum of compound 217, the chemical shifts of 
H3, H5, and H7a appeared upfield in comparison to those for 120 (Table 4B.5). 
Additionally, the chemical shifts of the aforementioned protons in 217·HCl appeared 
significantly downfield when compared with compound 120 (Table 4B.5). Comparison of 
the 13C NMR spectroscopic data of both 217 and 217·HCl with those published for 120 
seems to more closely aligned with 217·HCl (Table 4B.6). However, it was concluded that 
Reissig and Goti et al. did not make this salt, as there was still significant differences 
between both spectra (especially for the carbons identified in the product as C2, C3, C5, 
C7a, and C8). Despite both having been proposed to contain the same stereochemistry and 
absolute configuration, we could not conclude that our synthetic 217 was the same 
structure as 120 reported by Reissig and Goti et al. 
 1H NMR ( J in Hz) 13C NMR () 
position 
(+)-hyacinthacine 












1 4.01, t (7.6) 
4.14, apparent q 
(7.7) 
78.2 75.2 3.0 
2 3.80, t (7.6) 3.94, t (7.8) 81.0 78.1 2.9 
3 3.01, m 3.14, td (4.0, 9.1) 65.1 62.1 3.0 
5 2.81, dq (6.9, 7.6) 2.95, dq (6.6, 7.4) 61.4 58.4 3.0 
6 3.60, t (7.6) 3.74, t (7.7) 81.7 78.8 2.9 
7 3.99, t (7.6) 
4.14, apparent q 
(7.7) 
77.8 74.8 3.0 
7a 3.24, t (7.6) 3.38, t (7.6) 69.2 66.3 2.9 
8 
3.55, dd (4.1, 
12.0) 
3.50, dd (5.3, 
12.0) 
3.66, dd (4.7, 9.5) 65.7 62.8 2.9 
9 1.13, d (6.9) 1.27, d (6.7) 15.7 12.8 2.9 
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Table 4B.6: Comparison of literature 1H NMR (400 MHz, D2O) spectroscopic data of 
Reissig and Goti et al. Lit. 120131 with the 1H NMR (500 MHz, D2O) data of our synthetic 
217 and 217·HCl. 
 
Table 4B.7: Comparison of literature 13C NMR (100 MHz, D2O) spectroscopic data of 
Reissig and Goti et al. Lit. 120131 with the 13C NMR (125 MHz, D2O) data of our synthetic 
217 and 217·HCl. 
 
Since there is disagreement in the NMR spectroscopic data between compound 217 and its 
literature reported compound 120131 by Reissig and Goti et al. the structural elucidation of 
compound 217 is detailed below. All NOE enhancements for 217 can be found in the 
Appendix for this work but for brevity, only key correlations for compound compound 217 
are shown in Figure 4B.15. These correlations are observed between H7−H9, H7−H1, 
H5−H6, and H5−H7a; this suggested we had assigned the correct stereochemistry for the 
A-ring of 217. 
 1H NMR ( J in Hz) 
position 





hyacinthacine C5 217·HCl 
1 3.99, t (8.6) 4.07-3.97, m 4.24, t (8.7) 
2 3.80, dd (8.4, 9.6) 3.90, t (8.1) 3.99, dd (8.5, 10.2) 
3 3.41, dt (3.6, 9.6) 3.33, dt (4.9, 9.0) 3.78-3.70, m 
5 3.64-3.56, m 3.41, dt (5.7, 11.7) 4.06, qd (2.9, 7.0) 
6 3.95, t (3.0) 4.07-3.97, m 4.15, d (2.9) 
7 4.15, t (2.4) 4.18, t (4.0) 4.40, s 
7a 3.28, dd (1.0, 8.4) 3.07, dd (3.7, 8.1) 3.78-3.70, m 
8 3.64-3.56, m 3.67, t (4.0) 3.81, t (2.6) 
9 1.21, d (6.8) 1.24, d (7.1) 1.46, d (7.0) 
 13C NMR () 
position 





hyacinthacine C5 217·HCl 
1 76.7 78.0 75.6 
2 75.3 77.9 73.6 
3 63.4 62.2 65.2 
5 60.8 58.1 64.0 
6 79.1 79.7 or 78.6 79.4 
7 76.8 79.7 or 78.6 76.50 
7a 74.1 72.1 76.46 
8 59.1 62.9 56.5 







Figure 4B.20: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 217 of A) H7 and B) 
H5 and their respective key observed correlations projected onto Bottom: a DFT 
minimized molecular model [B3LYP/6-31G(d)] of 217. 
 
4B.7. Peracetylation of 217 
 
To further support the absolute configuration assigned to this structure, synthetic 217 was 
peracetylated to the pentaacetate 218. This procedure was based on precedent literature 
from previous members of the Pyne research group183 and involved dissolving 217 in a 
solution of pyridine and adding acetic anhydride along with 4-dimethylaminopyridine 
(Scheme 4B.13). The reaction returned a near quantitative yield of the desired pentaacetate 
product, as indicated by the LRESIMS [M+H]+ ion peak at m/z 430. After column 








































displayed significant correlations between H1−H7, H2−H7a, H5−H6, H2−H8, H6−H7a, 
and Me−H3 (See Appendix). For brevity, only the 1D NOE enhancements for H6 and H7 
have been included in this Chapter (Figure 4B.16). These correlations are consistent with 
our proposed structures for 218 and indirectly support the absolute configuration of 217. 
 






















Figure 4B.21: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 218 of A) H6 and B) 
H7 and their respective key observed correlations projected onto Bottom: a DFT 
minimized molecular model [B3LYP/6-31G(d)] of 218. 
 
Throughout the course of this work, the relative configurations assigned for each 
intermediate as well as each final product have been consistent with our NOE/ROESY 
NMR analyses. Moreover, the pyrrolizidines obtained in this work have been anticipated 
as their synthesis has been based on precedent work within the Pyne research group as well 
as the established mechanism of the O-mesylation then cyclization reaction. This 
specifically involves an initial O-mesylation of the less-hindered hydroxy of the amino-
diols 152, 153 and 166 (described in Chapter 2 and 3), followed by an SN2-type ring closure 
to form the desired pyrrolizidine products 165, 149 and 151. Although there is the potential 
for double inversion at the participating carbinol carbon, this only occurs if the secondary 
mesylate is displaced by a chloride ion prior to ring-closure. We are confident this did not 





























C6, C7 anti-diol 211 described in this Chapter fortuitously crystalized and unequivocally 
confirmed the stereochemistry and pyrrolizidine structure.  
Interestingly, it is noted that Reissig and Goti et al. successfully synthesised the proposed 
structure of hyacinthacine C5 but did not employ the same procedure to obtain its C5 
epimer 120. Instead they cyclized the bis-mesylated amino product 117A described earlier 
in Chapter 1 and so there is the possibility that cyclization could afford the surprisingly 
stable 4-membered bicyclic N-heterocycle192 219 (Scheme 4B.14). This issue has not yet 
been resolved and so highlights the difficulty often associated with assigning the structures 
of the hyacinthacine C-type analogues, synthetic or naturally derived. Further investigation 
is certainly required.  
 
Scheme 4B.29: Proposed synthesis of the alternative 4-membered bicyclic N-heterocycle 




Regardless, our synthetic purported compound for hyacinthacine C5, (+)-5-epi-
hyacinthacine C5 215 and (+)-6,7-di-epi-hyacinthacine C5 217 were cross examined with 
the hyacinthacine C-type natural products labelled hyacinthacines C1
105 or C4,
117 but no 
NMR spectroscopic match was apparent with any of the natural isolates. All final products 
168 
 
synthesized in this Chapter were subsequently assessed for their glycosidase inhibitory 
potential and these are reported in Chapter 6.  
 
4B.8. Chapter 4-Part B: Final remarks 
 
Chapter 4B has disclosed the successful synthetic approach that resulted in four of the 
eleven hyacinthacine C-type analogues synthesized in this Ph.D. work. A key finding was 
the synthesis of compound 216 and that it spectroscopically matched the NMR spectra 
obtained for natural isolate labelled hyacinthacine C5. In addition to this, the synthesis of 
purported compound for hyacinthacine C5 and 215 generated spectroscopic data that 
matched with those of the same compounds reported in literature, and so confirmed their 
structures. At this stage, we are confident that the structure for our synthetic 217 is correct 
since it, along with preceding intermediates have generated NMR spectroscopic evidence 
consistent with their assigned structures. Further work is required to identify the cause of 
the inconsistent spectroscopic data between 217 and compound 120 reported by Reissig 
and Goti et al., especially since these should be identical compounds. Regardless, the new-
found discovery of the true structure for natural hyacinthacine C5 led to its publication in 
the ACS Journal of Organic Chemistry along with the six hyacinthacine C5-type analogues 
described between Chapters 1-4B.132 All intermediates and final products that led to the 
final hyacinthacine C5-type analogues have undergone extensive NMR spectroscopic 
analysis and the reader will find almost all the 1D and 2D spectroscopic experimental 
results as part of this manuscripts Supporting Information. Alternatively, a copy of all the 





Chapter 5 : Synthesis of (‒)-7-epi-hyacinthacine 
C1, the corrected structure of natural 
hyacinthacine C1, (+)-6,7-di-epi-hyacinthacine C1 
and (+)-7-epi-hyacinthacine C1 
 
Chapters 2-4B detail both the successful and unsuccessful attempts that ultimately resulted 
in the synthesis of the natural (+)-hyacinthacine C5 (as well as six additional hyacinthacine 
C-type compounds) which allowed correction of its initially proposed structure. These 
compounds were readily accessible from two epimeric anti-1,2-amino diols 127 and 161. 
Until this Chapter, the work described largely focused on the chemical manipulation of the 
B-ring (stereocentres C5, C6 and C7) of the hyacinthacine C-type products through 
methods of syn-dihydroxylation, SN2 ring-opening of a cyclic sulfate, and also employing 
either the (R)- or (S)-α-methylallyl amine for the Petasis borono Mannich reaction. The 
successful pathway that led to these results was summarised and accepted as a publication 
in the ACS Journal of Organic Chemistry. Although the work towards elucidating the true 
structure for hyacinthacine C5 proved successful, none of the synthesized analogues solved 
the structural ambiguities between hyacinthacine C1 and C4. For this reason, our new 
objective was to synthesize the proposed compounds for these natural isolates. Herein, the 
report of the true structure and synthesis of the compound hyacinthacine C1 is described. 
In addition to this, our synthetic pathway also accessed another three diastereomers of 
hyacinthacine C1/C4. All final products were assessed as glycosidase inhibitors and will be 
discussed in Chapter 6. These results were also reported in a manuscript which at the time 
of writing this Ph.D. thesis, was accepted for publication in the ACS Journal of Natural 
Products. A comprehensive NMR spectroscopic experimental data set is available in the 
related Supporting Information for this article. 
 
5.1. Retrosynthetic analysis towards accessing hyacinthacine C1/C4-type 
analogues 
 
The proposed structure for hyacinthacine C1/C4 is shown in Figure 5.1. After reviewing 
the successful pathway that led to the structural elucidation of hyacinthacine C5, we 
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recognized that the revised structure of (+)-hyacinthacine C5 compared to hyacinthacine 
C1 and C4, contained a single opposite stereocentre at C1.  
 
 
Figure 5.1: The corrected structure for hyacinthacine C5 and the proposed structures for 
the natural isolates labelled hyacinthacine C1 and C4 with the single stereocentre C1 
difference highlighted in red. 
 
We envisioned that using our established chemistry would access this compound. More 
specifically, the retrosynthetic analysis detailing our initial synthetic approach towards 
accessing hyacinthacines C1/C4 is shown below (Scheme 5.1). For our synthetic approach 
to be successful, we recognized that the stereocentre at C1 would need to be subjected to 
inversion at some point during the synthesis. After revising our initial pathway described 
in Chapter 2, we identified that this stereocentre could be potentially inverted if the N-Boc 















This idea was influenced by precedent literature reported by Kim et al.193 Shown in 
Scheme 5.2, Kim and co-workers found that the carbonyl of the carbamate in the N-Boc 
protected 3,4-vicinal diol could induce a hydroxy inversion at either the 3 or the 4 position, 
provided the respective 5-membered cyclic sulfate 226 was synthesized. They 
unequivocally proved that the nucleophilic carbonyl would induce an SN2 like attack at 
either position via the formation of a hemisulfateanion/oxonium intermediate A. An 
irreversible fragmentation step then leads to the oxazolidinone product 227 as desired. The 
major difference between our N-Boc substrate 139 and the substrates reported by Kim et 
al. was the cyclic sulfate ring size formed. More specifically, Kim et al. only demonstrated 
this principle to effectively work for 5-membered cyclic sulfates. However, since it is 
possible to synthesize various 6-membered cyclic sulfates,194 we considered the 
overarching principle would remain true, and that either the oxazolidinone 224 or the 
corresponding oxazepinone would form via this mechanism. Provided oxazolidinone 224 
was successfully synthesized, using similar procedures previously described in Chapters 2 
and 3 (RCM reaction, UpJohn cis-dihydroxylation, mesylation then cyclisation) would 





Scheme 5.2: Kim and co-workers N-Boc conversion to the oxazolidinone 227 from the 
cyclic sulfate 226.193 
 
 
5.2. Synthesis of cyclic sulfate 225 and its conversion to oxazolidinone 
224 
 
Therefore, the N-Boc 139 was synthesized and converted to the corresponding cyclic 
sulfate 225 via our standard procedure (Et3N, sulfuryl chloride, CH2Cl2). Indication that 
the cyclic sulfate 225 had formed was inferred by a LRESIMS [M+H]+ ion peak at m/z 650 
and TLC analysis confirming full consumption of the starting material. Owing to our 
previous handling experiences with cyclic sulfate derivatives, the crude compound 225 
was subsequently converted to oxazolidinone 224 using the same procedure described by 
Kim et al.193 This procedure involved dissolving the newly formed cyclic sulfate 225 in a 
solution of acetonitrile followed by stirring the mixture at 50 oC for 2 h. After this time, a 
solution of THF, H2O and H2SO4 (8:3:1) was added to the mixture and was stirred at 40 
oC for 1 h. After neutralization, a TLC analysis confirmed that a new product spot had 
formed with an Rf and a LRESIMS [M+H]
+ ion peak at m/z 514 similar to our previous 
oxazolidinone 137 described in Chapter 2. The crude reaction mixture was then purified 
by column chromatography and returned the oxazolidinone 224 in 39% yield over two 
steps. In the synthesis of oxazolidinones 137 and 160 described in Chapters 2 and 3, the 
proton resonances at H4 and H5 were described as having a syn-relationship since they 
displayed a vicinal coupling constant, J4,5, of 7.1 Hz in the 
1H NMR spectrum. This is 
consistent with the 4,5-cis relative configuration. Unfortunately, we could not find clear 
resolution for the appropriate resonance for H4 and H5 as they overlapped with other 
resonances in the spectrum and so the J4,5 trans coupling constant could not be reliably 
determined. Although the success of the inversion was not definitively confirmed, the 1H 
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NMR spectrum (Figure 5.2) of the resultant oxazolidinone 224 was clearly different to the 
1H NMR spectrum of oxazolidinone 137 described in Chapter 2. Synthesis of the 
respective oxazepinone was disregarded on the basis that the 1H NMR spectrum olefinic 
resonances for H2′′′, H1′′′, H2′ and H3′ at δH 6.47, 6.02, 5.84 and 5.15 ppm, respectively, 
were deshielded in a pattern consistent with formation of the oxazolidinone, rather than 
the oxazepinone (Figure 5.2).    
 











Figure 5.2: A) 1H NMR spectrum (500 MHz, CDCl3) of 137 and B) 
1H NMR spectrum 
(500 MHz, CDCl3) of 224. 
 
Unfortunately, this reaction only proved to be a one-time-success. It was speculated that 
the sulfuryl chloride or the THF solvent stock used as in this reaction may have degraded 
over time since it is very reactive. Despite careful preparation and ensuring that all reagent 
and solvent stock containers were always stored under an inert atmosphere, the constant 
use and exposure throughout the course of this work may have lessened their integrity via 
unavoidable hydrolysis and or oxidation. This reaction was attempted many times but 
failed to recreate oxazolidinone 224. Successive attempts only resulted in complex 
mixtures. With the small amount of the oxazolidinone 224 in hand, the pathway was 
continued in an attempt to explore the feasibility of this methodology. Although seemingly 
high yielding reactions followed from the synthesis of the oxazolidinone 224, resultant 
intermediates were eventually exhausted due to gradual loss of yield and so could not be 
reliably characterised due to insufficient amounts. It was optimistically thought that we 
would obtain the final product, but this proved unsuccessful. Therefore, the following work 


















5.3. RCM reaction of oxazolidinone 224 
 
Oxazolidinone 224 was next subjected to our procedure for ring-closing metathesis. This 
afforded the RCM product 223 in a high yield of 95% (Scheme 5.4). The HRESIMS of 
223 displayed the [M+Na]+ ion peak at m/z 432.1790 and so suggested the successful 
synthesis of 223. In addition to this, the corresponding pyrrole was disregarded on the basis 
of the 1H NMR spectrum displaying a clear doublet for the methyl resonance identified at 
δH 1.55 ppm for H1′′ (Figure 5.3). More importantly, the 
1H NMR spectrum resonances 
for H7a and H1 clearly resolved at δH 4.98 and 4.37 ppm, respectively. The J1,7a coupling 
constant between both these resonances was calculated to be 10.8 Hz and is a higher value 
than the corresponding J4,5 cis coupling constant for RCM product 140 (Chapter 2). This 
correlates well with the trans relationship between H1 and H7a in compound 223. In 
addition to this, the 1H NMR spectrum generated for 223 was different to the RCM product 
140 discussed in Chapter 2 and so suggested 223 to be the diastereomer depicted in Scheme 
5.4.  
 
Scheme 5.4: Synthesis of RCM product 223. 
 
 








5.4. Syn-dihydroxylation of RCM product 223 
 
At this stage, only a small amount (15 mg) of the RCM intermediate 223 was available to 
undergo Upjohn Os(VIII)-catalyzed cis-dihydroxylation. These conditions had been well 
explored and so employing the same procedure to RCM 223 that was previously described 
in Chapters 2, 3 and 4, resulted in high conversion to the C6, C7 syn-diol 228 which was 
obtained in a 72% yield after column chromatography (Scheme 5.5). Due to the small scale 
of this reaction clear evidence to suggest formation of the minor (6S), (7R)- syn-diol was 
unable to be determined. If the reaction was completed on a larger scale both diol 228 and 
its minor diastereomer would have been isolated and characterised. Since it could not be 
recovered, synthesis of the (6S), (7R)- syn-diol could not be confirmed and for this reason 
has not been included. Regardless, diol 228 was characterised and was confirmed to be the 
(6R), (7S)- syn-diol from an extensive analysis of the ROESY NMR for this product. In 
particular, key proton resonance correlations were observed between H1''‒H6, H1''‒H7 
(weak) and H6‒H7 and are shown in Figure 5.4. 
 













Figure 5.4: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed correlations 
projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 228. 
 
5.5. The synthesis of acetonide 221 and shortfalls 
 
After column chromatography purification, only 12 mg of diol 228 was obtained. This was 
converted to its corresponding acetonide 221 by dissolving the syn-diol 228 in acetone, 
followed by the addition of two equivalents of copper(II) sulfate and a catalytic amount of 









































Scheme 5.6: Synthesis of acetonide 221. 
 
 
As anticipated, the reaction returned a clean conversion (95% yield after column 
chromatography) to the respective acetonide 221 as confirmed by HRESIMS, 1H and 13C 
NMR spectroscopic analysis. More specifically, the HRESIMS of 221 found a [M+H]+ ion 
peak at m/z 484.5720. The 13C NMR spectrum best displays the formation of the acetonide 
221 and so is shown in Figure 5.5 along with the 13C NMR spectrum of the parent diol 
228. In this comparison, three additional carbon resonances at δC 112.2, 26.1 and 24.4 ppm 
for the newly formed acetonide 221 are highlighted and coincide with C2 and both the C2 









Figure 5.5: A) 13C NMR spectrum (125 MHz, CDCl3) of 228 and B) 
13C NMR spectrum 
(125 MHz, CDCl3) of 221 with C2 and C2 contingent methyl resonances for 221 
highlighted in red. 
 
Unfortunately, it was at this point that this synthetic pathway was discontinued. The 
inability to synthesize more of the starting oxazolidinone 224 in combination with the 
small amount of product at this stage was considered impractical for future reactions and 
product characterisation.  
 
5.6. Revised synthetic strategy towards hyacinthacine C1/C4-type 
analogues  
 
These shortcomings led to the revision of our retrosynthetic plan towards synthesizing 
hyacinthacine C1/C4 type analogues and is shown in Scheme 5.7. More specifically, the 
pyrrolizidine 230 would be obtained from performing a Swern oxidation at C8 of 
compounds 149, 151 or 165 then subjecting the representative ketone 229 to 
diastereoselective reduction by L-selectride®. This would stereoselectively deliver a 
hydride to the less hindered face of the bicyclic compound and result in an overall inversion 
at this stereocentre. After this, either global deprotection or similar methodology used to 
generate the C6, C7 anti-diol (via the corresponding cyclic sulfate), would access a large 








the proposed structure of the natural isolates labelled hyacinthacine C1/C4. This approach 
was certainly considered at the beginning of this work. However, a previous group 
member, Kongdech Savaspun, found that performing the Swern oxidation, then L-
selectride® reduction on similar substrates returned unexpected product mixtures 
containing very low yields of the desired product as well as various lactam-carboxylic 
derivatives.127 On the other hand, other previous group members have demonstrated 
reasonable success using this approach on similar substrates.184, 191 The decision was 
therefore made to implement this pathway for pyrrolizidine compounds 149, 151 and 165. 
If successful, our established C6, C7 anti-diol chemistry would also be explored in an 
attempt to synthesize the compound of the putative structure assigned for the natural 
isolates labelled as hyacinthacine C1/C4. 
 










5.7. Swern oxidation of pyrrolizidines 149, 151 and 165 
 
5.7.1 Swern oxidation of pyrrolizidine 165 
 
The Swern oxidation was considered for all the synthesized pyrrolizidine substrates 149, 
151 and 165 described in Chapters 2,3 and 4B. Since pyrrolizidine 165 (described in 
Chapter 3) was on hand at the time this pathway was considered, it was used as the model 
study. More specifically, pyrrolizidine 165, along with an excess amount of Et3N (40 eq.), 
was added to the reaction mixture between oxalyl chloride and dimethyl sulfoxide. The 
mixture was then stirred at -78 oC for 1 h (Scheme 5.8). After this time, the appearance of 
a single product spot was observed by TLC analysis. After column chromatography ketone 
231 was successfully obtained in an 83% yield. 
 
Scheme 5.8: Swern oxidation of 165 to give ketone 231. 
 
 
It might seem an unorthodox observation, but it was noted that the reaction mixture 
contained a foul odour. Interestingly, this was a key indication that the desired ketone 231 
had formed. According to the mechanism shown in Scheme 5.9, a by-product of a 
successful oxidation reaction is the synthesis of dimethyl sulfide. In Scheme 5.9A, an 
initial reaction between DMSO and oxalyl chloride forms the dimethylchlorosulfonium 
ion B. Next (Scheme 5.9B), the addition of an alcohol (in this example, substrate 165 is 
used) at -78 oC leads to the formation of an alkoxysulfonium ion C via the loss of the 
chloride and alcohol proton as hydrogen chloride. In the presence of base (Et3N), 
deprotonation of this intermediate returns the sulfur ylide D, which undergoes an 
intramolecular deprotonation via a 5-membered transition state and ultimately fragments 
into the respective ketone 231 and the odorous by-product, dimethyl sulfide. If the reaction 
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is not kept near -78 oC, mixed thioacetals can result and prove detrimental to the product 
yield.  
 
Scheme 5.9: Proposed mechanism for the Swern oxidation of 165. 
 
 
To confidently confirm the desired ketone 231 had formed, the crude reaction was purified 
via column chromatography and the product was then subjected to extensive spectroscopic 
experiments. More specifically, the HRESIMS of 231 found a [M+H]+ ion peak at m/z 
438.2275 and indicated the loss of the mass of two protons. In addition to this, the gCOSY 
NMR spectrum of 231 identified that the pyrrolizidine ring only contained protons at H8b, 
H3a, H7, H8a, H6 and H4, at δH 5.04, 4.56, 3.94, 3.87 (2H), and 3.74 ppm, respectively 
(Figure 5.6A). Additionally, the 13C NMR spectrum displayed a downfield resonance at δC 
211.0 ppm, which was characteristic of the newly formed carbonyl at C8 (Figure 5.6B). 
The sharp C=O stretching band at 1716 cm-1 in the IR spectrum also supported this newly 







Figure 5.6: A) 1H NMR spectrum (500 MHz, CDCl3) of 231 and B) 
13C NMR spectrum 
(125 MHz, CDCl3) of 231. 
 
5.7.2 Swern oxidation of pyrrolizidine 151 
 
Having proved the successful oxidation at C8 of pyrrolizidine 165, the same Swern 
oxidation procedure was performed on pyrrolizidine 151 and also returned a high yield 
(80%) of the respective ketone product 232 (Scheme 5.10). This was confirmed after the 
product was subjected to extensive spectroscopic experiments. In addition to the 
HRESIMS of 232 indicating a characteristic [M+H]+ ion peak at m/z 438.2300,  ketone 
232 was confirmed to be successfully formed on the basis of the gCOSY NMR 
spectroscopic analysis which identified that the pyrrolizidine ring only contained protons 
at H8b, H3a, H7, H6, H8a, and H4 at δH 4.89, 4.54, 4.16, 3.96, 3.69 and 3.74 ppm, 
respectively (Figure 5.7A) . Additionally, the 13C NMR spectrum of 232 displayed a 
downfield resonance at δC 211.8 ppm, which was characteristic of the newly formed 
carbonyl at C8 (Figure 5.7B). The sharp C=O band at 1743 cm-1 in the IR spectrum also 






















Figure 5.7: A) 1H NMR spectrum (500 MHz, CDCl3) of 232 and B) 
13C NMR spectrum 
(125 MHz, CDCl3) of 232. 
 
5.7.3 Swern oxidation of pyrrolizidine 149 
 
In a similar manner, the pyrrolizidine 149 was subjected to our established Swern oxidation 
conditions (Scheme 5.11). Unlike the aforementioned products 231 and 232, the desired 
ketone 233 proved difficult to purify and seemed prone to degradation on silica medium. 
The synthesis of 233 was only inferred by an LRESIMS [M+H]+ ion peak at m/z 438 which 
was determined after a sample of the crude reaction mixture was analysed.  For this reason, 
the crude ketone 233 was unable to be completely characterised but was instead subjected 


















Scheme 5.11: Swern oxidation of 149 to give ketone 233. 
 
 
5.8. L-selectride® reduction of ketones 231, 232 and 233 
 
With the successfully synthesized ketones 231, 232 and 233 in hand, the next stage of the 
synthetic plan was to reduce the ketone moiety at C8 with the sterically hindered reagent 
L-selectride® in hope that the corresponding C8 alcohols would form. This was based on 
the mechanism and results described by Zhang et al. in 2009 for their L-selectride® 
reduction of ketone 234 shown in Scheme 5.12.195 In this reaction, Zhang and co-workers 
obtained almost exclusively the endo epimer. They attributed this result to the fact that the 
bulky hydride would attack the carbonyl predominantly at the less hindered convex face 
of the ketone 234.  
 




5.8.1 L-selectride® reduction of ketone 231 
 
We were confident that successful inversion at C8 would occur for our respective ketones, 
especially since the O-benzyl ether at C7 was on the concave face and would also sterically 
influence the delivery of the hydride in a similar manner described by Zhang et al.195 
Therefore, with ketone 231 in hand, this was subjected to a reduction with L-selectride® at 
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-78 oC (Scheme 5.13). After stirring at this temperature for 2 h, the TLC analysis showed 
a near complete consumption of the starting material and so the reaction was quenched 
with an aqueous ammonia solution. After column chromatography purification, the 
product was obtained in a 96% yield. The product was then subjected to various spectral 
analyses including 1H and 13C NMR spectroscopic experiments as well as other 2D NMR 
experiments in order to confirm the successful stereoinversion at C8. An initial 
confirmation that this reduction had been successful was determined by a HRESIMS 
analysis of the purified sample which found a characteristic [M+H]+ ion peak for 236 at 
m/z 440.2446.  
Unfortunately, due to the overlap of the H8 resonance with the OCH2Ph proton resonances 
in the 1H NMR spectrum, the ROESY NMR of the newly formed alcohol 236 could not 
be interpreted to unambiguously confirm that the hydroxy moiety at C8 had inverted. 
However, the 1H NMR spectrum of the suspected alcohol 236 (Figure 5.8A) was notably 
different to the 1H NMR spectrum of its parent diol 165 (Figure 5.8B), suggesting that 
ketone 231 had undergone a successful stereoinversion at C8. However, to truly confirm 
this had been the case, a portion of the alcohol 236 was converted to the C8 O-benzyl ether 
in hope that it would clearly resolve these proton resonances. Findings from this will be 
discussed further in section 5.11.  
 






Figure 5.8: A) 1H NMR spectrum (500 MHz, CDCl3) of 165 and B) 
1H NMR spectrum 
(500 MHz, CDCl3) of 236. 
 
5.8.2 L-selectride® reduction of ketone 232 
 
Pyrrolizidine ketones 232 and 233 were also individually subjected to reduction with L-
selectride®. Both reactions displayed a high degree of selectivity for returning a single 
diasteteromer. More specifically, reduction of ketone 232 returned exclusively the 
pyrrolizidine alcohol 237 in 66% yield (Scheme 5.14). In addition to the prominent 1H 
NMR spectroscopic differences between 237 and the parent C8 epimer 151, an extensive 
2D-NOESY analysis was performed to confirm the inversion at C8 in 237. Key positive 
correlations were observed between H4‒H3a, H4‒H8a, H1''‒H6, H8a‒H8b, H7‒H8, H8a‒
H8 and H7‒H1' (Figure 5.9), confirming formation of the intended product. 
 






















Figure 5.9: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed correlations 
projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 237 (C7 and C1' 
O-benzyl ethers not shown). 
 
5.8.3 L-selectride® reduction of ketone 233 
 
The crude ketone product 233 was also subjected to reduction by L-selectride® which 
successfully afforded the desired alcohol 238 in a 65% yield over two steps (Scheme 5.15). 
This was confirmed by a comparative analysis of the 1H NMR spectra between 238 and 
the parent alcohol 149 suggesting a successful inversion at the stereocentre C8. More 
convincingly, alcohol 238 was subjected to extensive 1D-NOE difference experiments 
which confirmed the relative configuration of the newly inverted stereocentre at C8. For 
brevity, only key positive NOE enhancements for H8 and H8b are shown. More 
specifically, correlations between H8‒H7, H8‒H8a and H8b‒H3a were observed (Figure 
5.10). It is worth noting the relatively weak correlation between H8b‒H8a might seem 
unusual since these protons are depicted on opposite faces of the pyrrolizidine core. 
However, due to the torsional strain and twist of the pyrrolizidine core, unexpected 
correlations such as this can be observed, but are usually of weaker intensities (note the 
stronger intensity of H8b‒H3a since they are expected to be on the same side of the 

























































Figure 5.10: Top: Selected 1D-NOE spectra (500 MHz, CDCl3) of 238 of A) H8 and B) 
H8b and their respective key observed correlations projected onto Bottom: a DFT 










































5.9. Synthesis of triols 239, 240 and 241 
 
The relative configurations of alcohols 237 and 238 were confidently assigned. The 
relative configuration of alcohol 236 was also confirmed through synthesis and 
characterisation of its respective O-benzyl ether which is discussed later in 5.11. Therefore, 
each alcohol was subjected to global deprotection. In Chapter 3, a related step-wise 
deprotection was performed and involved first deprotecting the acetonide moiety of each 
pyrrolizidine. This established procedure was easily transferable to pyrrolizidines 236, 237 
and 238 whereby they were each individually dissolved in EtOH/H2O (9:1, respectively), 
followed by the addition of several drops of 5 N HCl (Scheme 5.16). This successfully 
returned triols 239, 240 and 241 in 79%, 87% and 55% yield, respectively.  
 
Scheme 5.16: Acid hydrolysis of the acetonide moiety from pyrrolizidines 236, 237 and 







5.10. Hydrogenolysis of pyrrolizidines 239, 240 and 241 
 
Individual samples of alcohols 239, 240 and 241 were then debenzylated under 
hydrogenolysis conditions over PdCl2 to return novel hyacinthacine C1/C4-type 
compounds (‒)-5-epi-hyacinthacine C1 242 [[α]𝐷
25‒14.1 (c 0.90, H2O)], the corrected 
structure of (+)-hyacinthacine C1 243 [[α]𝐷
25+13.0 (c 0.20, H2O)], and (+)-6,7-di-epi-
hyacinthacine C1 244 [[α]𝐷
25+13.4 (c 0.20, H2O)], respectively in moderate to high yields 
of 80%, 52% and 61%, respectively following purification and neutralization by basic ion-
exchange chromatography (Scheme 5.17).  
 
Scheme 5.17: Hydrogenolysis of 239, 240 and 241 to give final hyacinthacine C1/C4-type 
analogues 242, 243 and 244, respectively. 
 
 
Each resultant product was then subjected to extensive spectroscopic analysis. To our 
delight, a comparative NMR analysis of our synthetic 243 against the spectroscopic data 
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reported for the original isolates labelled hyacinthacine C1 [[α]𝐷 +14.7 (c 0.28, H2O)]
105 
and hyacinthacine C4 [[α]𝐷 ‒37.9 (c 0.44, H2O)],
117 revealed that the 1H NMR spectrum 
multiplicities and chemical shifts of the natural isolate labelled hyacinthacine C1 were a 
close match with our synthetic compound 243 (Table 5.1). Additionally, a consistent 0.4 – 
0.6 ppm difference for the 13C NMR chemical shifts between both products (Table 5.1) 
was observed. The NMR sample of 243 contained a small amount of MeOH, since it would 
be easily removed prior to glycosidase testing. The 1H NMR spectrum of 243 was therefore 
referenced to the D2O solvent residual peak at 4.79 ppm and the 
13C NMR was referenced 
to internal MeOH. Comparatively, the 1H and 13C NMR spectrum chemical shifts of the 
natural (+)-hyacinthacine C1 are expressed in reference to the internal standard sodium 3-
(trimethylsilyl)propionate (TPS) in D2O.
105 This may explain the slight NMR 
spectroscopic differences observed between synthetic 243 and the natural product.  
Regardless, the specific rotation of synthetic 243 was found to be a close match with this 
natural product. In conjunction with the fact that the natural isolates hyacinthacine C4 and 
C1 cannot be the same structure, it was satisfactorily concluded that the true structure for 
hyacinthacine C1 is in fact, the C6 epimer 243. We were excited to solve this nearly 20-
year old literature mistake and were confidently able to propose that hyacinthacine C4 is 
most likely correct in its absolute configurational assignments.  
 
Table 5.1: Comparison of literature 1H NMR (500 MHz, D2O) and 
13C NMR (125 MHz, 
D2O) data of Kato et al.
105 Lit. (+)‒hyacinthacine C1 with the 
1H NMR (500 MHz, D2O) 
and 13C NMR (125 MHz, D2O) of our synthetic 243. 
 












1 4.15, t (3.9) 4.18, t (3.8) 74.6 74.1 0.5 
2 4.00, dd (3.9, 9.0) 4.02, dd (3.7, 9.2) 77.7 77.3 0.4 
3 3.44, dt (4.4, 9.0) 3.47, dt (4.6, 9.2) 64.7 64.1 0.6 
5 3.29, dt (3.9, 7.0) 3.31, dt (3.9, 7.1) 60.4 59.9 0.5 
6 3.89, dd (3.9, 4.6) 3.92, t (4.4) 77.1 76.6 0.5 
7 4.50, dd (4.6, 8.6) 4.53, dd (4.7, 8.6) 75.7 75.1 0.6 
7a 3.66, dd (3.9, 8.6) 3.68, dd (4.2, 11.1) 68.3 67.8 0.5 
8 3.66, m 3.68, dd (4.2, 11.1) 65.9 65.4 0.5 
9 1.27, d (7.0) 1.29, d (7.2) 12.8 12.4 0.4 
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The remaining two hyacinthacine C-type analogues (‒)-5-epi-hyacinthacine C1 242 and 
(+)-6,7-di-epi-hyacinthacine C1 244 were also cross examined with the spectroscopic data 
reported for the original isolate hyacinthacine C4, however they did not match the 
respective chemical shifts. A literature search also concluded these to be novel 
hyacinthacine C-type analogues as they had not yet been reported to date. The 1H and 13C 
NMR spectra along with 2D NMR spectroscopic data for 242, 243 and 244 are included 
in the Appendix of this Ph.D. work.  
 
5.11. Synthesis of compounds 245 and 246 
 
It was fortunate that the corrected compound for hyacinthacine C1 was successfully 
synthesized during this work. With this correction, it is suspected that the putative structure 
for hyacinthacine C4 is most likely correct in its assignment. However, the only way to 
confidently prove this is to synthesize this compound and then compare the obtained 
spectral data of the synthetic product with the natural isolate. When reviewing the putative 
structure for hyacinthacine C4, it was envisioned that we could potentially access this 
compound if we combined the recently established stereoinversion at C8 with the C6, C7 
cyclic sulfate ring-opening procedure described in Chapter 4A. The compounds chosen to 
undergo this transformation were pyrrolizidines 236 and 238 as they were available in the 
final months prior to finishing this Ph.D. work. Therefore, both pyrrolizidines were 
subjected to C8 O-benzyl ether protection in a similar manner to that described in Chapter 
4B, which returned the desired pyrrolizidine analogues 245 and 246 in 54% and 52% yield, 
respectively (Scheme 5.18). Indication that both pyrrolizidines had undergone a successful 
O-benzylation at C8 was inferred as both were found to contain a LRESIMS [M+H]+ ion 








Scheme 5.18: C8 O-Benzylation of pyrrolizidines 236 and 238 to give 245 and 246.  
 
 
It was at this point that the stereochemistry at C8 of pyrrolizidine 245 was confirmed 
through extensive spectroscopic analysis. More specifically, after purification, a clearly 
resolved 1H NMR spectrum of the product 245 was obtained and subsequently subjected 
to extensive 1D-NOE difference analysis. For brevity, only the NOE enhancement of H8 
is shown in Figure 5.11 and clearly displays the expected positive NOE correlation 
















Figure 5.11: Top: A selected 1D-NOE spectra (500 MHz, CDCl3) of 245 of H8 and its 
respective key observed correlations projected onto Bottom: a DFT minimized molecular 
model [B3LYP/6-31G(d)] of 245 (C8, C7 and C1' O-benzyl ethers not shown). 
 
Indeed, similar evidence and logic was used to check the stereochemistry of pyrrolizidine 
246 at the hydroxy group of C8. Since the parent compound 238 has already been described 
from a stereochemical point of view, detail for this compound will be discussed after the 
successful inversion at C6 or C7 has been described in Section 5.13. 
 
5.12. Acetonide hydrolysis of 245 and 246 
 
With the pyrrolizidines 245 and 246 in hand, each underwent individual hydrolysis of the 
acetonide moiety. This was performed in a similar manner to the acetonide hydrolysis of 
pyrrolizidine 165 described in Chapter 3 which entailed individually dissolving 245 and 
246 in a solution of EtOH/H2O (9:1, respectively), followed by the addition of several 
drops of 5 N HCl and stirred at room temperature until full consumption of the starting 
material was confirmed by TLC analysis (Scheme 5.19). The HRESIMS of 247 and 248 























that both had undergone successful hydrolysis of the acetonide moiety. Additionally, the 
13C NMR spectrum of compounds 247 and 248 clearly indicated the loss of this group 
when compared with their parent acetonides 245 and 246, respectively (Figure 5.12 and 
Figure 5.13).  
 









Figure 5.12: A) 13C NMR spectrum (125 MHz, CDCl3) of 245 and B) 
13C NMR spectrum 
(125 MHz, CDCl3) of 247 with C2 and C2 contingent methyl resonances for 245 




Figure 5.13: A) 13C NMR spectrum (125 MHz, CDCl3) of 246 and B) 
13C NMR spectrum 
(125 MHz, CDCl3) of 248 with C2 and C2 contingent methyl resonances for 246 











5.13. Synthesis of Cyclic sulfates 249 and 250 and attempts to ring 
opening with in situ formed CsOBz 
 
Both diols 247 and 248 were individually converted to their respective cyclic sulfates 249 
and 250 (Scheme 5.20), using our previously established methodology described in 
Chapter 4B.190 Prone to degradation, both cyclic sulfates were immediately treated with 
Cs2CO3 and benzoic acid and were expected to return two potential regioisomers for each 
of the cyclic sulfates 249 and 250. Unfortunately, the subsequent CsOBz ring-opening of 
cyclic sulfate 249 degraded the compound into an indeterminable mixture of products 
(Scheme 5.20). Due to time contraints, this reaction could only be performed as a one-time 
reaction trial and so the reaction conditions were not optimized nor re-attempted. In 
contrast, the CsOBz ring-opening of the cyclic sulfate 250 returned in 42% yield, the 
benzoate regioisomer 251 as confirmed initially by a gCOSY NMR analysis (Scheme 
5.20). More specifically it was observed that the proton sharing the stereogenic carbon 
with the newly added benzoate proved the most deshielded and characteristically appeared 
at δH > 5.0 ppm. In this case, the gCOSY analysis of 251 identified a strong correlation 
between H1″ (δH 1.25 ppm) and H5 (δH 3.93 ppm) which was subsequently found to 
resonate with the most deshielded proton at δH 5.30 ppm, which was deduced to be H6 
(Figure 5.14). 
 
Scheme 5.20: Synthesis of cyclic sulfates 249 and 250 and the attempted ring opening of 





The benzoate product 251 was then subjected to a comprehensive 2D-NOESY analysis 
which showed key correlations between protons H1''‒H7, H1''‒H3, H5‒H6, H1‒H7a, H1‒
H2, H7a‒H2 and H1'‒H2, suggesting the proposed relative configuration of structure 251 
to be correct (Figure 5.15). Interestingly, this result was consistent with the regioselectivity 
observed in the earlier proposed 1,2-diaxial-like ring-opening of the cyclic sulfate of 203 
as described in Chapter 4B (Scheme 4B.10). More specifically, for cyclic sulfate 250,  
attack at C8b requires a different reactive conformation in which the C4 methyl group is 
pseudo-axial and sterically blocks substitution at C8b. A referee of our publication in the 
ACS Journal of Natural Products suggested that the preference for nucleophilic 
substitution of the CsOBz at C3a could be the result of hyperconjugative stabilisation from 
the C4 methyl group (anti to the leaving group). Both these steric and stereoelectronic 
effects could be clearly valid, however determining their relative contributions will require 
further study. It is suspected that the C8b benzoate regioisomer was also formed but could 
not be obtained due to the insufficient amount of starting material in combination with the 

















Figure 5.14: gCOSY NMR spectrum (500 MHz, CDCl3) of 251 and a DFT minimized 




Figure 5.15: 2D ROESY NMR spectrum (500 MHz, CDCl3) with key observed 
correlations projected onto a DFT minimized molecular model [B3LYP/6-31G(d)] of 251 




























































5.14. Methanolysis of the benzoate 251 
 
After the Ph.D. stipend had exhausted, attempts to synthesize larger quantities of cyclic 
sulfates 249 and 250 were never revisited. This work therefore ended with the successful 
two-step global deprotection of benzoate regioisomer 251. More specifically, the C6 
benzoate of pyrrolizidine 251 was subjected to our previously established methanolysis 
procedure to give the diol product 252 in an 87% yield (Scheme 5.21). The HRESIMS of 
252 displayed the [M+H]+ ion peak at m/z 490.2597, thus confirming the successful de-
benzoylation.  
 
Scheme 5.21: Methanolysis of 251 to give diol 252 
 
 
The 1H NMR spectrum of the parent C6, C7 syn-diol 248 was then compared with the 1H 
NMR spectrum of the newly revealed C6, C7 anti-diol 252, where significant differences 
between these spectra were observed. From these results, we concluded that they were not 
the same product and that 252 was the C6, C7 anti-diol. Unfortunately, the relative 
closeness of the chemical shifts of each proton resonance in the 1H NMR spectrum of 252 
led to difficulties in definitively establishing the C6, C7 anti-diol relationship. However, 
we were confident that the proposed compound had been synthesized based on the previous 
spectroscopic investigation of benzoate 251. For this reason, diol 252 was taken through 
to the next step and subjected to hydrogenolysis.  
 
5.15. Synthesis of (+)-7-epi-hyacinthacine C1 253 
 
The final reaction reported in this Ph.D. work is the debenzylation of alcohol 252 under 
hydrogenolysis conditions over PdCl2 (Scheme 5.22). This was completed after 4 h and 
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confirmed to have successfully formed the desired product as the LRESIMS of 253 found 
a [M+H]+ ion peak at m/z 220.  Purification of 253 and neutralization by basic ion-
exchange chromatography returned the expected hyacinthacine C1/C4-type analogue (+)-
7-epi-hyacinthacine C1 253 [[α]𝐷
25+6.5 (c 0.10, H2O)] in 75% yield and was confirmed 
through extensive spectroscopic evidence (included in the Appendix for this Ph.D. work). 
 




With this compound, a Scifinder® search indicated that this compound and structure was 
novel. As with all the final hyacinthacine C-type products synthesized in this Ph.D. work, 
it was also assessed and characterised for its glycosidase inhibitory potential. When 
spectroscopically compared to hyacinthacine C4, the 
1H and 13C NMR spectroscopic data 
were notably different (Table 5.2), and so the hypothesis that the structure proposed for 










Table 5.2: Comparison of literature 1H NMR (500 MHz, D2O) and 
13C NMR (125 MHz, 
D2O) data of Kato et al. Lit. (+)‒hyacinthacine C4
117 with the 1H NMR (500 MHz, D2O) 
and 13C NMR (125 MHz, D2O) of our synthetic 253. 
 
5.16. Chapter 5: Final remarks  
 
The successful synthesis of four novel analogues of the hyacinthacine C1/C4 analogues, 
242, 243, 244 and 253, is described in this Chapter. The initial attempts to invert the cyclic 
sulfate of the N-Boc product 139 seemed promising but only worked once and so resulted 
in insufficient foundational products towards the synthesis of the hyacinthacine C1/C4-type 
analogues.  Its inclusion in this Chapter helps the reader to understand the basis that 
ultimately resulted in the successful synthesis of the four hyacinthacine C1/C4 -type 
analogues. Unfortunately, due to the time constraints, the synthesis of hyacinthacine C4 
was not achieved despite the inkling that its parent benzoate regiosiomer was synthesized 
as a minor product from the ring-opening of the cyclic sulfate 250. In addition to this, it 
was also unfortunate that trying to ring-open the cyclic sulfate 249 resulted in a complex 
mixture of products and could not be further investigated. Regardless, the key highlight 
was serendipitously synthesizing compound 243 which turned out to be the true and 
corrected structure for hyacinthacine C1. This new finding in addition to the other 
diastereomers synthesized in this study means that there is a strong possibility that the 
structure for hyacinthacine C4 proposed in 2007
117 is correct. This certainly warrants 
further exploration, but more importantly presents itself as a synthetic target for future 
projects.  Obtainment of four novel stereoisomers helped shed further light to the recently 
 1H NMR ( J in Hz) 13C NMR () 
position 
(+)‒hyacinthacine C4 
(Kato et al.)117  
253 
(+)‒hyacinthacine C4 
(Kato et al.) 117 
253 
1 4.18, t (4.0) 4.15, t (3.9) 75.2 69.3 
2 4.00, dd (4.0, 8.7) 3.97, dd (3.9, 9.1) 77.3 74.9 
3 3.38, dt (4.6, 8.7) 3.33-3.26, m 65.1 60.6 
5 2.96, dq (6.9, 9.2) 3.46, p (6.8) 62.0 57.0 
6 3.90, dd (8.2, 9.2) 4.11, dd (6.0, 7.4) 82.9 78.4 
7 4.15, t (8.2) 4.29, d (5.8) 80.0 71.4 
7a 3.57, dd (3.7, 8.2) 3.33-3.26, m 67.3 68.8 
8 3.65, d (4.6) 
3.74, dd (4.3, 11.6) 
3.61, dd (6.4, 11.7) 
66.4 63.0 
9 1.29, d (6.9) 1.12, d (7.0) 16.0 10.3 
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discovered field of hyacinthacine alkaloids, where now only a few structural assignment 
puzzles remain unsolved. On this respect, the most valuable contribution of this Chapter 
rests in the found evidence of identity of one of the synthesized pyrrolizidines with natural 
hyacinthacine C1, to which identical structure as hyacinthacine C4 had been assigned. The 
full characterization of all products leading to this structural correction have been included 
as part of our current J. Nat. Prod. manuscript (Supporting Information). Additionally, a 
copy of all the spectroscopic evidence of the final products has been included in the 







Chapter 6 : Glycosidase Inhibitory summary 
 
After their successful synthesis and characterisation, natural (+)-hyacinthacine C5 216, 
natural (+)-hyacinthacine C1 243, along with all synthesized epimers including the 
originally proposed structure for hyacinthacine C5, 155, 156, 169, 215, 217, 242, 244 and 
253 were sent to Japan and were assessed for their glycosidase inhibitory activities. The 
collaborative effort from both Assoc. Prof. Atsushi Kato and his student Masako Hoshino 
saw our final products tested against a panel of enzymes summarized in Tables 6.1, 6.2 
and 6.3. As a measure of their anti-diabetic and anti-obesity potential, our results were 
compared with the glycosidase inhibitory results from casuarine (Table 6.2). For clarity, 
the SAR will be discussed in two sections: the hyacinthacine C5-type analogues then the 
hyacinthacine C1/C4-type analogues synthesized.  
 
6.1. Glycosidase inhibitory potential of the hyacinthacine C5-type 
analogues (Table 6.1 and Table 6.2) 
 
The anti-diabetic and anti-obesity characteristics of our synthetic products are ultimately 
dependant on how well they can inhibit the α-glucosidases.196 This is because these 
enzymes are the key enzymes in catalysing the final step in the digestive process of 
carbohydrates. Inhibiting these enzymes can result in a reduction of postprandial plasma 
glucose concentrations and ultimately supress postprandial hyperglycemia.196 In this 
glycosidase inhibition study, a panel of enzymes, including key α-glucosidases were 
chosen. In this section, the glycosidase inhibitory activities of the seven hyacinthacine C5-
type analogues described in Chapters 2, 3 and 4B are discussed and summarised in Tables 
6.1 and 6.2. Considering first the C6, C7 syn-diol pyrrolizidines 155, 156, and 169, 
pyrrolizidines 155 and 156 showed weak to moderate inhibition of the α-glucosidase of rat 
intestinal isomaltase (IC50 values of 20 μM and 42 μM, respectively) and moderate 
inhibition against the α-glucosidase of rat intestinal sucrase (IC50 values of 13 μM and 9.9 
μM, respectively). Compound 155 displayed a weak inhibition of yeast α-glucosidase (IC50 
value of 83 μM) and rat intestinal maltase (IC50 value of 61 μM). It also displayed a 
moderate activity against the amylglucosidases from Aspergillus niger and Rhizopus sp. 
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(IC50 values of 25 μM and 16 μM, respectively). Compound 169 proved relatively inactive 
among the entire panel of enzymes.  
Upon testing the glycosidase inhibition for the C6, C7 anti-diol series (the originally 
proposed structure for hyacinthacine C5, 216, 217, and 215) results showed that compound 
215 proved relatively inactive among the entire panel of enzymes. Compound 217 
displayed a weak to moderate inhibition against α-glucosidases of yeast, rice, rat intestinal 
maltase and human lysosome (IC50 values of 123 μM, 99 μM, 21 μM and 15 μM, 
respectively) and weak inhibition against the amylglucosidase of Aspergillus niger (IC50 
value of 41 μM). From this series, only the putative hyacinthacine C5 and compound 216 
showed inhibition against the α-L-rhamnosidase of Penicillium decumbens (IC50 values of 
74 μM and 197 μM, respectively), however, the putative hyacinthacine C5 was only 
selective for this enzyme. Contrastingly, compound 216 proved less selective since it 
displayed a similar range of activities for yeast and rat intestinal maltase α-glucosidase 
(IC50 values of 195 μM and 108 μM, respectively). Compound 216 is the corrected 
structure for the natural isolate labelled as hyacinthacine C5 and so it was interesting to 
compare the glycosidase tests between our synthetic 216 and the 2007 natural isolate.117 
From the common enzymes tested, results seemed to differ between 216 and the natural 
isolate. For example, the 2007 natural isolate displayed a moderate activity against the 
amylglucosidases from Aspergillus niger (IC50 value of 57 μM), whereas synthetic 216 
displayed an IC50 value of 370 μM against this enzyme. The 2007 natural isolate was 
recorded as being relatively inert against the α-glucosidase of rat intestinal maltase (IC50 
value in excess of 1000 μM) and also against the β-galactosidase of bovine liver (IC50 value 
of 900 μM). Although we have unequivocally proven that compound 216 is the same 
structure, this compound was found to be relatively more active against these two enzymes 
with IC50 values of 630 μM and 42 μM, respectively. To account for these differences, we 
can only speculate that either provision of more sample was required for a more accurate 
result, or that the natural isolate may have been contaminated with extra-cellular plant 
matrix that may not have been evident in the NMR analysis; this could lead to an 
unknowingly impure sample and misleading mass and IC50 of product. Moreover, the 
enzyme purities between our study and the 2007 study by Kato et al.,117 may have been 




Table 6.1: Concentration of hyacinthacine C5-type analogues 216, 155, 156 and 217 giving 
50% inhibition of various glycosidases. 
 
a “-” : Not tested, bNI : No inhibition (less than 50 % inhibition at 1000 µM),  






Table 6.2: Concentration of hyacinthacine C5-type analogues the putative structure for 
hyacinthacine C5, 169, 215 and Casuarine giving 50% inhibition of various glycosidases. 
 
aNI : No inhibition (less than 50 % inhibition at 1000 µM), b(  ) : Inhibition % at 1000 






6.2. Glycosidase inhibitory potential of the hyacinthacine C1/C4-type 
analogues (Table 6.3) 
 
In this section, the glycosidase inhibitory activities of the four hyacinthacine C1/C4-type 
analogues, 242, 243, 244 and 253 described in Chapter 5 are discussed and are summarised 
in Table 6.3. From these four analogues, analogue 244 was found to be selective for the 
amyloglucosidase of Aspergillus niger and displayed a weak inhibition with an IC50 value 
of 95.5 µM. The corrected structure for hyacinthacine C1 243 displayed a weak to moderate 
inhibition for the α-glucosidase of rice, rat intestinal maltase and human lysosome (IC50 
values of 33.7, 78.2 and 55 µM, respectively). These results were then compared with 
glycosidase inhibitory results of the naturally occurring hyacinthacine C1.
105 Interestingly, 
a notable difference was found between the natural isolate and our synthetic 243. In 1999, 
the natural isolate was found to be relatively inert against the α-glucosidase of rice and rat 
intestinal maltase (IC50 values for both enzymes were in excess of 1000 μM), but selective 
and active against the amylglucosidase of Aspergillus niger (IC50 value of 84 μM). 
Comparatively, synthetic 243 was found to display the aforementioned α-glucosidase 
activities but proved inactive against the amylglucosidase of Aspergillus niger (IC50 value 
in excess of 1000 μM). These differences may have been the result of not enough sample 
being provided for a reliable glycosidase inhibition assessment, or maybe extra-cellular 
plant matrix that may not have been evident in the NMR analysis was apparent in the 
natural isolate sample. Regardless, there are too many variables, and this certainly warrants 
further investigation since we have unequivocally proven our synthetic 243 to be the same 
structure as the natural isolate labelled hyacinthacine C1 from 1999.
105 In contrast with 











Table 6.3: Concentration of hyacinthacine C1/C4-type analogues 242, 243, 244 and 253 
giving 50% inhibition of various glycosidases. 
 
aNI : No inhibition (less than 50 % inhibition at 1000 µM), b(  ) : Inhibition % at 1000 





6.3. Assessing the anti-diabetic and anti-obesity potential of our 11 
hyacinthacine C-type analogues 
 
To gain a better understanding of the structure-activity-relationship (SAR), all 
hyacinthacine C-type analogues synthesized in this Ph.D. were collectively compared.  
 
6.3.1. SAR Effects of the stereochemistry of the C5 methyl group 
 
From our results of all the enzyme inhibition results, we noted correlation between the 
orientation of the C5 methyl group and the IC50 against each glycosidase tested. More 
specifically, if the hyacinthacine C-type alkaloid contains a (5S)-methyl, the IC50 values 
increase with consequently a reduction in the selectivity and potency of the compound as 
a glycosidase inhibitor. Comparatively, for a decrease in the IC50, the hyacinthacine C-
type compounds containing an (5R)-methyl proved to be more suitable candidates for 
potential as glycosidase inhibitors. 
 
6.3.2. SAR Effects of the stereocentres at C1, C2 and C3 
 
Our observed glycosidase activities seemed to be influenced largely by the C1, C2 and C3 
stereocentres which are originally sourced from the starting sugar L-xylose.132 This trend 
can be best explained through comparison of the synthetic hyacinthacine C-type analogues 
described in this work, with the structurally analogous casuarine (one of the most powerful 
glucosidase inhibitors) shown in Table 6.2. More specifically, the glycosidase activities of 
our synthetic hyacinthacine C-type analogues were generally less potent than casuarine. 
Interestingly, it has been proven by crystal structure determination and computational 
methods, that casuarine perfectly mimics the stereochemical arrangement of glucose, with 
the A-ring overlapping the C3 to C6 portion of glucose.197-198  
In this Ph.D. work, the hyacinthacine C-type analogues discussed in section 6.1 contain an 
A-ring configuration to that of L-xylose. Inverting the configuration at C1 as operated in 
Chapter 5, leads to another related carbohydrate, namely L-lyxose. Both L-xylose and L-
lyxose are non-natural sugars. Since glucosidases are functionally deputed to recognize 
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glucose, it can be therefore generalized that iminosugars containing any configurational 
deviation from glucose (such as L-xylose and L-lyxose), decreases the glucose nature of 
the iminosugar, and so will diminish glucosidase inhibition activity.  
When the hyacinthacine C-type analogues described in section 6.1 were compared with 
the hyacinthacine C-type analogues described in section 6.2, it was observed that the 
potency and selectivity of the latter were relatively weak. Therefore, inverting the C1 
stereocentre decreases the potency and selectivity of the iminosugar as a glycosidase 
inhibitor. More specifically, hyacinthacine C5-type compounds 155, 156, 169, 215, 216, 
217 and the putative structure of hyacinthacine C5 contain identical configurations with 
that of casuarine at C7a, C1, C2 and C3.132 The relatively diminished glycosidase activity 
discussed in section 6.2 for compounds 242, 243, 244 and 253 can be compared with a 
worse mimicry of casuarine (and ultimately glucose), since only configurations at C7a, C2 
and C3 were preserved. Similarly, inverting C1 of casuarine gives rise to an allose related 
configuration and is responsible for a similar diminished glycosidase inhibition activity.197-
198 
6.3.3. SAR Effects of the C5 methyl group 
 
When all hyacinthacine C-type analogues synthesized in this study were compared with 
casuarine, it was observed that containing a methyl substituent at C5 resulted in a decrease 
in glycosidase inhibition properties.132 This behaviour appears to be general for related 
pyrrolizidines reported in literature. For example, a comparison of 7-deoxycasuarine198 and 
its 5-methyl substituted homologue199 shows a one order magnitude loss of activity 
towards the amyloglucosidase of A. niger (IC50 value of 4.5 µM and 39 µM, respectively). 
In another example, australine200 and its 5-methyl substituted homologue, hyacinthacine 
B4
113 display a similar loss of activity towards the amyloglucosidase of A. niger (IC50 value 
of 5.8 µM and 89 µM, respectively). It is therefore reasonable to suggest that in general, 





Chapter 7 : Conclusions 
 
The initial aims for this project were to:   
1. Develop a novel synthetic strategy to prepare hyacinthacine C-type analogues in 
an efficient and flexible manner 
2. Elucidate and correct the structure for either hyacinthacine C1, C4 or C5. 
3. Generate a moderate number of hyacinthacine C-type configurational analogues 
and use the data generated from glycosidase inhibition studies to determine a 
general structure-activity relationship.  
Chapters 2 and 3 report the synthetic strategy employed towards the synthesis of the 
hyacinthacine C-type analogues. These Chapters detail the successful synthesis of (+)-7-
epi-hyacinthacine C5 155, (‒)-6-epi-hyacinthacine C5 156 and (+)-5,6-di-epi-
hyacinthacine C5 169. The spectroscopic data for these compounds did not match any of 
the spectroscopic data reported for hyacinthacines C1, C4 or C5. However, these results led 
us to consider implementing a C6, C7 anti-diol configuration in the final hyacinthacine C-
type analogues.  
Chapter 4A describes our unsuccessful attempts towards generating the C6, C7 anti-diol 
within the final hyacinthacine C-type analogues. These results led to the conclusion that 
installing the C6, C7 anti-diol is most effective after the pyrrolizidine core has been formed 
and can be achieved via synthesis of the corresponding cyclic sulfate then subsequent SN2 
ring-opening of the cyclic sulfate moiety with a benzoate nucleophile. This approach is 
discussed in Chapter 4B and details the successful synthesis of four hyacinthacine C-type 
products which include: the corrected structure of the natural (+)-hyacinthacine C5 216, 
(+)-6,7-di-epi-hyacinthacine C5 217, the originally proposed structure for (+)-
hyacinthacine C5 and (+)-5-epi-hyacinthacine C5 215.  Our synthetic product 216 displayed 
essentially identical 1H and 13C NMR spectroscopic data for the natural isolate labelled 
hyacinthacine C5. Thus, the correct structure of hyacinthacine C5 has the opposite 
configuration at the three contiguous stereogenic centres, C5, C6, and C7, to that of the 









Figure 7.1: DFT minimized molecular models [B3LYP/6-31G(d)] of the putative structure 
of hyacinthacine C5 and its corrected structure 216 (hydroxy protons not shown). 
 
 Unfortunately, we could not conclude that our synthetic hyacinthacine C5-type analogue 
217 was the same as the compound 120 reported by Reissig and Goti et al.131 More 
specifically, there was a significant spectroscopic difference between the 1H and 13C NMR 
spectroscopic data for both products. The parent crystalline compound 149 that led to the 
synthesis of compound 217, was unequivocally confirmed to be correct by X-ray 
crystallographic analysis and so in addition to the extensive spectroscopic analysis of 217, 
we were confident that we had synthesized the correct structure. After reviewing the 
pathway reported by Reissig and Goti et al.,131 we were able to propose that they may have 
unexpectedly synthesized and isolated the 4-membered bicyclic N-heterocycle 220 rather 
than 120 (Scheme 7.1).  
 
Corrected structure for natural 











































Scheme 7.1: The unconfirmed but potential synthesis of  N-heterocycle 220 by Reissig 
and Goti et al.131    
 
 
The remaining four hyacinthacine C-type analogues synthesized in this work are detailed 
in Chapter 5. These include (‒)-5-epi-hyacinthacine C1 242, the corrected structure of 
hyacinthacine C1 243, (+)-6,7-di-epi-hyacinthacine C1 244 and (+)-7-epi-hyacinthacine C1 
253. Our synthetic product 243 displayed essentially identical 1H and 13C NMR 
spectroscopic for the natural isolate labelled hyacinthacine C1.
105 Thus, the correct 
structure of hyacinthacine C1 has the opposite configuration at C6 to that of the originally 
proposed structure (Figure 7.2). It is suspected that the torsional strain and twist of the 
pyrrolizidine core may have resulted in either an observed (or absence of) several NOESY 







Figure 7.2: DFT minimized molecular models [B3LYP/6-31G(d)] of the putative structure 
of hyacinthacine C1 and its corrected structure 243 (hydroxy protons not shown). 
 
The successful synthesis of all eleven hyacinthacine C-type analogues in this work is 


















Putative (incorrect) structure for 
hyacinthacine C1 
 
Corrected structure for natural 

























All eleven hyacinthacine C-type analogues synthesized in this work were each assessed 
for their glycosidase inhibitory activities. The hyacinthacine C-type analogues described 
in Chapters 2-4B were derived from L-xylose. Inverting the stereocentre at C1 as described 
for the hyacinthacine C-type analogues synthesized in Chapter 5, led to another related 
carbohydrate, namely L-lyxose. In comparison to the structurally analogous casuarine (one 
of the most powerful glucosidase inhibitors), the synthetic hyacinthacine C-type analogues 
synthesize in this Ph.D. work were generally less potent than casuarine. The SAR for these 
compounds suggest that the diminished glycosidase activity was a result of steric hindrance 
induced by the C5-methyl (regardless of orientation), as well as configurational deviations 
away from glucose (such as L-xylose and L-lyxose). Both these factors seem to decrease 
the glucose nature of the iminosugar, and so will diminish glucosidase inhibition activity. 
However, both (‒)-6-epi-hyacinthacine C5 156 and (+)-7-epi-hyacinthacine C5 155 
displayed noteworthy inhibition against the α-glucosidase of rat intestinal sucrase (IC50 
values of 13 μM and 9.9 μM, respectively) and so can be used as a foundation towards 
investigating suitable drug candidates for anti-diabetic and anti-obesity medications. 
The work described in this thesis is believed to satisfactorily meet the aforementioned aims 
initially proposed in 2015. Although we were unable to synthesize the putative structure 
for hyacinthacine C1/C4, the correction of the structure of hyacinthacine C1 means that 
there is a strong possibility that the structure for the 2007 natural isolate labelled as 
hyacinthacine C4 is correctly assigned.
















Silica gel 60 230–400 Mesh was used for flash column chromatography (FCC) 
purifications. LRESIMS data was aquired on a single quadrupole, (MeOH as solvent) mass 
spectrometer. HRESIMS were determined on a quadrupole time–of–flight mass 
spectrometer. FTIR data were determined on neat samples. The optical rotation was 
measured using a 2 mL cell at room temperature. An average of 40 measurements was 
used to calculate the specific rotation. 1H NMR (500 MHz) and 13C NMR (125 MHz) 
spectra were recorded in deuterochloroform (CDCl3), deuterium oxide (D2O) or deuterated 
methanol (CD3OD) solutions. All signals obtained in CDCl3 were relative to the 
tetramethylsilane (TMS) signal for 1H NMR and the CDCl3 signal for 
13C NMR, referenced 
at 0.00 ppm and 77.16 ppm, respectively. All signals which were recorded in CD3OD were 
relative to the CD2HOD signal for 
1H NMR and the CD3OD
 for 13C NMR, referenced at 
3.31 and 49.00 ppm, respectively. All signals which were recorded in D2O were relative 
to the D2O signal for 
1H NMR, referenced at 4.49 ppm. For 13C NMR the referencing of 
peaks is relative to internal MeOH ( 49.50 ppm). NMR assignments were based upon 
gCOSY, APT, gHSQC, and NOESY or ROESY experiments. In some cases, 13C NMR 
signals that were absent in the standard 13C NMR spectrum were identified using gHSQC 
experiments. Pyrrolizidine compounds are named using systematic nomenclature. The 
NMR assignments of those compounds are based on the numbering system of the 
hyacinthacine alkaloids and not the systematic name. The three–dimensional structures 
generated were prepared with ChemDraw 16.0 and Avogadro: an open–source molecular 
builder and visualization tool. Version 1.2.0.201 The Density Functional Theory (DFT) 
used to minimize the 3D structures was calculated with B3LYP/6–31G(d)202-204 using the 
Gaussian 09 basis set.205 ORTEP representations shown for the crystal structures were 
generated in accordance with CrysAlis PRO 1.171.38.46; cell refinement: CrysAlis PRO 
1.171.38.46; data reduction: CrysAlis PRO 1.171.38.46, CrysAlis PRO 1.171.38.43; cell 
refinement: CrysAlis PRO 1.171.38.43; data reduction: CrysAlis PRO 1.171.38.43.206 
Program(s) used to solve the structure: SIR92;207 program(s) used to refine structure: 
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CRYSTALS;208 molecular graphics: PLATON;209 software and other references used to 
prepare material for this document and resultant publication(s): CRYSTALS.210-215  
 
Chapter 2  
 





In this order, concentrated H2SO4 (0.10 mL, 1.9 mmol), CuSO4 (2.1 g, 13.4 mmol) and L–
xylose (1.0 g, 6.7 mmol) were added to anhydrous acetone (20 mL). The mixture was 
vigorously stirred under a nitrogen atmosphere at rt for 28 h, causing the solution to turn 
yellow. TLC analysis indicated full consumption of the starting material. The CuSO4 was 
removed via vacuum filtration through a celite pad. The filter cake was washed with 
additional acetone (3 x 5 mL) and the combined filtrate and washings were basified by the 
addition of concentrated NH3 solution (0.4 mL). The precipitated (NH4)2SO4 was filtered 
and the solvent was concentrated in vacuo to give at yellow syrup. After treatment with 
HCl (11 mL, 0.24 M) and continual stirring at rt for 45 min, TLC analysis confirmed the 
formation of the desired product. The solution was neutralised with NaHCO3 to pH 7–8, 
followed by concentration in vacuo. The resultant residue was then dissolved in 
chloroform, dried (MgSO4), filtered and concentrated in vacuo to give the desired 
acetonide 129 as a pale–yellow oil (1.3 g, quant.) which was used for the next step without 
any purification. The 1H and 13C NMR spectroscopic data of this product were consistent 
with those published.149-151, 216 
 
Rf (EtOAc) = 0.40 
LRESIMS m/z 191 (100%) [M+H]+ 
1H NMR (500 MHz, CDCl3) δ 5.99 (1H, d, J = 3.5 Hz, H1), 4.53 (1H, d, J = 3.5 Hz, H2), 
4.33 (1H, s, H3), 4.22 – 4.11 (3H, m, H4, H5), 4.09 – 4.04 (1H, m, OH), 3.84 (1H, bs, 
OH), 1.49 (3H, s, Ac–CH3), 1.32 (3H, s, Ac–CH3).  
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13C NMR (125 MHz, CDCl3) δ 111.8 (AcC), 104.7 (C1), 85.3 (C2), 79.8 (C4), 75.6 (C3), 
60.3 (C5), 26.6 (AcCH3), 26.1 (AcCH3). [Ac = acetonide] 
General method for O-benzylation  
 





A solution of the acetonide 129 (0.50 g, 2.6 mmol) in THF (3 mL) was slowly added to a 
cooled (0 oC) and stirred suspension of sodium hydride (0.38 g, 9.5 mmol) (60% dispersion 
in mineral oil) in anhydrous THF (15 mL) under a nitrogen atmosphere. The reaction 
mixture was heated at reflux for 5 min and then cooled to rt. Benzyl bromide (0.75 mL, 
6.31 mmol) and TBAI (0.15 g, 0.39 mmol) were added to the mixture, which was heated 
at reflux for 15 min. By this time, TLC analysis had confirmed full consumption of the 
starting material. The reaction mixture was cooled to 0 oC, and quenched dropwise with 
water (10 mL). The mixture was extracted with Et2O (3 x 10 mL) and the combined 
extracts were dried (MgSO4), filtered and concentrated in vacuo. The resultant brown oil 
was purified by FCC (gradient of 3:20 EtOAc/ n-hexane to 1:5 EtOAc/n-hexane) to afford 
the bis–benzylated acetonide 130, as a pale–yellow oil (0.83 g, 86%). The 1H and 13C NMR 
spectroscopic data of this product were consistent with those published.149-151, 216 
  
Rf (1:5 EtOAc/n-hexane) = 0.30 
LRESIMS m/z 371 (100%) [M+H]+ 
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.17 (10H, m, ArH), 5.93 (1H, d, J = 3.7 Hz, H1), 
4.68 – 4.54 (3H, m, H2, H3՛), 4.49 (2H, 2 x d, J = 12.0, 9.9 Hz, H5՛), 4.41 (1H, td, J = 6.1, 
3.2 Hz, H4), 3.96 (1H, d, J = 3.2 Hz, H3), 3.77 (2H, qd, J = 9.9, 6.1 Hz, H5,), 1.47 (3H, s, 
AcCH3), 1.30 (3H, s, AcCH3).  
13C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 137.7 (ArC), 128.5 (2 x ArCH), 128.5 (2 x 
ArCH), 128.0 (2 x ArCH), 127.9 (2 x ArCH), 127.7 (2 x ArCH), 111.7 (AcC), 105.2 (C1), 
82.4 (C2), 81.8 (C3), 79.3 (C4), 73.6 (C5՛), 72.0 (C3՛), 67.7 (C5), 26.9 (AcCH3), 26.4 










To a solution of 130, (0.880 g, 2.38 mmol) in AcOH/H2O (20 mL, 30% v/v) was added 5 
M HCl (1 mL). TLC analysis confirmed full consumption of the starting material after 
heating the reaction to 45 oC for 3 h by which this time the solution was neutralised by the 
addition of NaHCO3 (0.5 g or until pH 7). The solution was then evaporated under reduced 
pressure to 20 mL and extracted with CH2Cl2 (3 x 15 mL), the combined extracts were 
dried (MgSO4), filtered and concentrated in vacuo. FCC (1:5 EtOAc/n-hexane) resulted in 
a mixture of anomers (3:1, a:b, respectively) as a clear oil that solidified to a waxy solid 
overnight (0.52 g, 83%). The 1H and 13C NMR spectroscopic data of this product were 
consistent with those published.149-151, 216   
 
Rf (1:5 EtOAc/n-hexane) = 0.20  
LRESIMS m/z 331 (100%) [M+H]+ 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.21 (20H, m, ArH), 5.45 (1H, d, J = 4.2 Hz H1a), 
5.11 (1H, d, J = 3.3 Hz, H1b), 4.69 – 4.43 (9H, m, H3՛a, b, H5՛a, b, H4a), 4.41 (1H, tt, J = 
5.1, 3.3 Hz, H4b), 4.20 (1H, d, J = 2.6 Hz, H2b), 4.17 – 4.10 (2H, m, H2a, H3b), 4.01 – 
3.91 (2H, m, OHa, H3a), 3.75 (1H, q, J = 5.1Hz, H4a ), 3.86– 3.62 (4H, m, H5a, H5b), 
3.21 (1H, s, OH), 2.03 (1H, s, OH).  
13C NMR (125 MHz, CDCl3) δ 137.9 (ArCa), 137.9 (ArCb), 137.6 (ArCa), 137.4 (ArCb), 
128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.8, 127.6 (20 x ArCH), 103.5 (C1b), 
96.0 (C1a), 83.6 (C3a), 82.9 (C3b), 79.9 (C4b), 79.3 (C2b), 77.5 (C4a), 75.6 (C2a), 73.7 








General Method for the Petasis (Borono-Mannich) reaction 
 
(2S,3S,4R,5R,E)-1,3-Bis(benzyloxy)-5-(((R)-but-3-en-2-yl)amino)-7-phenylhept-6-
ene-2,4-diol (127)149  
 
Triethylamine (434 µL, 2.83 mmol) was added to a solution of (R)–α–methylallyl 
amine·HCl (0.220 g, 3.12 mmol) in EtOH (50 mL) and the solution was stirred at rt for 20 
min. (+)–3,4–Di–O–benzyl–α,β–L–xylofuranose (0.930 g, 2.83 mmol) was added to the 
reaction mixture, followed by the addition of (E)–2–phenylvinylboronic acid (0.460 g, 
3.12 mmol). TLC analysis confirmed complete consumption of the starting material after 
stirring at rt for 3 d, whereby the mixture was concentrated in vacuo, affording a brown 
viscous oil. The crude product was dissolved in EtOAc (50 mL) and washed with 0.5 M 
NaOH (2 x 40 mL) solution. The organic fraction was dried (MgSO4), filtered, 
concentrated in vacuo and purified by FCC (3:97 MeOH/CH2Cl2) affording the desired 
product 127 as a brown oil (0.900 g, 65%). To prepare the crystalline hydrochloride salt 
of 127, a portion of 127 (0.100 g) was dissolved in CH2Cl2 (5 mL) and washed with 1N 




Rf 0.20 (3:97 MeOH/CH2Cl2). 
LRESIMS m/z 488 (100%) [M+H]+. 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.20 (15H, m, 
ArH), 6.48 (1H, d, J = 16.0 Hz, H7), 6.10 (1H, dd, J = 16.0, 8.7 Hz, H6), 5.72 (1H, ddd, J 
= 17.3, 10.2, 7.2 Hz, H2՛), 5.09 (1H, d, J = 10.2 Hz, H3՛cis), 4.98 (1H, d, J = 16.8 Hz, 
H3՛trans), 4.64 (2H, s, OCH2Ph), 4.51 – 4.42 (2H, m, OCH2Ph), 4.05 (1H, dd, J = 8.3, 5.5 
Hz, H2), 3.97 (1H, t, J = 4.6 Hz, H4), 3.69 – 3.49 (4H, m, H3, H1, H5), 3.30 (1H, dq, J = 
12.6, 6.2, Hz, H1՛), 1.10 (3H, d, J = 6.4 Hz, H1՛՛).  
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13C NMR (125 MHz, CDCl3) δ 142.0 (C2՛), 138.3 (ArC), 138.2 (ArC), 136.8 (ArC), 133.6 
(C7), 128.8 (ArCH), 128.3 (ArCH), 128.0 (C6, ArCH), 128.0 (ArCH), 127.0 (ArCH), 
126.7 (ArCH), 114.9 (C3՛), 80.1 (C3), 74.5 (OCH2Ph), 73.6 (OCH2Ph), 72.4 (C4), 71.5 
(C1), 70.3 (C2), 60.6 (C5), 53.0 (C1՛), 20.3 (C1՛՛).  
 
127.HCl  
Rf 0.15 (5:97 MeOH/CH2Cl2).  
MP: 165 – 170 oC.  
1H NMR (500 MHz, CDCl3) δ 7.47 – 7.07 (15H, m, ArH), 6.69 (1H, d, J = 16.0 Hz, H7), 
6.43 (1H, dd, J = 16.0, 9.9 Hz, H6), 6.03 (1H, ddd, J = 17.5, 10.4, 7.4 Hz, H2՛), 5.32 – 5.20 
(2H, m, H3՛), 4.80 (1H, d, J = 10.9 Hz, OCH2Ph), 4.68 – 4.57 (1H, m, H5), 4.55 – 4.29 
(3H, m, OCH2Ph, H4), 4.20 (1H, dd, J = 9.9, 3.4 Hz), 4.10 (2H, dd, J = 6.3, 4.3 Hz), 3.81 
– 3.68 (2H, m, H3, H1՛), 3.63 (1H, dd, J = 6.8, 1.9 Hz, H2), 3.53 (1H, dd, J = 9.4, 6.5 Hz, 
H1), 3.42 (1H, dd, J = 9.4, 6.0 Hz, H1), 1.46 (3H, d, J = 6.8 Hz, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 138.7 (C2՛), 137.9 (ArC), 137.6 (ArC), 135.2 (ArC), 134.7 
(C7), 128.9 (ArCH), 128.8 (ArCH), 128.4 (ArCH), 127.9 (ArCH), 127.69 (ArCH), 127.68 
(ArCH), 127.19 (ArCH), 120.18 (C3՛), 78.8 (C3), 74.8 (OCH2Ph), 73.2 (OCH2Ph), 70.9 
(C4), 69.9 (C1), 68.6 (C2), 62.1(C5), 54.9 (C1՛), 16.7 (C1՛՛). 
 
(2R,3R,4R,5R)-4-(Benzyloxy)-5-((benzyloxy)methyl)-1-((R)-but-3-en-2-yl)-2-((E)-
styryl)pyrrolidin-3-ol (131)149  
 
Triethylamine (47 µL, 0.34 mmol) was slowly added to a solution of 127 (166 mg, 0.340 
mmol) in anhydrous CH2Cl2 (5 mL) at 0 
oC under a N2 atmosphere. Whilst stirring, a 0.13 
M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.62 mL, 0.340 mmol) was 
slowly added to the reaction mixture. The reaction mixture was heated at 40 oC and stirred 
for 10 h or until TLC analysis confirmed full consumption of the starting material. The 
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reaction was quenched through the addition of a sat. NaHCO3 solution (4 mL) and 
extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts were dried over MgSO4, 
gravity filtered and concentrated in vacuo to give an orange oil. Purification by FCC 
(5%MeOH/CH2Cl2) gave 131 as a yellow oil (101 mg, 63%). 
 
Rf (5%MeOH/CH2Cl2) = 0.45 
LRESIMS m/z 470 [M+H]+. 
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.14 (15H, m, ArH), 6.58 (1H, dd, J = 16.0, 9.7 Hz, 
H1՛՛՛), 6.48 (1H, d, J = 16.0 Hz, H2՛՛՛), 5.80 (1H, ddd, J = 17.4, 10.3, 7.6 Hz, H2՛), 5.06 (1H, 
d, J = 17.4 Hz, H3՛trans), 4.94 (1H, d, J = 10.3 Hz, H3՛cis), 4.63 – 4.46 (4H, m, OCH2Ph), 
4.01 – 3.89 (3H, m, H2, H3, H4), 3.57 (1H, dd, J = 9.7, 3.4 Hz, H1՛՛՛՛), 3.53 – 3.43 (2H, m, 
H1՛, H1՛՛՛՛), 3.33 (1H, s, H5), 1.15 (3H, d, J = 6.3 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 142.8 (C2′), 138.5 (ArC), 137.8 (ArC), 137.4 (ArC), 131.3 
(C2‴), 130.3 (C1‴), 128.7 (ArCH), 128.5 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.8 (2 
x ArCH), 127.7 (ArCH), 127.3 (ArCH), 126.4 (ArCH), 114.5 (C3′), 88.6 (C4), 77.9 (C3), 






To a solution of 131 (120 mg, 0.255 mmol) in anhydrous CH2Cl2 (20 mL) under N2 
conditions was added p–toluenesulfonic acid monohydrate (73 mg, 0.384 mmol). The 
reaction mixture was held at reflux for 30 min or until TLC confirmed the full consumption 
of the starting material. After cooling to room temperature, the reaction mixture was 
concentrated in vacuo to give a dark brown oil. The oil was dissolved in anhydrous CH2Cl2 
(20 mL) and purged with a balloon of argon gas. Hoveda Grubb’s II generation ruthenium 
catalyst (11 mg, 0.051 mmol) was added to the solution and purged with another balloon 
of argon gas. The reaction mixture was heated at reflux for 3 days under an argon gas 
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atmosphere. After TLC confirmed the full consumption of the starting material, the 
reaction mixture was washed with Na2CO3 (3 x 5 mL), dried over MgSO4 followed by 
concentration in vacuo to give a black oil. Purification by FCC (2% MeOH/CH2Cl2) gave 
the title compound 132 as a black oil (61 mg, 65%). 
 
Rf (2%MeOH/CH2Cl2) = 0.27 
[α]𝐷
25 –27.0 (c 0.75, CHCl3).  
IR max (cm-1): 3390, 2980, 2862, 1110, 896, 733 cm–1 
LRESIMS m/z 366 (100%) [M+H]+.  
HRESIMS found 366.2075, calcd for C23H28NO3, 366.2069 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.20 (10H, m, ArH), 5.84 (1H, d, J = 5.9 Hz, H7), 
5.69 (1H, d, J = 5.9 Hz, H6), 4.73 – 4.49 (4H, m, OCH2Ph), 4.37 – 4.27 (2H, m, H7a, H5), 
3.98 (1H, s, H1), 3.88 (1H, t, J = 4.3 Hz, H2), 3.67 – 3.49 (3H, m, H3, H1′), 1.26 (3H, d, 
J = 5.3 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 137.7 (ArC), 136.1 (ArC), 133.8 (C6), 128.47 (ArCH), 
128.4 (ArCH), 127.9 (ArCH), 127.78 (ArCH), 127.75 (ArCH), 127.6 (ArCH), 127.4 (C7), 
89.1 (C2), 80.7 (C1), 73.8 (OCH2Ph), 73.5 (C1′′), 72.5 (OCH2Ph), 64.2 (C5 or C7a), 64.0 
(C5 or C7a), 62.1 (C3), 18.0 (C1′). 
 
(1R,2R,3R)-2-(Benzyloxy)-3-((benzyloxy)methyl)-5-methyl-2,3-dihydro-1H-
pyrrolizin-1-ol (133)149  
 
Compound 132 (55 mg, 0.15 mmol) was dissolved in acetone/water (3:1, 12 mL,) and the 
solution was cooled to 0 oC. N–methylmorpholine–N–oxide (35 mg, 0.30 mmol) and 
potassium osmate dihydrate (4 mg, 0.011 mmol) were added and the solution was stirred 
vigorously at 35 oC for 48 h. The reaction was concentrated in vacuo, affording a black 
viscous oil which was diluted with H2O (20 mL) and extracted with EtOAc (3 x 15 mL). 
The combined extracts were dried (MgSO4), filtered and concentrated in vacuo to afford a 
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black oil which was subsequently purified by FCC (5:95 MeOH/CH2Cl2). This gave pure 
compound 133 (37 mg, 68%) as a black oil and recovered starting material 132 (8 mg, 
15%). 
Rf (5%MeOH/CH2Cl2) = 0.70 
LRESIMS m/z 386 [M+Na]+. 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.23 (9H, m, ArH), 7.14 – 7.08 (1H, m, ArH), 6.04 
(1H, d, J = 2.9 Hz, H7), 5.97 (1H, bs, H6), 4.92 – 4.84 (1H, m, H1), 4.73 (1H, d, J = 12.0 
Hz, OCH2Ph), 4.61 (1H, d, J = 12.0 Hz, OCH2Ph), 4.47 (1H, d, J = 12.1 Hz, OCH2Ph), 
4.41 (1H, d, J =12.1 Hz, OCH2Ph), 4.35 (1H, s, H2), 4.26 (1H, bs, H3), 3.71 (2H, bs, H1′), 
3.22 (1H, d, J = 10.4 Hz, OH), 2.11 (3H, s, H1′′). 
13C NMR (125 MHz, CDCl3) δ 137.7 (ArC), 136.8 (ArC), 136.7 (C7a), 128.7 (2 x ArCH), 
128.6 (2 x ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.9 (4 x ArCH), 123.5 (C5), 111.5 
(C6), 101.6 (C7), 93.2 (C2), 73.6 (OCH2Ph), 71.8 (OCH2Ph), 71.0 (C1), 69.4 (C8), 62.7 
(C3), 11.9 (C9). 
 
(4R,5R)-5-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-3-((R)-but-3-en-2-yl)-4-




Procedure A: Compound 127 (540 mg, 1.11 mmol) was dissolved in anhydrous CH2Cl2 
(40 mL) and cooled to 0 oC under an atmosphere of nitrogen. Triethylamine (310 µL, 2.22 
mmol) was added and after 15 min triphosgene (164 mg, 0.555 mmol) was added 
portionwise and the solution was allowed to warm to rt. After stirring for 1 h, TLC analysis 
confirmed full consumption of the starting material. The reaction was diluted with H2O 
(15 mL) and extracted with CH2Cl2 (3 x 15 mL). The combined extracts were dried 
(MgSO4), filtered and concentrated in vacuo to afford a brown oil which whereby 
purification by FCC (gradient of 1:5 EtOAc/n-hexane to 1:1 EtOAc/n-hexane) produced 
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an inseparable mixture of isomers (37%, 1:2) consisting of the oxazolidinone and the 
oxazepinone respectively. Pure samples of 137 (12 mg) and 138 (20 mg) could be obtained 
for analytical purposes.  
Procedure B: To solution of 139 (500 mg, 0.851 mmol) in dry THF (15 mL) at 0 oC was 
added NaH (85.0 mg, 2.13 mmol, 60% in mineral oil). The mixture was heated at 65 oC 
for 45 min, or until full consumption of 139 by TLC analysis. The reaction mixture was 
cooled to 0 oC, and quenched by the slow addition of water (10 mL). The solution was 
extracted with EtOAc (3 x 20 mL). The combined extracts were dried (MgSO4), filtered 
and concentrated in vacuo. Purification by FCC (1:1 EtOAc/n-hexane) returned the 
oxozolidinone 137 as a pale–yellow oil (372 mg, 85%).  
 
137: 
Rf 0.65 (1:1 EtOAc/n-hexane). 
LRESIMS m/z 536 (100%) [M+Na]+.  
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.19 (13H, m, ArH), 7.18 – 7.00 (2H, m, ArH), 6.56 
(1H, d, J = 15.8 Hz, H2՛՛՛), 6.12 (1H, dd, J = 15.8, 10.9 Hz, H1՛՛՛), 5.99 – 5.89 (1H, m, H2՛), 
5.25 – 5.09 (2H, m, H3՛), 4.87 – 4.76 (2H, m, H5, OCH2Ph), 4.56 (1H, d, J = 11.2 Hz, 
OCH2Ph), 4.47– 4.39 (2H, m, H4, H1՛), 4.32 (2H, s, OCH2Ph), 3.96 (1H, s, H2՛՛՛՛), 3.79 
(1H, dd, J = 7.0, 2.3 Hz, H1՛՛՛՛), 3.53 – 3.39 (2H, m, H3՛՛՛՛), 2.37 (1H, s, OH), 1.30 (3H, d, 
J = 6.5 Hz, H1՛՛). 13C NMR (125 MHz, CDCl3) δ 156.9 (C2), 137.93 (ArC), 137.89 (ArC), 
136.9 (C2՛), 135.6 (ArC), 135.4 (C2՛՛՛), 129.2 (2 x ArCH), 128.9 (ArCH), 128.7 (4 x ArCH), 
128.5 (2 x ArCH), 127.9 (ArCH ), 127.2 (ArCH), 127.3 (2 x ArCH), 126.7 (2 x ArCH), 
124.7 (C1՛՛՛), 117.1 (C3՛), 77.8 (C5), 76.5 (C1՛՛՛՛), 74.2 (OCH2Ph), 73.1 (OCH2Ph), 70.6 
(C3՛՛՛՛), 68.9 (C2՛՛՛՛), 60.0 (C4), 51.7 (C1՛), 18.4 (C1՛՛).  
 
138:  
Rf 0.65 (1:1 EtOAc/n-hexane).  
LRESIMS m/z 536 (100%) [M+Na]+.  
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.16 (13H, m, ArH), 7.12 – 7.06 (2H, m, ArH), 6.69 
(1H, dd, J = 15.9, 9.0 Hz, H1‴), 6.43 (1H, d, J = 15.9 Hz, H2‴), 6.06 (1H, ddd, J = 17.4, 
10.5, 5.1 Hz, H2′), 5.34 (1H, d, J = 10.0 Hz, H3′cis), 5.31 (1 H, d, J = 16.2 Hz, H3′trans), 
4.79 (1H, td, J = 6.8, 1.8 Hz, H1′), 4.62 (1H, d, J = 11.8 Hz, OCH2Ph), 4.53 – 4.50 (3H, 
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m, H7 and 2 x OCH2Ph), 4.40 (1 H, d, J = 11.2 Hz, OCH2Ph), 4.07 – 4.04 (1H, m, H5), 
4.01 (1 H, dd, J = 9.0, 4.3 Hz, H4), 3.83 (1H, dd, J = 9.3, 6.0 Hz, H1‴′), 3.78 (1H, d, J = 
9.3 Hz, H1‴′), 3.75 – 3.73 (1H, m, H6), 1.84 (1H, d, J = 5.8 Hz, OH), 1.28 (3H, d, J = 6.8 
Hz, H1″).  
13C NMR (125 MHz, CDCl3) δ 158.4 (C2), 139.2 (C2′), 138.0 (ArC), 137.6 (ArC), 136.5 
(ArC), 131.6 (C2‴), 128.7 (ArCH), 128.6 (2 x ArCH), 128.3 (ArCH), 128.1 (ArCH), 128.0 
(ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.3 (C1‴), 126.8 (ArCH), 118.1 (C3′), 78.2 (C6), 
74.8 (C7), 73.6 (OCH2Ph), 72.9 (OCH2Ph), 69.0 (C5), 68.4 (C1‴′), 61.6 (C4), 55.6 (C1′), 
16.1 (C1″).  
 
tert-Butyl ((3R,4R,5S,6S,E)-5,7-Bis(benzyloxy)-4,6-dihydroxy-1-phenylhept-1-en-3-
yl)((R)-but-3-en-2-yl)carbamate (139).  
 
To a solution of 127 (1.10 g, 2.25 mmol) in dry 1,2–dichloroethane (10 mL) was added 
dry N,N–diisopropylethylamine (784 µL, 4.50 mmol) and di–tert–butyl–dicarbonate 
(0.980 g, 4.50 mmol). The reaction mixture was stirred at 70 oC for 48 h. CH2Cl2 (15 mL) 
was added and the solution was washed with 1 M HCl (2 x 20 mL), and brine. The organic 
fraction was dried (MgSO4), filtered and concentrated in vacuo. Purification by FCC (1:4 
EtOAc/n-hexane, then to 5:95 MeOH/CH2Cl2) gave 139 (0.820 g, 62%) and recovered 
starting material 127 (0.250 g, 23%) as pale–yellow and brown oils, respectively.  
 
Rf 0.30 (3:7 EtOAc/n-hexane). 
[α]𝐷
25+46.5 (c 1.00, CHCl3).  
IR max (cm-1): 3383, 3029, 2976, 2869, 1680, 1253, 1094 cm–1 
LRESIMS m/z 588 (100%) [M+H]+.  
HRESIMS found 588.3311, calcd for C36H46NO6, 588.3325 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.40 – 7.19 (15H, m, ArH), 6.59 (1H, dd, J = 16.1, 7.0 Hz, 
H6), 6.49 (1H, d, J = 16.1 Hz, H7), 5.97 (1H, ddd, J = 17.0, 10.7, 4.9 Hz, H2՛), 5.06 (1H, 
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t, J = 13.8 Hz, H3՛), 4.74 (1H, d, J = 11.2 Hz, OCH2Ph), 4.67 (1H, d, J = 11.2 Hz, OCH2Ph), 
4.51 (1H, d, J = 11.8 Hz, OCH2Ph), 4.46 (1H, d, J = 11.8 Hz, OCH2Ph), 4.40 – 4.27 (2H, 
m, H1՛, H5), 4.09 (2H, s, H4, H2), 3.65 (1H, bs, H3), 3.56 (2H, app. q, J = 9.5, 8.2 Hz, 
H1A,B), 1.47 (9H, s, (CH3)3C), 1.26 (2H, d, J = 6.7 Hz, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 139.8 (C2՛), 138.2 (CO), 138.1 (ArC), 137.0 (ArC), 133.25 
(C7), 128.5 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.7 
(ArCH), 127.6 (ArCH), 126.6 (C6), 115.4 (C3՛), 80.8 (CH3)3C), 78.5 (C3), 74.9 (C4 or 
C2), 74.5 (OCH2Ph), 73.4 (OCH2Ph), 71.4 (C1), 70.8 (C4 or C2), 59.6 (C1՛), 54.5 (C5), 
28.6 (CH3)3C), 18.2 (C1՛՛).  
 
General method for Ring-closing Metathesis 
  
(1R,5R,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-5-methyl-5,7a-
dihydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (140)149  
 
A solution of 137 (162 mg, 0.316 mmol) in anhydrous CH2Cl2 (10 mL) was treated with 
Grubbs’ II ruthenium catalyst (14 mg, 0.016 mmol). The mixture was heated at reflux for 
4 h under a nitrogen atmosphere, by which time, TLC analysis confirmed full consumption 
of the starting material. The solution was concentrated in vacuo to afford a black oil. 
Purification by FCC (gradient of 1:1 EtOAc/n-hexane to 4:1 EtOAc/n-hexane) afforded 
the title compound 140 as a pale–brown gum (110 mg, 85%).  
 
Rf 0.19 (1:1 EtOAc/n-hexane).  
LRESIMS m/z 432 (100%) [M+Na]+.  
1H NMR (500 MHz, CDCl3) δ 7.40 – 7.19 (10H, m, ArH), 5.81 (1H, d, J = 6.6 Hz, H7), 
5.79 (1H, d, J = 6.6 Hz, H6), 5.04 (1H, s, H1), 4.86 (1H, dd, J = 8.5, 4.8, H7a), 4.68 (1H, 
d, J = 11.2, OCH2Ph), 4.54 (1H, d, J = 11.2 Hz, OCH2Ph), 4.50 (1H, d, J = 11.8 Hz, 
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OCH2Ph), 4.45 (1H, d, J = 11.8 Hz, OCH2Ph), 4.26 (1H, app. t, J = 6.3 Hz, H5), 3.95 (1H, 
dd, J = 6.1, 3.7 Hz, H2՛), 3.65 – 3.56 (3H, m, H3՛, H1՛), 2.51 (1H, d, J = 5.7, OH), 1.39 
(3H, d, J = 6.8, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 156.5 (C3), 137.9 (ArC), 137.5 (ArC), 137.4 (C6), 128.5 
(2 x ArCH), 128.4 (2 x ArCH), 128.2 (2 x ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.8 (2 
x ArCH), 123.8 (C7), 77.0 (C1՛), 75.9 (C7a), 73.9 (OCH2Ph), 73.4 (OCH2Ph), 71.1 (C3՛), 





Compound 141 was synthesized from 139 (305 mg, 0.519 mmol), using the general 
method for ring–closing metathesis. The crude black oil was purified by FCC 
(5%MeOH/CH2Cl2) to give 141 as a grey oil (175 mg, 70%). 
 
Rf (2:5 EtOAc/n-hexane) = 0.64 
[α]𝐷
25 +73.5 (c 0.27, CHCl3).  
IR max (cm-1): 3300, 2956, 2847, 1823, 1590, 1009 cm–1 
LRESIMS m/z 506 (100%) [M+Na]+  
HRESIMS found 506.2542, calcd for C28H37NO6Na, 506.2519 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.4 – 7.2 (10H, m, ArH), 5.9 – 5.6 (2H, m, H3, H4), 4.7 
(2H, bs, OCH2Ph), 4.6 – 4.4 (3H, m, OCH2Ph, H5), 4.1 (2H, bs, H3′, H1′), 3.8 – 3.5 (3H, 
m, H2′, H4′), 1.5 (9H, s, (CH3)3C), 1.3 – 1.2 (3H, m, H1′′). 
13C NMR (125 MHz, CDCl3) δ 139.0 (ArC), 138.8 (CO) 137.2 (ArC), 134.2 (C4), 128.6 
(ArCH), 128.2 (ArCH), 128.0 (ArCH), 125.1 (C3), 79.9 (C2′), 74.7 (OCH2Ph), 73.6 




General method for cis-dihydroxylation 
 
(1R,5R,6S,7R,7aR)-1-((1R,2S)-1,3-Bis(benzyloxy)-2-hydroxypropyl)-6,7-dihydroxy-
5-methyltetrahydro-1H,3H-pyrrolo[1,2-c]oxazol-3-one (142) and (1R,5R,6R,7S,7aR)-
1-((1R,2S)-1,3-bis(benzyloxy)-2-hydroxypropyl)-6,7-dihydroxy-5-methyltetrahydro-
1H,3H-pyrrolo[1,2-c]oxazol-3-one (143).  
 
Compound 140 (177 mg, 0.432 mmol) was dissolved in acetone/water (3:1, 12 mL,) and 
the solution was cooled to 0 oC. N–methylmorpholine–N–oxide (103 mg, 0.879 mmol) and 
potassium osmate dihydrate (9.6 mg, 0.026 mmol) were added and the solution was stirred 
vigorously at 35 oC for 48 h. The reaction was concentrated in vacuo, affording a black 
viscous oil which was diluted with H2O (20 mL) and extracted with EtOAc (3 x 15 mL). 
The combined extracts were dried (MgSO4), filtered and concentrated in vacuo to afford a 
black oil which was subsequently purified by FCC (gradient of 5:95 MeOH/CH2Cl2 to 1:9 
MeOH/CH2Cl2). This gave pure samples of the title compounds 142 (10 mg, 5%), and 143 
(7 mg, 4%), as colourless oils, and a 3.5:1 mixture of 142 and 143 (132 mg, 69%).  
 
142: 
Rf 0.10 (5:95 MeOH/CH2Cl2). 
[α]𝐷
25–4.1 (c 1.00, CHCl3).  
IR max (cm-1): 3394, 2940, 1454, 1375, 1259, 1212, 1154, 1071, 1028, 866 cm–1 
LRESIMS m/z 466 (100%) [M+Na]+.  
HRESIMS found 466.1858, calcd for C24H29NO7Na, 466.1842 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.21 (10H, m, ArH), 4.93 – 4.81 (2H, m, H1, 
OCH2Ph), 4.62 (1H, d, J = 11.3 Hz, OCH2Ph), 4.43 (1H, d, J = 11.5 Hz, OCH2Ph), 4.35 
(1H, d, J = 11.5 Hz, OCH2Ph), 4.08 (1H, t, J = 8.4, H7a) 4.05– 3.98 (2H, m, H6, H2՛), 3.89 
(1H, dd, J = 8.0, 1.8 Hz, H1՛), 3.78 (1H, d, J = 4.4 Hz, H7), 3.60 – 3.51 (2H, m, H5, H3՛), 




13C NMR (125 MHz, CDCl3) δ 156.7 (C3), 137.5 (ArC), 137.2 (ArC), 128.9 (ArCH), 
128.8 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 79.6 (C7), 
75.6 (C1՛), 74.6 (C1), 74.5 (OCH2Ph), 73.8 (OCH2Ph), 70.7 (C3՛), 68.4 (C6, C2՛), 65.1 
(C7a), 59.7 (C5), 15.4 (C1՛՛).  
 
143:  
Rf 0.08 (5:95 MeOH/CH2Cl2). 
[α]𝐷
25+24.9 (c 1.00, CHCl3).  
LRESIMS m/z 466 (100%) [M+Na]+. 
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.29 (8H, m, ArH), 7.29 – 7.15 (2H, m, ArH), 4.99 
– 4.86 (2H, m, H1, OCH2Ph), 4.56 (1H, d, J = 11.2 Hz, OCH2Ph), 4.42 (1H, d, J = 11.4 
Hz, OCH2Ph), 4.38 (1H, d, J = 9.0 Hz, H1՛), 4.33 (1H, d, J = 11.4 Hz, OCH2Ph), 4.28 (1H, 
ddd, J = 10.7, 9.6, 3.8 Hz, H6), 4.04 (1H, d, J = 2.1 Hz, H7), 3.92 – 3.84 (2H, m, H7a, 
OH), 3.82 – 3.70 (2H, m, H5, H2՛), 3.49 (1H, dd, J = 8.6, 5.0 Hz, H3՛), 3.23 (1H, t, J = 8.5 
Hz, H3՛), 2.75 (1H, d, J = 10.5 Hz, OH), 2.72 (1H, d, J = 9.2 Hz, OH), 1.48 (3H, d, J = 7.0 
Hz, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 156.7 (C3), 137.6 (ArC), 136.8 (ArC), 129.0 (ArCH), 
128.9 (ArCH), 128.7 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 77.1 (C1), 
75.2 (C1՛), 74.9 (C6), 74.9 (OCH2Ph), 73.9 (OCH2Ph), 70.8 (C7), 70.8 (C3՛), 68.7 (C2՛), 
62.5 (C7a), 54.5 (C5), 11.9 (C1՛՛).  
 
tert-Butyl (2R,3S,4R,5R)-2-((1R,2S,3S)-2,4-bis(benzyloxy)-1,3-dihydroxybutyl)-3,4-
dihydroxy-5-methylpyrrolidine-1-carboxylate (144)  
 
Compound 144 was synthesized from 141 (20.0 mg, 0.0414 mmol) using the general 
method for cis–dihydroxylation. The product 144 was purified by FCC (5:95 
MeOH/CH2Cl2) to give the title compound as a clear oil (20 mg, 95%).  
 




25 +25.5 (c 1.50, CHCl3).  
IR max (cm-1): 3431, 2908, 2793, 1609, 1101, 1065, 1031, 949 cm–1 
LRESIMS m/z 540 (100%) [M+Na]+  
HRESIMS found 540.2597, calcd for C28H39NO8Na, 540.2573 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.19 (10H, m, ArH), 4.72 (2H, s, OCH2Ph), 4.57 
(1H, d, J = 11.7 Hz, OCH2Ph), 4.51 (1H, d, J = 11.7 Hz, OCH2Ph), 4.45 (1H, t, J = 4.7 Hz, 
H3), 4.27 – 4.19 (1H, m, H2′), 4.14 (1H, bs, H3′), 3.95 – 3.76 (3H, m, H4, H2, H5), 3.76 
– 3.61 (3H, m, H4′, H1′), 1.45 (9H, s, (CH3)3C), 1.22 (3H, d, J = 6.8 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 138.7 (ArC), 138.6 (CO) 137.0 (ArC), 129.0 (ArCH), 
128.9 (ArCH), 128.7 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.24 
(ArCH), 128.22 (ArCH), 128.0 (ArCH), 80.0 (C1′), 77.4 (C4), 74.7 (OCH2Ph), 73.8 
(OCH2Ph), 71.4 (C4′), 70.80 (C3′), 70.79 (C2′), 70.78 (C3), 65.8 (C2), 59.8 (C5), 28.8 
(CH3)3C), 18.7 (C1′′). 
 







To anhydrous acetone (2 mL) was added in order, concentrated H2SO4 (1.6 µL, 0.032 
mmol), anhydrous CuSO4 (36 mg, 0.23 mmol) and a solution of compound 142 (51 mg, 
0.11 mmol) in acetone (1 mL). After vigorous stirring at rt for 1 h under a nitrogen 
atmosphere, TLC analysis confirmed full consumption of the starting diol. The reaction 
mixture was vacuum filtrated through a celite pad, and the pad was washed with additional 
acetone (3 x 2 mL). The filtrate was basified with 30% NH3 solution (10.5 µL) and the 
(NH4)2SO4 precipitate was separated from the solution by gravity filtration. The filtrate 
was concentrated in vacuo and purified by FCC (2:98 MeOH/diethyl ether) to afford 
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compound 146 as a clear oil (52 mg, 99%). Using this exact same method, compound 143 
(40 mg, 0.088 mmol), was also treated under similar conditions, using acetone (2 mL), 
H2SO4 (1.3 µL, 0.026 mmol), anhydrous CuSO4 (29 mg, 0.18 mmol), additional acetone 
(3 x 2 mL) and concentrated NH3 (8.4 µL). Purification by FCC (2:98 MeOH/diethyl 
ether), afforded compound 147 as a clear oil (42 mg, 99%). This method was also used on 
a mixture of the two isomers 142 and 143. More specifically, to dry acetone (5 mL) was 
added in order, concentrated H2SO4 (4 µL, 0.076 mmol), anhydrous CuSO4 (95 mg, 0.596 
mmol) and a solution of 3.5:1 respective mixture of 142 and 143 (132 mg, 0.298 mmol) in 
acetone (2 mL). Using the same method as above, the title compounds 146 (102 mg, 71%) 
and 147 were separated (34 mg, 24%) as colourless oils after purification by FCC (2:98 
MeOH/diethyl ether).  
 
146: 
Rf 0.60 (2:98 MeOH/diethyl ether). 
[α]𝐷
25–43.8 (c 1.00, CHCl3).  
IR max (cm-1): 3301, 2890, 1454, 1372, 1210, 1152, 733 cm–1.  
LRESIMS m/z 506 (100%) [M+Na]+.  
HRESIMS found 506.2180, calcd for C27H33NO7Na, 506.2155 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.19 (10H, m, ArH), 4.90 (1H, dd, J = 8.4, 6.1 Hz, 
H4), 4.73 (2H, q, J = 11.1 Hz, OCH2Ph), 4.59 (1H, app. t, J = 8.7 Hz, H3a), 4.50 (2H, q, J 
= 11.8 Hz, OCH2Ph), 4.19 – 4.06 (3H, m, H3b, H8a, H2՛), 3.89 (1H, dd, J = 5.9, 2.9 Hz, 
H1՛), 3.60 (2H, qd, J = 9.6, 6.2 Hz, H3՛), 3.52 (1H, qd, J = 7.0, 4.4 Hz, H8), 2.52 (1H, d, J 
= 7.1 Hz, OH), 1.54 – 1.46 (6H, m, C2–CH3, H1՛՛), 1.26 (3H, s, C2–CH3).  
13C NMR (125 MHz, CDCl3) δ 156.2 (C6), 138.1 (ArC), 137.7 (ArC), 128.7 (ArCH), 
128.7 (ArCH), 128.5 (ArCH), 128.3 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 114.8 (C2), 
88.3 (C8a), 77.8 (C3a), 77.5 (C1՛), 75.2 (C4), 74.0 (OCH2Ph), 73.5 (OCH2Ph), 71.0 (C3՛), 
69.2 (C2՛), 67.5 (C3b), 59.4 (C8), 27.6 (C2–CH3), 25.5 (C2–CH3), 15.0 (C1՛՛).  
 
147:  
Rf 0.17 (2:98 MeOH/diethyl ether).  
[α]𝐷
25+52.7 (c 1.00, CHCl3).  
IR max (cm-1): 3239, 2916, 1454, 1380, 1246, 1208, 753 cm–1.  
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LRESIMS m/z 506 (100%) [M+Na]+. 
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.21 (10H, m, ArH), 4.98 (1H, t, J = 8.0 Hz, H4), 
4.92 (1H, d, J = 11.4 Hz, OCH2Ph), 4.66 (1H, dd, J = 5.5, 3.7 Hz, H3a ), 4.60 – 4.47 (3H, 
m, H8a, OCH2Ph), 4.41 (2H, m, OCH2Ph, H1՛), 3.88 (1H, d, J = 5.8 Hz, H2՛), 3.68 (1H, 
dd, J = 7.1, 3.5 Hz, H3b), 3.57 (1H, dd, J = 9.4, 7.0 Hz, H3՛), 3.41 (1H, dd, J = 9.4, 5.6 Hz, 
H3՛), 3.33 (1H, dt, J = 11.1, 5.6 Hz, H8), 2.43 (1H, d, J = 7.4 Hz, OH), 1.69 (3H, d, J = 7.0 
Hz, H1՛՛), 1.48 (3H, s, C2–CH3), 1.21 (3H, s, C2–CH3).  
13C NMR (125 MHz, CDCl3) δ 154.5 (C6), 138.2 (ArC), 137.3 (ArC), 128.9 (ArCH), 
128.6 (ArCH), 128.5 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 95.0 (C2), 
83.3 (C8a), 80.5 (C3a), 78.2 (C4), 75.7 (C1՛), 74.2 (OCH2Ph), 73.6 (OCH2Ph), 71.6 (C3՛), 






Triethylamine (20.0 µL, 0.145 mmol) was slowly added to a solution of 146, (70 mg, 0.145 
mmol) in anhydrous CH2Cl2 (10 mL) at 0 
oC under a N2 atmosphere. Whilst stirring, a 
0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (5.58 mL, 0.725 mmol) 
was slowly added to the reaction mixture. After stirring at 0 oC for 3 h, TLC analysis 
confirmed full consumption of the starting material and so the reaction was quenched 
through the addition of sat. NaHCO3 solution (15 mL) and extracted with CH2Cl2 (3 x 15 
mL) to give a pale–yellow oil. Purification of the residue by FCC (5%MeOH/CH2Cl2) gave 
148 as a pale–yellow oil (81 mg, 99%). 
 
Rf (5%MeOH/CH2Cl2) = 0.63 
[α]𝐷
25 –64.1 (c 1.00, CHCl3) 
IR max (cm-1): 3024, 2932, 2856, 1743, 1508, 1098, 1043, 961 cm–1. 
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LRESIMS m/z 584 [M+Na]+. 
HRESIMS found 584.2040, calcd for C28H35NO9SNa, 584.1930 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.21 (10H, m, ArH), 5.15 (1H, ddd, J = 8.1, 4.4, 2.4 
Hz, H2՛), 4.88 (1H, dd, J = 8.9, 2.0 Hz, H4), 4.78 (1H, d, J = 11.2 Hz, OCH2Ph), 4.59 (1H, 
d, J = 11.2 Hz, OCH2Ph), 4.52 (2H, s, OCH2Ph), 4.46 (1H, t, J = 5.8 Hz, H3a), 4.29 (1H, 
dd, J = 9.0, 4.8 Hz, H3b), 4.00 – 3.87 (4H, m, H8a, H1՛, H3՛), 3.51 (1H, qd, J = 7.1, 4.0 
Hz, H8), 3.05 (3H, s, OMs), 1.50 (3H, s, C2–CH3), 1.35 (3H, d, J = 6.9 Hz, H1՛՛), 1.26 (3H, 
s, C2–CH3). 
13C NMR (125 MHz, CDCl3) δ 155.0 (C6), 137.4 (ArC), 136.3 (ArC), 128.8 (ArCH), 
128.62 (ArCH), 128.64 (ArCH), 128.3 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 114.1 (C2), 
88.9 (C1՛), 79.1 (C2՛), 77.3 (C3a), 77.1 (C8a), 73.4 (OCH2Ph), 72.6 (OCH2Ph), 72.5 (C4), 






Triethylamine (49 µL, 0.35 mmol) was slowly added to a solution of 147, (32 mg, 0.066 
mmol) in anhydrous CH2Cl2 (8 mL) at 0 
oC under a N2 atmosphere. Whilst stirring, a 0.13M 
solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.69 mL, 0.351 mmol) was 
slowly added to the reaction mixture. After stirring at 0 oC for 3 h, TLC analysis confirmed 
full consumption of the starting material and so the reaction was quenched through the 
addition of sat. NaHCO3 solution (15 mL) and extracted with CH2Cl2 (3 x 15 mL) to give 
a pale–yellow oil. Purification of the residue by FCC (5%MeOH/CH2Cl2) gave 150 as a 
pale–yellow oil (31 mg, 83%). 
 
Rf (5%MeOH/CH2Cl2) = 0.73 
[α]𝐷
25 +33.8 (c 1.00, CHCl3) 
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IR max (cm-1): 3024, 2953, 2850, 1758, 1512, 1102, 967 cm–1. 
LRESIMS m/z 584 [M+Na]+. 
HRESIMS found 584.1986, calcd for C28H35NO9SNa, 584.1930 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.42 – 7.29 (10H, m, ArH), 5.04 (1H, d, J = 7.0 Hz, H2՛), 
5.01 – 4.92 (2H, m, H4, OCH2Ph), 4.85 (1H, t, J = 4.5 Hz, H8b), 4.66 (1H, d, J = 11.7 Hz, 
OCH2Ph), 4.62 (1H, t, J = 4.5 Hz, H8a), 4.51 – 4.44 (3H, m, H1՛, OCH2Ph), 3.91 – 3.83 
(2H, m, H3՛, H3b), 3.43 – 3.32 (2H, m, H3՛, H8), 3.01 (3H, s, OMs), 1.77 (3H, d, J = 7.1 
Hz, H1՛՛), 1.59 (3H, s, C2–CH3), 1.31 (3H, s, C2–CH3). 
13C NMR (125 MHz, CDCl3) δ 158.3 (C6), 137.6 (ArC), 137.2 (ArC), 129.2 (ArCH), 
128.8 (ArCH), 128.6 (ArCH), 128.3 (ArCH), 128.0 (ArCH), 112.5 (C2), 83.6 (C8a), 80.42 
(C8b or C2՛), 80.41 (C8b or C2՛), 77.6 (C4), 75.2 (C1՛), 74.4 (OCH2Ph), 73.5 (OCH2Ph), 
69.9 (C3՛), 64.0 (C3b), 58.4 (C8), 39.1 (OMs), 26.2 (C2–CH3), 24.2 (C2–CH3), 10.2 (C1՛՛). 
 
General method for oxazolidinone hydrolysis 
 
(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((3aS,4S,6R,6aR)-2,2,6-trimethyltetrahydro-4H-
[1,3]dioxolo[4,5-c]pyrrol-4-yl)butane-1,3-diol (152).  
 
A solution of NaOH (46.0 mg, 1.15 mmol) in H2O (3 drops) was added to a solution of 
oxazolidinone 146 (185 mg, 0.383 mmol) in EtOH (3 mL) in a microwave reaction tube. 
The tube was capped and the solution was stirred and irradiated in a CEM microwave 
reactor for 1 h (the temperature control was set at 110 oC, and the maximum applied power 
at 200 W). After cooling to rt, the reaction mixture was concentrated in vacuo, diluted with 
a solution of saturated NaCl (5 mL) and extracted with EtOAc (3 x 10 mL). The combined 
extracts were concentrated in vacuo to give a brown oil. Purification by FCC (5:95 
MeOH/CH2Cl2) gave the target compound 152 as a pale–yellow oil (151 mg, 86%).  
 
Rf 0.27 (5:95 MeOH/CH2Cl2).  
[α]𝐷
25–65.4 (c 1.00, CHCl3).  
IR max (cm-1): 3344, 3063, 2984, 1453, 1208, 1064, 607 cm–1.  
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LRESIMS m/z 458 (100%) [M+H]+.  
HRESIMS found 458.2554, calcd for C26H36NO6, 458.2543 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.24 (10H, m, ArH), 4.70 (2H, app. q, J = 11.3 Hz, 
OCH2Ph), 4.61 (1H, dd, J = 7.0, 4.7 Hz, H3a), 4.52 (2H, app. q, J = 11.5 Hz, OCH2Ph), 
4.06 (1H, dd, J = 8.8, 5.0 Hz, H3՛), 4.01 (1H, dd, J = 7.0, 5.2 Hz, H6a), 3.74 (1H, dd, J = 
7.0, 5.5 Hz, H1՛), 3.70 – 3.60 (3H, m, H4՛, H2՛), 3.08 (1H, dd, J = 7.1, 4.7 Hz, H4), 3.05 – 
2.98 (1H, m, H6), 2.76 (2H, bs, OH), 1.48 (3H, s, C2–CH3), 1.28 (3H, s, C2–CH3), 1.04 
(3H, d, J = 6.6 Hz, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 137.9 (ArC), 137.9 (ArC), 128.6 (ArCH), 128.5 (ArCH), 
128.4 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.9 (2 x ArCH), 114.0 (C2), 86.7 (C6a), 
83.0 (C3a), 80.1 (C2՛), 74.3 (OCH2Ph), 73.4 (OCH2Ph), 72.3 (C1՛), 70.9 (C4՛), 70.1 (C3՛), 
66.5 (C4), 59.5 (C6), 27.4 (C2–CH3), 25.2 (C2–CH3), 18.7 (C1՛՛).  
 
(1R,2S,3S)-2,4-Bis(benzyloxy)-1-((3aR,4S,6R,6aS)-2,2,6-trimethyltetrahydro-4H-
[1,3]dioxolo[4,5-c]pyrrol-4-yl)butane-1,3-diol (153).  
 
Compound 153 was synthesized from the acetonide 147 (205 mg, 0.414 mmol) using the 
general method for oxazolidinone hydrolysis. The crude product was purified by FCC 
(5:95 MeOH/CH2Cl2) to give the desired product 147 as a pale–yellow oil (165 mg, 87%).  
 
Rf 0.22 (5:95 MeOH/CH2Cl2). 
[α]𝐷
25‒24.9 (c 1.00, CHCl3).  
IR max (cm-1): 3423, 3065, 2989, 1453, 1230, 1067 cm–1.  
LRESIMS m/z 458 (100%) [M+H]+.  
HRESIMS found 458.2540, calcd for C26H36NO6, 458.2543 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.20 (10H, m, ArH), 4.75 – 4.70 (2H, m, H3a, 
OCH2Ph), 4.63 (1H, d, J = 11.4 Hz, OCH2Ph), 4.52 (2H, s, OCH2Ph), 4.42 (1H, t, J = 4.8 
Hz, H6a), 4.06 – 3.98 (2H, m, H1՛, H3՛), 3.73 (1H, dd, J = 9.9, 4.2 Hz, H4՛), 3.67 (1H, dd, 
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J = 6.1, 3.9 Hz, H2՛), 3.61 (1H, dd, J = 9.8, 4.6 Hz, H4՛), 2.77 – 2.65 (2H, m, H6, H4), 1.28 
(3H, s, C2–CH3), 1.25 (3H, s, C2–CH3), 1.15 (d, J = 6.6 Hz, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 138.3 (ArC), 138.2 (ArC), 128.7 (ArCH), 128.7 (ArCH), 
128.2 (ArCH), 128.1 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 110.8 (C2), 82.7 (C6a), 82.6 
(C3a), 82.6 (C2՛), 74.1 (OCH2Ph), 73.8 (OCH2Ph), 71.0 (C4՛), 70.8 (C3՛), 70.2 (C1՛), 64.5 








Procedure A: Triethylamine (16 µL, 0.12 mmol) was slowly added to a solution of 152 
(53.0 mg, 0.116 mmol) in anhydrous CH2Cl2 (8 mL) at 0 
oC under a N2 atmosphere. Whilst 
stirring, a 0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (0.893 mL, 
0.116 mmol) was slowly added to the reaction mixture. After stirring at 0 oC for 1.5 h, 
TLC analysis confirmed full consumption of the starting material and so the reaction was 
quenched through the addition of a sat. NaHCO3 solution (2 mL) and extracted with 
CH2Cl2 (3 x 5 mL). The combined organic extracts were dried over MgSO4, gravity filtered 
from inorganic salts and concentrated in vacuo to give a yellow oil. Purification by FCC 
(gradient of CH2Cl2 to 5%MeOH/CH2Cl2) gave the two title compounds, 154 as colourless 
crystals (44 mg, 32%) and 149 as a yellow oil (15 mg, 30%).  
 
Procedure B: To a solution of the amino–diol 152 (297 mg, 0.650 mmol) in dry CH2Cl2 
(20 mL) at 0 oC was added Et3N (136 µL, 0.975 mmol), PPh3 (256 mg, 0.975 mmol) and 
CBr4 (323 mg, 0.975 mmol). The mixture was stirred at 0 
oC for 5 min then allowed to 
warm to room temperature for 30 min by which time TLC analysis confirmed full 
consumption of the starting material. The mixture was poured into water (15 mL) and 
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subsequently extracted with CH2Cl2 (3 x 20 mL). The combined extracts were dried 
(MgSO4), filtered and concentrated in vacuo to give a yellow oil. The residue was purified 
by FCC (3:5 EtOAc/n-hexane) to give 149 as a pale–yellow oil (248 mg, 87%). After this, 
compound 149 was dissolved in ethanol and was subjected to slow evaporation at room 
temperature over 48 h, resulting in the formation of large colourless crystals. 
 
154: 
Rf 0.38 (5%MeOH/CH2Cl2).  
[α]𝐷
25 –2.7 (c 1.00, CHCl3).  
M.P: 75 – 80 oC.  
IR max (cm-1): 3484, 3400, 3064, 2958, 1333, 1153, 913, 622 cm–1.  
LRESIMS m/z 636 [M+Na]+.  
HRESIMS found 636.1913, calcd for C28H39NO10S2Na, 636.1913 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.45 – 7.23 (10H, m, ArH), 4.98 (2H, d, J = 4.2 Hz, H5, 
H3՛), 4.78 (2H, dd, J = 44.9, 10.7 Hz, OCH2Ph), 4.53 (2H, dd, J = 25.1, 11.7 Hz, OCH2Ph), 
4.38 (1H, d, J = 4.8 Hz, H4), 4.14 (1H, s, H1), 4.10 – 3.90 (2H, m, H3, H1՛), 3.85 (3H, dd, 
J = 16.9, 7.3 Hz, H4՛, H2՛), 3.00 (6H, d, J = 19.3 Hz, 2 x OMs), 2.78 (1H, d, J = 7.2 Hz, 
OH), 1.49 (3H, s, CH3), 1.36 (3H, d, J = 6.8 Hz, H1՛՛), 1.28 (3H, s, CH3).  
13C NMR (125 MHz, CDCl3) δ 137.7 (ArC), 137.5 (ArC), 128.7 (2 x ArCH), 128.7 (2 x 
ArCH), 128.5 (2 x ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.0 (2 x ArCH), 111.9 (C7), 
86.3 (C4), 81.8 (C5), 79.5 (C3՛), 76.7 (C1), 74.3 (OCH2Ph), 73.7 (OCH2Ph), 71.1 (C2՛), 
68.8 (C3 or C1՛), 68.5 (C4՛), 63.6 (C3 or C1՛), 38.7 (OMs), 36.8 (OMs), 26.6 (CH3), 24.4 
(CH3), 21.8 (C1՛՛).  
 
149: 
Rf 0.25 (5:95 MeOH/CH2Cl2).  
[α]𝐷
25+15.6 (c 1.00, CHCl3).  
M.P: 92 – 94 oC 
IR max (cm-1): 3397, 2983, 1520, 1493, 1120, 1066, 866 cm–1.  
LRESIMS m/z 440 (100%) [M+H]+.  




1H NMR (500 MHz, CDCl3) δ 7.44 – 7.16 (10H, m, ArH), 4.68 (1H, d, J = 12.0 Hz, 
OCH2Ph), 4.63 (1H, dd, J = 6.8, 3.5 Hz, H8b), 4.58 (1H, d, J = 11.9 Hz, OCH2Ph), 4.49 
(1H, d, J = 11.9 Hz, OCH2Ph), 4.45 (1H, d, J = 12.0 Hz, OCH2Ph), 4.28 (1H, s, H8), 4.17 
(1H, t, J = 7.3 Hz, H3a), 3.83 (1H, s, H7), 3.63 (1H, d, J = 3.4 Hz, H8a), 3.45 (1H, dd, J = 
9.2, 2.8 Hz, H1՛), 3.35 (1H, dd, J = 9.2, 4.0 Hz, H1՛), 3.31 – 3.25 (2H, m, H4, H6), 1.49 
(3H, s, C2–CH3), 1.28 (6H, s, C2–CH3, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 137.7 (ArC), 137.2 (ArC), 128.5 (ArC), 128.0 (ArC), 
128.0 (ArC), 127.8 (ArC), 127.4 (ArC), 114.1 (C2), 88.4 (C7), 85.7 (C3a), 83.8 (C8b), 
78.3 (C8a), 76.3 (C8), 73.8 (OCH2Ph), 73.1 (C1՛), 71.5 (OCH2Ph), 63.7 (C4 or C6), 63.5 
(C4 or C6), 27.8 (C2–CH3), 25.6 (C2–CH3), 14.9 (C1՛՛).  
 
(3aS,4R,6R,7R,8R,8aS,8bR)-7-(Benzyloxy)-6-((benzyloxy)methyl)-2,2,4-
trimethylhexahydro-4H-[1,3]dioxolo[4,5-a]pyrrolizin-8-ol (151).  
 
Triethylamine (7.7 µL, 0.055 mmol) was slowly added to a solution of 153 (23 mg, 0.0503 
mmol) in anhydrous DCE (8 mL) at 0 
oC under a N2 atmosphere. Whilst stirring, a 0.13M 
solution of methanesulfonyl chloride in anhydrous CH2Cl2 (423 µL, 0.0553 mmol) was 
slowly added dropwise to the reaction mixture. After stirring at 0 oC for 30 min, the 
reaction mixture was quenched through the addition of a sat. NaHCO3 solution (2 mL) and 
extracted with CH2Cl2 (3 x 5 mL) followed by concentration in vacuo. The crude brown 
oil was dissolved in DCE followed by the addition of triethylamine (7.7 µL, 0.0553 mmol). 
The reaction mixture with was heated at 80 oC for 20 h. TLC analysis confirmed full 
consumption of the starting material and so the reaction was quenched through the addition 
of NaHCO3 solution (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined 
extracts were dried (MgSO4), filtered and concentrated in vacuo to give a yellow oil. 
Purification by FCC (5:95 MeOH/CH2Cl2) gave pyrrolizidine 151 as a clear film (19 mg, 
87%).  
 




25+28.7 (c 1.00, CHCl3).  
IR max (cm-1): 3390, 3033, 2983, 1544, 1502, 1065, 864 cm–1.  
LRESIMS m/z 462 (100%) [M+Na]+.  
HRESIMS found 462.2247, calcd for C26H33NO5Na, 462.2256 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.22 (10H, m, ArH), 4.68 (1H, d, J = 11.9 Hz, 
OCH2Ph), 4.63 (1H, t, J = 5.5 Hz, H8b), 4.57 – 4.49 (4H, m, OCH2Ph, H8, H3a), 4.46 (1H, 
d, J = 12.1 Hz, OCH2Ph), 4.02 (1H, dd, J = 6.4, 4.1 Hz, H7), 3.60 (1H, dt, J = 6.8, 3.6 Hz, 
H6), 3.52 (1H, dd, J = 10.1, 4.1 Hz, H1՛), 3.47 (1H, dd, J = 10.1, 3.2 Hz, H1՛), 3.24 (1H, 
dd, J = 5.0, 3.6 Hz, H8a), 3.06 (1H, dt, J = 7.0, 4.1 Hz, H4), 1.48 (3H, s, C2–CH3), 1.33 – 
1.27 (6H, m, C2–CH3, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 138.2 (ArC), 128.4 (ArCH), 128.3 (ArCH), 
128.0 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.5 (ArCH), 112.0 (C2), 91.2 (C7), 85.1 
(C3a or C8), 80.2 (C8b), 74.7 (C3a or C8), 74.4 (C8a), 73.4 (OCH2Ph), 72.0 (OCH2Ph), 
69.8 (C1՛), 62.9 (C6), 57.6 (C4), 26.1 (C2–CH3), 24.0 (C2–CH3), 12.0 (C1՛՛).  
 
General method for O-Benzyl and acetonide deprotection 
 
(1R,2R,3R,5R,6R,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-
1,2,6,7-tetraol [(+)-7-epi-hyacinthacine C5] (155).  
 
To a nitrogen purged solution of compound 149 (15 mg, 0.034 mmol) in MeOH (3 mL) 
was added PdCl2 (9.0 mg, 0.051 mmol). A balloon of H2 was attached to the system, and 
the reaction mixture was stirred at rt for 24 h. After LRESIMS analysis confirmed full 
consumption of the starting material, the mixture was filtered through a pad of celite and 
washed with additional MeOH (6 mL). The combined filtrates were concentrated in vacuo 
to give a yellow film. An Amberlyst A–26 resin (0.750 g) basic ion–exchange 
chromatography column, was prepared by mixing the resin with a 15% aqueous ammonia 
solution (v/v) and allowing it to stand for 15 min followed by washing the column with 
distilled water until a pH close to 7 was achieved. The compound was dissolved in distilled 
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water (2 mL) and held on the column for 15 min before its elution with water (3 x 3 mL). 
Concentration in vacuo provided (+)-7-epi-hyacinthacine C5 155 (6.6 mg, 88%) as a 
colourless film.  
 
[α]𝐷
25+5.4 (c 1.00, H2O).  
IR max (cm-1): 3362, 1637, 1074, 1055 cm–1.  
LRESIMS m/z 242 (100%) [M+Na]+.  
HRESIMS found 242.1014, calcd for C9H17NO5Na, 242.1004 [M+Na]
+. 
1H NMR (500 MHz, D2O) δ 4.15 (1H, dd, J = 5.0, 2.7 Hz, H7), 3.94 (1H, t, J = 7.3 Hz, 
H2), 3.90 – 3.78 (2H, m, H1, H6), 3.71 – 3.59 (2H, m, H8), 3.21 – 3.13 (2H, m, H7a, H5), 
3.10 (1H, dt, J = 7.2, 5.0 Hz, H3), 1.26 (3H, d, J = 7.0 Hz, H9). 
13C NMR (125 MHz, D2O) δ 78.5 (C1 or C6), 77.9 (C2), 75.9 (C6 or C1), 73.6 (C7), 72.6 
(C7a), 62.9 (C8), 62.2 (C3), 58.8 (C5), 13.2 (C9).  
 
(1R,2R,3R,5R,6S,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-
1,2,6,7-tetraol [(–)-6-epi-hyacinthacine C5] (156).  
 
(–)-6-Epi-hyacinthacine C5 156 was synthesized by the general method for O–benzyl 
deprotection from 151 (10.0 mg, 0.0227 mmol). The crude product was filtered through a 
pad of celite and washed with additional MeOH (6 mL). The combined filtrates were 
concentrated in vacuo returning a yellow film. The compound was isolated through basic 
ion–exchange chromatography followed by concentration in vacuo providing the title 
compound 156 as a colourless film (4.8 mg, 98%). 
 
[α]𝐷
25–7.2 (c 1.00, H2O).  
IR max (cm-1): 3300, 2909, 1420, 1098, 1055 cm–1. 
LRESIMS m/z 220 (100%) [M+H]+.  




1H NMR (500 MHz, D2O) δ 4.39 – 4.28 (2H, m, H1, H7), 4.03 (1H, t, J = 4.5 Hz, H6), 
3.91 (1H, t, J = 8.3 Hz, H2), 3.67 (2H, d, J = 4.8 Hz, H8), 3.38 (1H, quint, J = 4.8 Hz, H3), 
3.31 (1H, t, J = 7.6 Hz, H7a), 3.24 (1H, dt, J = 7.0, 5.4 Hz, H5), 1.25 (3H, d, J = 7.1 Hz, 
H9).  
13C NMR (125 MHz, D2O) δ 78.5 (C2), 74.8 (C6), 74.4 (C1), 70.8 (C7), 67.5 (C7a), 63.1 









To anhydrous DMF (10 mL) under an N2 atmosphere was added 3–chloro–1–butene (3.32 
mL, 0.0330 mmol) and pthalimide potassium salt (6.72 g, 0.0363 mmol). The solution was 
heated at reflux for 3 h and poured hot onto 200 g of ice. The reaction mixture was 
extracted with chloroform (3 x 20 mL). The combined extracts were washed with 1 N KOH 
(20 mL), water (20 mL), 0.5 N HCl (20 mL) and water (20 mL). The organic layer was 
dried (MgSO4), filtered and concentrated in vacuo to give brown needle like crystals. The 
product was recrystalised from 95% EtOH to give colourless needle shaped crystals 157 
(6.64 g, quant.) which were used for the next step without further purification. The 1H and 
13C NMR spectroscopic data of this product were consistent with those published.180 
 
LRESIMS m/z 202 (100%) [M+H]+.  
1H NMR (500 MHz, CDCl3) δ 7.83 (2H, ddt, J = 10.1, 7.7, 3.8 Hz, ArH), 7.71 (2H, dd, J 
= 5.6, 3.1 Hz, ArH), 6.20 (1H, ddd, J = 17.0, 10.3, 6.6 Hz, H3՛), 5.24 (1H, d, J = 17.2 Hz, 
H4՛trans), 5.17 (1H, d, J = 10.3 Hz, H4՛cis), 4.94 (1H, quint, J = 7.0 Hz, H2՛), 1.59 (3H, d, J 
= 7.1 Hz, CH3). 
13C NMR (125 MHz, CDCl3) δ 167.8 (CO), 136.7 (ArC), 133.8 (ArC), 131.9 (ArC), 123.1 




To a solution of 157 (5.00 g, 0.0248 mmol) in 95% EtOH (5 mL) at 0 oC was added 
hydrazine hydrate (3.08 mL, 0.0496 mmol as a 50–60% solution). The reaction mixture 
was heated at 60 oC for 3 h whereby it formed a white gelatinous solid. The solid was 
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cooled to 0 oC and treated with conc. HCl (12 mL, 0.124 mmol) until the solid turned to a 
less viscous white paste. The paste was concentrated in vacuo and dissolved in water (10 
mL). The phthalimide by–product was removed by washing the aqueous layer once with 
diethyl ether which was discarded. The aqueous layer was made alkaline with KOH. The 
product was extracted with diethyl ether (4 x 50 mL). The combined extracts were acidified 
with 4 N HCl/EtOH followed by concentration in vacuo to give a brown crystalline product 
which was recrystalised from EtOH/diethyl ether (1:2) to give small brown crystals (2.53 
g, 95%).180  
 
LRESIMS m/z 94 (100%) [M+Na]+.  
1H NMR (500 MHz, CDCl3) δ 8.45 (3H, s, NH3), 6.01 (1H, ddd, J = 17.1, 10.5, 6.4 Hz, 
H2), 5.46 (1H, d, J = 17.2 Hz, H1trans), 5.33 (1H, d, J = 10.5 Hz, H1cis), 4.04 – 3.92 (1H, 
m, H3), 1.53 (3H, d, J = 6.5 Hz, CH3). 
13C NMR (125 MHz, CDCl3) δ 134.8 (C2), 119.1 (C1), 49.8 (C3), 18.8 (CH3). 
 
(2S,3S,4R,5R,E)-1,3-Bis(benzyloxy)-5-(((S)-but-3-en-2-yl)amino)-7-phenylhept-6-
ene-2,4-diol (161) and (2S,3S,4R,5R,E)-1,3-bis(benzyloxy)-5-(((R)-but-3-en-2-
yl)amino)-7-phenylhept-6-ene-2,4-diol (127) 
 
Compound 161 was synthesized by the general method for the Petasis reaction using (+)–
3,4–Di–O–benzyl–α,β–L–xylofuranose (2.00 g, 6.06 mmol), Et3N (845 µM, 6.06 mmol), 
(E)–2–phenylvinylboronic acid (896 mg, 6.06 mmol) and (R,S)–α–methylallyl amine·HCl 
(652 mg, 6.06 mmol) instead of the enatiomerically pure (R)–amine. The mixture was 
purified by FCC (5:95 MeOH/CH2Cl2) to give inseperable diastereomers as a brown oil 
(2.00 g, 65%, as a 2:1 mixture of 1՛S 161 and 1՛R 127 epimers). 1H and 13C NMR 
spectroscopic data of the formed 1՛R epimer matched the corresponding data of compound 
127 described above.  




LRESIMS m/z 488 (100%) [M+H]+. 
1H NMR (500 MHz, CDCl3) δ 7.54 – 7.08 (m), 6.48 (1H, d, J = 16.0 Hz, H7 (127), 6.41 
[1H, d, J = 16.0 Hz, H7 (161)], 6.07 [1H, dd, J = 16.0, 8.8 Hz, H6 (127)], 6.00 [1H, dd, J 
= 16.0, 8.9 Hz, H6 (161)], 5.71 [1H, ddd, J = 17.3, 10.3, 7.1 Hz, H2՛ (127)], 5.62 – 5.51 
[1H, m, H2՛ (161)], 5.10 – 4.96 (m), 4.70 – 4.46 (m), 4.10 – 4.04 (m), 3.94 [1H, t, J = 5.3 
Hz, H4 (127)], 3.88 [1H, t, J = 5.3 Hz, H4 (161)], 3.70 – 3.54 (m), 3.50 [1H, dd, J = 8.9, 
5.2 Hz, H1, (127)], 3.44 [1H, dd, J = 8.9, 5.8 Hz, H1 (161)], 3.32 – 3.23 (m), 2.88 (s), 1.11 
[3H, d, J = 6.4 Hz, H1՛՛ (127)], 1.06 [3H, d, J = 6.5 Hz, H1՛՛ (161)].  
13C NMR (125 MHz, CDCl3) δ 141.9 [C2՛ (127)], 141.5 [C2՛ (161)], 138.1 (ArC), 138.0 
(ArC), 136.6 (ArC), 136.5 (ArC), 133.4 [C7 (161)], 133.2 [C7 (127)], 128.6 (ArC), 128.5 
(ArC), 128.5 (ArC), 128.43 (ArC), 128.42 (ArC), 128.2 (ArC), 128.1 (ArC), 127.92 (ArC), 
127.85 (ArC), 127.8 (ArC), 127.73 (ArC), 127.71 (ArC), 126.5 (ArC), 126.4 (ArC), 116.0 
[C3՛ (161)], 114.5 [C3՛ (127)], 80.2 [C3 (161)], 80.0 [C3 (127)], 74.3 [OCH2Ph (127)], 
74.2 [OCH2Ph (161)], 73.38 [OCH2Ph (161)], 73.35 [OCH2Ph (127)], 72.9 [C4 (161)], 
72.3 [C4 (127)], 71.3 [C1 (127)], 71.2 [C1 (161)], 70.4 [C2 (161)], 70.1 [C2 (127)], 60.6 




((E)-styryl)oxazolidin-2-one (137, 160) and (4R,5R,6S,7S)-6-(benzyloxy)-7-
((benzyloxy)methyl)-3-(but-3-en-2-yl)-5-hydroxy-4-((E)-styryl)-1,3-oxazepan-2-one 
(138, 162).  
 
A 2 : 1 mixture of 127 and 161 (50.0 mg, 0.102 mmol) were dissolved in anhydrous CH2Cl2 
(15 mL) and cooled to 0 oC under an atmosphere of nitrogen. Triethylamine (28 µL, 0.204 
mmol) was added and after 15 min triphosgene (15.1 mg, 0.0510 mmol) was added 
portionwise and the solution was allowed to warm to rt. After stirring for 1 h, TLC analysis 
confirmed full consumption of the starting material, leading to the subsequent in vacuo 
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concentration of the reaction mixture. Purification via FCC (gradient of 1:5 EtOAc/n-
hexane to 1:1 EtOAc/n-hexane) produced an inseparable mixture of the four title isomers 
consisting of the oxazolidinones 137, 160 and the oxazepinones 138, 162 as confirmed by 
1H NMR analysis and LRESIMS (43%).  
 
Rf 0.65 (1:1 EtOAc/n-hexane).  
LRESIMS m/z 536 (100%) [M+Na]+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.02 (m), 6.73 – 6.61 [m, H1՛՛՛ (138 and 162)], 6.60 
– 6.51 [m, H2՛՛՛ (137 and 160)], 6.41 [d, J = 15.9 Hz, H2՛՛՛ (138)], 6.34 [d, J = 15.8 Hz, H2՛՛՛ 
(162)], 6.17 – 6.03 {m, H1՛՛՛ [137 and 160, H2՛ (138)]}, 5.93 [ddd, J = 17.4, 10.6, 4.7 Hz, 
H2՛ (137 and 162)], 5.83 [ddd, J = 17.1, 10.3, 6.5 Hz, H2՛ (160)], 5.30 – 5.21 (m), 5.21 – 
5.07 (m), 5.07 – 5.00 (m), 4.89 – 4.71 (m), 4.61 – 4.43 (m), 4.37 – 4.25 (m), 4.11 – 4.03 
(m), 4.02 – 3.95 (m), 3.82 [dd, J = 9.5, 6.1 Hz, H1՛՛՛՛ (162)], 3.79 – 3.71 (m), 3.51 – 3.42 
(m), 1.38 [d, J = 7.1 Hz, H1՛՛ (160], 1.34 [d, J = 6.9 Hz, H1՛՛ (162)], 1.29 [d, J = 7.0 Hz, 
H1՛՛ (137)], 1.27 [d, J = 6.3 Hz, H1՛՛ (138)].  
13C NMR (125 MHz, CDCl3) δ 158.6 [C2 (162)], 158.5 [C2 (138)], 157.0 [C2 (137)], 
156.9 [C2 (160)], 139.2 [C2՛ (138)], 138.3 [C2՛ (162)], 138.2, 137.88, 137.86, 137.8, 137.7, 
137.5, 137.5, 136.8, 136.6, 136.4, 135.7, 135.5, 135.42, 135.39, 131.8, 131.2, 128.8, 128.6, 
128.5, 128.4, 128.38, 128.36, 128.2, 127.91, 127.87, 127.85, 127.7, 127.6, 127.59, 127.56, 
127.3, 126.70, 126.67, 126.7, 126.57, 124.55 [C1՛՛՛ (137)], 124.4 [C1՛՛՛ (160)], 117.3 , 117.2 
[C3՛ (137)], 116.1, 116.0 [C3՛ (160)], 78.6, 78.2 , 77.8 [C5 (137)], 77.4, 76.5 [C1՛՛՛՛ (160)], 
76.3 [C1՛՛՛՛ (137)], 74.8, 74.7, 74.1 [OCH2Ph (137)], 74.0 [OCH2Ph (160)], 73.4, 73.1 
[OCH2Ph (160)], 73.1 [OCH2Ph (137)], 72.6, 72.5, 70.7 [C3՛՛՛՛ (160)], 70.6 [C3՛՛՛՛ (137)], 
68.9 [C2՛՛՛՛ (160)], 68.8 [C2՛՛՛՛ (137)], 68.4, 67.9, 62.1 [C4 (162)], 61.6 [C4 (138)], 60.1 [C4 
(160)], 60.0 [C4 (137)], 55.6 [C1՛ (138)], 55.3 [C1՛ (162)], 51.8 [C1՛ (160)], 51.7 [C1՛ 
(137)], 18.4 [C1՛՛ (137)], 17.2 [C1՛՛ (160)], 16.7 [C1՛՛ (162)], 16.0 [C1՛՛ (138)].  
 
Conversion of 138 and 162 to 137 and 160, respectively. DBU (11.1 µL, 0.0745 mmol) 
was added to a solution of the above mixture of oxazolidinones 137, 160 and oxazepinones 
138, 162 (25.5 mg, 0.0497 mmol) in MeOH (3 mL) under a nitrogen atmosphere. After 4 
h of stirring, TLC analysis confirmed full consumption of the starting materials. The 
reaction mixture was concentrated in vacuo followed by dissolution in CH2Cl2 (5 mL). The 
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solution was washed with a saturated solution of NH4Cl (2 x 3 mL), dried (MgSO4), filtered 
and concentrated in vacuo. This afforded an inseparable mixture (1:2.5) of 137 and its C1՛ 
epimer 160 (25.3 mg, 99%). No further purification was required based on 1H NMR and 
TLC analysis.  
 
Rf (1:1 EtOAc/n-hexane) = 0.65 
LRESIMS m/z 536 (100%) [M+Na]+.  
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.18 (m, ArH), 7.17 – 7.04 (m, ArH), 6.61 – 6.52 
(m), 6.18 – 6.05 (m), 5.95 [ddd, J = 16.8, 10.4, 5.8 Hz, H2՛ (137)], 5.84 [ddd, J = 17.0, 
10.3, 6.4 Hz, H2՛ (160)], 5.24 – 5.16 (m), 5.14 – 5.07 (m), 5.06 – 4.99 (m), 4.89 – 4.81 
(m), 4.80 – 4.71 (m), 4.62 – 4.53 (m), 4.53 – 4.35 (m), 4.35 – 4.23 (m), 4.03 – 3.92 (m), 
3.80 – 3.72 (m), 3.55 – 3.43 (m), 1.38 [d, J = 7.1 Hz, H1՛՛ (160)], 1.29 [d, J = 7.0 Hz, H1՛՛ 
(137)]. 
13C NMR (125 MHz, CDCl3) δ 157.0 [C2 (137)], 156.9 [C2 (160)], 138.4 [C2՛ (160)], 
138.0, 137.9, 137.0 [C2՛ (137)], 135.7, 135.6 [C2՛՛՛ (160)], 135.5 [C2՛՛՛ (160)], 128.9, 128.6, 
128.5, 128.02, 127.97, 127.9, 127.8, 127.72, 127.71, 126.79, 126.77, 124.9 [C2՛՛՛ (137)], 
124.7 [C1՛՛՛ (160)], 117.2 [C3՛ (137)], 116.0 [C3՛ (160)], 77.8, 77.4, 76.7, 76.5, 74.2 
[OCH2Ph (137)], 74.1 [OCH2Ph (160)], 73.20 [OCH2Ph (160)], 73.17 [OCH2Ph (137)], 
70.84 [C3՛՛՛՛ (160)], 70.76 [C3՛՛՛՛ (137)], 69.0 [C2՛՛՛՛ (160)], 68.9 [C2՛՛՛՛ (137)], 60.2 [C4 



















The title compounds 140 and 159 were synthesized from the above mixture of 137 and its 
C1՛ epimer 160 (486 mg, 0.946 mmol), using the general method for ring–closing 
metathesis. The crude black oil was purified by FCC (1:1 EtOAc/n-hexane) to give pure 
samples of compounds 140 (105 mg, 27%) and 159 (205 mg, 53%) as grey oils. 1H and 
13C NMR spectroscopic data of the formed product matched the corresponding data of 
compound 140 described above. 
 
159: 
Rf (1:1 EtOAc/n-hexane) = 0.45 
[α]𝐷
25+58.1 (c 1.00, CHCl3) 
IR max (cm-1): 3340, 2937, 2870, 1643, 1414, 1329, 1210, 1073, 957 cm–1 
LRESIMS m/z 432 (100%) [M+Na]+.  
HRESIMS found 432.1782, calcd for C24H27NO5Na, 432.1787 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (10H, m, ArH), 5.97 (1H, dt, J = 6.1, 2.2 Hz, 
H7), 5.86 (1H, dt, J = 6.0, 1.6 Hz, H6), 5.02 (1H, t, J = 7.8 Hz, H1), 4.79 (2H, app. t, J = 
9.1 Hz, H7a and OCH2Ph), 4.68 (1H, dt, J = 8.8, 5.5, 4.5, 2.7 Hz, H5), 4.50 (2H, d, J = 2.9 
Hz, OCH2Ph), 4.42 (1H, d, J = 11.8 Hz, OCH2Ph), 3.88 (1H, q, J = 8.0, 7.3 Hz, H2՛), 3.68 
(1H, dd, J = 7.5, 2.2 Hz, H1՛), 3.56 (1H, dd, J = 9.2, 6.1 Hz, H3՛), 3.47 (1H, dd, J = 9.2, 
6.8 Hz, H3՛), 2.49 (1H, d, J = 8.0 Hz, OH), 1.22 (3H, d, J = 6.8 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 162.5 (C3), 137.8 (ArC), 137.7 (ArC), 137.6 (C7), 128.5 
(2 x ArCH), 128.4 (2 x ArCH), 128.1 (2 x ArCH), 127.94 (ArCH), 127.92 (ArCH), 127.82 
(2 x ArCH), 124.81 (C6), 78.6 (C1), 77.2 (C1՛), 74.4 (OCH2Ph), 73.4 (OCH2Ph), 70.6 






Compound 163 was synthesized from 159 (151 mg, 0.369 mmol) using the general method 
for cis–dihydroxylation. The product 163 was purified by FCC (5:95 MeOH/CH2Cl2) to 
give small white crystals (160 mg, 98%).  
 
Rf (5:95 MeOH/CH2Cl2) = 0.32 
[α]𝐷
25+36.2 (c 1.00, CHCl3) 
M.P: 145 – 150 oC  
IR max (cm-1): 3429, 2921, 2858, 1709, 1293, 1126, 1028, 696 cm–1 
LRESIMS m/z 466 (100%) [M+Na]+.  
HRESIMS found 466.1863, calcd for C24H29NO7Na, 466.1842 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.44 – 7.16 (10H, m, ArH), 4.91 (2H, app. dd, J = 9.4, 6.5 
Hz, H1 and OCH2Ph), 4.63 (1H, d, J = 11.2 Hz, OCH2Ph), 4.46 (1H, d, J = 11.5 Hz, 
OCH2Ph), 4.37 (1H, d, J = 11.5 Hz, OCH2Ph), 4.33 (1H, dd, J = 7.9, 2.0 Hz, H7a), 3.96 
(1H, s, H7), 3.90 – 3.80 (3H, m, H6, H1՛, H2՛), 3.64 (1H, quint, J = 6.7 Hz, H5), 3.57 – 
3.49 (2H, m, H3՛ and OH), 3.37 (1H, dd, J = 9.1, 6.7 Hz, H3՛), 2.69 (1H, s, OH), 2.61 (1H, 
d, J = 8.0 Hz, OH), 1.35 (3H, d, J = 6.6 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 161.6 (C3), 137.2 (ArC), 137.2 (ArC), 128.8 (ArCH), 
128.7 (ArCH), 128.6 (ArCH), 128.31 (ArCH), 128.27 (ArCH), 128.1 (ArCH), 81.3 (C6, 
C1՛, C2՛), 76.8 (C1), 75.62 (C7a), 74.56 (OCH2Ph), 73.7 (OCH2Ph), 71.8 (C7), 70.9 (C3՛), 









Compound 158 was synthesized from 163 (141 mg, 0.317 mmol) by the general method 
for acetonide protection of cis–diols. Purification by FCC (5:95 MeOH/CH2Cl2) returned 
product 158 as large colourless crystals (150 mg, 98%).  
 
Rf (5:95 MeOH/CH2Cl2) = 0.56 
[α]𝐷
25+26.05 (c 1.00, CHCl3) 
M.P: 70 – 75 oC 
IR max (cm-1): 3394, 2936, 2860, 1756, 1261, 1045, 740, 698 cm–1 
LRESIMS m/z 506 (100%) [M+Na]+.  
HRESIMS found 506.2211, calcd for C27H33NO7Na, 506.2155 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.20 (10H, m, ArH), 5.03 (1H, dd, J = 8.8, 7.0 Hz, 
H4), 4.94 (1H, d, J = 11.4 Hz, OCH2Ph), 4.68 (1H, dd, J = 5.2, 3.6 Hz, H3a), 4.59 (1H, d, 
J = 11.4 Hz, OCH2Ph), 4.51 (1H, d, J = 11.7 Hz, OCH2Ph), 4.46 – 4.38 (3H, m, OCH2Ph, 
H8a, H1՛), 4.22 (1H, q, J = 7.4 Hz, H8), 3.96 (1H, dd, J = 7.1, 3.5 Hz, H3b), 3.89 (1H, q, 
J = 6.8 Hz, H2՛), 3.58 (1H, dd, J = 9.4, 6.9 Hz, H3՛), 3.43 (1H, dd, J = 9.5, 5.6 Hz, H3՛), 
2.34 (1H, d, J = 7.7 Hz, OH), 1.46 (3H, s, C2–CH3), 1.20 – 1.11 (6H, m, C2–CH3, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 160.8 (C6), 137.9 (ArC), 137.8 (ArC), 128.7 (ArCH), 
128.44 (ArCH), 128.35 (ArCH), 127.94 (ArCH), 127.86 (ArCH), 127.7 (ArCH), 112.7 
(C2), 87.8 (C8a or C1՛), 80.7 (C3a), 79.2 (C4), 75.5 (C8a or C1՛), 74.0 (OCH2Ph), 73.4 










Triethylamine (53 µL, 0.38 mmol) was slowly added to a solution of 158, (37 mg, 0.077 
mmol) in anhydrous CH2Cl2 (10 mL) at 0 
oC under a N2 atmosphere. Whilst stirring, a 
0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.9 mL, 0.38 mmol) 
was slowly added to the reaction mixture. After stirring at 0 oC for 1 h, TLC analysis 
confirmed full consumption of the starting material and so the reaction was quenched 
through the addition of sat. NaHCO3 solution (15 mL) and extracted with CH2Cl2 (3 x 15 
mL) to give a pale–yellow oil. Purification of the residue by FCC (5%MeOH/CH2Cl2) gave 
164 as a pale–yellow oil (43 mg, 99%). 
 
Rf (5%MeOH/CH2Cl2) = 0.76 
[α]𝐷
25+16.7 (c 0.75, CHCl3) 
IR max (cm-1): 3067, 2942, 2852, 1741, 1550, 1098, 982 cm–1. 
LRESIMS m/z 584 (100%) [M+Na]+  
HRESIMS found 584.1943, calcd for C28H35NO9Na, 584.1930 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.49 – 7.25 (10H, m, ArH), 5.04 – 4.90 (3H, m, H2′, H4, 
OCH2Ph), 4.83 (1H, dd, J = 5.3, 3.7 Hz, H3a), 4.64 (1H, d, J = 11.6 Hz, OCH2Ph), 4.55 
(1H, dd, J = 8.7, 2.2 Hz, H1′), 4.52 – 4.47 (3H, m, OCH2Ph, H8a), 4.22 (1H, q, J = 7.3 Hz, 
H8), 4.09 (1H, dd, J = 7.2, 3.7 Hz, H3b), 3.85 (1H, dd, J = 10.9, 7.5 Hz, H3′), 3.42 (1H, 
dd, J = 11.0, 3.6 Hz, H3′), 3.01 (3H, s, OMs), 1.46 (3H, s, C2–CH3), 1.29 (3H, s, C2–CH3), 
1.22 (3H, d, J = 7.4 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 160.2 (C6), 137.3 (ArC), 136.9 (ArC), 129.0 (ArCH), 
128.6 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 112.6 (C2), 
87.9 (C8a), 80.7 (C3a), 80.1 (C4), 78.5 (C2՛), 74.8 (C1՛), 74.3 (OCH2Ph), 73.3 (OCH2Ph), 







Compound 166 was synthesized from 158 (113 mg, 0.234 mmol) by the general method 
for oxozlididnone hydrolysis. The product was purified by FCC (5:95 MeOH/CH2Cl2) to 
give 166 as a pale–brown solid (90 mg, 84%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.38 
[α]𝐷
25–2.6 (c 1.00, CHCl3) 
IR max (cm-1): 3412, 3030, 2967, 1498, 1352, 1072, 1051, 647 cm–1 
LRESIMS m/z 458 (100%) [M+H]+.  
HRESIMS found 458.2530, calcd for C26H36NO6, 458.2543 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.18 (10H, m, ArH), 4.76 (1H, t, J = 4.0 Hz, H3a), 
4.72 (1H, d, J = 11.5 Hz, OCH2Ph), 4.66 (1H, d, J = 11.5 Hz, OCH2Ph), 4.52 (2H, s, 
OCH2Ph), 4.36 (1H, d, J = 5.4 Hz, H6a), 4.08 – 3.99 (2H, m, H1՛, H3՛), 3.74 – 3.68 (2H, 
m, H4՛, H2՛), 3.58 (1H, dd, J = 9.8, 4.8 Hz, H4՛), 3.28 (1H, q, J = 7.4 Hz, H6), 3.09 (1H, 
dd, J = 9.0, 4.0 Hz, H4), 2.32 (2H, bs, 2 x OH), 1.28 (6H, s, 2 x C2–CH3), 1.03 (3H, d, J 
= 7.4 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.0 (ArC), 137.9 (ArC), 128.6 (ArCH), 128.5 (ArCH), 
128.0 (ArCH), 128.0 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 110.9 (C2), 86.5 (C6a), 82.4 
(C2՛), 81.8 (C3a), 74.0 (OCH2Ph), 73.7 (OCH2Ph), 70.7 (C4՛), 69.8 (C1՛ and C3՛), 61.8 











Triethylamine (44 µL, 0.32 mmol) was slowly added to a solution of 166 (145.7 mg, 0.319 
mmol) in anhydrous DCE (15 mL) at 0 
oC under a nitrogen atmosphere. Whilst stirring, a 
0.13M solution of methanesulfonyl chloride in anhydrous CH2Cl2 (2.45 mL, 0.319 mmol) 
was slowly added dropwise to the reaction mixture. After stirring at 0 oC for 30 min, the 
reaction mixture was quenched through the addition of a sat. NaHCO3 solution (2 mL) and 
extracted with CH2Cl2 (3 x 5 mL) followed by concentration in vacuo. The crude brown 
oil was dissolved in DCE followed by the addition of triethylamine (44 µL, 0.319 mmol). 
The reaction mixture with was heated at 80 oC for 20 h. TLC analysis confirmed full 
consumption of the starting material and so the reaction was quenched through the addition 
of NaHCO3 solution (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined 
extracts were dried (MgSO4), filtered and concentrated in vacuo to give a yellow oil. 
Purification by FCC (5:95 MeOH/CH2Cl2) gave the title compound 165 as a pale–yellow 
oil (106 mg, 76%).  
 
 Rf (5:95 MeOH/CH2Cl2) = 0.35  
[α]𝐷
25+29.9 (c 1.00, CHCl3) 
IR max (cm-1): 3358, 2981, 2862, 1702, 1643, 1211, 1089, 1023, 683 cm–1 
LRESIMS m/z 440 (100%) [M+H]+.  
HRESIMS found 440.2432, calcd for C26H34NO5, 440.2437 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.48 – 7.17 (10H, m, ArH), 4.77 (1H, t, J = 6.0 Hz, H8b), 
4.72 (1H, d, J = 12.0 Hz, OCH2Ph), 4.67 (1H, t, J = 6.0 Hz, H8), 4.62 – 4.54 (2H, m, 2 x 
OCH2Ph), 4.49 (1H, d, J = 12.1 Hz, OCH2Ph), 4.35 (1H, dd, J = 6.1, 3.6 Hz, H3a), 3.91 
(1H, t, J = 6.5 Hz, H7), 3.54 – 3.46 (3H, m, H1՛, H8a), 3.34 – 3.24 (2H, m, H4, H6), 1.51 
(3H, s, C2–CH3), 1.31 (3H, s, C2–CH3), 1.08 (3H, d, J = 6.7 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.5 (ArC), 138.1 (ArC), 128.4 (ArCH), 128.4 (ArCH), 
127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 113.1 (C2), 88.7 (C7), 88.0 (C3a), 80.0 
257 
 
(C8b), 76.0 (C8), 73.4 (OCH2Ph), 72.4 (OCH2Ph), 72.0 (C1՛), 71.4 (C8a), 67.2 (C6), 64.3 
(C4), 26.9 (C2–CH3), 24.5 (C2–CH3), 19.0 (C1՛՛). 
 





To a solution of 165 (20 mg, 0.05 mmol) in EtOH/H2O (1/9, 5 mL), was added 5 N HCl 
(0.5 mL). The mixture was stirred at room temperature for 4 h by which time TLC analysis 
confirmed the consumption of starting material. The reaction mixture was neutralized by 
the addition of a saturated solution of NaHCO3 until a pH of 7 was achieved. The solution 
was evaporated to 5 mL under reduced pressure and extracted with EtOAc (3 x 15 mL), 
the combined extracts were washed with saturated NaCl (15 mL), dried (MgSO4), filtered 
and concentrated in vacuo to give a brown oil. Purification by FCC (5:95 MeOH/CH2Cl2) 
gave the title compound 168 as a pale–yellow oil (16 mg, 89%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.14 
[α]𝐷
25+13.0 (c 1.00, CHCl3) 
IR max (cm-1): 3357, 2918, 2863, 1653, 1539, 1120, 1078, 698 cm–1 
LRESIMS m/z 400 (100%) [M+H]+.  
HRESIMS found 400.2126, calcd for C23H30NO5, 400.2124 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.18 (10H, m, ArH), 4.69 – 4.59 (2H, m, OCH2Ph), 
4.57 – 4.46 (3H, m, OCH2Ph, H1), 4.06 (1H, d, J = 4.3 Hz, H7), 3.96 (1H, d, J = 2.5 Hz, 
H2), 3.73 (1H, t, J = 3.5 Hz, H7a), 3.66 (1H, dd, J = 9.2, 3.8 Hz, H6), 3.59 (1H, dd, J = 
9.7, 3.6 Hz, H1՛), 3.51 (1H, dd, J = 9.6, 3.7 Hz, H1՛), 3.21 (1H, q, J = 3.5 Hz, H3), 2.78 
(1H, dt, J = 12.4, 6.2 Hz, H5), 1.22 (3H, d, J = 6.1 Hz, H1՛՛). 
258 
 
13C NMR (125 MHz, CDCl3) δ 137.3 (ArC), 137.0 (ArC), 128.8 (ArCH), 128.7 (ArCH), 
128.4 (ArCH), 128.2 (ArCH), 128.2 (ArCH), 88.5 (C2), 79.5 (C6), 74.9 (C1), 74.7 (C7a), 
74.0 (OCH2Ph), 73.0 (C1՛), 72.5 (OCH2Ph), 71.8 (C7), 70.4 (C3), 66.3 (C5), 19.0 (C1՛՛). 
 
(1R,2R,3R,5S,6S,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-
1,2,6,7-tetraol [(‒)-5,6-di-epi-hyacinthacine C5] (169) 
 
(‒)-5,6-Di-epi-hyacinthacine C5 169 was synthesized by the general method of O–benzyl 
deprotection from 168 (15 mg, 0.037 mmol). The crude product was filtered through a pad 
of celite and washed with additional MeOH (6 mL). The combined filtrates were 
concentrated in vacuo returning a yellow film. The title compound 169 was isolated 
through basic ion–exchange chromatography followed by concentration in vacuo, as a 
colourless film (8 mg, 99%). 
 
[α]𝐷
25–6.9 (c 1.00, H2O) 
IR max (cm-1): 3332, 2981, 1623, 1578, 1478, 1065, 699 cm–1 
LRESIMS m/z 220 (100%) [M+H]+.  
HRESIMS found 220.1176, calcd for C9H18NO5, 220.1185 [M+H]
+. 
1H NMR (500 MHz, D2O) δ 4.33 (1H, t, J = 7.4 Hz, H1), 4.13 (1H, t, J = 4.1 Hz, H7), 
3.89 (1H, t, J = 8.7 Hz, H2), 3.76 – 3.68 (2H, m, H6 and H8), 3.65 (1H, dd, J = 11.9, 4.7 
Hz, H8), 3.26 (1H, dt, J = 5.7, 2.8 Hz, H7a), 2.84 (1H, dq, J = 12.7, 6.4 Hz, H5), 2.78 (1H, 
dt, J = 9.1, 4.3 Hz, H3), 1.20 (3H, d, J = 6.2 Hz, H9). 
13C NMR (125 MHz, D2O) δ 79.1 (C6), 78.0 (C2), 73.0 (C1), 70.8 (C3), 69.8 (C7), 67.8 









To a solution of compound 137 (425 mg, 0.828 mmol) in THF (25 mL) at 0 oC, was slowly 
added sodium hydride (50 mg, 1.24 mmol 60% dispersion in mineral oil). The reaction 
mixture was heated at reflux under a nitrogen atmosphere for 5 min, and cooled to rt. 4–
Methoxybenzyl chloride (225 µL, 1.66 mmol) and TBAI (46 mg, 0.124 mmol) were added 
and the mixture was heated at reflux for 18 h. By this time, TLC analysis had confirmed 
full consumption of the starting material. The reaction mixture was cooled to 0 oC, and 
quenched by the dropwise addition of water (10 mL). The mixture was extracted with 
diethyl ether (3 x 15 mL) and the combined extracts were dried (MgSO4), filtered and 
concentrated in vacuo. The resultant orange oil was purified by FCC (1:1 diethyl ether/n-
hexane) to afford product 175 as a yellow oil (451 mg, 86%). 
 
Rf (1:1 diethyl ether/n-hexane) = 0.17 
[α]𝐷
25 +48.3 (c 0.96, CHCl3).  
IR max (cm-1): 3027, 2950, 1618, 1540, 1245, 1108, 1083, 832 cm–1 
LRESIMS m/z 656 (100%) [M+Na]+  
HRESIMS found 656.3102, calcd for C40H43NO6Na, 656.2988 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.06 (17H, m, ArH), 6.88 (2H, dd, J = 8.2, 4.7 Hz, 
ArH), 6.10 (1H, d, J = 15.9 Hz, H2′′′), 5.99 (1H, dd, J = 15.9, 9.5 Hz, H1′′′), 5.83 (1H, ddd, 
J = 17.1, 10.4, 5.7 Hz, H2′), 5.20 (1H, d, J = 10.4 Hz, H3′cis), 5.10 (1H, d, J = 17.1 Hz, 
H3′trans), 4.78 – 4.52 (4H, m, OCH2Ph, H5), 4.44 – 4.28 (4H, m, OCH2Ph, OCH2Ar, H1′), 
3.87 – 3.73 (5H, m, H4, H1′′′′, OCH3), 3.71 – 3.60 (3H, m, H3′′′′, H2′′′′), 1.20 (3H, d, J = 
6.9 Hz, H1′′). 
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13C NMR (125 MHz, CDCl3) δ 159.7 (ArC), 157.0 (C2), 138.3 (ArC), 138.2 (ArC), 137.0 
(C2′), 135.7 (ArC), 135.2 (C2′′′), 130.6 (ArCH), 130.3 (ArCH), 128.9 (ArCH), 128.6 
(ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.4 (ArCH), 128.0 (ArCH), 127.7 (ArCH), 127.6 
(ArCH), 127.5 (ArCH), 126.7 (ArCH), 125.1 (C1′′′), 116.9 (C3′), 114.1 (ArCH), 77.4 (C5), 
76.6 (C2′′′′), 74.5 (C4), 73.9 (OCH2Ph), 73.1 (OCH2Ph), 71.6 (OCH2Ar), 69.4 (C3′′′′), 59.8 





Compound 176 was synthesized from 175 (330 mg, 0.521 mmol), using the general 
method for ring–closing metathesis. The crude black oil was purified by FCC (3:7 
EtOAc/n-hexane) to give 176 as a grey oil (215 mg,78%). 
 
Rf (3:7 EtOAc/n-hexane) = 0.32 
[α]𝐷
25 +19.9 (c 1.00, CHCl3).  
IR max (cm-1): 2980, 2824, 1767, 1698, 1513, 1454, 1375, 1222, 1103, 1083, 831 cm–1 
LRESIMS m/z 552 (100%) [M+Na]+  
HRESIMS found 552.2375, calcd for C32H35NO6Na 552.2362 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.40 – 7.14 (12H, m, ArH), 6.84 (2H, d, J = 8.6 Hz, ArH), 
5.67 (1H, dt, J = 6.1, 1.9 Hz, H7), 5.57 (1H, dt, J = 6.1, 1.9 Hz, H6), 4.89 – 4.82 (1H, m, 
H7a), 4.77 (1H, dd, J = 8.8, 2.4 Hz, H1), 4.71 (1H, d, J = 11.5 Hz, OCH2Ph), 4.59 (1H, d, 
J = 11.3 Hz, OCH2Ph), 4.54 – 4.41 (4H, m, OCH2Ph, OCH2Ar), 4.20 (1H, dqd, J = 8.5, 
6.3, 3.2 Hz, H5), 3.90 – 3.82 (2H, m, H3′, H2′), 3.79 (3H, s, OCH3), 3.73 (1H, dd, J = 11.0, 
6.4 Hz, H3′), 3.46 (1H, dd, J = 5.3, 2.5 Hz, H1′), 1.24 (3H, d, J = 6.8 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 159.4 (ArC), 157.5 (C3), 138.4 (ArC), 137.7 (ArC), 136.8 
(C7), 130.4 (ArCH), 129.8 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.7 
(ArCH), 127.6 (ArCH), 123.4 (C6), 113.8 (ArCH), 77.8 (C1′), 76.9 (C2′), 75.6 (C1), 73.4 
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(OCH2Ph), 73.1 (OCH2Ph), 72.6 (OCH2Ar), 70.6 (C3′), 68.7 (C7a), 59.9 (C5), 55.3 
(OCH3), 15.7 (C1′′). 
 
(1R,5R,6S,7R,7aR)-1-((1S,2S)-1,3-Bis(benzyloxy)-2-((4-methoxybenzyl)oxy)propyl)-




Compounds 180 and 183 were synthesized from 176 (202 mg, 0.381 mmol) using the 
general method for cis–dihydroxylation. Both products were purified by FCC (3:97 
MeOH/CH2Cl2) to give the title compounds 180 (38 mg, 18%) and 183 (134 mg, 62%) as 
clear oils.  
 
180: 
Rf (3:97 MeOH/CH2Cl2) = 0.49 
[α]𝐷
25 +3.2 (c 2.75, CHCl3).  
IR max (cm-1): 3390, 2907, 2827, 1743, 1675, 1510, 1225, 1179, 1171, 1081 cm–1 
LRESIMS m/z 586 (100%) [M+Na]+  
HRESIMS found 586.2416, calcd for C32H37NO8Na 586.2417 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.18 (12H, m, ArH), 6.87 (2H, d, J = 8.4 Hz, ArH), 
4.81 – 4.64 (5H, m, OCH2Ph, H1), 4.46 – 4.32 (4H, m, OCH2Ph, OCH2Ar), 4.13 (1H, dd, 
J = 6.6, 3.4 Hz, H7a), 4.06 – 3.98 (1H, m, H6), 3.84 – 3.60 (8H, m, OCH3, H5, H7, H3′, 
H2′), 3.15 (1H, dd, J = 8.8, 2.1 Hz, H1′), 2.67 (1H, d, J = 10.3 Hz, OH), 1.43 (3H, d, J = 
7.0 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 159.7 (ArC), 157.0 (C3), 137.5 (ArCH), 137.1 (ArCH), 
130.4 (ArCH), 129.5 (ArCH), 128.8 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.2 (ArCH), 
128.1 (ArCH), 127.9 (ArCH), 114.0 (ArCH), 76.0 (C7a), 75.8 (C1), 75.4 (C7), 74.6 (C6), 
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74.4 (OCH2Ph), 73.6 (OCH2Ph), 71.6 (OCH2Ar), 70.6 (C2′ or C5), 68.4 (C3′), 62.9 (C1′), 
55.4 (OCH3), 54.7 (C2′ or C5), 11.8 (C1′′). 
 
183:  
Rf (3:97 MeOH/CH2Cl2) = 0.49 
[α]𝐷
25 +14.2 (c 1.00, CHCl3). 
LRESIMS m/z 564 (100%) [M+H]+  
1H NMR (500 MHz, CDCl3) δ 7.36 – 7.17 (12H, m, ArH), 6.85 (2H, d, J = 8.1 Hz, ArH), 
4.83 (1H, dd, J = 8.8, 4.3 Hz, H1), 4.73 – 4.62 (2H, m, OCH2Ph), 4.58 (1H, d, J = 11.6 Hz, 
OCH2Ph), 4.52 – 4.41 (3H, m, OCH2Ph, OCH2Ar), 4.11 – 4.04 (1H, t, J = 7.2 Hz, H7), 
3.99 (1H, q, J = 4.6 Hz, H2′), 3.92 (1H, t, J = 8.4 Hz, H7a), 3.78 (4H, s, OCH2Ph, H3′), 
3.68 (2H, td, J = 8.8, 6.8, 4.0 Hz, H3′, H6), 3.46 – 3.40 (1H, m, H5), 1.23 (3H, d, J = 6.8 
Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 159.5 (ArC), 156.6 (C3), 137.9 (ArCH), 137.5 (ArCH), 
130.0 (ArCH), 129.8 (ArCH), 128.5 (ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 
127.8 (ArCH), 113.9 (ArCH), 79.7 (C6), 77.3 (C1′), 76.6 (C2′), 76.3 (C1), 74.2 (OCH2Ph), 
73.5 (OCH2Ph), 72.9 (OCH2Ar), 69.5 (C3′), 68.3 (C7), 65.3 (C7a), 58.9 (C5), 55.3 (OCH3), 
14.8 (C1′′). 
 




[1,3,2]dioxathiolo[4',5':3,4]pyrrolo[1,2-c]oxazol-6-one 2,2-dioxide (181) 
 
To a solution of the diol 183 (212 mg, 0.376 mmol) in anhydrous CH2Cl2 (10 mL) at 0 
oC 
under a nitrogen atmosphere was added Et3N (134 µL, 0.96 mmol) and SOCl2 (46 µL, 0.57 
mmol) dropwise. After stirring at 0 oC for 1 h, TLC analysis confirmed the consumption 
of starting material. The reaction was quenched with water (10 mL) and the mixture was 
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extracted with CH2Cl2 (3 x 15 mL). The combined extracts were dried (MgSO4), filtered 
and concentrated in vacuo to give 181 as a brown oil (235 mg) which was used for the next 
step without further purification. 
 
LRESIMS m/z 660 (100%) [M+Cl]–  
 
(1R,5R,6R,7R,7aR)-1-((1S,2S)-1,3-Bis(benzyloxy)-2-((4-methoxybenzyl)oxy)propyl)-




To a solution of the cyclic sulfate 181 (235 mg, 0.376 mmol) in dry DMSO (5 mL) was 
added benzoic acid (184 mg, 1.50 mmol) and cesium carbonate (490 mg, 1.50 mmol). The 
reaction mixture was stirred under a nitrogen atmosphere at 40 oC for 20 h. After 
LRESIMS confirmed the consumption of starting material, a mixture of THF (8 mL), 
distilled water (3 mL) and conc. H2SO4 (1 mL) was added to the mixture and stirred at 40 
oC for 20 h. The reaction mixture was neutralized with saturated NaHCO3 until a pH of 7 
was achieved, followed by extraction with CH2Cl2 (3 x 15 mL). The combined extracts 
were dried (MgSO4), filtered and concentrated in vacuo to give a brown oil. The resultant 
oil was eluted from a silica plug (2:3 EtOAc/n-hexane) to give a light brown oil (63 mg) 
which was subsequently subjected to O–benzoyl hydrolysis to afford 185 (37 mg, 18% 




Rf (5:95 MeOH/CH2Cl2) = 0.43 
[α]𝐷
25 ‒16.1 (c 2.00, CHCl3).  
IR max (cm-1): 3412, 2932, 2803, 1756, 1623, 1512, 1256, 1187, 1143, 1009 cm–1 
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LRESIMS m/z 564 (100%) [M+H]+.  
HRESIMS found 564.2589, calcd for C32H38NO8, 564.2597 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.23 (10H, m, ArH), 7.21 (2H, d, J = 8.1 Hz, ArH), 
6.85 (2H, d, J = 8.1 Hz, ArH), 4.84 (1H, dd, J = 8.6, 5.8 Hz, H1), 4.71 – 4.57 (4H, m, 
OCH2Ph. OCH2Ar), 4.44 (2H, q, J = 11.3 Hz, OCH2Ph), 4.00 (1H, t, J = 6.1 Hz, H6), 3.93 
(1H, t, J = 5.6 Hz, H7), 3.89 (2H, bs, H2′, OH), 3.84 – 3.71 (5H, m, OCH3, 7a, H3′), 3.71 
– 3.58 (3H, m, H5, H3′, H1′), 1.31 (3H, d, J = 6.9 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 159.6 (ArC), 157.8 (C3), 137.8 (ArC), 137.4 (ArC), 130.1 
(ArCH), 129.5 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.3 
(ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 114.0 (ArCH), 79.7 (C7), 76.4 
(C7a), 76.2 (C2′), 75.2 (C1), 74.1 (C6), 73.5 (OCH2Ph), 73.2 (OCH2Ph), 72.5 (OCH2Ar), 
69.1 (C3′), 65.2 (C1′), 55.3 (OCH3), 55.2 (C5), 11.0 (C1′′). 
 
186: 
Rf (5:95 MeOH/CH2Cl2) = 0.28 
[α]𝐷
25 +68.4 (c 0.56, CHCl3). 
LRESIMS m/z 564 (100%) [M+H]+.  
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.19 (12H, m, ArH), 6.86 (2H, d, J = 8.0 Hz, ArH), 
4.82 (1H, dd, J = 8.2, 5.0 Hz, H1), 4.77 – 4.62 (3H, m, OCH2Ph), 4.51 – 4.42 (3H, m, 
OCH2Ph, OCH2Ar), 4.08 (1H, t, J = 4.6 Hz, H7a), 3.87 (2H, bs, OH, H7), 3.79 (4H, d, J = 
4.9 Hz, OCH3, H6), 3.74 – 3.68 (3H, m, H3′, H1′), 3.66 – 3.56 (1H, m, H2′), 3.36 (1H, q, 
J = 7.8, 7.2 Hz, H5), 1.59 (3H, d, J = 7.0 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 159.5 (ArC), 157.9 (C3), 137.8 (ArC), 136.7 (ArC), 130.1 
(ArCH), 129.8 (ArCH), 128.79 (ArCH), 128.76 (ArCH), 128.66 (ArCH), 128.65 (ArCH), 
128.5 (ArCH), 128.3 (ArCH), 128.0 (ArCH), 127.98 (ArCH), 127.97 (ArCH), 127.96 
(ArCH), 127.8 (ArCH), 114.0 (ArCH), 84.2 (C6), 76.3 (C7), 76.0 (C7a), 75.4 (C2′), 74.2 
(OCH2Ph), 74.1 (C1), 73.5 (OCH2Ph), 72.1 (OCH2Ar), 69.4 (C3′), 65.8 (C1′), 62.5 (C5), 











Compound 187 was synthesized from 185 (35 mg, 0.062 mmol) by the general method for 
O–benzylation. The product 187 was purified by FCC (1:1 EtOAc/n-hexane) to give the 
target compound as an orange oil (43 mg, 94%). 
 
Rf (1:1 EtOAc/n-hexane) = 0.64 
[α]𝐷
25 +102.1 (c 1.50, CHCl3).  
IR max (cm-1): 3059, 2967, 2849, 1798, 1622, 1542, 1212, 1135, 1164 cm–1 
LRESIMS m/z 744 (100%) [M+H]+.  
HRESIMS found 744.3543, calcd for C46H50NO8, 744.3536 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.44 – 7.02 (22H, m, ArH), 6.79 (2H, d, J = 8.1 Hz, ArH), 
4.91 – 4.81 (2H, m, OCH2Ph, H1), 4.67 (1H, d, J = 11.7 Hz, OCH2Ph), 4.48 – 4.16 (9H, 
m, OCH2Ph, OCH2Ar, H7), 3.69 (3H, s, OCH3), 3.66 – 3.58 (1H, m, H3′), 3.55 (2H, bs, 
H1′, H2′), 3.49 (2H, d, J = 7.8 Hz, H5, H6), 3.44 – 3.34 (2H, m, H3′, H7a), 1.56 (3H, d, J 
= 7.2 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 159.6 (ArC), 157.9 (C3), 138.4 (ArC), 138.0 (ArC), 137.4 
(ArC), 137.1 (ArC), 130.2 (ArCH), 129.8 (ArCH), 128.8 (ArCH), 128.6 (ArCH), 128.6 
(ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.86 (ArCH), 
127.85 (ArCH), 127.67 (ArCH), 127.66 (ArCH), 127.2 (ArCH), 114.0 (ArCH), 87.4 (C1′ 
or C2′), 80.9 (C1′ or C2′), 76.6 (C1), 76.0 (C7), 75.5 (C6), 74.5 (OCH2Ph), 73.4 (OCH2Ph), 










Compound 196 was synthesized from 165 (115 mg, 0.262 mmol) by the general method 
for O–benzylation. The product 196 was purified by FCC (1:4 EtOAc/n-hexane) to give a 
yellow oil (122 mg, 87%). 
 
Rf (3:7 EtOAc/n-hexane) =0.56 
[α]𝐷
25+19.3 (c 1.00, CHCl3) 
IR max (cm-1): 2987, 1557, 1531, 1278, 1089, 695 cm–1 
LRESIMS m/z 530 (100%) [M+H]+.  
HRESIMS found 530.2901, calcd for C33H40NO5, 530.2906 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.50 – 7.15 (15H, m, ArH), 4.68 (1H, d, J = 11.8 Hz, 
OCH2Ph), 4.61 (1H, t, J = 5.6 Hz, H8b), 4.59 – 4.52 (5H, m, OCH2Ph, H8), 4.47 (1H, d, J 
= 12.2 Hz, OCH2Ph), 4.38 (1H, dd, J = 5.8, 2.6 Hz, H3a), 4.02 (1H, t, J = 6.2 Hz, H7), 
3.60 – 3.48 (2H, m, H1՛, H8a), 3.47 – 3.36 (3H, m, H1՛, H6, H4), 1.51 (3H, s, C2–CH3), 
1.31 (3H, s, C2–CH3), 1.04 (3H, d, J = 7.0 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.9 (ArC), 138.8 (2 x ArC), 128.6 (ArCH), 128.5 
(ArCH), 128.5 (ArCH), 128.1 (ArCH), 128.04 (ArCH), 128.00 (ArCH), 127.8 (ArCH), 
127.7 (ArCH), 127.7 (ArCH), 112.7 (C2), 89.2 (C3a), 87.1 (C7), 83.3 (C8), 82.0 (C8b), 
73.5 (OCH2Ph), 72.6 (OCH2Ph), 72.5 (OCH2Ph), 72.5 (C1՛), 69.8 (C8a), 66.4 (C6), 62.9 











Compound 197 was synthesized from 149 (19 mg, 0.043 mmol) by the general method for 
O–benzylation. The product was purified by FCC (gradient of 3:20 EtOAc/n-hexane to 1:5 
EtOAc/n-hexane) to give the target compound 197 as a clear oil (21 mg, 89%). 
 
Rf (1:4 EtOAc/n-hexane) = 0.50 
[α]𝐷
25+85.5 (c 1.00, CHCl3) 
IR max (cm-1): 2980, 1682, 1374, 1247, 1055 cm–1 
LRESIMS m/z 530 (100%) [M+H]+.  
HRESIMS found 530.2923, calcd for C33H40NO5, 530.2906 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.50 – 7.10 (15H, m, ArH), 4.60 (1H, dd, J = 6.9, 3.7 Hz, 
H8b) 4.57 – 4.34 (6H, m, OCH2Ph), 4.21 (1H, t, J = 6.8 Hz, H3a), 4.02 (1H, s, H8), 3.99 
(1H, s, H7), 3.66 (1H, t, J = 2.7 Hz, H8a), 3.48 – 3.20 (3H, m, H1՛, H6, H4), 1.50 (3H, s, 
C2–CH3), 1.29 (6H, s, C2–CH3, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.39 (ArC), 138.11 (ArC), 137.97 (ArC), 128.41 
(ArCH), 128.36 (ArCH), 128.32 (ArCH), 127.69 (ArCH), 127.64 (ArCH), 127.60 (ArCH), 
127.57 (ArCH), 127.55 (ArCH), 113.95 (C2), 86.40 (C3a), 85.79 (C7), 84.89 (C8), 83.58 
(C8b), 74.44 (C8a), 73.19 (OCH2Ph), 72.65 (C1՛), 71.26 (OCH2Ph), 71.20 (OCH2Ph), 















Compound 198 was synthesized from 151 (24 mg, 0.055 mmol) by the general method for 
O–benzylation. The product was purified by FCC (1:4 EtOAc/n-hexane) to give the target 
compound 198 as an orange oil (23 mg, 78%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.50 
[α]𝐷
25+5.9 (c 1.00, CHCl3) 
IR max (cm-1): 2995, 1679, 1443, 1256, 1055, 683 cm–1 
LRESIMS m/z 530 (100%) [M+H]+.  
HRESIMS found 530.2930, calcd for C33H40NO5, 530.2906 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ7.39 – 7.21 (15H, m, ArH), 4.61 (1H, d, J = 11.9 Hz, 
OCH2Ph), 4.56 – 4.44 (7H, m, OCH2Ph, H8b, H3a), 4.39 (1H, t, J = 4.1 Hz, H8), 4.17 (1H, 
dd, J = 6.1, 4.2 Hz, H7), 3.59 (1H, dd, J = 5.8, 3.9 Hz, H6), 3.49 (2H, qd, J = 10.1, 4.2 Hz, 
H1՛), 3.31 (1H, t, J = 4.0 Hz, H8a), 3.02 (1H, dt, J = 7.0, 2.8 Hz, H4), 1.49 (3H, s, C2–
CH3), 1.31 (6H, app. d, J = 4.9 Hz, C2–CH3 and H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.8 (ArC), 138.5 (ArC), 138.4 (ArC), 128.3 (ArCH), 
128.3 (ArCH), 128.2 (ArCH), 127.9 (ArCH), 127.82 (ArCH), 127.78 (ArCH), 127.6 
(ArCH), 127.5 (ArCH), 127.3 (ArCH), 112.0 (C2), 89.3 (C7), 85.5 (C3a or C8b), 82.0 
(C8), 80.7 (C3a or C8b), 73.3 (OCH2Ph), 72.0 (OCH2Ph), 71.9 (OCH2Ph or C8a), 71.7 











Compound 199 was synthesized from 196 (122 mg, 0.230 mmol) using the general method 
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to 
give 199 as a brown oil (95 mg, 85%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.26 
[α]𝐷
25+3.5 (c 1.00, CHCl3) 
IR max (cm-1): 3397, 2887, 1676, 1592 1479, 1064, 687 cm–1 
LRESIMS m/z 490 (100%) [M+H]+  
HRESIMS found 490.2602, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.48 – 7.07 (15H, m, ArH), 4.61 (1H, d, J = 11.6 Hz, 
OCH2Ph), 4.57 – 4.36 (6H, m, OCH2Ph, H1), 4.16 (1H, t, J = 4.0 Hz, H2), 3.95 (1H, t, J = 
4.3 Hz, H7), 3.81 (1H, t, J = 4.1 Hz, H7a), 3.69 (1H, dd, J = 9.2, 3.9 Hz, H6), 3.51 (2H, d, 
J = 6.5 Hz, H1՛), 3.26 (1H, q, J = 5.8 Hz, H3), 2.84 (1H, quint, J = 6.5 Hz, H5), 1.25 (3H, 
d, J = 6.2 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.3 (ArC), 138.1 (ArC), 137.4 (ArC), 128.8 (ArCH), 
128.7 (ArCH), 128.6 (ArCH), 128.30 (ArCH), 128.28 (ArCH), 128.1 (ArCH), 128.0 
(ArCH), 127.9 (ArCH), 127.9 (ArCH), 84.3 (C2), 82.1 (C1), 79.7 (C6), 73.5 (OCH2Ph), 












methylhexahydro-1H-pyrrolizine-1,2-diol (200).  
 
Compound 200 was synthesized from 197 (22 mg, 0.042 mmol) using the general method 
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to 
give the desired product 200 as a pale–yellow oil (20 mg, 98%). 
 
Rf 0.20 (5:95 MeOH/CH2Cl2). 
[α]𝐷
25–38.9 (c 1.00, CHCl3).  
IR max (cm-1): 3324, 3089, 2922, 2853, 1600, 1496, 1095, 608.  
LRESIMS m/z 490 (100%) [M+H]+.  
HRESIMS found 490.2577, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.16 (15H, m, ArH), 4.68 – 4.40 (6H, m, OCH2Ph), 
4.01 (1H, t, J = 3.7 Hz, H2), 3.98 (1H, t, J = 5.0 Hz, H7), 3.91 (1H, t, J = 3.8 Hz, H1), 3.70 
(1H, t, J = 6.0 Hz, H6), 3.50 (1H, t, J = 4.3 Hz, H7a), 3.44 (2H, d, J = 6.5 Hz, H1՛), 3.32 
(1H, td, J = 6.5, 3.6 Hz, H3), 3.22 (1H, quint, J = 6.9 Hz, H5), 3.08 (2H, bs, OH), 1.19 
(3H, d, J = 6.9 Hz, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 138.22 (ArC), 137.97 (ArC), 137.94 (ArC), 128.36 
(ArCH), 128.29 (ArCH), 127.68 (ArCH), 127.65 (ArCH), 127.62 (ArCH), 127.53 (ArCH), 
86.01 (C1), 85.37 (C2), 77.11 (C6), 74.76 (C7a), 73.83 (C7), 73.19 (OCH2Ph), 72.15 












methylhexahydro-1H-pyrrolizine-1,2-diol (201).  
 
Compound 201 was synthesized from 198 (50 mg, 0.094 mmol) using the general method 
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to 
give the desired product 201 as a brown oil (39 mg, 85%).  
 
Rf 0.26 (5:95 MeOH/CH2Cl2).  
[α]𝐷
25+24.4 (c 1.00, CHCl3).  
IR max (cm-1): 3334, 3063, 2926, 1623, 1453, 1368, 1027, 737.  
LRESIMS m/z 490 (100%) [M+H]+.  
HRESIMS found 490.2585, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.21 (15H, m, ArH), 4.60 – 4.43 (6H, m, OCH2Ph), 
4.31 (1H, t, J = 3.3 Hz, H1), 4.24 (1H, dd, J = 7.5, 4.8 Hz, H7), 4.11 (1H, t, J = 3.1 Hz, 
H2), 3.89 (1H, t, J = 4.7 Hz, H6), 3.78 – 3.70 (2H, m, H7a, H3), 3.42 (2H, dd, J = 7.1, 3.3 
Hz, H1՛), 3.37 (1H, dd, J = 7.1, 4.6 Hz, H5), 1.25 (3H, d, J = 7.0 Hz, H1՛՛).  
13C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 138.1 (ArC), 137.0 (ArC), 128.6 (ArCH), 
128.4 (ArCH), 128.4 (ArCH), 128.10 (ArCH), 128.08 (ArCH), 127.70 (ArCH), 127.69 
(ArCH), 127.6 (ArCH), 85.3 (C2), 82.5 (C1), 75.0 (C6), 73.3 (OCH2Ph), 72.9 (C7), 72.0 











methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (202) 
 
Compound 202 was synthesized from the diol 199 (55 mg, 0.11 mmol) by using the general 
method for the synthesis of a cyclic sulfate. The resultant crude brown oil 202 (61 mg) was 
used for the next step without further purification. 
 
LRESIMS m/z 586 (100%) [M+Cl]–. 
 
(3aR,4R,6R,7R,8R,8aS,8bS)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-4-
methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (203) 
 
Compound 203 was synthesized from the diol 200 (48 mg, 0.098 mmol) by using the 
general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 203 (54 
mg) was used for the next step without further purification. 
 
















Compound 204 was synthesized from the diol 201 (40 mg, 0.082 mmol) by using the 
general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 204 (45 
mg) was used for the next step without further purification. 
 
LRESIMS m/z 586 (100%) [M+Cl]–.  
 
General method for ring opening of cyclic sulfates with benzoate 
 
(1S,2S,3S,5R,6R,7R,7aS)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-2-hydroxy-3-
methylhexahydro-1H-pyrrolizin-1-yl benzoate (205) and  
(1R,2R,3S,5R,6R,7R,7aR)-6,7-bis(benzyloxy)-5-((benzyloxy)methyl)-1-hydroxy-3-
methylhexahydro-1H-pyrrolizin-2-yl benzoate (206) 
 
To a solution of the cyclic sulfate 202 (61 mg, 0.11 mmol) in dry DMSO (1 mL) was added 
benzoic acid (67 mg, 0.55 mmol) and cesium carbonate (180 mg, 0.55 mmol). The reaction 
mixture was stirred under a nitrogen atmosphere at 50 oC for 20 h. After LRESIMS 
confirmed the consumption of starting material, a mixture of THF (2 mL), distilled water 
(0.75 mL) and conc. H2SO4 (0.25 mL) was added to the mixture and stirred at 60 
oC for 20 
h. The reaction mixture was neutralized with saturated NaHCO3 until a pH of 7 was 
achieved, followed by extraction with CH2Cl2 (3 x 15 mL). The combined extracts were 
dried (MgSO4), filtered and concentrated in vacuo to give a brown oil. Purification by FCC 





Rf (1:1 diethyl ether/n-hexane) = 0.26 
[α]𝐷
25–12.2 (c 1.00, CHCl3) 
IR max (cm-1): 3367, 3089, 2946, 1687, 1525, 1167, 1038, 598 cm–1 
LRESIMS m/z 594 (100%) [M+H]+.  
HRESIMS found 594.2874, calcd for C37H40NO5, 594.2856 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J = 7.7 Hz, o–Bz), 7.60 (1H, t, J = 7.5 Hz, p–
Bz), 7.46 (2H, t, J = 7.7 Hz, m–Bz), 7.36 – 7.19 (15H, m, ArH), 5.13 (1H, t, J = 5.7 Hz, 
H7), 4.63 – 4.47 (6H, m, OCH2Ph), 4.28 (1H, t, J = 4.0 Hz, H1), 4.14 (1H, t, J = 3.1 Hz, 
H2), 3.94 (1H, t, J = 6.7 Hz, H6), 3.73 (1H, t, J = 5.3 Hz, H7a), 3.63 (1H, s, OH), 3.52 – 
3.45 (2H, q, J = 9.4, 7.4 Hz, H1՛), 3.35 (1H, t, J = 9.2, 4.5 Hz, H3), 3.21 (1H, quint, J = 6.5 
Hz, H5), 1.24 (3H, d, J = 6.2 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 167.8 (CO), 138.4 (ArC), 138.0 (ArC), 137.9 (ArC), 133.6 
(ArC), 129.9 (ArCH), 129.4 (ArCH), 128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.4 
(ArCH), 128.8 (ArCH), 127.73 (ArCH), 127.69 (ArCH), 127.6 (ArCH), 127.6 (ArCH), 
87.7 (C1), 86.4 (C2), 85.1 (C7), 82.5 (C6), 73.3 (OCH2Ph), 71.94 (OCH2Ph), 71.90 
(OCH2Ph), 71.7 (C1՛), 71.5 (C7a), 68.7 (C3), 66.5 (C5), 19.3 (C1՛՛). 
 
206: 
Rf (1:1 diethyl ether/n-hexane) = 0.38 
[α]𝐷
25+54.7 (c 1.00, CHCl3) 
IR max (cm-1): 3369, 3097, 2958, 1608, 1539, 1137, 1023, 699 583 cm–1 
LRESIMS m/z 594 (100%) [M+H]+.  
1H NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J = 7.5 Hz, o–Bz), 7.56 (1H, t, J = 7.5 Hz, p–
Bz), 7.43 (2H, t, J = 7.6 Hz, m–Bz), 7.38 – 7.23 (15H, m, ArH), 5.31 (1H, d, J = 4.0 Hz, 
H6), 4.62 – 4.51 (3H, m, OCH2Ph), 4.53 – 4.43 (3H, m, OCH2Ph), 4.30 (1H, d, J = 2.6 Hz, 
H1), 4.22 (1H, d, J = 2.4 Hz, H2), 4.10 (1H, t, J = 6.1 Hz, H7), 3.98 (1H, dd, J = 4.6, 2.2 
Hz, H7a), 3.56 (1H, t, J = 9.0 Hz, H1՛), 3.52 – 3.38 (3H, m, OH, H1՛, H5), 3.30 (1H, ddd, 
J = 8.6, 5.9, 2.4 Hz, H3), 1.15 (3H, d, J = 6.5 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 165.9 (CO), 138.4 (ArC), 137.9 (ArC), 137.0 (ArC), 133.1 
(ArC), 129.8 (ArCH), 128.6 (ArCH), 128.43 (ArCH), 128.36 (ArCH), 128.3 (ArCH), 
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128.1 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 
84.9 (C2), 83.2 (C6), 82.3 (C1), 75.4 (C7), 73.3 (OCH2Ph), 73.2 (C7a), 72.1 (OCH2Ph), 
72.0 (C1՛), 71.7 (OCH2Ph), 69.8 (C3), 62.5 (C5), 16.1 (C1՛՛). 
 
(1S,2S,3R,5R,6R,7R,7aR)-6,7-bis(benzyloxy)-5-((benzyloxy)methyl)-1-hydroxy-3-
methylhexahydro-1H-pyrrolizin-2-yl benzoate (207) and 
 (1R,2R,3R,5R,6R,7R,7aS)-6,7-Bis(benzyloxy)-5-((benzyloxy)methyl)-2-hydroxy-3-
methylhexahydro-1H-pyrrolizin-1-yl benzoate (208)  
 
Compounds 207 and 208 were synthesized from the cyclic sulfate 203 (61 mg, 0.11 mmol) 
using the general method for ring opening of cyclic sulfates with benzoate. Purification by 
FCC (1:1 EtOAc/n-hexane) gave an inseparable and complex mixture of 207 and 208 (32 
mg, 49%). This mixture was subsequently subjected to O–benzoyl hydrolysis (see General 
method below) to afford 213 (5 mg, 19%) and 214 (20 mg, 75%) which were separable by 
FCC (5:95 MeOH/CH2Cl2).  
 
Rf (1:1 EtOAc/n-hexane) = 0.50 














methylhexahydro-1H-pyrrolizin-2-yl benzoate (209) and  
(1S,2S,3R,5R,6R,7R,7aS)-6,7-bis(benzyloxy)-5-((benzyloxy)methyl)-2-hydroxy-3-
methylhexahydro-1H-pyrrolizin-1-yl benzoate (210)  
 
Compounds 209 and 210 were synthesized from the cyclic sulfate 204 (45 mg, 0.082 
mmol) using the general method for ring opening of cyclic sulfates with benzoate. 
Purification by FCC (2:3 EtOAc/n-hexane) gave pure samples of the two title compounds, 
209 (11 mg, 23%) and 210 (19 mg, 39%), as clear yellow films. 
 
209: 
Rf (2:3 EtOAc/n-hexane) = 0.56 
[α]𝐷
25+13.4 (c 1.00, CHCl3) 
IR max (cm-1): 3340, 3063, 2922, 1707, 1496, 1154, 1027, 583 cm–1 
LRESIMS m/z 594 (100%) [M+H]+.  
HRESIMS found 594.2877, calcd for C37H40NO6, 594.2856 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 8.04 (2H, d, J = 7.7 Hz, o–Bz), 7.57 (1H, t, J = 7.4 Hz, p–
Bz), 7.44 (2H, t, J = 7.7 Hz, m–Bz), 7.38 – 7.20 (15H, m, ArH), 5.04 (1H, dd, J = 7.3, 4.5 
Hz, H6), 4.69 – 4.43 (6H, m, OCH2Ph), 4.30 – 4.19 (2H, m, H1, H7), 4.14 (1H, s, H2), 
3.87 (1H, dd, J = 7.1, 2.5 Hz, H7a), 3.55 (1H, d, J = 6.9 Hz, H3), 3.45 (1H, d, J = 9.4 Hz, 
H1՛), 3.42 – 3.30 (2H, m, H1՛, H5), 1.32 (3H, d, J = 7.0 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 166.7 (CO), 138.3 (ArC), 138.0 (ArC), 137.2 (ArC), 133.2 
(ArC), 129.9 (ArCH), 129.8 (ArCH), 128.7 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.3 
(ArCH), 128.1 (ArCH), 128.0 (ArCH), 127.7 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 86.3 
(C6), 85.2 (C2), 82.5 (C1), 77.2 (C7), 73.2 (OCH2Ph), 72.2 (C1՛), 71.8 (OCH2Ph), 71.7 
(OCH2Ph), 71.4 (C7a), 62.5 (C3), 58.4 (C5), 15.3 (C1՛՛). 
 
210: 




25+9.0 (c 1.00, CHCl3) 
IR max (cm-1): 3330, 3112, 2970, 1646, 1453, 1095, 906, 565 cm–1 
LRESIMS m/z 594 (100%) [M+H]+.  
1H NMR (500 MHz, CDCl3) δ 8.02 (2H, d, J = 7.8 Hz, o–Bz), 7.57 (1H, t, J = 7.4 Hz, p–
Bz), 7.43 (2H, t, J = 7.6 Hz, m–Bz), 7.37 – 7.22 (15H, m, ArH), 5.16 (1H, d, J = 3.2 Hz, 
H7), 4.63 – 4.42 (7H, m, OCH2Ph, H1), 4.14 (1H, s, H2), 4.02 (1H, d, J = 3.7 Hz, H6), 
3.84 (1H, t, J = 7.8 Hz, H3), 3.66 (1H, d, J = 3.2 Hz, H7a), 3.58 (1H, dt, J = 10.6, 5.1 Hz, 
H5), 3.44 (2H, d, J = 7.8 Hz, H1՛), 1.38 (3H, d, J = 7.0 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 166.3 (CO), 138.4 (ArC), 137.9 (ArC), 136.5 (ArC), 133.2 
(ArC), 130.0 (ArCH), 129.8 (ArCH), 129.7 (ArCH), 128.6 (ArCH), 128.4 (ArCH), 128.4 
(ArCH), 128.3 (ArCH), 128.24 (ArCH), 128.20 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 
127.5 (ArCH), 85.6 (C2), 85.3 (C1), 85.1 (C7), 79.5 (C6), 76.4 (C7a), 73.2 (OCH2Ph), 
72.7 (C1՛), 72.0 (OCH2Ph), 71.6 (OCH2Ph), 63.5 (C3), 61.2 (C5), 11.4 (C1՛՛). 
 





To a solution of 205 (23 mg, 0.039 mmol) in MeOH (5 mL) was added solid K2CO3 (8.2 
mg, 0.060 mmol). After stirring at 40 oC for 2 h, all volatiles were evaporated and the 
residue was dissolved in EtOAc. The solution was washed with water (3 x 5 mL) and brine 
(5 mL), dried (MgSO4), filtered and concentrated in vacuo to give a brown oil. The crude 
product was purified by FCC (5:95 MeOH/CH2Cl2) to give the product 211 as colourless 
crystals (15 mg, 79%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.28 
[α]𝐷
25+14.6 (c 1.00, CHCl3) 
M.P: 115 – 120 oC  
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IR max (cm-1): 3370, 3078, 2968, 2930, 1679, 1502, 1467, 1320, 1089, 687 cm–1 
LRESIMS m/z 490 [M+H]+.  
HRESIMS found 490.2617, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.21 (15H, m, ArH), 4.61 – 4.41 (6H, m, OCH2Ph), 
4.10 (1H, t, J = 3.6 Hz, H2), 4.07 (1H, t, J = 3.6 Hz, H1), 3.97 (1H, t, J = 7.5 Hz, H7), 3.68 
(1H, t, J = 8.1 Hz, H6), 3.48 – 3.40 (3H, m, H1՛ and H7a), 3.23 (1H, dt, J = 9.8, 4.5 Hz, 
H3), 3.06 (2H, s, OH), 2.93 (1H, dq, J = 12.6, 6.4 Hz, H5), 1.17 (3H, d, J = 6.2 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.3 (ArC), 138.01 (ArC), 138.00 (ArC), 128.42 (ArCH), 
128.40 (ArCH), 128.3 (ArCH), 127.8 (ArCH), 127.69 (ArCH), 127.67 (ArCH), 127.5 
(ArCH), 87.2 (C1), 86.0 (C2), 83.1 (C6), 80.2 (C7), 73.2 (OCH2Ph), 72.3 (C7a), 71.9 





Compound 212 was synthesized from 206 (8.0 mg, 0.014 mmol) using the general method 
for O–benzoyl deprotection. The crude brown oil was purified by FCC (5:95 
MeOH/CH2Cl2) to give the product 212 as a clear yellow oil (6.0 mg, 90%.) 
 
Rf (5:95 MeOH/CH2Cl2) = 0.15 
[α]𝐷
25+17.4 (c 1.00, CHCl3) 
IR max (cm-1): 3387, 3049, 2922, 1643, 1428, 1354, 1067, 697 cm–1 
LRESIMS m/z 490 [M+H]+.  
HRESIMS found 490.2613, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.53 – 7.05 (15H, m, ArH), 4.64 – 4.40 (6H, m, OCH2Ph), 
4.32 (1H, s, H1), 4.22 – 4.14 (2H, m, H2 and H7), 4.09 (1H, s, H7a), 3.94 (1H, s, H6), 3.61 




13C NMR (125 MHz, CDCl3) δ 138.1 (ArC), 137.7 (ArC), 136.7 (ArC), 128.6 (ArCH), 
128.5 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.74 
(ArCH), 127.70 (ArCH), 127.66 (ArCH), 84.8 (C2), 81.4 (C1), 81.2 (C6), 76.8 (C7a), 73.3 




methylhexahydro-1H-pyrrolizine-1,2-diol (213)  
 
Compound 213 was synthesized from 209 (11 mg, 0.017 mmol) using the general method 
for O–benzoyl deprotection. Purification by FCC (5:95 MeOH/CH2Cl2) returned the 
product 213 as a brown film (7.5 mg, 90%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.20 
[α]𝐷
25–25.4 (c 1.00, CHCl3) 
IR max (cm-1): 3360, 3068, 2937, 1640, 1450, 1029, 681 cm–1 
LRESIMS m/z 490 (100%) [M+H]+.  
HRESIMS found 490.2608, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.10 (15H, m, ArH), 4.67 – 4.36 (6H, m, OCH2Ph), 
4.19 (1H, t, J = 2.6 Hz, H1), 4.09 (1H, s, H2), 3.99 (1H, dd, J = 7.5, 4.7 Hz, H7), 3.89 (1H, 
dd, J = 7.5, 2.8 Hz, H7a), 3.67 (1H, dd, J = 7.5, 4.6 Hz, H6), 3.53 – 3.40 (3H, m, H3, H1՛), 
3.17 (1H, quint, J = 6.5, 6.1 Hz, H5), 2.02 (1H, bs, OH), 1.29 (3H, d, J = 6.9 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 137.9 (ArC), 137.0 (ArC), 128.6 (ArCH), 
128.4 (ArCH), 128.4 (ArCH), 128.13 (ArCH), 128.07 (ArCH), 127.8 (ArCH), 127.7 
(ArCH), 127.7 (ArCH), 127.7 (ArCH), 85.0 (C2), 84.4 (C6), 82.3 (C1), 79.4 (C7), 73.3 











Compound 214 was synthesized from benzoate 210 (15 mg, 0.025 mmol) using the general 
method for O–benzoyl deprotection, except that the reaction was stirred at rt for 1 h. The 
crude brown oil was purified by FCC (5:95 MeOH/CH2Cl2) to give the product 214 as a 
clear brown film (10 mg, 83%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.14 
[α]𝐷
25–1.62 (c 1.00, CHCl3) 
IR max (cm-1): 3389, 2890, 1654, 1489, 1054 cm–1 
LRESIMS m/z 490 (100%) [M+H]+.  
HRESIMS found 490.2615, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.45 – 7.17 (15H, m, ArH), 4.64 – 4.43 (6H, m, OCH2Ph), 
4.14 – 4.08 (3H, m, H7, H1, H2), 3.81 (1H, dd, J = 3.8, 1.8 Hz, H6), 3.73 (1H, td, J = 6.9, 
3.0 Hz, H3), 3.65 (1H, q, J = 5.2, 4.5 Hz, H5), 3.56 (1H, t, J = 3.1 Hz, H7a), 3.44 (2H, d, 
J = 1.6 Hz, H1՛), 1.28 (3H, d, J = 7.0 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 137.8 (ArC), 136.9 (ArC), 128.6 (ArCH), 
128.5 (ArCH), 128.3 (ArCH), 128.12 (ArCH), 128.10 (ArCH), 127.8 (ArCH), 127.7 
(ArCH), 127.6 (ArCH), 85.8 (C1 or C7 or C2), 85.0 (C1 or C7 or C2), 81.5 (C6), 81.3 (C1 
or C7 or C2), 76.8 (C7a), 73.2 (OCH2Ph), 72.3 (OCH2Ph), 71.8 (OCH2Ph), 71.6 (C1՛), 











1,2,6,7-tetraol [Initially proposed structure of (+)-hyacinthacine C5]  
 
The compound initially proposed to be (+)-hyacinthacine C5
117 was synthesized by the 
general method of O–benzyl deprotection from 211 (20 mg, 0.04 mmol). The crude 
product was filtered through a pad of celite and washed with additional MeOH (6 mL). 
The combined filtrates were concentrated in vacuo returning a yellow film. The title 
compound was isolated through basic ion–exchange chromatography followed by 
concentration in vacuo, as a colourless film (9.0 mg, 99%).  
 
[α]𝐷
25+9.5 (c 1.00, H2O) 
IR max (cm-1): 3302, 2952, 2926, 1603, 1545, 1212, 1079, 694 cm–1  
LRESIMS m/z 220 [M+H]+.  
HRESIMS found 220.1177, calcd for C9H18NO5, 220.1185 [M+H]
+. 
 1H NMR (500 MHz, D2O) δ 4.15 (1H, t, J = 7.0 Hz, H1), 4.11 (1H, t, J = 7.1 Hz, H7), 
3.96 (1H, t, J = 7.0 Hz, H2), 3.74 – 3.61 (3H, m, H6, H8), 3.05 (1H, t, J = 6.8 Hz, H7a), 
2.96 – 2.87 (2H, m, H5, H3), 1.20 (3H, d, J = 6.2 Hz, H9). 
13C NMR (125 MHz, D2O) δ 82.9 (C6), 80.2 (C1), 79.6 (C7), 79.3 (C2), 71.2 (C7a), 71.1 
(C5), 66.0 (C3), 62.9 (C8), 17.8 (C9). 
 
(1R,2R,3R,5S,6R,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-




(+)–6,7-Di-epi-hyacinthacine C5 215 was synthesized by the general method of O–benzyl 
deprotection from 212 (6.0 mg, 0.012 mmol). The crude product was filtered through a 
pad of celite and washed with additional MeOH (6 mL). The combined filtrates were 
concentrated in vacuo returning a yellow film. The title compound 215 was isolated 
through basic ion–exchange chromatography followed by concentration in vacuo, as a 
white solid (2.0 mg, 78%).  
 
[α]𝐷
25 +10.3 (c 1.00, H2O) 
IR max (cm-1): 3298, 2963, 1593, 1546, 1273, 1086, 699 cm–1 
LRESIMS m/z 220 (100%) [M+H]+.  
HRESIMS found 220.1175, calcd for C9H18NO5, 220.1185 [M+H]
+. 
1H NMR (500 MHz, D2O) δ 4.28 (1H, t, J = 7.5 Hz, H1), 4.21 (1H, dd, J = 4.7, 2.4 Hz, 
H7), 4.13 (1H, dd, J = 4.2, 2.4 Hz, H6), 3.96 (1H, t, J = 8.4 Hz, H2), 3.78 (1H, dd, J = 
12.3, 4.0 Hz, H8), 3.68 (1H, dd, J = 12.0, 4.6 Hz, H8), 3.46 (1H, dd, J = 7.2, 4.6 Hz, H7a), 
3.14 (1H, q, J = 6.1, 4.9, 4.3 Hz, H5), 2.78 (1H, dd, J = 9.3, 4.6 Hz, H3), 1.17 (3H, d, J = 
6.9 Hz, H9). 
13C NMR (125 MHz, D2O) δ 82.2 (C6), 81.2 (C2), 76.8 (C7), 75.6 (C1), 73.1 (C3), 71.6 
(C7a), 65.2 (C5), 64.2 (C8), 16.5 (C9). 
 
(1R,2R,3R,5R,6R,7R,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-
1,2,6,7-tetraol [Corrected structure for (+)-hyacinthacine C5] (216) 
 
The compound for the corrected structure of (+)-hyacinthacine C5 216 was synthesized by 
the general method of O–benzyl deprotection from 213 (7.0 mg, 0.014 mmol). The crude 
product was filtered through a pad of celite and washed with additional MeOH (6 mL). 
The combined filtrates were concentrated in vacuo returning a yellow film. The title 
compound 216 was isolated through basic ion–exchange chromatography followed by 





25+5.25 (c 1.00, H2O) 
IR max (cm-1): 3296, 2928, 1602, 1430, 1072 cm–1 
LRESIMS m/z 220 (100%) [M+H]+.  
HRESIMS found 220.1201, calcd for C9H18NO5, 220.1185 [M+H]
+. 
1H NMR (500 MHz, D2O) δ 4.14 (2H, apparent q, J = 7.7 Hz, H7 and H1), 3.94 (1H, t, J 
= 7.8 Hz, H2), 3.74 (1H, t, J = 7.7 Hz, H6), 3.66 (2H, dd, J = 9.5, 4.7 Hz, H8), 3.38 (1H, 
t, J = 7.6 Hz, H7a), 3.14 (1H, td, J = 9.1, 4.7, 4.0 Hz, H3), 2.95 (1H, dq, J = 6.6, 7.4 Hz, 
H5), 1.27 (3H, d, J = 6.7 Hz, H9). 
13C NMR (125 MHz, D2O) δ 78.8 (C6), 78.1 (C2), 75.2 (C1), 74.9 (C7), 66.3 (C7a), 62.8 
(C8), 62.1 (C3), 58.4 (C5), 12.8 (C9). 
 
(1R,2R,3R,5R,6S,7S,7aR)-3-(Hydroxymethyl)-5-methylhexahydro-1H-pyrrolizine-
1,2,6,7-tetraol [(+)-6,7-di-epi-hyacinthacine C5] (217) 
 
(+)–5-Epi-hyacinthacine C5 217 was synthesized by the general method of O–benzyl 
deprotection from 214 (10 mg, 0.020 mmol). The crude product was filtered through a pad 
of celite and washed with additional MeOH (6 mL). The combined filtrates were 
concentrated in vacuo returning a green film. The title compound 217 was isolated through 
basic ion–exchange chromatography followed by concentration in vacuo, as a colourless 
film (3.4 mg, 75%).  
 
[α]𝐷
25+6.8 (c 1.00, H2O) 
IR max (cm-1): 3290, 2943, 1593, 1375, 1208, 1079 cm–1  
LRESIMS m/z 220 (100%) [M+H]+.  
HRESIMS found 220.1180, calcd for C9H18NO5, 220.1185 [M+H]
+. 
1H NMR (500 MHz, D2O) δ 4.18 (1H, t, J = 4.0 Hz, H7), 4.07 – 3.97 (2H, m, H6, H1), 
3.90 (1H, t, J = 8.1 Hz, H2), 3.67 (2H, t, J = 4.0 Hz, H8), 3.41 (1H, dt, J = 11.7, 5.7 Hz, 
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H5), 3.33 (1H, dt, J = 9.0, 4.9 Hz, H3), 3.07 (1H, dd, J = 8.1, 3.7 Hz, H7a), 1.24 (3H, d, J 
= 7.1 Hz, H9). 
13C NMR (125 MHz, D2O) δ 79.7 (C6 or C7), 78.6 (C6 or C7), 78.0 (C1), 77.9 (C2), 72.1 
(C7a), 62.9 (C8), 62.2 (C3), 58.1 (C5), 10.7 (C9). 
 
(1R,2R,3R,5R,6S,7S,7aR)-3-(acetoxymethyl)-5-methylhexahydro-1H-pyrrolizine-
1,2,6,7-tetrayl tetraacetate (218) 
 
To a solution of 217 (8.0 mg, 0.037 mmol) in pyridine (147 µL, 1.83 mmol) was added 
acetic anhydride (173 µL, 1.83 mmol) and a crystal of 4–dimethylaminopyridine. The 
mixture was stirred at rt for 24 h, by which time LRESIMS analysis confirmed full 
consumption of the starting material. The reaction was quenched through the addition of 
sat. NaHCO3 solution (3 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined extracts 
were dried (MgSO4), filtered and concentrated in vacuo to give an orange oil. Purification 
by FCC (3:97 MeOH/CH2Cl2) gave the pentaacetylated product 218 as a pale–yellow film 
(15 mg, 95%). 
 
Rf (3:95 MeOH/CH2Cl2) = 0.35 
[α]𝐷
25+12.9 (c 1.00, CHCl3) 
IR max (cm-1): 2934, 1736, 1432, 1368, 1217, 1033, 886, 603 cm–1  
LRESIMS m/z 430 (100%) [M+H]+  
HRESIMS found 430.1731, calcd for C19H28NO10, 430.1713 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 5.36 (1H, t, J = 4.8 Hz, H1), 5.24 (1H, t, J = 4.8 Hz, H2), 
5.20 (2H, dd, J = 7.6, 3.8 Hz, H6, H7), 4.04 (2H, qd, J = 11.3, 5.8 Hz, H1՛), 3.72 – 3.57 
(2H, m, J = 6.1 Hz, H3, H5), 3.41 (1H, t, J = 4.5 Hz, H7a), 2.14 – 2.05 (15H, m, 5 x 
AcCH3), 1.25 (3H, d, J = 7.1 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 170.8 (CO), 170.2 (CO), 169.9 (CO), 169.7 (CO), 169.6 
(CO), 80.4 (C6), 79.5 (C7), 78.6 (C2), 77.6 (C1), 73.1 (C7a), 65.5 (C1՛), 60.4 (C3), 58.6 
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Compound 225 was synthesized from the N–Boc diol 139 (60 mg, 0.10 mmol) by using 
the general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 225 
(66 mg) was used for the next step without further purification. 
 





Cyclic sulfate 225 (66 mg, 0.10 mmol) was dissolved in anhydrous MeCN (10 mL) and 
heated to 50 oC and stirred for 2 h. After TLC confirmed the consumption of starting 
material, the reaction mixture was cooled to rt, followed by the addition of a solution of 
THF (4 mL), distilled water (1.5 mL) and conc. H2SO4 (0.5 mL). The reaction mixture was 
heated at 50 oC and stirred for 1 h. After TLC confirmed the full consumption of starting 
material, the reaction mixture was allowed to cool to rt and neutralized with saturated 
NaHCO3 until a pH of 7 was achieved. The solution was extracted with CH2Cl2 (3 x 15 
mL), dried (MgSO4), filtered and concentrated in vacuo. Purification by FCC (2:3 
EtOAc/n-hexane) returned the oxozolidinone 224 as a pale–yellow oil (20 mg, 39%). 
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Rf (1:1 EtOAc/n-hexane) = 0.64 
[α]𝐷
25 +20.2 (c 2.00, CHCl3).  
IR max (cm-1): 3430, 3028, 2976, 1789, 1214, 1078, 1065, 1083, 951 cm–1 
LRESIMS m/z 536 (100%) [M+Na]+.  
HRESIMS found 536.2408, calcd for C32H35NO5Na, 536.2413 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.40 – 7.22 (15H, m, Ar), 6.47 (1H, d, J = 15.8 Hz, H2′′′), 
6.02 (1H, dd, J = 15.8, 9.0 Hz, H1′′′), 5.84 (1H, ddd, J = 16.8, 10.7, 5.9 Hz, H2′), 5.15 – 
5.09 (2H, m, H3′), 4.77 (1H, d, J = 10.9 Hz, OCH2Ph), 4.64 (1H, d, J = 11.0 Hz, OCH2Ph), 
4.53 (1H, dd, J = 8.9, 5.1 Hz, H4), 4.50 – 4.44 (2H, m, OCH2Ph), 4.39 – 4.31 (2H, m H5, 
H1′), 3.91 (1H, t, J = 3.8 Hz, H1′′′′), 3.84 (1H, td, J = 5.8, 3.8 Hz, H2′′′′), 3.48 (1H, dd, J 
= 9.7, 5.6 Hz, H3′′′′), 3.43 (1H, dd, J = 9.7, 5.6 Hz, H3′′′′), 2.46 (1H, d, J = 6.2 Hz, OH), 
1.28 (3H, d, J = 7.0 Hz H1′′). 
13C NMR (125 MHz, CDCl3) δ 156.6 (C2), 137.5 (ArC), 137.4 (ArC), 136.8 (C2′), 135.7 
(ArC), 133.9 (C2′′′), 128.7 (ArCH), 128.64 (ArCH), 128.62 (ArCH), 128.5 (ArCH), 128.4 
(ArCH), 128.3 (C1′′′), 128.2 (ArCH), 127.9 (ArCH), 126.6 (ArCH), 117.1 (C3′), 79.9 (C5), 
78.9 (C1′′′′), 75.7 (OCH2Ph), 73.5 (OCH2Ph), 70.8 (C3′′′′), 69.4 (C2′′′′), 58.2 (C7a), 51.7 





Compound 223 was synthesized from 224 (20 mg, 0.039 mmol), using the general method 
for ring–closing metathesis. The crude black oil was purified by FCC (1:1 EtOAc/n-
hexane) to give 223 as a grey oil (15 mg, 95%). 
 
Rf (1:1 EtOAc/n-hexane) = 0.64 
[α]𝐷
25 ‒6.6 (c 1.37, CHCl3).  
IR max (cm-1): 3345, 2998, 2885, 1632, 1456, 1279, 1098, 1020, 965 cm–1 
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LRESIMS m/z 432 (100%) [M+Na]+.  
HRESIMS found 432.1793, calcd for C24H27NO5Na, 432.1787 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (10H, m, ArH), 5.83 (1H, d, J = 6.1 Hz, H6), 
5.76 (1H, d, J = 6.1 Hz, H7), 4.98 (1H, d, J = 8.9 Hz, H7a), 4.83 (1H, d, J = 11.2 Hz, 
OCH2Ph), 4.62 (1H, d, J = 11.2 Hz, OCH2Ph), 4.50 – 4.46 (2H, m, OCH2Ph), 4.37 (1H, 
dd, J = 9.0, 3.5 Hz, H1), 4.30 (1H, t, J = 6.2 Hz, H5), 3.98 (1H, s, H1′), 3.86 (1H, d, J = 
6.9 Hz, H2′), 3.54 (1H, dd, J = 9.4, 6.4 Hz, H3′), 3.44 (1H, dd, J = 9.4, 6.3 Hz, H3′), 2.34 
(1H, d, J = 7.2 Hz, OH), 1.55 (3H, d, J = 6.7 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 157.0 (C3), 137.55 (ArC), 137.49 (ArC), 136.4 (C7), 
128.53 (ArCH), 128.52 (ArCH), 128.4 (ArCH), 128.2 (ArCH), 128.0 (ArCH), 127.9 
(ArCH), 127.3 (C6), 83.1 (C1), 77.0 (C1′), 75.2 (OCH2Ph), 73.5 (OCH2Ph), 70.8 (C3′), 





Compound 228 was synthesized from 223 (15 mg, 0.037 mmol) using the general method 
for cis–dihydroxylation. The product was purified by FCC (5:95 MeOH/CH2Cl2) to give 
228 as a light brown oil (12 mg, 72%).  
 
Rf (1:1 EtOAc/n-hexane) = 0.64 
[α]𝐷
25 +9.1 (c 0.40, CHCl3).  
IR max (cm-1): 3443, 2912, 2829, 1758, 1643, 1509, 1265, 1198, 1086 cm–1 
LRESIMS m/z 466 (100%) [M+Na]+.  
HRESIMS found 466.1834, calcd for C24H29NO7Na, 466.1842 [M+Na]
+. 
1H NMR (500 MHz, CDCl3) δ 7.40 – 7.22 (10H, m, ArH), 4.86 – 4.77 (2H, m, OCH2Ph, 
H1), 4.59 (1H, d, J = 11.3 Hz, OCH2Ph), 4.49 – 4.32 (2H, m, OCH2Ph), 4.25 – 4.15 (2H, 
m, H6, H7a), 4.04 (1H, s, H7), 3.96 (1H, s, H1′), 3.83 (1H, s, H2′), 3.72 – 3.62 (1H, m, 
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H5), 3.59 – 3.52 (1H, m, H3′), 3.46 – 3.40 (1H, m, H3′), 3.32 (1H, s, OH), 2.84 (1H, s, 
OH), 2.70 (1H, s, OH), 1.46 (3H, d, J = 6.7 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 156.8 (C3), 137.4 (ArC), 137.2 (ArC), 128.7 (ArCH), 
128.6 (ArCH), 128.5 (ArCH), 128.29 (ArCH), 128.25 (ArCH), 128.1 (ArCH), 77.9 (C1), 
77.0 (C1′), 75.3 (C6), 75.2 (OCH2Ph), 73.7 (OCH2Ph), 70.9 (C3′), 70.8 (C2′), 70.3 (C7), 





Compound 221 was synthesized from 228 (12 mg, 0.027 mmol) by the general method for 
acetonide protection of cis–diols. Purification by FCC (7:15) to give 221 as a pale–yellow 
oil (13 mg, 95%).  
 
Rf (1:1 EtOAc/n-hexane) = 0.64 
[α]𝐷
25 +30.1 (c 0.40, CHCl3). 
IR max (cm-1): 2955, 2843, 1798, 1623, 1556, 1190, 1099 cm–1 
LRESIMS m/z 484 (100%) [M+H]+.  
HRESIMS found 484.2342, calcd for C27H34NO7, 484.2335  [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.24 (10H, m, ArH), 4.83 – 4.77 (2H, m, OCH2Ph, 
H4), 4.60 (1H, d, J = 11.3 Hz, OCH2Ph), 4.56 (1H, dd, J = 5.5, 4.0 Hz, H8a), 4.53 – 4.46 
(3H, m, OCH2Ph, H3a), 4.01 (1H, t, J = 4.4 Hz, H3b), 3.94 – 3.86 (2H, m, H1′, H3′), 3.53 
(1H, dd, J = 9.5, 6.3 Hz, H3′), 3.45 – 3.33 (2H, m, H3′, H8), 1.64 (3H, d, J = 7.0 Hz, H1′′), 
1.46 (3H, s, C2–CH3), 1.30 (3H, s, C2–CH3). 
13C NMR (125 MHz, CDCl3) δ 157.1 (C4), 137.6 (ArC), 137.6 (ArC), 128.5 (ArCH), 
128.4 (ArCH), 128.1 (ArCH), 127.9 (ArCH), 127.9 (ArCH), 112.2 (C2), 83.8 (C8a), 78.8 
(C3a), 77.7 (C1′), 75.4 (C4), 75.2 (OCH2Ph), 73.5 (OCH2Ph), 71.0 (C3′), 70.5 (C2′), 62.9 
(C3b), 57.2 (C8), 26.1 (C2–CH3), 24.4 (C2–CH3), 10.1 (C1′′). 
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To a cooled (–78 oC), stirred solution of DMSO (93 µL, 1.3 mmol) in CH2Cl2 (5 mL) was 
added oxalyl chloride (56.0 µL, 0.653 mmol). After stirring for 5 min, a solution of 165 
(29 mg, 0.0653 mmol) in CH2Cl2 (2 mL) was added to the mixture followed by the addition 
of triethylamine (364 µL, 2.61 mmol). After stirring at –78 oC for 1 h, TLC analysis 
confirmed full consumption of the starting material. The reaction mixture was quenched 
with the addition of water (5 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were dried (MgSO4), filtered and concentrated in vacuo. Purification by 
FCC (3:7 EtOAc/n-hexane) afforded the ketone 231 as an opaque yellow oil (24 mg, 83%). 
 
Rf (3:7 EtOAc/n-hexane) = 0.25 
[α]𝐷
25+22.7 (c 1.00, CHCl3) 
IR max (cm-1): 3030, 2910, 2875, 1716, 1451, 1380, 1227, 1095, 691 cm–1 
LRESIMS m/z 438 (100%) [M+H]+. 
HRESIMS found 438.2275, calcd for C26H32NO5, 438.2280 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.24 (10H, m, ArH), 5.04 – 4.95 (2H, m, OCH2Ph, 
H8b), 4.69 (1H, d, J = 11.8 Hz, OCH2Ph), 4.56 – 4.46 (3H, m, OCH2Ph, H3a), 3.94 (1H, 
dd, J = 9.3, 1.3 Hz, H7), 3.89 – 3.83 (2H, m, H8a, H6), 3.79 (1H, q, J = 7.3 Hz, H4), 3.63 
(1H, dd, J = 10.2, 2.7 Hz, H1′), 3.45 (1H, dd, J = 10.3, 4.9 Hz, H1′), 1.46 (3H, s, C2–CH3), 
1.25 (3H, s, C2–CH3), 1.07 (3H, d, J = 7.3 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 211.0 (C8), 138.1 (ArC), 137.8 (ArC), 128.4 (ArCH), 
128.3 (ArCH), 128.1 (ArCH), 127.78 (ArCH), 127.76 (ArCH), 127.68 (ArCH), 112.66 
(C2), 88.4 (C3a), 84.1 (C8b), 80.3 (C7), 73.3 (OCH2Ph), 72.6 (OCH2Ph), 70.4 (C1′), 70.2 







Compound 232 was synthesized from the tricyclic alcohol 151 (35 mg, 0.080 mmol) by 
using the general method for the Swern oxidation. The product was purified by FCC (2:3 
EtOAc/n-hexane) to give the target compound 232 as an opaque yellow oil (28 mg, 80%).  
 
Rf (2:3 EtOAc/n-hexane) = 0.25 
[α]𝐷
25+95.2 (c 1.00, CHCl3) 
IR max (cm-1): 3379, 2980, 2849, 1716, 1612, 1452, 1363, 1212, 1002, 678 cm–1 
LRESIMS m/z 438 (100%) [M+H]+. 
HRESIMS found 438.2300, calcd for C26H32NO5, 438.2280 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.36 – 7.21 (10H, m, ArH), 5.03 (1H, d, J = 11.6 Hz, 
OCH2Ph), 4.89 (1H, t, J = 5.5 Hz, H8b), 4.59 (1H, d, J = 11.6 Hz, OCH2Ph), 4.54 (1H, dd, 
J = 5.8, 4.1 Hz, H3a), 4.46 (2H, s, OCH2Ph), 4.16 (1H, dd, J = 8.5, 1.5 Hz, H7), 3.96 (1H, 
ddd, J = 8.6, 3.5, 2.1 Hz, H6), 3.69 (1H, dd, J = 5.2, 1.5 Hz, H8a), 3.65 (1H, dd, J = 10.4, 
3.5 Hz, H1′), 3.43 (1H, dd, J = 10.5, 2.1 Hz, H1′), 3.30 (1H, qd, J = 7.2, 4.0 Hz, H4), 1.47 
– 1.41 (6H, m, C2–CH3, H1′′), 1.26 (3H, s, C2–CH3). 
13C NMR (125 MHz, CDCl3) δ 211.8 (C8), 138.0 (ArC), 137.9 (ArC), 128.4 (ArCH), 
128.2 (ArCH), 128.12 (ArCH), 128.11, 127.8 (ArCH), 127.7 (ArCH), 112.5 (C2), 84.4 
(C3a), 83.5 (C8b), 80.9 (C7), 73.4 (OCH2Ph), 73.0 (OCH2Ph), 72.4 (C8a), 69.0 (C1′), 












Compound 233 was synthesized from the tricyclic alcohol 149 (71 mg, 0.16 mmol) by 
using the general method for the Swern oxidation. The resultant yellow oil 233 (71 mg) 
was used for the next step without further purification.  
 
LRESIMS m/z 438 (100%) [M+H]+. 
 






To a cooled (–78 oC) solution of the cyclic ketone 231 (52 mg, 0.12 mmol) in THF (5 mL) 
was added a solution of L–selectride® (1.0 M solution in THF, 476 µL, 0.476 mmol). The 
reaction mixture was stirred for 1 h at –78 oC then allowed to warm to room temperature 
and stirred for 2 h. By this time, TLC analysis confirmed full consumption of the starting 
material, by which time the reaction mixture was quenched with the addition of an NH4Cl 
solution (1.0 M, 7 mL). The product was extracted with EtOAc (3 x 10 mL), dried 
(MgSO4), filtered and concentrated in vacuo. Purification by FCC (3:97 MeOH/ CH2Cl2) 
afforded the title product 236 as an orange oil (50 mg, 96%). 
 
Rf (3:97 MeOH/CH2Cl2) = 0.45 
[α]𝐷
25+25.3 (c 1.00, CHCl3) 
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IR max (cm-1): 3398, 3133, 2982, 1620, 1503, 1062, 864, 698 cm–1 
LRESIMS m/z 440 (100%) [M+H]+. 
HRESIMS found 440.2430, calcd for C26H34NO5, 440.2437 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.23 (10H, m, ArH), 4.86 (1H, t, J = 6.0 Hz, H8b), 
4.73 (1H, d, J = 11.7 Hz, OCH2Ph), 4.58 – 4.52 (2H, m, OCH2Ph, H8), 4.50 – 4.45 (2H, 
m, OCH2Ph), 4.39 (1H, dd, J = 6.2, 4.9 Hz, H3a), 4.26 (1H, d, J = 4.8 Hz, OH), 3.89 (1H, 
dd, J = 7.5, 5.2 Hz, H7), 3.62 (1H, t, J = 5.2 Hz, H8a), 3.54 – 3.49 (1H, m, H1′), 3.49 – 
3.42 (2H, m, H1′, H6), 3.34 (1H, dd, J = 6.9, 5.2 Hz, H4), 1.53 (3H, s, C2–CH3), 1.31 (3H, 
s, C2–CH3), 1.13 (3H, d, J = 6.7 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 138.4 (ArC), 138.3 (ArC), 128.3 (ArCH), 128.3 (ArCH), 
127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 113.5 (C2), 88.6 (C3a), 82.2 
(C8b), 81.9 (C7), 73.2 (OCH2Ph), 72.4 (OCH2Ph), 71.8 (C1′), 71.2 (C8), 67.1 (C6), 66.3 





Compound 237 was synthesized from the tricyclic ketone 232 (28 mg, 0.064 mmol) by 
using the general method for the reduction of a ketone to a secondary alcohol with L–
selectride®. The product was purified by FCC (5:95 MeOH/CH2Cl2) to give the target 
compound 237 as an orange oil (19 mg, 66%).  
 
Rf (5:95 MeOH/CH2Cl2) = 0.25 
[α]𝐷
25+52.1 (c 1.00, CHCl3) 
IR max (cm-1): 3290, 2989, 2926, 2873, 1585, 1484, 1095, 694 cm–1 
LRESIMS m/z 440 (100%) [M+H]+. 
HRESIMS found 440.2430, calcd for C26H34NO5, 440.2437 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.20 (10H, m, ArH), 4.75 – 4.61 (3H, m, OCH2Ph, 
H8b, H8), 4.54 (1H, dd, J = 6.0, 4.4 Hz, H3a), 4.52 – 4.46 (3H, m, OCH2Ph), 3.99 (1H, 
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dd, J = 8.1, 4.7 Hz, H7), 3.76 – 3.69 (2H, m, OH, H6), 3.49 (1H, dd, J = 7.3, 4.6 Hz, H8a), 
3.42 (1H, dd, J = 9.8, 3.4 Hz, H1′), 3.30 (1H, dd, J = 9.8, 6.3 Hz, H1′), 3.12 (1H, qd, J = 
7.0, 4.2 Hz, H4), 1.43 (3H, s, C2–CH3), 1.33 (3H, d, J = 7.1 Hz, H1′′), 1.26 (3H, s, C2–
CH3). 
13C NMR (125 MHz, CDCl3) δ 138.7 (ArC), 138.2 (ArC), 128.3 (ArCH), 128.1 (ArCH), 
127.8 (ArCH), 127.7 (ArCH), 127.6 (ArCH), 127.3 (ArCH), 111.8 (C2), 85.4 (C3a), 82.6 
(C7), 82.4 (C8), 73.3 (OCH2Ph), 72.8 (OCH2Ph), 72.4 (C1′), 71.3 (C8a), 70.4 (C8b), 63.2 





Compound 238 was synthesized from the crude tricyclic ketone 233 (71 mg, 0.16 mmol) 
by using the general method for the reduction of a ketone to a secondary alcohol with L–
selectride®. The product was purified by FCC (5:95 MeOH/CH2Cl2) to give the target 
compound 238 as an orange oil (46 mg, 65%).  
  
Rf (5:95 MeOH/CH2Cl2) = 0.45 
[α]𝐷
25 ‒72.0 (c 1.00, CHCl3) 
IR max (cm-1): 3340, 2967, 2872, 1516, 1496, 1140, 1066, 866, 635 cm–1. 
LRESIMS m/z 440 (100%) [M+H]+. 
HRESIMS found 440.2446, calcd for C26H34NO5, 440.2437 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.19 (10H, m, ArH), 4.86 (1H, dd, J = 6.3, 3.2 Hz, 
H8b), 4.58 (1H, d, J = 11.7 Hz, OCH2Ph), 4.55 – 4.47 (3H, m, OCH2Ph), 4.23 (1H, t, J = 
5.7 Hz, H3a), 4.19 (1H, d, J = 4.7 Hz, H8), 3.87 (1H, t, J = 4.3 Hz, H7), 3.61 (1H, t, J = 
4.1 Hz, H8a), 3.47 – 3.36 (2H, m, H1՛, H4), 3.36 – 3.26 (2H, m, H1՛, H6), 1.50 (3H, s, C2–
CH3), 1.32 (3H, s, C2–CH3), 1.21 (3H, d, J = 7.0 Hz, H՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.4 (ArC), 137.5 (ArC), 128.6 (ArCH), 128.4 (ArCH), 
128.1 (ArCH), 127.9 (ArCH), 127.59 (ArCH), 127.56 (ArCH), 112.7 (C2), 87.3 (C3a), 
295 
 
83.4 (C7), 79.0 (C8b), 73.3 (OCH2Ph), 72.8 (C8a), 72.7 (C1՛), 72.3 (OCH2Ph), 69.2 (C8), 





Compound 239 was synthesized from 236 (50 mg, 0.11 mmol) using the general method 
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to 
give the desired product 239 as a pale–yellow oil (36 mg, 79%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.15 
[α]𝐷
25‒67.4 (c 1.00, CHCl3) 
IR max (cm-1): 3334, 3063, 2925, 2868, 1679, 1512, 1082, 656 cm–1 
LRESIMS m/z 400 (100%) [M+H]+. 
HRESIMS found 400.2118, calcd for C23H30NO5, 400.2124 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.20 (10H, m, ArH), 4.59 – 4.46 (4H, m, OCH2Ph), 
4.34 (1H, t, J = 4.3 Hz, H7), 4.31 (1H, t, J = 5.5 Hz, H1), 4.03 (1H, dd, J = 7.4, 4.0 Hz, 
H6), 3.70 – 3.58 (2H, m, H2, H7a), 3.49 (2H, d, J = 4.5 Hz, H1′), 3.13 (1H, dt, J = 8.0, 4.5 
Hz, H3), 2.86 (1H, quint, J = 6.3 Hz, H5), 1.19 (3H, d, J = 6.2 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 138.2 (ArC), 136.9 (ArC), 128.7 (ArCH), 128.4 (ArCH), 
128.4 (ArCH), 128.1 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 82.6 (C7), 79.4 (C1), 73.4 
(C6), 73.1 (C7a), 72.7 (OCH2Ph), 72.2 (OCH2Ph), 71.0 (C1′), 67.4 (C2), 66.7 (C5), 65.7 









Compound 240 was synthesized from 237 (19 mg, 0.042 mmol) using the general method 
for hydrolysis of an acetonide. The product was purified by FCC (8:92 MeOH/CH2Cl2) to 
give 240 as a yellow oil (15 mg, 87%). 
 
Rf (8:92 MeOH/CH2Cl2) = 0.25 
[α]𝐷
25+12.2 (c 1.00, CHCl3) 
IR max (cm-1): 3340, 3119, 2926, 2893, 1568, 1478, 1058, 634 cm–1 
LRESIMS m/z 400 (100%) [M+H]+. 
HRESIMS found 400.2133, calcd for C23H30NO5, 400.2124 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (10H, m, ArH), 4.60 (1H, d, J = 12.2 Hz, 
OCH2Ph), 4.53 – 4.45 (3H, m, OCH2Ph), 4.44 (1H, dd, J = 8.2, 5.0 Hz, H7), 4.18 (1H, t, J 
= 3.8 Hz, H1), 4.02 (1H, dd, J = 8.0, 3.4 Hz, H2), 3.81 (1H, t, J = 4.5 Hz, H6), 3.72 (1H, 
dd, J = 8.2, 3.4 Hz, H7a), 3.61 (1H, dt, J = 8.1, 4.0 Hz, H3), 3.47 (2H, dd, J = 3.9, 1.6 Hz, 
H1′), 3.42 – 3.34 (1H, m, H5), 1.24 (3H, d, J = 7.1 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 138.3 (ArC), 137.1 (ArC), 128.7 (ArCH), 128.4 (ArCH), 
128.3 (ArCH), 128.0 (ArCH), 127.8 (ArCH), 127.6 (ArCH), 82.3 (C2), 74.9 (C6), 74.4 
(C7), 73.4 (OCH2Ph), 73.1 (OCH2Ph), 71.3 (C1′), 70.8 (C1), 66.8 (C7a), 60.4 (C3), 57.9 












Compound 241 was synthesized from alcohol 238 (40 mg, 0.09 mmol) using the general 
method for hydrolysis of an acetonide. The product was purified by FCC (8:92 
MeOH/CH2Cl2) to give the desired product 241 as a brown oil (20 mg, 55%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.30 
[α]𝐷
25+68.2 (c 1.00, CHCl3) 
IR max (cm-1): 3387, 3100, 2878, 1657, 1520, 1467, 1075, 696 cm–1 
LRESIMS m/z 400 (100%) [M+H]+. 
HRESIMS found 400.2127, calcd for C23H30NO5, 400.2124 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.21 (10H, m, ArH), 4.54 – 4.45 (4H, m, OCH2Ph), 
4.39 (1H, t, J = 5.1 Hz, H7), 4.13 (1H, t, J = 3.9 Hz, H1), 3.88 (1H, dd, J = 7.9, 3.8 Hz, 
H2), 3.80 (1H, t, J = 4.4 Hz, H6), 3.53 – 3.43 (3H, m, H1՛, H7a), 3.40 – 3.30 (2H, m, H5, 
H3), 1.10 (3H, d, J = 7.0 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.3 (ArC), 137.3 (ArC), 128.6 (ArCH), 128.4 (ArCH), 
128.2 (ArCH), 128.0 (ArCH), 127.6 (ArCH), 127.5 (ArCH), 83.5 (C2), 79.0 (C6), 73.3 
(OCH2Ph), 72.7 (OCH2Ph), 71.9 (C1՛), 71.5 (C7a), 69.1 (C7), 67.5 (C1), 60.7 (C5), 58.8 














(‒)-5-epi-hyacinthacine C1 242 was synthesized by the general method for O–benzyl 
deprotection from 239 (34 mg, 0.085 mmol). The crude product was filtered through a pad 
of celite and washed with additional MeOH (6 mL). The combined filtrates were 
concentrated in vacuo returning a clear film. The compound was isolated through basic 
ion–exchange chromatography followed by concentration in vacuo providing the title 
compound 242 as a colourless film (15 mg, 80%). 
 
[α]𝐷
25‒14.1 (c 1.00, H2O) 
IR max (cm-1): 3331, 2956, 1590, 1578, 1439, 1067, 812, 732, 643 cm–1 
LRESIMS m/z 220 (100%) [M+H]+. 
HRESIMS found 220.1177, calcd for C9H18NO5, 220.1185 [M+H]
+. 
1H NMR (500 MHz, D2O) δ 4.41 (1H, t, J = 4.9 Hz, H1), 4.37 (1H, t, J = 5.0 Hz, H7), 
3.97 (1H, dd, J = 7.3, 4.4 Hz, H2), 3.72 – 3.60 (3H, m, H6, H8), 3.58 (1H, t, J = 5.4 Hz, 
H7a), 3.08 – 3.01 (2H, m, H3, H5), 1.21 (3H, d, J = 6.4 Hz, H9). 
13C NMR (125 MHz, D2O) δ 78.4 (C6), 74.5 (C2), 72.6 (C1), 72.0 (C7), 70.6 (C3), 65.1 












The compound for the corrected structure of (+)-hyacinthacine C1 243 was synthesized by 
the general method for O–benzyl deprotection from 240 (11 mg, 0.025 mmol). The crude 
product was filtered through a pad of celite and washed with additional MeOH (6 mL). 
The combined filtrates were concentrated in vacuo returning a clear film. The compound 
was isolated through basic ion–exchange chromatography followed by concentration in 
vacuo providing the title compound 243 as a colourless film (3.0 mg, 52%). 
 
[α]𝐷
25+3.0 (c 1.00, H2O) 
IR max (cm-1): 3349, 2925, 1598, 1420, 1071, 967, 651 cm–1 
LRESIMS m/z 220 (100%) [M+H]+. 
HRESIMS found 220.1183, calcd for C9H18NO5, 220.1185 [M+H]
+. 
1H NMR (500 MHz, D2O) δ 4.53 (1H, dd, J = 8.6, 4.7 Hz, H7), 4.18 (1H, t, J = 3.8 Hz, 
H1), 4.02 (1H, dd, J = 9.2, 3.7 Hz, H2), 3.92 (1H, t, J = 4.4 Hz, H6), 3.68 – 3.62 (3H, m, 
H8, H7a), 3.47 (1H, dt, J = 9.2, 4.6 Hz, H3), 3.31 (1H, dt, J = 7.1, 3.9 Hz, H5), 1.29 (3H, 
d, J = 7.2 Hz, H9). 
13C NMR (125 MHz, D2O) δ 77.3 (C2), 76.6 (C6), 75.1 (C7), 74.1 (C1), 67.8 (C7a), 65.4 












(+)-6,7-di-epi-hyacinthacine C1 244 was synthesized by the general method for O–benzyl 
deprotection from 241 (18 mg, 0.045 mmol). The crude product was filtered through a pad 
of celite and washed with additional MeOH (6 mL). The combined filtrates were 
concentrated in vacuo returning a yellow film. The compound was isolated through basic 
ion–exchange chromatography followed by concentration in vacuo providing the title 
compound 244 as a colourless film (6.0 mg, 61%). 
 
[α]𝐷
25+13.4 (c 1.00, H2O) 
IR max (cm-1): 3302, 2967, 1620, 1578, 1439, 1190, 1056, 687 cm–1 
LRESIMS m/z 220 (100%) [M+H]+. 
HRESIMS found 220.1197, calcd for C9H18NO5, 220.1185 [M+H]
+. 
1H NMR (500 MHz, D2O) δ 4.33 (1H, t, J = 4.7 Hz, H7), 4.17 (1H, t, J = 4.3 Hz, H1), 
3.99 (1H, dd, J = 8.1, 4.1 Hz, H2), 3.86 (1H, t, J = 5.4 Hz, H6), 3.66 – 3.57 (2H, m, H8), 
3.40 (1H, t, J = 4.6 Hz, H7a), 3.21 (1H, quint, J = 6.7 Hz, H5), 3.14 (1H, dt, J = 8.0, 4.9 
Hz, H3), 1.17 (3H, d, J = 7.0 Hz, H9). 
13C NMR (125 MHz, D2O) δ 77.5 (C6), 74.8 (C2), 70.2 (C6), 69.7 (C1), 69.1 (C7), 62.7 














Compound 245 was synthesized from 236 (46 mg, 0.11 mmol) by the general method for 
O–benzylation. The product was purified by FCC (2:3 EtOAc/n-hexane) to give the target 
compound 245 as a yellow oil (30 mg, 54%). 
 
Rf (2:3 EtOAc/n-hexane) = 0.55 
[α]𝐷
25+47.6 (c 1.00, CHCl3) 
IR max (cm-1): 2328, 1645, 1320, 962, 664 cm–1 
LRESIMS m/z 530 (100%) [M+H]+.  
HRESIMS found 530.2919, calcd for C33H40NO5, 530.2906 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.45 – 7.12 (15H, m, ArH), 4.80 – 4.72 (2H, m, OCH2Ph, 
H8b), 4.71 – 4.64 (1H, m, OCH2Ph), 4.55 – 4.50 (2H, m, OCH2Ph), 4.46 (1H, d, J = 12.2 
Hz, OCH2Ph), 4.39 (1H, d, J = 12.0 Hz, OCH2Ph), 4.33 (1H dd, J = 6.4, 4.4 Hz, H3a), 4.13 
(1H, t, J = 5.2 Hz, H8), 3.87 (1H, dd, J = 7.4, 5.5 Hz, H7), 3.50 (1H, t, J = 5.2 Hz, H8a), 
3.48 – 3.42 (2H, m, H6, H1′), 3.42 – 3.37 (1H, m, H1′), 3.30 (1H, qd, J = 6.7, 4.3 Hz, H4), 
1.43 (3H, s, C2–CH3), 1.30 (3H, s, C2–CH3), 1.10 (3H, d, J = 6.7 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 139.0 (ArC), 138.50 (ArC), 138.46 (ArC), 128.24 (ArCH), 
128.18 (ArCH), 128.1 (ArCH), 127.82 (ArCH), 127.77 (ArCH), 127.69 (ArCH), 127.44 
(ArCH), 127.41 (ArCH), 127.3 (ArCH), 113.3 (C2), 88.7 (C3a), 81.6 (C7), 80.7 (C8b), 
76.9 (C8), 73.4 (OCH2Ph), 73.2 (OCH2Ph), 72.5 (OCH2Ph), 71.9 (C1′), 67.6 (C6), 66.7 










Compound 246 was synthesized from 238 (62 mg, 0.14 mmol) by the general method for 
O–benzylation. The product was purified by FCC (1:4 EtOAc/n-hexane) to give the target 
compound 246 as a yellow oil (39 mg, 52%). 
 
Rf (2:3 EtOAc/n-hexane) = 0.30 
[α]𝐷
25‒12.9 (c 1.00, CHCl3) 
IR max (cm-1): 2978, 1612, 1514, 1254, 1042, 678 cm–1 
LRESIMS m/z 530 (100%) [M+H]+.  
HRESIMS found 530.2925, calcd for C33H40NO5, 530.2906 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.20 (15H, m, ArH), 5.10 (1H, dd, J = 6.6, 3.0 Hz, 
H8b), 4.64 – 4.60 (3H, m, OCH2Ph), 4.56 (1H, d, J = 12.1 Hz, OCH2Ph), 4.47 (2H, s, 
OCH2Ph), 4.21 (1H, t, J = 6.8 Hz, H3a), 4.13 (1H, dd, J = 6.3, 4.3 Hz, H8), 3.84 (1H, dd, 
J = 4.4, 2.2 Hz, H7), 3.71 (1H, dd, J = 6.5, 3.0 Hz, H8a), 3.37 – 3.23 (3H, m, H6, H4, H1՛), 
3.12 (1H, dd, J = 9.5, 7.6 Hz, H1՛), 1.49 (3H, s, C2–CH3), 1.31 (3H, s, C2–CH3), 1.23 (3H, 
d, J = 7.0 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.4 (ArC), 138.3 (ArC), 138.2 (ArC), 128.4 (ArCH), 
128.36 (ArCH), 128.35 (ArCH), 127.71 (ArCH), 127.65 (ArCH), 127.6 (ArCH), 113.5 
(C2), 86.1 (C3a), 81.0 (C8b), 80.5 (C7), 77.4 (C8), 73.2 (OCH2Ph), 73.1 (C1՛), 72.4 
(OCH2Ph), 71.8 (OCH2Ph), 71.1 (C8a), 63.2 (C6), 61.2 (C4), 27.8 (C2–CH3), 25.7 (C2–










Compound 247 was synthesized from 245 (64 mg, 0.12 mmol) using the general method 
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to 
give the title compound 247 as a yellow oil (50 mg, 85%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.25 
[α]𝐷
25 +10.5 (c 2.15, CHCl3).  
IR max (cm-1): 3347, 3065, 2943, 2889, 1631, 1035, 673 cm–1 
LRESIMS m/z 490 (100%) [M+H]+.  
HRESIMS found 490.2581, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (15H, m, ArH), 4.89 – 4.78 (1H, m, OCH2Ph), 
4.76 (1H, d, J = 11.4 Hz, OCH2Ph), 4.61 (2H, s, OCH2Ph), 4.56 – 4.47 (2H, m, OCH2Ph), 
4.33 (1H, dd, J = 6.9, 4.3 Hz, H1), 4.08 (1H, apparent q, J = 4.1 Hz, H7), 4.00 (1H, t, J = 
4.5 Hz, H2), 3.73 (1H, t, J = 5.7 Hz, H7a), 3.60 (1H, dd, J = 8.7, 4.1 Hz, H6), 3.43 (1H, 
dd, J = 9.8, 4.6 Hz, H1′), 3.34 (1H, dd, J = 9.8, 5.8 Hz, H1′), 3.23 (1H, q, J = 5.1 Hz, H3), 
2.90 (1H, quint, J = 6.5 Hz, H5), 1.20 (3H, d, J = 6.3 Hz, H1′′). 
13C NMR (125 MHz, CDCl3) δ 138.1 (ArC), 137.3 (ArC), 137.2 (ArC), 128.6 (ArCH), 
128.5 (ArCH), 128.4 (ArCH), 128.10 (ArCH), 128.12 (ArCH), 127.9 (ArCH), 127.8 
(ArCH), 127.7 (ArCH), 80.6 (C2), 80.2 (C6), 79.5 (C1), 73.5 (OCH2Ph), 73.4 (OCH2Ph), 











Compound 248 was synthesized from 246 (38 mg, 0.072 mmol) using the general method 
for hydrolysis of an acetonide. The product was purified by FCC (5:95 MeOH/CH2Cl2) to 
give the desired product 248 as a brown oil (30 mg, 85%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.15 
[α]𝐷
25+18.4 (c 1.00, CHCl3) 
IR max (cm-1): 3327, 3099, 2912, 2843, 1589, 1075, 678 cm–1 
LRESIMS m/z 490 (100%) [M+H]+.  
HRESIMS found 490.2612, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.41 – 7.20 (15H, m, ArH), 4.74 (1H, d, J = 11.6 Hz, 
OCH2Ph), 4.63 (1H, d, J = 11.7 Hz, OCH2Ph), 4.59 – 4.39 (5H, m, OCH2Ph, H7), 4.10 
(1H, t, J = 4.2 Hz, H1), 3.94 – 3.86 (1H, m, H2), 3.83 (1H, t, J = 4.8 Hz, H6), 3.68 (1H, t, 
J = 5.1 Hz, H7a), 3.60 – 3.40 (4H, m, H5, H3, H1՛), 1.96 (1H, s, OH), 1.16 (3H, d, J = 6.9 
Hz, C1՛՛). 
13C NMR (125 MHz, CDCl3) δ 138.1 (ArC), 138.0 (ArC), 137.6 (ArC), 128.45 (ArCH), 
128.35 (ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.60 (ArCH), 127.58 (ArCH), 82.0 (C2), 
78.1 (C6), 75.0 (C1), 73.4 (OCH2Ph), 73.3 (OCH2Ph), 72.6 (OCH2Ph), 71.3 (C7a), 71.1 












Compound 249 was synthesized from the diol 247 (43 mg, 0.088 mmol) by using the 
general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 249 (48 
mg) was used for the next step without further purification. 
 
LRESIMS m/z 586 (100%) [M+Cl]–. 
 
(3aR,4R,6R,7R,8S,8aS,8bS)-7,8-Bis(benzyloxy)-6-((benzyloxy)methyl)-4-
methylhexahydro-4H-[1,3,2]dioxathiolo[4,5-a]pyrrolizine 2,2-dioxide (250) 
 
Compound 250 was synthesized from the diol 248 (25 mg, 0.051 mmol) by using the 
general method for the synthesis of a cyclic sulfate. The resultant crude brown oil 250 (28 
mg) was used for the next step without further purification. 
 












Compound 251 was synthesized from the cyclic sulfate 250 (28 mg, 0.051 mmol) using 
the general method for ring opening of cyclic sulfates with benzoate. Purification by FCC 
(3:2 EtOAc/n-hexane) returned the title compound 251 (13 mg, 42%) as a brown oil.  
 
Rf (3:2 EtOAc/n-hexane) = 0.25 
[α]𝐷
25+8.5 (c 1.00, CHCl3) 
IR max (cm-1): 3380, 3093, 1710, 1576, 1104, 1011, 608 cm–1 
LRESIMS m/z 594 (100%) [M+H]+.  
HRESIMS found 594.2843, calcd for C37H40NO6, 594.2856 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 8.00 (2H, d, J = 7.7 Hz, o–Bz), 7.54 (1H, dd, J = 7.8 Hz, 
p–Bz), 7.39 (2H, t, J = 7.8 Hz, m–Bz), 7.36 – 7.17 (15H, m, ArH), 5.30 (1H, t, J = 5.8 Hz, 
H6), 4.77 (1H, dd, J = 6.9, 5.5 Hz, H7), 4.71 (1H, d, J = 12.0 Hz, OCH2Ph), 4.67 (1H, d, 
J = 12.0 Hz, OCH2Ph), 4.57 – 4.47 (3H, m, OCH2Ph), 4.42 (1H, d, J = 12.0 Hz, OCH2Ph), 
4.13 (1H, t, J = 4.5 Hz, H1), 3.93 – 3.86 (2H, m, H5, H2), 3.69 (1H, q, J = 5.7 Hz, H3), 
3.59 (1H, t, J = 5.9 Hz, H7a), 3.44 (2H, d, J = 5.3 Hz, H1՛), 1.25 (3H, d, J = 8.8 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 167.2 (CO), 138.4 (ArC), 138.3 (ArC), 137.9 (ArC), 133.2 
(ArCH), 129.8 (ArCH), 128.40 (ArCH), 128.37 (ArCH), 128.33 (ArCH), 128.26 (ArCH), 
127.7 (ArCH), 127.63 (ArCH), 127.58 (ArCH), 127.5 (ArCH), 84.6 (C6), 81.8 (C2), 75.4 
(C1), 74.3 (C7), 73.4 (OCH2Ph), 72.9 (OCH2Ph), 72.3 (OCH2Ph), 72.2 (C1՛), 70.8 (C7a), 










Compound 252 was synthesized from benzoate 251 (11 mg, 0.017 mmol) using the general 
method for O–benzoyl deprotection, except that the reaction was stirred at rt for 1 h. The 
crude brown oil was purified by FCC (5:95 MeOH/CH2Cl2) to give the product 252 as a 
clear brown film (7.0 mg, 87%). 
 
Rf (5:95 MeOH/CH2Cl2) = 0.20 
[α]𝐷
25+29.8 (c 1.00, CHCl3) 
IR max (cm-1): 3362, 3101, 2967, 1542, 1489 1027, 872, 696 cm–1 
LRESIMS m/z 490 (100%) [M+H]+.  
HRESIMS found 490.2597, calcd for C30H36NO5, 490.2593 [M+H]
+. 
1H NMR (500 MHz, CDCl3) δ 7.39 – 7.22 (15H, m, ArH), 4.83 (1H, d, J = 11.2 Hz, 
OCH2Ph), 4.68 – 4.51 (5H, m, OCH2Ph), 4.40 (1H, t, J = 2.2 Hz, H7), 4.22 (1H, t, J = 4.5 
Hz, H1), 4.12 (1H, dd, J = 8.2, 3.7 Hz, H2), 4.09 – 4.01 (1H, m, H7a), 4.01 – 3.92 (2H, m, 
H5, H6), 3.76 (1H, dt, J = 8.5, 4.5 Hz, H3), 3.67 (1H, dd, J = 10.4, 5.0 Hz, H1՛), 3.61 (1H, 
dd, J = 10.4, 3.9 Hz, H1՛), 1.31 (3H, d, J = 6.7 Hz, H1՛՛). 
13C NMR (125 MHz, CDCl3) δ 137.8 (ArC), 136.9 (ArC), 136.6 (ArC), 128.8 (ArCH), 
128.6 (ArCH), 128.5 (ArCH), 128.4 (ArCH), 128.34 (ArCH), 128.30 (ArCH), 128.1 
(ArCH), 127.9 (ArCH), 127.8 (ArCH), 127.7 (ArCH), 81.1 (C6), 80.9 (C2), 75.8 (C1), 
75.4 (C7), 74.3 (OCH2Ph), 73.7 (OCH2Ph), 73.5 (OCH2Ph), 73.3 (C7a), 68.7 (C1՛), 61.0 












(+)-7-epi-hyacinthacine C1 253 was synthesized by the general method of O–benzyl 
deprotection from 252 (6.0 mg, 0.012 mmol). The crude product was filtered through a 
pad of celite and washed with additional MeOH (6 mL). The combined filtrates were 
concentrated in vacuo returning a yellow film. The title compound 253 was isolated 
through basic ion–exchange chromatography followed by concentration in vacuo, as a 
colourless film (2.0 mg, 75%).  
 
[α]𝐷
25+6.5 (c 1.00, H2O) 
IR max (cm-1): 3303, 2981, 1702, 1570, 1412, 1087, 1078, 656 cm–1 
LRESIMS m/z 220 (100%) [M+H]+. 
HRESIMS found 220.1181, calcd for C9H18NO5, 220.1185 [M+H]
+. 
1H NMR (500 MHz, D2O) δ 4.29 (1H, d, J = 5.8 Hz, H7), 4.15 (1H, t, J = 3.9 Hz, H1), 
4.11 (1H, dd, J = 7.4, 6.0 Hz, H6), 3.97 (1H, dd, J = 9.1, 3.9 Hz, H2), 3.74 (1H, dd, J = 
11.6, 4.3 Hz, H8), 3.61 (1H, dd, J = 11.7, 6.4 Hz, H8), 3.46 (1H, quint, J = 6.8 Hz, H5), 
3.33 – 3.26 (2H, m, H7a, H3), 1.12 (3H, d, J = 7.0 Hz, H9). 
13C NMR (125 MHz, D2O) δ 78.4 (C6), 74.9 (C2), 71.4 (C7), 69.3 (C1), 68.8 (C7a), 63.0 
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Figure A.1: 1H NMR spectrum (500 MHz, D2O) of 155 
 


































Figure A.3: gCOSY spectrum (500 MHz, D2O) of 155 
 









Figure A.6: 1H NMR spectrum (500 MHz, D2O) of 156 
 





































Figure A.8: gCOSY spectrum (500 MHz, D2O) of 156 
 









Figure A.11: 1H NMR spectrum (500 MHz, D2O) of 169 
 








































Figure A.13: gCOSY spectrum (500 MHz, D2O) of 169 
 









Figure A.16: 1H NMR spectrum (500 MHz, D2O) of the purported hyacinthacine C5 
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Figure A.18: gCOSY spectrum (500 MHz, D2O) of the purported hyacinthacine C5 
 









Figure A.21: 1H NMR spectrum (500 MHz, D2O) of 215 
 








































Figure A.23: gCOSY spectrum (500 MHz, D2O) of 215 
 










Figure A.26: 1H NMR spectrum (500 MHz, D2O) of 216 
 






































Figure A.28: gCOSY spectrum (500 MHz, D2O) of 216 
 









Figure A.31: 1H NMR spectrum (500 MHz, D2O) of 217 
 

































Figure A.33: gCOSY spectrum (500 MHz, D2O) of 217 
 




























































































































Figure A.36: 1H NMR spectrum (500 MHz, CDCl3) of 218 
 




Figure A.38: gCOSY spectrum (500 MHz, CDCl3) of 218 
 





























































































































Figure A.41: 1H NMR spectrum (500 MHz, D2O) of 242 
 



































Figure A.43: gCOSY spectrum (500 MHz, D2O) of 242 
 









Figure A.46: 1H NMR spectrum (500 MHz, D2O) of 243 
 





































Figure A.48: gCOSY spectrum (500 MHz, D2O) of 243 
 









Figure A.51: 1H NMR spectrum (500 MHz, D2O) of 244 
 
 







































Figure A.53: gCOSY spectrum (500 MHz, D2O) of 244 
 



































































































Figure A.56: 1H NMR spectrum (500 MHz, D2O) of 253 
 


































Figure A.58: gCOSY spectrum (500 MHz, D2O) of 253 
 
































































Here I have included an unconventional section, highlighting a few moments throughout 
the course of this work that deserve to be included in this thesis.  
The first of these is the winning of the C&En May “Chemistry in Photos” contest. Below 
is the photo I took, along with the small card I received from the C&En office in 
Washington, DC, USA. The photo shows ammonia sulfate (white solid) and a copper-
ammonia complex (deep blue). It was the by-product of the acetonide protection of L-
xylose. This work up procedure usually involves physically separating the hydrated copper 
sulfate (light blue) via vaccum filtration, followed by a separate removal of the precipitated 
ammonia sulfate using gravity filtration. Instead of gravity filtering the white precipitate, 
I re-used the vaccum filter (containing copper sulfate) and below is what resulted. I was 
lucky that the copper sulfate did not re-dissolve into my collecting flask as the copper-
ammonia complex, as this would have defeated the purpose of the initial removal of the 
copper. It made for a nice photo though and was printed in C&En captioned “Ice Faux 
Floes”. Many thanks to the C&En team, and particularly Dr Reeser for ensuring I received 







The second mention was prior to the publishing our second body of work in the ACS 
Journal of Natural Products. My wife Shenae is extremely talented in arts, graphic and 
digital design. She has supported this project in numerous ways including her art. Below 
is an art piece that she drew depicting the corrected structure of hyacinthacine C1. We 
released ownership of this masterpiece to accompany our manuscript following its 







Towards the end of 2018, I presented at the RACI NSW Natural Products Chemistry 
Symposium held at UNSW. I was very fortunate to win the prize for the “Best Student 
Oral Presentation”. There were some fantastic speakers on the day and so it was amazing 











The final highlight included in this section was my receiving of the prestigious Larry and 
Marilyn Hick award for 2018. This award is presented for the “Best Published Article by 
a Postgraduate Student” for that year. The paper that won this award is discussed in 
Chapters 2,3 and 4B and was published in the ACS Journal of Organic Chemistry.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
